var images_info;if (!images_info) images_info =[]; images_info["86"]={"86021":{"type":"graphic_picture","displayName":"Nail nipper","title":"Heavy-duty nail nipper used in trimming, paring, and nail surgery","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Heavy-duty nail nipper used in trimming, paring, and nail surgery</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86021_Nailnipper.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86021 Version 2.0</div></div></div>"},"86022":{"type":"graphic_picture","displayName":"Nail grinder 2","title":"Nail grinder","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail grinder</div><div class=\"cntnt\"><img style=\"width:504px; height:224px;\" src=\"images/DERM/86022_Nailgrinder2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86022 Version 2.0</div></div></div>"},"86023":{"type":"graphic_picture","displayName":"Nail elevator and spatula","title":"Nail elevator and dental spatula used in performing an avulsion of the nail","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail elevator and dental spatula used in performing an avulsion of the nail</div><div class=\"cntnt\"><img style=\"width:504px; height:259px;\" src=\"images/DERM/86023_Nailelevatorspatula.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86023 Version 2.0</div></div></div>"},"86024":{"type":"graphic_picture","displayName":"Elevator under nail","title":"Nail elevator under the nail plate during partial nail avulsion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail elevator under the nail plate during partial nail avulsion</div><div class=\"cntnt\"><img style=\"width:504px; height:418px;\" src=\"images/DERM/86024_Elevatorundernail.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Elizabeth Billingsley, MD, Dept of Dermatology, Penn State Hershey.</div><div id=\"graphicVersion\">Graphic 86024 Version 2.0</div></div></div>"},"86025":{"type":"graphic_picture","displayName":"Nail splitter","title":"Nail splitter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail splitter</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86025_Nailsplitter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86025 Version 2.0</div></div></div>"},"86026":{"type":"graphic_figure","displayName":"Normal thoracic aorta","title":"Normal thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Normal thoracic aorta</div><div class=\"cntnt\"><img style=\"width:506px; height:645px;\" src=\"images/SURG/86026_Normal-thoracic-aorta.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86026 Version 1.0</div></div></div>"},"86027":{"type":"graphic_movie","displayName":"Row exercise for scapular stabilizers","title":"Row exercise for scapular stabilizers","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Row exercise for scapular stabilizers</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86027_Rowexerscapstabilvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86027_Rowexerscapstabilimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rowing exercises performed against resistance help to strengthen the muscles involved in stabilizing the scapula.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86027 Version 1.0</div></div></div>"},"86028":{"type":"graphic_movie","displayName":"Shoulder extension exercise for scapular stabilizers","title":"Shoulder extension exercise for scapular stabilizers","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder extension exercise for scapular stabilizers</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86028_Shextenscapstabilvideo.mp4\" style=\"width:496px;height:304px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86028_Shextenscapstabilimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shoulder extension exercises performed against resistance are among the exercises used to strengthen the muscles that stabilize the scapula.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86028 Version 1.0</div></div></div>"},"86029":{"type":"graphic_figure","displayName":"Anterolateral thoracotomy","title":"Anterolateral thoracotomy","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Anterolateral thoracotomy</div><div class=\"cntnt\"><img style=\"width:497px; height:651px;\" src=\"images/SURG/86029_Anterolateral_thoracotomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86029 Version 1.0</div></div></div>"},"86030":{"type":"graphic_figure","displayName":"Control of the lung hilum","title":"Control of the lung hilum","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Control of the lung hilum</div><div class=\"cntnt\"><img style=\"width:527px; height:678px;\" src=\"images/SURG/86030_Control_of_the_lung_hilum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During resuscitative thoracotomy, control of the pulmonary hilum is obtained by dividing the inferior pulmonary ligament&nbsp;and clamping&nbsp;across the left mainstem bronchus and pulmonary artery and veins. The lung can be twisted clock-wise, which compress the pulmonary&nbsp;vessels against the bronchus, if an appropriate vascular clamp is unavailable.&nbsp;</div><div id=\"graphicVersion\">Graphic 86030 Version 1.0</div></div></div>"},"86031":{"type":"graphic_figure","displayName":"Pericardiotomy","title":"Pericardiotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardiotomy</div><div class=\"cntnt\"><img style=\"width:364px; height:373px;\" src=\"images/SURG/86031_Pericardiotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During resuscitative thoracotomy, the pericardiotomy is made anterior and parallel to the phrenic nerve, while compressing the lung posteriorly away from the heart.</div><div id=\"graphicVersion\">Graphic 86031 Version 1.0</div></div></div>"},"86032":{"type":"graphic_figure","displayName":"Cross-clamping the thoracic aorta","title":"Cross-clamping the thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross-clamping the thoracic aorta</div><div class=\"cntnt\"><img style=\"width:369px; height:377px;\" src=\"images/SURG/86032_Cross_clamping_the_thoracic_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Access to the thoracic aorta is best achieved by incising the parietal pleura overlying the aorta and retracting the lung anteriorly. Blunt dissection is used to develop a space between the&nbsp;esophagus and aorta to permit&nbsp;aortic cross-clamping above the diagphragm without damaging the intercostal vessels. When the aorta is collapsed, as in the hypotensive patient, palpation of&nbsp;the naso- or orogastric&nbsp;tube can aid in differentiating the esophagus from the&nbsp;aorta.</div><div id=\"graphicVersion\">Graphic 86032 Version 1.0</div></div></div>"},"86033":{"type":"graphic_figure","displayName":"Open cardiac massage","title":"Open cardiac massage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open cardiac massage</div><div class=\"cntnt\"><img style=\"width:395px; height:458px;\" src=\"images/SURG/86033_Open_cardiac_massage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open chest cardiac massage is performed with the heart compressed between the palms of both hands. Cardiac compression with one hand should be <STRONG>avoided</STRONG> because the pulmonary outflow tract is vulnerable to penetration by the thumb.</div><div id=\"graphicVersion\">Graphic 86033 Version 1.0</div></div></div>"},"86034":{"type":"graphic_figure","displayName":"Repair of cardiac injury","title":"Repair of cardiac injury","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Repair of cardiac injury</div><div class=\"cntnt\"><img style=\"width:533px; height:445px;\" src=\"images/SURG/86034_Repair_of_cardiac_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During resuscitative thoracotomy, temporizing maneuvers to control bleeding from cardiac injuries may include direct digital pressure on the wound while the patient is transported to the operating room, stapling the cardiac wound closed using a skin stapler with care to avoid the epicardial vessels, or suture closure of the cardiac injury.<br />Venous and atrial wounds can be repaired in a simple, running fashion using 3-0 or 4-0 sutures as depicited (A).<br />Appropriately trained individuals may choose to suture repair isolated ventricular cardiac injuries, usually using double-armed polypropylene (eg, Prolene) suture, preferably on a cardiovascular (CV) needle. Digital compression over the cardiac injury should be maintained while placing pledgeted horizontal mattress sutures with care to avoid injury to the epicardial vessels. As the finger is carefully withdrawn, an assistant gently pulls up on the suture, crossing the ends. Additional sutures can be placed, as needed, prior to tying the sutures.</div><div id=\"graphicVersion\">Graphic 86034 Version 2.0</div></div></div>"},"86035":{"type":"graphic_picture","displayName":"Scapular row exercise","title":"Scapular row exercise","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Scapular row exercise</div><div class=\"cntnt\"><img style=\"width:517px; height:199px;\" src=\"images/EM/86035_Scap_row_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Start by holding tubing with some tension with the&nbsp;arms fully extended. Pull your shoulder blades back together; imagine you are pinching a pencil between your shoulder blades. As you pull back, allow your elbows to bend as if they were sliding along a table top. Complete the pull on a 2 count, and then slowly return to starting position on a 4 count. Perform 25 repetitions to complete one set, rest 30 seconds, and repeat for 2 sets of 25 repetitions. Be sure to pull with your shoulder blades; your arms should follow the shoulder blade movement.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86035 Version 1.0</div></div></div>"},"86037":{"type":"graphic_picture","displayName":"Scapular extension exercise","title":"Scapular extension exercise","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Scapular extension exercise</div><div class=\"cntnt\"><img style=\"width:513px; height:193px;\" src=\"images/EM/86037_Scap_extens_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Start by holding the tubing with some tension when the arms are fully extended. Pull shoulder blades back together; imagine that you are pinching a pencil between your shoulder blades. Pull to a 2 count, and then slowly return to the starting position on a 4 count. Perform 25 repetitions to complete one set, rest 30 seconds, and repeat the set. Be sure to pull with your shoulder blades; your arms should follow the shoulder blade movement. Elbows remain straight throughout the exercise.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86037 Version 1.0</div></div></div>"},"86038":{"type":"graphic_table","displayName":"Risk factors for lead exposure in pregnancy and lactation","title":"Risk factors for lead exposure in pregnancy and during lactation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for lead exposure in pregnancy and during lactation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Recent emigration from or residency in areas where ambient lead contamination is high</td> </tr> <tr> <td class=\"indent1\">Women from countries where leaded gasoline is still being used (or was recently phased out) or where industrial emissions are not well controlled</td> </tr> <tr> <td class=\"subtitle1_single\">Living near a point source of lead</td> </tr> <tr> <td class=\"indent1\">Examples include lead mines, smelters, or battery recycling plants (even if the establishment is closed)</td> </tr> <tr> <td class=\"subtitle1_single\">Working with lead or living with someone who does</td> </tr> <tr> <td class=\"indent1\">Women who work in or who have family members who work in an industry that uses lead (eg, lead production, battery manufacturing, paint manufacturing, ship building, ammunition production, or plastic manufacturing)</td> </tr> <tr> <td class=\"subtitle1_single\">Using lead-glazed ceramic pottery</td> </tr> <tr> <td class=\"indent1\">Women who cook, store, or serve food in lead-glazed ceramic pottery made in a traditional process and usually imported by individuals outside the normal commercial channels</td> </tr> <tr> <td class=\"subtitle1_single\">Eating nonfood substances (pica)</td> </tr> <tr> <td class=\"indent1\">Women who eat or mouth nonfood items that may be contaminated with lead, such as soil or lead-glazed ceramic pottery</td> </tr> <tr> <td class=\"subtitle1_single\">Using alternative or complementary substances, herbs, or therapies</td> </tr> <tr> <td class=\"indent1\">Women who use imported home remedies or certain therapeutic herbs traditionally used by East Indian, Indian, Middle Eastern, West Asian, and Hispanic cultures that may be contaminated with lead</td> </tr> <tr> <td class=\"subtitle1_single\">Using imported cosmetics or certain food products</td> </tr> <tr> <td class=\"indent1\">Women who use imported cosmetics, such as kohl or surma or certain imported foods or spices that may be contaminated with lead</td> </tr> <tr> <td class=\"subtitle1_single\">Engaging in certain high-risk hobbies or recreational activities</td> </tr> <tr> <td class=\"indent1\">Women who engage in high-risk activities (eg, stained glass production or pottery making with certain leaded glazes and paints) or have family members who do</td> </tr> <tr> <td class=\"subtitle1_single\">Renovating or remodeling older homes without lead hazard controls in place</td> </tr> <tr> <td class=\"indent1\">Women who have been disturbing lead paint, creating lead dust, or both or have been spending time in such a home environment</td> </tr> <tr> <td class=\"subtitle1_single\">Consumption of lead-contaminated drinking water</td> </tr> <tr> <td class=\"indent1\">Women whose homes have leaded pipes or source lines with lead</td> </tr> <tr> <td class=\"subtitle1_single\">Having a history of previous lead exposure or evidence of elevated body burden of lead</td> </tr> <tr> <td class=\"indent1\">Women who may have high body burdens of lead from past exposure, particularly those who have deficiencies in certain key nutrients (calcium or iron)</td> </tr> <tr> <td class=\"subtitle1_single\">Living with someone identified with an elevated lead level</td> </tr> <tr> <td class=\"indent1\">Women who may have exposure in common with a child, close friend, or other relative living in the same environment</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Guidelines for the identification and management of lead exposure in pregnant and lactating women. Atlanta 2010. Available at: <a href=\"http://www.cdc.gov/nceh/lead/publications/leadandpregnancy2010.pdf\" target=\"_blank\">http://www.cdc.gov/nceh/lead/publications/leadandpregnancy2010.pdf</a>.</div><div id=\"graphicVersion\">Graphic 86038 Version 3.0</div></div></div>"},"86046":{"type":"graphic_figure","displayName":"Median sternotomy","title":"Median sternotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Median sternotomy</div><div class=\"cntnt\"><img style=\"width:432px; height:421px;\" src=\"images/SURG/86046_Median_sternotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a midline sternotomy, the incision is made in the anterior chest from the sternal notch to the xiphoid process. At each end of the incision, the tissue is bluntly dissected to access the retrosternal space. While the anesthesiologist holds ventilation, the sternum is divided using a sternal saw, or&nbsp;alternatively, the sternum can be divided using a Lebsche knife.</div><div id=\"graphicVersion\">Graphic 86046 Version 2.0</div></div></div>"},"86047":{"type":"graphic_figure","displayName":"Repair of innominate artery injury","title":"Repair of innominate artery injury","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Repair of innominate artery injury</div><div class=\"cntnt\"><img style=\"width:478px; height:708px;\" src=\"images/SURG/86047_Repair_innominate_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To repair injuries to the innominate artery, the mediastinum is explored through a median sternotomy. If hematoma obscures the view of the the left innominate vein, which is a key landmark for identifying the location of the great vessels, the pericardium can be opened to identify the aortic root. Tracing the ascending aorta as it leaves the heart safely identifies the great vessels. If needed, the left innominate vein can be retracted or ligated (B) to improve exposure of the innominate artery and carotid arteries, which can be controlled proximally by placing clamps at their origins (C). Control of these vessels beyond the injury may be possible through the median sternotomy, or may require an additional incision (not shown: right cervical extension of the median sternotomy, supraclavicular subclavian artery exposure, infraclavicular subclavian artery exposure). Once proximal and distal control are achieved, the vessel can be debrided and repaired. Primary repair (suture closure) or a patch angioplasty can be used if the injury is not extensive (not shown). If the damage is more significant, an interposition graft (D) or bypass graft (E) may be necessary.</div><div id=\"graphicVersion\">Graphic 86047 Version 1.0</div></div></div>"},"86049":{"type":"graphic_figure","displayName":"Vascular control of the subclavian and axillary arteries","title":"Vascular control of the subclavian and axillary arteries","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Vascular control of the subclavian and axillary arteries</div><div class=\"cntnt\"><img style=\"width:522px; height:366px;\" src=\"images/SURG/86049_Approaches_to_the_subclavian_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For managing proximal to mid subclavian pathologies, control of the subclavian artery at its origin&nbsp;may be necessary prior to exposing the more distal subclavian or axillary artery. A left anterior thoracotomy incision can be used to control the subclavian artery at its origin. The incision is made medially&nbsp;in the second rib space and carried down along the superior margin of the third rib to enter the chest. The more distal subclavian artery can be controlled using a supraclavicular or infraclavicular incision.<BR>The supraclavicular incision requires sufficient&nbsp;experience to avoid injury to important structures in the vicinity of the artery (eg, phrenic nerve, thoracic duct).&nbsp;If a large hematoma is present,&nbsp;the more lateral infraclavicular incision&nbsp;may be a better choice for initial control. The supraclavicular&nbsp;incision is made one fingerbreadth above the clavicle starting at the lateral edge of the sternocleidomastoid muscle. The proximal axillary artery can be controlled using an infraclavicular incision as it exits the thoracic outlet. Similar to the subclavian artery, if a large hematoma is present in the axilla, a supraclavicular incision to control the subclavian artery proximal to the hematoma may be a better choice over entering the hematoma to control the axillary artery. The infraclavicular incision is made about 1 cm inferior to the clavicle over the lateral aspect of the deltopectoral groove.</div><div id=\"graphicVersion\">Graphic 86049 Version 1.0</div></div></div>"},"86050":{"type":"graphic_figure","displayName":"Fleur-de-lis incision","title":"Fleur-de-lis incision","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Fleur-de-lis incision</div><div class=\"cntnt\"><img style=\"width:495px; height:646px;\" src=\"images/SURG/86050_Fleur_de_lis_incision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86050 Version 1.0</div></div></div>"},"86052":{"type":"graphic_figure","displayName":"Subclavian carotid transposition","title":"Subclavian carotid transposition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subclavian carotid transposition</div><div class=\"cntnt\"><img style=\"width:394px; height:684px;\" src=\"images/SURG/86052_Subclavian_carotid_transposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform subclavian-to-carotid transposition, the subclavian artery is divided proximal to the vertebral artery, and the subclavian artery stump is oversewn. The common carotid artery is exposed and, after obtaining proximal and distal control, an incision is made on its lateral aspect. The subclavian artery is then turned upward, trimmed and sutured to the common carotid artery. The end-to-side anastomosis is performed using a running 6-0 prolene suture. Cerebral protection is not usually required when operating on an otherwise normal common carotid artery due to the collateral flow from the external carotid to the internal carotid artery.</div><div id=\"graphicVersion\">Graphic 86052 Version 1.0</div></div></div>"},"86053":{"type":"graphic_picture","displayName":"Supraspinatus active abduction","title":"Supraspinatus active abduction","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Supraspinatus active abduction</div><div class=\"cntnt\"><img style=\"width:513px; height:178px;\" src=\"images/EM/86053_Supraspin_act_abduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Start in a standing position with both arms fully extended at the elbow, arms at a 45 degree angle from the body and thumbs pointing up to the sky. Raise both arms to the height of the shoulder on a 2 count, slowly return to the starting position on a 4 count, and repeat for a total of 15 repetitions. Make sure to lift from the shoulder; do not allow the shoulder blades to shrug upwards. Rest for 30 seconds and repeat for a total of 3 sets.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86053 Version 1.0</div></div></div>"},"86054":{"type":"graphic_figure","displayName":"Claviculectomy for subclavian artery exposure","title":"Claviculectomy for subclavian artery exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Claviculectomy for subclavian artery exposure</div><div class=\"cntnt\"><img style=\"width:360px; height:626px;\" src=\"images/SURG/86054_Claviculectomy-for-subclavian-artery-exposure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Claviculectomy is an alternate method for exposing the&nbsp;distal subclavian artery, permitting direct repair of complex injuries of the subclavian artery and veins. The incision is made directly over the clavicle and carried down to the periostium using electrocautery. The periosteum is divided longitudinally along the axis of the clavicle. A Gigle saw or equivalent is used to transect the clavicle medially and laterally, which may be more expedient and less morbid than attempting to remove the entire clavicle at the sternum. The underlying scalenus anticus muscle is identified and divided as it inserts on the first rib. The subclavian artery should then be easily exposed and controlled.</div><div id=\"graphicVersion\">Graphic 86054 Version 2.0</div></div></div>"},"86055":{"type":"graphic_movie","displayName":"Supraspinatus isometric abduction exercise","title":"Supraspinatus isometric abduction exercise","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Supraspinatus isometric abduction exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86055_Supraspisometabductvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86055_Supraspisometabductimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric exercises with the shoulder held in mid-abduction&nbsp;are performed early in rehabilitation to begin strengthening the supraspinatus muscle.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86055 Version 1.0</div></div></div>"},"86056":{"type":"graphic_figure","displayName":"Covered stent for arterial injury","title":"Covered stent for arterial injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Covered stent for arterial injury</div><div class=\"cntnt\"><img style=\"width:417px; height:363px;\" src=\"images/SURG/86056_Covered_stent_arterial_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subclavian injuries can be treated using a covered stent as depicted in the illustration. A brachial or femoral approach (or both) can be used to access the injured vessel. The diameter of the stent should be 1 to 2 mm larger than the native vessel. Before stent-grafting, the need to preserve vertebral artery or internal mammary artery flow needs to be taken into consideration.</div><div id=\"graphicVersion\">Graphic 86056 Version 2.0</div></div></div>"},"86057":{"type":"graphic_movie","displayName":"Supraspinatus active abduction exercise","title":"Supraspinatus active abduction exercise","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Supraspinatus active abduction exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86057_Supraspactiveabductvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86057_Supraspactiveabductimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active shoulder abduction exercises are used to strengthen the supraspinatus muscle prior to the addition of resistance.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86057 Version 1.0</div></div></div>"},"86058":{"type":"graphic_movie","displayName":"Supraspinatus abduction exercise with resistance","title":"Supraspinatus abduction exercise with resistance","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Supraspinatus abduction exercise with resistance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86058_Supraspabductresistvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86058_Supraspabductresistimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shoulder abduction against resistance is used to strengthen the supraspinatus muscle.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86058 Version 1.0</div></div></div>"},"86059":{"type":"graphic_movie","displayName":"Shoulder external rotation isometric exercise","title":"Shoulder external rotation isometric exercise","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation isometric exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86059_Shextrotatisometrvideo.mp4\" style=\"width:448px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86059_Shextrotatisometrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric holds performed with the shoulder externally rotated are used&nbsp;early during rehabilitation&nbsp;to strengthen the muscles that perform external rotation.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86059 Version 1.0</div></div></div>"},"86060":{"type":"graphic_waveform","displayName":"Variable decelerations","title":"Variable decelerations","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Variable decelerations</div><div class=\"cntnt\"><img style=\"width:600px; height:276px;\" src=\"images/OBGYN/86060_Variable_decelerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recurrent variable decelerations with absent to&nbsp;minimal variability.</div><div class=\"graphic_reference\">Courtesy of Bruce K Young, MD.</div><div id=\"graphicVersion\">Graphic 86060 Version 3.0</div></div></div>"},"86062":{"type":"graphic_waveform","displayName":"Variable decelerations with minimal to absent variability","title":"Variable decelerations with minimal to absent variability","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Variable decelerations with minimal to absent variability</div><div class=\"cntnt\"><img style=\"width:600px; height:279px;\" src=\"images/OBGYN/86062_Sev_variable_decelerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variability is minimal to absent.</div><div class=\"graphic_reference\">Courtesy of Bruce K Young, MD.</div><div id=\"graphicVersion\">Graphic 86062 Version 3.0</div></div></div>"},"86064":{"type":"graphic_waveform","displayName":"Normal variability and accelerations","title":"Normal variability and accelerations","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Normal variability and accelerations</div><div class=\"cntnt\"><img style=\"width:600px; height:241px;\" src=\"images/OBGYN/86064_Normal_variab_accelerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Bruce K Young, MD.</div><div id=\"graphicVersion\">Graphic 86064 Version 1.0</div></div></div>"},"86068":{"type":"graphic_movie","displayName":"Shoulder external rotation exercise with resistance","title":"Shoulder external rotation exercise with resistance","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation exercise with resistance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86068_Shextrotatresistvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86068_Shextrotatresistimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active external rotation agains resistance is&nbsp;among the progression of exercises designed to strengthen the muscles involved in shoulder external rotation.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86068 Version 1.0</div></div></div>"},"86069":{"type":"graphic_algorithm","displayName":"Management of multiple magnet ingestion","title":"Algorithm for management of multiple magnet ingestion","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of multiple magnet ingestion</div><div class=\"cntnt\"><img style=\"width:630px; height:741px;\" src=\"images/PEDS/86069_Manage_magnet_ingest_multi.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If magnet might be, or is known to be, a high-powered type (neodymium, or \"rare earth\" type).<BR>Δ&nbsp;Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a radiograph, and be misdiagnosed as a single magnet.&nbsp;<BR>◊ The following \"magnet precautions\" should be used for any child&nbsp;who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until the magnet has passed out of the gastrointestinal tract.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86069 Version 5.0</div></div></div>"},"86070":{"type":"graphic_picture","displayName":"Shoulder external rotation against resistance","title":"Shoulder external rotation against resistance","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation against resistance</div><div class=\"cntnt\"><img style=\"width:512px; height:211px;\" src=\"images/EM/86070_Shld_ext_rot_ag_resist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anchor tubing&nbsp;to a fixed object&nbsp;(eg, a door knob, banister, or column), stand perpendicular to the wall holding the tubing in your outside hand. Make&nbsp;sure to keep your elbow bent to 90 degrees when performing the exercise. Pinch a towel or something small between your arm and ribs to be sure your arm stays against your side. Start with your arm across your&nbsp;abdomen, then slowly rotate your arm away from your body over two seconds&nbsp;until&nbsp;it is&nbsp;about 90 degrees from your body,&nbsp;then slowly return to starting position&nbsp;over four seconds. Repeat the movement 15 times to complete one set. Do 3 sets of 15 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86070 Version 2.0</div></div></div>"},"86071":{"type":"graphic_movie","displayName":"Shoulder active internal rotation exercise","title":"Shoulder active internal rotation exercise","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder active internal rotation exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86071_Shactivinternrotatvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86071_Shactivinternrotatimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active internal rotation is among the exercises used to strengthen the subscapularis muscle.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86071 Version 1.0</div></div></div>"},"86073":{"type":"graphic_movie","displayName":"Shoulder internal rotation exercise with resistance","title":"Shoulder internal rotation exercise with resistance","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder internal rotation exercise with resistance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86073_Shinterrotatresistvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86073_Shinterrotatresistimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal rotation against resistance is among the exercises used to strengthen the subscapularis muscle.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86073 Version 1.0</div></div></div>"},"86075":{"type":"graphic_movie","displayName":"Shoulder internal rotation exercise with weight","title":"Shoulder internal rotation exercise with weight","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder internal rotation exercise with weight</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86075_Shinterrotatweightvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86075_Shinterrotatweightimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal rotation exercises to strengthen the subscapularis muscle can be performed against resistance provided by tubing or weights, as in this video.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86075 Version 1.0</div></div></div>"},"86076":{"type":"graphic_picture","displayName":"Shoulder internal rotation against resistance","title":"Shoulder internal rotation against resistance","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Shoulder internal rotation against resistance</div><div class=\"cntnt\"><img style=\"width:512px; height:219px;\" src=\"images/EM/86076_Shld_in_rot_ag_resist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anchor tubing&nbsp;to a fixed object&nbsp;(eg, a door knob, banister, or column) and&nbsp;stand perpendicular to the wall holding the tubing in your inside hand. Be sure to keep your elbow bent to 90 degrees throughout the exercise. Pinch a towel or something small between your arm and ribs to be sure your arm stays against your side. Start with your arm about 90 to 100 degrees away from your body and then slowly rotate your arm into your body&nbsp;using a&nbsp;two second count&nbsp;until you touch your&nbsp;abdomen, then slowly return to starting position over&nbsp;a 4 second count. Repeat the movement 15 times to complete one set, then rest 30 seconds. Repeat for 3 sets of 15 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86076 Version 2.0</div></div></div>"},"86078":{"type":"graphic_movie","displayName":"Shoulder internal rotation 90 90 with resistance","title":"Shoulder internal rotation 90 90 position with resistance","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder internal rotation 90 90 position with resistance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86078_Shintrot90resistvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86078_Shintrot90resistimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active internal rotation against resistance, with the arm held in 90 degrees of elbow flexion and 90 degrees of shoulder abduction, is a relatively advanced exercise performed later during rehabiliation.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86078 Version 1.0</div></div></div>"},"86079":{"type":"graphic_movie","displayName":"Shoulder external rotation 90 90 with resistance","title":"Shoulder external rotation 90 90 position with resistance","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation 90 90 position with resistance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86079_Shextrota90resistvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86079_Shextrota90resistimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active external rotation against resistance in a “90-90” position is a relatively advanced rehabilitation exercise to help patients&nbsp;who are ready to begin&nbsp;resuming their usual daily activities.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86079 Version 1.0</div></div></div>"},"86080":{"type":"graphic_movie","displayName":"Shoulder posterior capsule stretch","title":"Shoulder posterior capsule stretch","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Shoulder posterior capsule stretch</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86080_Shpostcapsstretchvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:400px; height:300px;\" src=\"images/EM/86080_Shpostcapsstretchimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stretching of the posterior capsule is performed throughout the rehabilitation of patients with a&nbsp;shoulder impingement syndrome.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86080 Version 1.0</div></div></div>"},"86081":{"type":"graphic_movie","displayName":"Sleeper stretch for shoulder","title":"Sleeper stretch for shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Sleeper stretch for shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86081_Sleeperstretchshvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86081_Sleeperstretchshimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sleeper stretch is included among the flexibility exercises performed throughout the rehabilitation of shoulder impingement syndromes.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86081 Version 1.0</div></div></div>"},"86082":{"type":"graphic_picture","displayName":"Shoulder internal rotation 90 90 position","title":"Shoulder internal rotation in a 90 90 position","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Shoulder internal rotation in a 90 90 position</div><div class=\"cntnt\"><img style=\"width:511px; height:214px;\" src=\"images/EM/86082_Shld_in_rot_90_post.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anchor the tubing at&nbsp;about head height and face away from the object to which it is anchored.&nbsp;Keep&nbsp;the involved arm in a 90-90 position throughout the exercise. Next, rotate your arm forward away from the wall&nbsp;over a two second&nbsp;count until your hand is about even with your shoulder, then slowly return back to the starting position&nbsp;over a&nbsp;four second&nbsp;count. Repeat 15 times to complete one set, then rest 30 seconds. Repeat for 3 sets of 15 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86082 Version 2.0</div></div></div>"},"86083":{"type":"graphic_picture","displayName":"Shoulder external rotation 90 90 position","title":"Shoulder external rotation in a 90 90 position","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation in a 90 90 position</div><div class=\"cntnt\"><img style=\"width:512px; height:203px;\" src=\"images/EM/86083_Shld_ext_rot_90_pos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fix the tubing in front of you about waist height and continue to face the object to which it is anchored. Keep your involved arm in a 90-90 position throughout the exercise. Next, rotate your arm away from the wall&nbsp;over a two second&nbsp;count until your hand is about even with your ear, then slowly&nbsp;rotate your arm back to the starting position&nbsp;over a four second&nbsp;count. Repeat 15 times to complete one set, then rest 30 seconds. Repeat for 3 sets of 15 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86083 Version 2.0</div></div></div>"},"86084":{"type":"graphic_picture","displayName":"Sleeper stretch","title":"Sleeper stretch","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Sleeper stretch</div><div class=\"cntnt\"><img style=\"width:513px; height:200px;\" src=\"images/EM/86084_Sleeper_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on your side with the involved shoulder directly beneath you. Keep the elbow bent at 90 degrees and use the top hand to help rotate the forearm downward (ie, internal rotation). Hold for 30 seconds. Release the pressure for 5 to 10 seconds and repeat. Perform three repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86084 Version 1.0</div></div></div>"},"86085":{"type":"graphic_picture","displayName":"Corner stretch","title":"Corner stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corner stretch</div><div class=\"cntnt\"><img style=\"width:267px; height:541px;\" src=\"images/EM/86085_Corner_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand in the corner with your arms in a 90-90 position and each forearm braced against adjacent walls. Move one foot forward and gently lean forward until you feel a stretch in your chest and shoulders. Hold for 30 seconds. Release the pressure for 5 to 10 seconds and repeat. Perform 3 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86085 Version 1.0</div></div></div>"},"86086":{"type":"graphic_picture","displayName":"Pectoralis minor stretch","title":"Pectoralis minor stretch","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Pectoralis minor stretch</div><div class=\"cntnt\"><img style=\"width:511px; height:209px;\" src=\"images/EM/86086_Pectoralis_min_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand with your elbow straight and your body at about a 45 degree angle from the wall. Raise your hand between waist and chest height and place your palm flush to the wall. Next, rotate your body away from the wall until you feel a stretch in the front of your biceps area. Hold for 30 seconds. Release the pressure for 5 to 10 seconds. Perform 3 repetitions.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86086 Version 1.0</div></div></div>"},"86087":{"type":"graphic_table","displayName":"Pediatric SIRS vital signs and laboratory values by age","title":"Pediatric systemic inflammatory response syndrome vital signs and laboratory values by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric systemic inflammatory response syndrome vital signs and laboratory values by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group</td> <td class=\"subtitle1\" colspan=\"2\">Heart rate (beats/minute)</td> <td class=\"subtitle1\" rowspan=\"2\">Respiratory rate (breaths/minute)</td> <td class=\"subtitle1\" rowspan=\"2\">Leukocyte count (leukocytes x 10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"subtitle1\" rowspan=\"2\">Systolic blood pressure (mmHg)</td> </tr> <tr> <td class=\"subtitle2\">Tachycardia</td> <td class=\"subtitle2\">Bradycardia</td> </tr> <tr> <td>Newborn (0 days to 1 week)</td> <td>&#62;180</td> <td>&#60;100</td> <td>&#62;50</td> <td>&#62;34</td> <td>&#60;59</td> </tr> <tr> <td>Neonate (1 week to 1 month)</td> <td>&#62;180</td> <td>&#60;100</td> <td>&#62;40</td> <td>&#62;19.5 or &#60;5</td> <td>&#60;79</td> </tr> <tr> <td>Infant (1 month to 1 year)</td> <td>&#62;180</td> <td>&#60;90</td> <td>&#62;34</td> <td>&#62;17.5 or &#60;5</td> <td>&#60;75</td> </tr> <tr> <td>Toddler and preschool (&#62;1 to 5 years)</td> <td>&#62;140</td> <td>NA</td> <td>&#62;22</td> <td>&#62;15.5 or &#60;6</td> <td>&#60;74</td> </tr> <tr> <td>School age (&#62;5 to 12 years)</td> <td>&#62;130</td> <td>NA</td> <td>&#62;18</td> <td>&#62;13.5 or &#60;4.5</td> <td>&#60;83</td> </tr> <tr> <td>Adolescent (&#62;12 to &#60;18 years)</td> <td>&#62;110</td> <td>NA</td> <td>&#62;14</td> <td>&#62;11 or &#60;4.5</td> <td>&#60;90</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides the vital sign and laboratory value modifications for the pediatric definition of the systemic inflammatory response syndrome. For the full definition, refer to UpToDate topics on the systemic inflammatory response syndrome (SIRS) and sepsis in children.</div><div class=\"graphic_footnotes\">NA: not applicable.</div><div class=\"graphic_reference\">Originally published in: Goldstein B, Giroir B, Randolph A, et al. International pediatric spesis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2. Correction published in: Gebara BM. Values for systolic blood pressure. Pediatr Crit Care Med 2005; 6:500. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86087 Version 11.0</div></div></div>"},"86088":{"type":"graphic_diagnosticimage","displayName":"Lactotroph macroadenoma shrinkage dopamine","title":"Shrinkage of a lactotroph macroadenoma in response to dopamine agonist treatment","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Shrinkage of a lactotroph macroadenoma in response to dopamine agonist treatment</div><div class=\"cntnt\"><img style=\"width:518px; height:175px;\" src=\"images/ENDO/86088_Lacto_macro_shrink_dop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shrinkage of a lactotroph adenoma in response to treatment with the dopamine agonist cabergoline as shown by post-gadolinium magnetic resonance imaging. A 37-year-old man presented with headaches and was found to have an enormous sellar mass (A, arrow) and a prolactin of 7248 ng/mL. He was treated with cabergoline and after two months the prolactin had decreased to 745 ng/mL and the size of the mass had decreased markedly (B, arrow). After 12 months of cabergoline treatment, the prolactin had decreased to 9.2 ng/mL and the mass had decreased even further (C, arrow).</div><div class=\"graphic_reference\">Courtesy of Julia Kharlip, MD.</div><div id=\"graphicVersion\">Graphic 86088 Version 2.0</div></div></div>"},"86090":{"type":"graphic_table","displayName":"DDx ALCL","title":"Differential diagnosis of anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of anaplastic large cell lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr class=\"divider_bottom\"> <td>ALK-positive anaplastic large cell lymphoma</td> <td>Large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm (\"hallmark cells\"). High proliferative fraction. Often shows a cohesive growth pattern often preferentially in the lymph node sinuses or paracortex.</td> <td>Homogeneous and strong expression of CD30 in a membrane and Golgi pattern. Usually express one or more T cell antigens (ie, CD2, CD3, CD5, CD7). Do not express B cell antigens. CD15 and PAX5/BSAP are negative.</td> <td>ALK positivity can be detected by immunostains or molecular genetics and is universally present. The majority demonstrate rearranged TCR genes.</td> </tr> <tr class=\"divider_bottom\"> <td>ALK-negative anaplastic large cell lymphoma</td> <td>Disease involves the lymph nodes and/or extracutaneous extranodal tissues. Histology resembles ALK-positive ALCL.</td> <td>Immunophenotype similar to ALK-positive ALCL</td> <td>ALK negative. TCR genes rearranged.</td> </tr> <tr class=\"divider_bottom\"> <td>Primary cutaneous anaplastic large cell lymphoma</td> <td>Disease is confined to the skin. Histology resembles ALK-positive ALCL.</td> <td>Immunophenotype similar to ALK-positive ALCL</td> <td>ALK negative. TCR genes rearranged.</td> </tr> <tr class=\"divider_bottom\"> <td>Diffuse large B cell lymphoma</td> <td>Large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction. May morphologically resemble ALCL.</td> <td>Express pan B cell antigens (CD19, CD20, CD22, CD79a). Small subset of tumors with ALK gene rearrangements may be positive for ALK by immunostaining.</td> <td>The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. Rare tumors have ALK gene rearrangements.</td> </tr> <tr> <td>Hodgkin lymphoma</td> <td>The reticular variant of lymphocyte depleted Hodgkin lymphoma may be difficult to distinguish morphologically from ALCL. The HL tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background.</td> <td>The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45. PAX5/BSAP are expressed. T cell antigens are generally negative (rare exceptions). ALK negative.</td> <td>There is no single cytogenetic change that is typical or diagnostic. Carry IgH gene rearrangements. ALK negative.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALK: anaplastic lymphoma kinase gene; ALCL: anaplastic large cell lymphoma; TCR: T cell receptor; HL: Hodgkin lymphoma.</div><div id=\"graphicVersion\">Graphic 86090 Version 3.0</div></div></div>"},"86092":{"type":"graphic_picture","displayName":"Acrokeratosis verruciformis","title":"Acrokeratosis verruciformis of Hopf","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acrokeratosis verruciformis of Hopf</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86092_Acrokeratosis_verruciformis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86092 Version 4.0</div></div></div>"},"86093":{"type":"graphic_picture","displayName":"Acrokeratosis verruciformis punctate keratoses","title":"Acrokeratosis verruciformis of Hopf: Palmar pits and punctate keratoses","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acrokeratosis verruciformis of Hopf: Palmar pits and punctate keratoses</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86093_Acrokera_verru_punc_kera.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86093 Version 5.0</div></div></div>"},"86094":{"type":"graphic_table","displayName":"Features of genetically determined hyper-IgM syndrome","title":"Characteristic features of genetically determined hyperimmunoglobulin M syndrome*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic features of genetically determined hyperimmunoglobulin M syndrome*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Disease</td> </tr> <tr> <td class=\"subtitle2\">CD40L deficiency (HIGM1)</td> <td class=\"subtitle2\">CD40 deficiency (HIGM3)</td> <td class=\"subtitle2\">AID deficiency (HIGM2)</td> <td class=\"subtitle2\">AID deficiency, C-terminus variant</td> <td class=\"subtitle2\">HIGM4</td> <td class=\"subtitle2\">UNG deficiency (HIGM5)</td> </tr> <tr> <td><strong>Gene defect</strong></td> <td><em>CD40LG</em></td> <td><em>CD40</em></td> <td><em>AICDA</em></td> <td><em>AICDA</em></td> <td>Unknown</td> <td><em>UNG</em></td> </tr> <tr> <td><strong>Inheritance</strong></td> <td>XL</td> <td>AR</td> <td>AR</td> <td>AD</td> <td>AR</td> <td>AR</td> </tr> <tr> <td><strong>Type of infections</strong></td> <td>Bacterial<sup>&#182;</sup>, opportunistic<sup>&#916;</sup></td> <td>Bacterial<sup>&#182;</sup>, opportunistic<sup>&#916;</sup></td> <td>Bacterial<sup>&#182;</sup></td> <td>Bacterial<sup>&#182;</sup></td> <td>Bacterial<sup>&#182;</sup></td> <td>Bacterial<sup>&#182;</sup></td> </tr> <tr> <td><strong>Liver/biliary tract disease</strong></td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Autoimmunity</strong></td> <td>Yes, but rare</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Expected, but not reported</td> </tr> <tr> <td><strong>Lymphoid hyperplasia</strong></td> <td>No</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Defect of CSR</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Defect of SHM</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Yes<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Cellular defect</strong></td> <td>T cells and B cells</td> <td>B cells, dendritic cells, monocytes</td> <td>B cells</td> <td>B cells</td> <td>B cells</td> <td>B cells</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD40L: CD40 ligand; HIGM: hyperimmunoglobulin M syndrome (hyper-IgM); AID: activation-induced cytidine deaminase; UNG: uracil N-glycosylase; XL: X-linked; AR: autosomal recessive; AD: autosomal dominant; CSR: class-switch recombination; SHM: somatic hypermutation.<br />* Hyper-IgM syndrome may also occur in some patients with post-meiotic segregation increased 2 protein (PMS2) deficiency, NF-kappa-B essential modifier (NEMO) deficiency, ataxia-telangiectasia, or Nijmegen breakage syndrome.<br />¶ Recurrent sinopulmonary infections are primarily caused by encapsulated bacteria (eg, <EM>Streptococcus pneumoniae</EM> and <EM>Haemophilus influenzae</EM>).<br />Δ Opportunistic infections are primarily caused by <EM>Pneumocystis</EM>, <EM>Cryptosporidium</EM>, and <EM>Histoplasma</EM> organisms.<br /><FONT class=lozenge>◊</FONT> Biased pattern of somatic hypermutation, in which mutations at deoxycytocine (dC)/deoxyguanine (dG) pairs are almost all transitions (G&gt;A and C&gt;T).</div><div id=\"graphicVersion\">Graphic 86094 Version 5.0</div></div></div>"},"86095":{"type":"graphic_table","displayName":"Cryptosporidium infection prevention in CD40L deficiency","title":"Strategies to prevent <EM>Cryptosporidium</EM> infection in patients with CD40L deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to prevent <EM>Cryptosporidium</EM> infection in patients with CD40L deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Drinking water should be boiled and/or filtered</td> </tr> <tr> <td>Avoid swimming in lakes, ponds, and nonchlorinated pools</td> </tr> <tr> <td>Avoid contact with farm animals</td> </tr> <tr> <td>Prophylactic use of azithromycin may reduce the risk of infection&nbsp;and is usually indicated, but its long-term efficacy in preventing<em> Cryptosporidium</em> infection is not known</td> </tr> <tr> <td>In addition, the following surveillance studies should be done every 6 to 12 months: <ul> <li>Test the stools by polymerase chain reaction (PCR) for the presence of <em>Cryptosporidium </em></li> <li>Perform liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transpeptidase [GGT], alkaline phosphatase, bilirubin) </li> <li>Liver ultrasound </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD40L: CD40 ligand.</div><div id=\"graphicVersion\">Graphic 86095 Version 4.0</div></div></div>"},"86096":{"type":"graphic_figure","displayName":"Anterior neck anatomy dissection","title":"Anterior neck anatomy dissection","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Anterior neck anatomy dissection</div><div class=\"cntnt\"><img style=\"width:610px; height:399px;\" src=\"images/EM/86096_Antneckanatomydissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 6th ed, Moore KL, Dalley AF, Agur AM (Ed), Lippincott Williams &amp; Wilkins, Baltimore, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86096 Version 6.0</div></div></div>"},"86097":{"type":"graphic_figure","displayName":"Primary surgical repair for truncus arteriosus","title":"Primary surgical repair for truncus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Primary surgical repair for truncus arteriosus</div><div class=\"cntnt\"><img style=\"width:492px; height:534px;\" src=\"images/PEDS/86097_Repairtruncarterios.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repair of simple truncus arteriosus.<br />(A) The infant is placed on cardiopulmonary bypass with either bicaval cannulation or single venous cannulation in the right atrium. The aorta is cannulated as distally as possible to allow cross-clamping proximal to the aortic cannulation site for division of the pulmonary arteries from the truncal vessel. Snares are placed on the right and left pulmonary arteries to prevent pulmonary overcirculation during warming and to allow delivery of cardioplegic solution to the myocardium. After cardioplegia is achieved, the snares are released from the pulmonary arteries and the pulmonary bifurcation is excised from the back of the truncal artery, with care being taken to avoid the origin of the left coronary artery posteriorly. An incision is made in the right ventricle, with care being taken to avoid major epicardial coronary branches and the base of the truncal valve.<br />(B) The defect in the main trunk is closed with a patch of pulmonary homograft material or pericardium. Cardioplegic solution is then administered to observe any leaking of the suture line because the area will be difficult to expose after complete repair. The VSD is exposed through the ventriculotomy incision. There is no muscle rim typically present at the superior margin of the VSD, and therefore the patch is secured to the epicardial portion of the ventriculotomy incision superiorly.<br />(C) The VSD is closed with an ovoid patch of polyethylene terephthalate (Dacron) material sewn to the superior margin of the ventriculotomy incision. Typically, a rim of muscle is present inferiorly between the ventricular septal defect and the tricuspid valve septal leaflet, and in these patients a running suture line can be created that avoids the conduction tissue. If the muscle bridge is not present, the inferior margin of the suture line is carried along the base of the septal tricuspid valve leaflet on the right ventricular aspect to avoid the conducting tissue.<br />(D) The pulmonary arteries are reconstructed with a pulmonary homograft. To prevent kinking of the homograft with distention, it is trimmed 2 to 3 mm distal to the commissural attachments of the pulmonary valve. To provide an adequate anastomosis and size match to the pulmonary bifurcation using a large pulmonary homograft of 12 to 18 mm in diameter, an incision is carried into the origin of the right pulmonary artery for a short distance and more significantly into the left pulmonary artery if additional opening is necessary. An anastomosis is then created between the pulmonary homograft and the pulmonary bifurcation.<br />(E) The pulmonary homograft is then sewn proximally to the superior aspect of the ventriculotomy incision for approximately one-third of its circumference. If adequate muscle is present on the pulmonary homograft, it can be sewn directly down to the right ventricular outflow tract. However, if inadequate tissue is present, the outflow tract is augmented with a gusset of polytetrafluoroethylene (PTFE) material, as shown in the inset, to create a gentle take-off of the homograft from the right ventricular outflow tract to avoid compression.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; VSD: ventricular septal defect; PTFE: polytetrafluoroethylene.</div><div class=\"graphic_reference\">Reproduced with permission from: Spray TL. Truncus arteriosus. In: Mastery of Cardiothoracic Surgery, 2nd ed, Kaiser LR, Kron IL, Spray TL (Eds), Lippincott William &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 86097 Version 7.0</div></div></div>"},"86104":{"type":"graphic_figure","displayName":"Conventional manometry and HRM with EPT","title":"Conventional manometry and high resolution manometry with esophageal pressure topography","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Conventional manometry and high resolution manometry with esophageal pressure topography</div><div class=\"cntnt\"><img style=\"width:617px; height:491px;\" src=\"images/GAST/86104_Conv_manometry_HRM_EPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Manometry quantifies intraluminal esophageal and LES pressure during swallowing to detect abnormalities of peristalsis and sphincter relaxation. Conventional manometry achieved this with relatively few pressure sensors (red dots in schematic on the left and red lines in the center panel). Hence data from conventional manometry can only be accurately displayed as pressure versus time plots as in the center panel with large gaps in the esophageal lumen between pressure recording sites. High resolution manometry fills these gaps with a multitude of closely spaced pressure sensors (blue dots in the schematic on the left and white lines in the center panel). Alternatively, high resolution manometry can be displayed as a \"Clouse plot\" in esophageal pressure topography as in the right panel with pressure plotted as a continuum, interpolating values between the closely spaced sensors and displaying the pressure magnitude by color. When displayed in pressure topographic, stereotypic features of the topographic architecture of the peristaltic contraction become evident, labeled as the 1st, 2nd, 3rd, and 4th contractile segments and the proximal, middle, and distal pressure troughs. The 4th contractile segment is the LES. The onset of the swallow, timed by upper sphincter relaxation, is indicated by the vertical dotted line.</div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter; CDP: contractile deceleration point; EGJ: esophagogastric junction; CS: contractile segment; s: second; LES: lower esophageal sphincter.</div><div id=\"graphicVersion\">Graphic 86104 Version 2.0</div></div></div>"},"86107":{"type":"graphic_figure","displayName":"Subtypes of EGJ pressure morphology on EPT","title":"Subtypes of esophagogastric junction pressure morphology on esophageal pressure topography","html":"<div class=\"graphic\"><div style=\"width: 1023px\" class=\"figure\"><div class=\"ttl\">Subtypes of esophagogastric junction pressure morphology on esophageal pressure topography</div><div class=\"cntnt\"><img style=\"width:1003px; height:604px;\" src=\"images/GAST/86107_Sbtyp_EGJ_prs_mrphl_EPT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EGJ morphology subtypes. For each panel, the instantaneous spatial pressure variation plot corresponding to the red line on the pressure topography plot is illustrated by the black line to the right. The spatial pressure variation plot illustrates the pressure profile from top to bottom, interpolating intermediate values between the measured values that occur at 1 cm intervals. The two main EGJ components are the LES and CD, which cannot be independently quantified when they are superimposed as with a type I EGJ (panel A). The RIP, shown by the white horizontal dashed line, lies near the proximal margin of the EGJ. During inspiration (I) EGJ pressure increases, whereas it decreases during expiration (E).<br />Type II EGJ pressure morphology is illustrated in panel B. Note the two peaks on the instantaneous spatial pressure variation plot; the nadir pressure between the peaks is greater than the intragastric pressure. The RIP is at the level of the CD.<br />Panels C and D correspond to type III EGJ pressure morphology, defined as the presence of two peaks of the instantaneous spatial pressure variation plot with the nadir pressure between the peaks equal to or less than intragastric pressure. The RIP is at the CD with type IIIa (panel C), whereas it is at the level of the LES in type IIIb (panel D).</div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction; s: seconds; LES: lower esophageal sphincter; CD: crural diaphragm; E: expiration; I: inspiration; RIP: respiratory inversion point.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al, and The International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</A>. Copyright © 2015. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 86107 Version 3.0</div></div></div>"},"86108":{"type":"graphic_figure","displayName":"Localization of the CDP and measurement of DL on EPT plot","title":"Localization of the contractile deceleration point (CDP) and measurement of distal latency (DL) on an esophageal pressure topography plot","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Localization of the contractile deceleration point (CDP) and measurement of distal latency (DL) on an esophageal pressure topography plot</div><div class=\"cntnt\"><img style=\"width:604px; height:464px;\" src=\"images/GAST/86108_Local_CDP_meas_DL_EPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologically, the CDP is the landmark in the distal esophagus where bolus transport transitions from peristalsis to the globular phrenic ampulla (note the conformation of the ampulla distal to the CDP in the fluoroscopy inset). On the pressure topography plot, the CDP is localized by the intersection of tangents drawn to the 30 mmHg isobaric contour (black line) for the early and late phases of the contraction. Note that for the early phase of the contraction (peristalsis), the slope of the tangent is the CFV, indicative of the propagation velocity of peristalsis. The DL, a measure of whether or not the distal esophageal contraction is timely or premature, is measured as the interval between UES relaxation and the CDP, with 4.5 seconds being the lower limit of normal.</div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter; CDP: contractile deceleration point; CFV: contractile front velocity; EGJ: esophagogastric junction; S: second; DL: distal latency.</div><div id=\"graphicVersion\">Graphic 86108 Version 2.0</div></div></div>"},"86112":{"type":"graphic_figure","displayName":"Measurement of IRP on EPT plot","title":"Measurement of integrated relaxation pressure (IRP) on an esophageal pressure topography plot","html":"<div class=\"graphic\"><div style=\"width: 941px\" class=\"figure\"><div class=\"ttl\">Measurement of integrated relaxation pressure (IRP) on an esophageal pressure topography plot</div><div class=\"cntnt\"><img style=\"width:921px; height:592px;\" src=\"images/GAST/86112_Measurement_IRP_EPT_plot.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The IRP is a complex metric that involves localizing the margins of the esophagogastric junction (EGJ), demarcating the time window following deglutitive upper sphincter relaxation within which EGJ relaxation will occur, and applying an e-sleeve measurement within that 10-second time box. The IRP pressure in mmHg is the mean pressure during the four seconds during which the e-sleeve value was least. In this example, the heavy black line is the 8 mmHg isobaric contour, which isolates the 4 seconds of maximal EGJ relaxation, interrupted by a crural contraction. The IRP value (5.3 mmHg) is the mean e-sleeve pressure during the two time intervals circumscribed with ovals.</div><div id=\"graphicVersion\">Graphic 86112 Version 2.0</div></div></div>"},"86115":{"type":"graphic_figure","displayName":"Contractile vigor and contraction pattern","title":"Contractile vigor and contraction pattern","html":"<div class=\"graphic\"><div style=\"width: 1088px\" class=\"figure\"><div class=\"ttl\">Contractile vigor and contraction pattern</div><div class=\"cntnt\"><img style=\"width:1068px; height:691px;\" src=\"images/GAST/86115_Cntrctl_vgr_cntrct_pttrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contractile vigor is assessed using the DCI: a contraction with a DCI &lt;100 mmHg&bull;s&bull;cm is failed (panel A), a contraction with a DCI &gt;100 but &lt;450 mmHg&bull;s&bull;cm is weak (panel B), and a hypercontractile swallow is defined as a DCI &gt;8000 mmHg&bull;s&bull;cm (panel C). Premature contraction is defined as a DL &lt;4.5 seconds (panel D). A weak contraction (DCI &lt;450 mmHg&bull;s&bull;cm) with a reduced distal latency is considered failed (panel E). A contraction with a normal DCI (450 to 8000 mmHg&bull;s&bull;cm) and a large break in the 20 mmHg isobaric contour (&gt;5 cm) is a fragmented contraction (panel F).</div><div class=\"graphic_footnotes\">DCI: distal contractile integral; DL: distal latency.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al, and The International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</a>. Copyright &copy; 2015. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 86115 Version 2.0</div></div></div>"},"86116":{"type":"graphic_figure","displayName":"Computing the DCI using EPT","title":"Computing the distal contractile integral (DCI) using esophageal pressure topography","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Computing the distal contractile integral (DCI) using esophageal pressure topography</div><div class=\"cntnt\"><img style=\"width:602px; height:458px;\" src=\"images/GAST/86116_Computing_DCI_EPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;DCI is the measure of the vigor of the distal esophageal contraction utilized in the Chicago Classification. As such it is measured between the proximal and distal pressure troughs for the duration of contraction within this region. To exclude vascular artifacts and intrabolus pressures from the measurement, only pressures greater than 20 mmHg are considered. Hence, the sum of all pressures within the white dotted rectangle in the figure equals the DCI; the units of measurement for the DCI are mmHg-s-cm.</div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter; EGJ: esophagogastric junction; s: seconds; DCI:&nbsp;distal contractile integral.</div><div id=\"graphicVersion\">Graphic 86116 Version 2.0</div></div></div>"},"86117":{"type":"graphic_figure","displayName":"Patterns of esophageal pressurization in EPT","title":"Patterns of esophageal pressurization in esophageal pressure topography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Patterns of esophageal pressurization in esophageal pressure topography</div><div class=\"cntnt\"><img style=\"width:599px; height:395px;\" src=\"images/GAST/86117_Patterns_esoph_press_EPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With compartmentalized pressurization (panel A) the swallowed bolus becomes trapped between the advancing peristaltic contraction and the outflow obstruction caused by a poorly relaxing EGJ in a patient with EGJ outflow obstruction. The black line indicated the 30 mmHg isobaric contour signifying that the compartmentalized pressurization exceeds 30 mmHg. Panel B illustrates panesophageal pressurization, spanning from the UES to the EGJ in a patient with type II achalasia. This patient also exhibits proximal esophageal pressurization associated with an isolated distal contraction later in that plot. Areas of bolus pressurization are characterized by areas of vertical lines on the 30 mmHg isobaric contour; they can be conceptualized as being the result of multiple pressure sensors being contained within an isobaric enclosed space.</div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction; UES: upper esophageal sphincter.</div><div id=\"graphicVersion\">Graphic 86117 Version 2.0</div></div></div>"},"86118":{"type":"graphic_algorithm","displayName":"Chicago Classification stepwise algorithm interpretation of EPT","title":"Stepwise algorithm using the Chicago Classification for the interpretation of esophageal pressure topography (EPT)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Stepwise algorithm using the Chicago Classification for the interpretation of esophageal pressure topography (EPT)</div><div class=\"cntnt\"><img style=\"width:720px; height:514px;\" src=\"images/GAST/86118_Chicago_class_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IRP: integrated relaxation pressure; ULN: upper limit of normal; PEP: panesophageal pressurization; DL: distal latency; EGJ: esophagogastric junction; DCI: distal contractile integral.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</a>. Copyright &copy; 2014. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 86118 Version 3.0</div></div></div>"},"86119":{"type":"graphic_table","displayName":"Pressure topography metrics in the Chicago Classification","title":"Pressure topography metrics utilized in the Chicago Classification version 3.0 along with their closest equivalent in conventional manometry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pressure topography metrics utilized in the Chicago Classification version 3.0 along with their closest equivalent in conventional manometry</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Conventional manometry correlate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Contractile deceleration point</strong><br /> (time, position)*</td> <td>Inflection point along the 30 mmHg isobaric contour (or pressure greater than intrabolus pressure in instances of compartmentalized pressurization) at which propagation velocity slows, demarcating peristalsis from ampullary emptying. The CDP must be localized within 3 cm of the proximal margin of the LES.</td> <td>No correlate in conventional manometry</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Distal contractile integral</strong><br /> (mmHg&#8226;s&#8226;cm)<sup>&#182;</sup></td> <td>Amplitude x duration x length (mmHg&#8226;s&#8226;cm) of the distal esophageal contraction exceeding 20 mmHg between the transition zone and the proximal margin of the LES</td> <td>Average of 10 swallows at two recording sites positioned 3 and 8 cm above the LES <ul class=\"decimal_heading\"> <li>Nutcracker &#62;180 mmHg </li> <li>Revised definitions &#62;220 to 260 mmHg </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Distal latency</strong><br /> (seconds)*</td> <td>Interval between UES relaxation and the CDP (&#60;4.5 seconds is abnormal)</td> <td>No correlate in conventional manometry</td> </tr> <tr> <td><strong>Integrated relaxation pressure</strong><br /> (mmHg)<sup>&#182;</sup></td> <td>Mean of the 4 seconds of maximal EGJ relaxation in the 10-second window beginning at UES relaxation, referenced to gastric pressure. Contributing times can be interrupted by diaphragmatic contractions (&#62;15 mmHg is abnormal).</td> <td>LES measured with best estimate through the LES (&#62;8 mmHg is abnormal)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CDP: contractile deceleration point; LES: lower esophageal sphincter; UES: upper esophageal sphincter; EGJ: esophagogastric junction.<br />* Normal values are independent of the manometric hardware utilized.<br />&para; Normal values are dependent on the specific manometric hardware utilized.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</a>. Copyright &copy; 2014. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 86119 Version 2.0</div></div></div>"},"86120":{"type":"graphic_table","displayName":"The Chicago Classification 3.0 esophageal motility","title":"The Chicago Classification (version 3.0) of esophageal motility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Chicago Classification (version 3.0) of esophageal motility</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Achalasia and EGJ outflow obstruction</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td>Type I achalasia (classic achalasia)</td> <td> <p>Elevated median IRP (&#62;15 mmHg*), 100% failed peristalsis (DCI &#60;100 mmHg).</p> Premature contractions with DCI values less than 450 mmHg&#8226;s&#8226;cm satisfy criteria for failed peristalsis.</td> </tr> <tr> <td>Type II achalasia (with esophageal compression)</td> <td> <p>Elevated median IRP (&#62;15 mmHg*), 100% failed peristalsis, panesophageal pressurization with &#8805;20% of swallows.</p> Contractions may be masked by esophageal pressurization and DCI should not be calculated.</td> </tr> <tr> <td>Type III achalasia (spastic achalasia)</td> <td> <p>Elevated median IRP (&#62;15 mmHg*), no normal peristalsis, premature (spastic) contractions with DCI &#62;450 mmHg&#8226;s&#8226;cm with &#8805;20% of swallows.</p> May be mixed with panesophageal pressurization.</td> </tr> <tr> <td>EGJ outflow obstruction</td> <td>Elevated median IRP (&#62;15 mmHg*), sufficient evidence of peristalsis such that criteria for types I to III achalasia are not met.<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1\">Major disorders of peristalsis</td> <td class=\"subtitle1\">(Not encountered in normal subjects)</td> </tr> <tr> <td>Absent contractility</td> <td> <p>Normal median IRP, 100% failed peristalsis.</p> <p>Achalasia should be considered when IRP values are borderline and when there is evidence of esophageal pressurization.</p> Premature contractions with DCI values less than 450 mmHg&#8226;s&#8226;cm meet criteria for failed peristalsis.</td> </tr> <tr> <td>Distal esophageal spasm</td> <td>Normal median IRP, &#8805;20% premature contractions with DCI &#62;450 mmHg&#8226;s&#8226;cm*. Some normal peristalsis may be present.</td> </tr> <tr> <td>Hypercontractile esophagus (jackhammer)</td> <td> <p>At least two swallows with DCI &#62;8000 mmHg&#8226;s&#8226;cm.*<sup>&#916;</sup></p> Hypercontractility may involve, or even be localized to, the LES.</td> </tr> <tr> <td class=\"subtitle1\">Minor disorders of peristalsis</td> <td class=\"subtitle1\">(Characterized by contractile vigor and contraction pattern)</td> </tr> <tr> <td>Ineffective esophageal motility (IEM)</td> <td> <p>&#8805;50% ineffective swallows.</p> <p>Ineffective swallows can be failed or weak (DCI &#60;450 mmHg&#8226;s&#8226;cm).</p> Multiple repetitive swallow assessment may be helpful in determining peristaltic reserve.</td> </tr> <tr> <td>Fragmented peristalsis</td> <td>&#8805;50% fragmented contractions with DCI &#62;450 mmHg&#8226;s&#8226;cm.</td> </tr> <tr> <td class=\"subtitle1\">Normal esophageal motility</td> <td class=\"subtitle1\">Not fulfilling any of the above classifications.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction; IRP: integrated relaxation pressure; DCI: distal contractile integral; LES: lower esophageal sphincter.<br />* Cutoff value dependent on the manometric hardware; this is the cutoff for the Sierra device.<br />&para; Potential etiologies: early achalasia, mechanical obstruction, esophageal wall stiffness, or manifestation of hiatal hernia.<br />&Delta; Hypercontractile esophagus can be a manifestation of outflow obstruction as evident by instances in which it occurs in association with an IRP greater than the upper limit of normal.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</a>. Copyright &copy; 2014. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 86120 Version 2.0</div></div></div>"},"86138":{"type":"graphic_figure","displayName":"Anatomic landmarks for emergency cricothyrotomy","title":"Anatomic landmarks for emergency cricothyrotomy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Anatomic landmarks for emergency cricothyrotomy</div><div class=\"cntnt\"><img style=\"width:541px; height:346px;\" src=\"images/EM/86138_Landmarks-cricothyrotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Understanding of the local anatomy is critical to the performance of cricothyrotomy. The laryngeal prominence forms the superior edge of the thyroid cartilage, where there&nbsp;is often a prominent, palpable&nbsp;“V-shaped” notch. The vocal cords are housed within and protected by the thyroid cartilage. The hyoid bone lies cephalad to the thyroid cartilage and in patients where the thyroid cartilage is not prominent&nbsp;it&nbsp;can be mistaken for the thyroid prominence. The cricoid cartilage is a complete cartilaginous ring located caudal to the thyroid cartilage. The cricothyroid membrane lies between the thyroid and cricoid cartiages.</div><div id=\"graphicVersion\">Graphic 86138 Version 2.0</div></div></div>"},"86141":{"type":"graphic_figure","displayName":"HeartMate XVE","title":"The HeartMate XVE pulsatile left ventricular assist device ","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">The HeartMate XVE pulsatile left ventricular assist device </div><div class=\"cntnt\"><img style=\"width:510px; height:572px;\" src=\"images/CARD/86141_Heartmate_XVE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with the permission of Thoratec Corporation.</div><div id=\"graphicVersion\">Graphic 86141 Version 1.0</div></div></div>"},"86142":{"type":"graphic_figure","displayName":"HeartMate II","title":"The HeartMate II axial flow left ventricular assist device ","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">The HeartMate II axial flow left ventricular assist device </div><div class=\"cntnt\"><img style=\"width:473px; height:526px;\" src=\"images/CARD/86142_Heartmate_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with the permission of: Thoratec Corporation.</div><div id=\"graphicVersion\">Graphic 86142 Version 1.0</div></div></div>"},"86143":{"type":"graphic_figure","displayName":"Jarvik 2000 LVAD","title":"The Jarvik 2000 left ventricular assist device","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">The Jarvik 2000 left ventricular assist device</div><div class=\"cntnt\"><img style=\"width:598px; height:573px;\" src=\"images/CARD/86143_Jarvik_2000_LVAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the intraventricular position of the device.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2012 Jarvik Heart, Inc. www.jarvikheart.com/.</div><div id=\"graphicVersion\">Graphic 86143 Version 2.0</div></div></div>"},"86144":{"type":"graphic_figure","displayName":"HeartWare LVAD","title":"The HeartWare Ventricular Assist System","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">The HeartWare Ventricular Assist System</div><div class=\"cntnt\"><img style=\"width:576px; height:576px;\" src=\"images/CARD/86144_HeartWare_LVAD_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the rotor is magnetically levitated.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2012 HeartWare, Inc. www.heartware.com.</div><div id=\"graphicVersion\">Graphic 86144 Version 2.0</div></div></div>"},"86145":{"type":"graphic_figure","displayName":"The SynCardia Total Artificial Heart","title":"The SynCardia Total Artificial Heart ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The SynCardia Total Artificial Heart </div><div class=\"cntnt\"><img style=\"width:343px; height:540px;\" src=\"images/CARD/86145_SynCardia_total_arti_heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy: syncardia.com. Reproduced with permission. Copyright &copy; 2013 SynCardia Systems, Inc.</div><div id=\"graphicVersion\">Graphic 86145 Version 1.0</div></div></div>"},"86161":{"type":"graphic_table","displayName":"Treatment NTM children","title":"Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Usual maximum daily dose</td> <td class=\"subtitle1\">Potential adverse effects and target dose ranges</td> </tr> <tr class=\"divider_bottom\"> <td>Amikacin*<sup>&#182;</sup></td> <td> <p>15 to 30 mg/kg per day divided in three doses <strong>or</strong> 15 to 20 mg/kg once daily for daily dosing;</p> 25 mg/kg per day in one dose for three times per week dosing<sup>&#916;</sup></td> <td>IV, IM</td> <td>1.5 g/day</td> <td> <p>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity</p> <p>For every eight hour dosing*: Adjust dose for trough &#60;3 to 5 mcg/mL and peak 20 to 25 mcg/mL</p> For once daily dosing*: Adjust dose for trough 0.5 to 1 mcg/mL (at 18 hours) and peak 40 to 50 mcg/mL</td> </tr> <tr class=\"divider_bottom\"> <td>Azithromycin</td> <td> <p>5 to 12 mg/kg per day in one dose for daily dosing;</p> 10 mg/kg per day in one dose for three times per week dosing</td> <td>Oral, IV</td> <td> <p>Oral: 600 mg/day</p> IV: 500 mg/day</td> <td>Prolongation of the QT interval; nausea; vomiting; diarrhea; decreased hearing; dizziness; hepatitis; phlebitis (IV)</td> </tr> <tr class=\"divider_bottom\"> <td>Cefoxitin<sup>&#182;</sup></td> <td>160 mg/kg per day divided in four doses</td> <td>IV, IM</td> <td>12 g/day</td> <td>Bone marrow suppression; interstitial nephritis; hypersensitivity (fever, rash); may interfere with serum creatinine assay (falsely elevates creatinine)</td> </tr> <tr class=\"divider_bottom\"> <td>Ciprofloxacin<sup>&#182;</sup></td> <td>20 mg/kg per day divided in two doses</td> <td>Oral, IV</td> <td> <p>Oral: 1.5 g/day</p> IV: 800 mg/day</td> <td>Tendon damage; prolongation of the QT interval; CNS stimulation; nausea; vomiting; diarrhea</td> </tr> <tr class=\"divider_bottom\"> <td>Clarithromycin<sup>&#182;</sup></td> <td>15 to 30 mg/kg per day divided in two doses (for daily or three times per week dosing)<sup>&#916;</sup></td> <td>Oral</td> <td>1 g/day</td> <td>Prolongation of the QT interval; nausea; vomiting; diarrhea; taste disturbance; decreased hearing; hepatitis<sup>&#9674;</sup>; anterior uveitis<sup>&#9674;</sup>; arthralgia<sup>&#9674;</sup>; granulocytopenia<sup>&#9674;</sup>; significant drug-drug interactions (particularly with rifamycins)</td> </tr> <tr class=\"divider_bottom\"> <td>Doxycycline</td> <td>2 to 4 mg/kg per day in one or two doses</td> <td>Oral, IV</td> <td>200 mg/day</td> <td>Tooth discoloration in children &#60;8 years; nausea; vomiting; diarrhea; photosensitivity; rash; hyperpigmentation; phlebitis (IV); and injection site pain (IV)</td> </tr> <tr class=\"divider_bottom\"> <td>Ethambutol<sup>&#182;</sup></td> <td> <p>15 mg/kg per day in one dose for daily dosing;</p> 25 mg/kg per day in one dose for three times per week dosing<sup>&#916;</sup></td> <td>Oral</td> <td>2.5 g/day</td> <td>Optic neuritis (usually reversible)<sup>&#167;</sup>; red-green color blindness<sup>&#165;</sup>; gastrointestinal disturbances; hypersensitivity</td> </tr> <tr class=\"divider_bottom\"> <td>Isoniazid</td> <td> <p>5 mg/kg per day for NTM infection;</p> 10 to 15<sup>&#135; </sup>mg/kg per day in one dose if cannot definitively exclude&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><em>Mycobacterium</em></span><em> tuberculosis</em></td> <td>Oral, IM</td> <td>300 mg/day</td> <td> <p>Mild hepatic enzyme elevation; hepatitis<sup>&#135;</sup>; peripheral neuritis; hypersensitivity (fever, rash); diarrhea and gastric irritation (caused by vehicle in syrup)</p> Pyridoxine supplementation of 1 to 2 mg/kg per day (up to 50 mg/day) is suggested to prevent peripheral neuropathy in exclusively breastfed infants, children and adolescents on meat- and milk-deficient diets, children with nutritional deficiencies, children and adolescents with symptomatic HIV infection, and pregnant adolescents</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin<sup>&#182;</sup></td> <td> <p>&#60;5 years: 20 mg/kg per day in two doses;</p> &#8805;5 years: 10 mg/kg once daily</td> <td>Oral, IV</td> <td>500 mg/day</td> <td>Tendon damage; CNS stimulation; nausea; vomiting; diarrhea</td> </tr> <tr class=\"divider_bottom\"> <td>Linezolid</td> <td> <p>&#60;12 years: 30 mg/kg per day in three doses;</p> &#8805;12 years: 600 mg twice per day</td> <td>Oral, IV</td> <td>1200 mg/day</td> <td>Nausea; vomiting; diarrhea; leukopenia; anemia; thrombocytopenia; pancytopenia; peripheral neuropathy; optic neuritis; serotonin syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Meropenem<sup>&#182;</sup></td> <td> <p>&#60;50 kg: 30 to 60 mg/kg per day divided in three doses;</p> &#8805;50 kg: 3 g/day in three divided doses</td> <td>IV</td> <td>3 g/day</td> <td>May lower seizure threshold; bone marrow suppression; interstitial nephritis</td> </tr> <tr class=\"divider_bottom\"> <td>Moxifloxacin</td> <td>400 mg per day in one dose (for adolescents)</td> <td>Oral</td> <td>400 mg/day</td> <td>Tendon damage; CNS stimulation; nausea; vomiting; diarrhea</td> </tr> <tr class=\"divider_bottom\"> <td>Pyrazinamide<sup>&#182;</sup></td> <td> <p>30 to 40 mg/kg per day for daily dosing;</p> <p>50 mg/kg per day for twice weekly dosing</p> </td> <td>Oral</td> <td>2 g/day</td> <td>Arthralgia; gastrointestinal tract upset; hepatotoxicity; hyperuricemia&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Rifabutin<sup>&#182;</sup><sup>&#134;</sup></td> <td>10 to 20 mg/kg per day in one dose (for daily or three times per week dosing)</td> <td>Oral</td> <td>300 mg/day</td> <td>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis<sup>&#9674;</sup>; \"flu-like\" syndrome; thrombocytopenia; renal failure; myalgia; arthralgia<sup>&#9674;</sup>; granulocytopenia<sup>&#9674;</sup>; anterior uveitis<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Rifampin (rifampicin)<sup>&#134;</sup></td> <td>10 to 20 mg/kg per day in one dose (for daily or three times per week dosing)</td> <td>Oral, IV</td> <td>600 mg/day</td> <td>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis; \"flu-like\" syndrome; thrombocytopenia; renal failure; multiple significant drug-drug interactions</td> </tr> <tr class=\"divider_bottom\"> <td>Streptomycin*<sup>&#182;</sup></td> <td>15 to 40 mg/kg per day in one dose or in two divided doses (preferred for IV)</td> <td>IM, IV (if IM not tolerated)</td> <td>1 g/day</td> <td> <p>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity; hypersensitivity reaction</p> Adjust dose for trough &#60;3 to 5 mcg/mL and peak 15 to 30 mcg/mL for every 12 hour dosing*</td> </tr> <tr class=\"divider_bottom\"> <td>Tobramycin*<sup>&#182;</sup></td> <td>7.5 mg/kg per day in three doses or 7 mg/kg once daily</td> <td>IM, IV</td> <td>300 mg/day</td> <td> <p>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity</p> <p>For every&nbsp;eight hour dosing*: Adjust dose for trough &#60;1 mcg/mL and peak 6 to 8 mcg/mL</p> For once daily dosing*: Adjust dose for trough &#60;1 mcg/mL at 18 hours and peak 15 to 22 mcg/mL</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole<sup>&#182;</sup><br /> (TMP-SMX, cotrimoxazole)</td> <td>8 to 12 mg/kg per day of the TMP component divided in two doses</td> <td>Oral, IV</td> <td>320 mg/day of TMP component</td> <td>Rash; hypersensitivity reaction (fever, rash, Stevens-Johnson syndrome); bone marrow suppression; nausea; vomiting; diarrhea; IV formulation requires substantial dilution, which may result in large volumes (which may be problematic for patients with renal insufficiency or fluid overload)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Combinations of two to four of the above agents are selected based upon type of NTM infection and susceptibility testing. Consultation with a specialist in infectious diseases may be warranted. (Please refer to UpToDate topics on NTM infections in children.)</div><div class=\"graphic_footnotes\">NTM: nontuberculous mycobacterial infection (also known as atypical mycobacterial infection); IV: intravenous; IM: intramuscular; CNS: central nervous system; HIV: human immunodeficiency virus.<br />* Monitor drug levels to ensure efficacy and avoid toxicity. The targeted range varies depending upon the clinical syndrome, patient characteristics (eg, cystic fibrosis), and the institution. Consultation with an infectious diseases specialist or pharmacist regarding the appropriate therapeutic range is suggested. Aminoglycoside toxicity is dependent upon duration of treatment and aminoglycoside-free period of dosing interval. (Refer to UpToDate topic on aminoglycosides.)<br />¶ Doses are for children with normal renal function.<br />Δ Clinical data in adults indicate that three-times-weekly therapy is as effective as daily therapy, with reduced toxicity, for mild to moderate disease.<br /><FONT class=lozenge>◊</FONT> Anterior uveitis, arthralgia, neutropenia, and liver function abnormalities may occur when clarithromycin is used in combination with rifabutin.<br />§ Usually reversible; rare at doses of 15 to 25 mg/kg in children with normal renal function.<br />¥ Rarely occurs in children, who metabolize ethambutol more rapidly than adults.<br />‡ The incidence of hepatotoxicity may be increased when isoniazid doses &gt;10 mg/kg are used in combination with rifampin.<br />† Dose may require modification based upon drug-drug interactions, particularly with clarithromycin.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antimicrobial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS&nbsp;(Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tuberculosis. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.805.</LI>&#xD;&#xA;<LI>Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: Literature review and recommendations. Int J Tuberc Lung Dis 2006; 10:1318.</LI>&#xD;&#xA;<LI>Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</LI>&#xD;&#xA;<LI>Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 86161 Version 12.0</div></div></div>"},"86162":{"type":"graphic_picture","displayName":"Disseminated NTM skin lesions","title":"Cutaneous lesions in disseminated nontuberculous mycobacteria infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesions in disseminated nontuberculous mycobacteria infection</div><div class=\"cntnt\"><img style=\"width:540px; height:351px;\" src=\"images/PEDS/86162_DisseminatNTMskinlesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disseminated nontuberculous mycobacteria with generalized cutaneous lesions in a boy with acute lymphoblastic leukemia in remission.</div><div class=\"graphic_reference\">From: American Academy of Pediatrics. Diseases Caused by Nontuberculous Mycobacteria (Atypical Mycobacteria, Mycobacteria Other Than Mycobacterium tuberculosis). Red Book: 2012 Report of the Committee on Infectious Diseases, 29<SUP>th</SUP> ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Copyright © 2012 American Academy of Pediatrics. Used with permission.</div><div id=\"graphicVersion\">Graphic 86162 Version 10.0</div></div></div>"},"86165":{"type":"graphic_figure","displayName":"Development of the atrial septum primum","title":"Development of the atrial septum primum","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Development of the atrial septum primum</div><div class=\"cntnt\"><img style=\"width:541px; height:486px;\" src=\"images/PEDS/86165_Development-of-the-atrial-septum-primum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86165 Version 2.0</div></div></div>"},"86166":{"type":"graphic_table","displayName":"Testosterone treatment PI","title":"Androgen replacement medicines (testosterone)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Androgen replacement medicines (testosterone)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Brand name in US</td> <td class=\"subtitle1\">How it's given</td> <td class=\"subtitle1\">How often it's used</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td> <p>Delatestryl (testosterone enanthate)</p> <p>Depo-Testosterone (testosterone cypionate)</p> </td> <td>Injection (shot)</td> <td>Every 1 to 2 weeks</td> <td>Shot can be given at home. Hormone levels can go up and down between shots.&nbsp; May cost less than other testosterone medicines.</td> </tr> <tr> <td>Androderm</td> <td>Patch worn on arm or upper body</td> <td>Every night</td> <td>Can cause a skin rash in some people.</td> </tr> <tr> <td>AndroGel</td> <td>Gel put on the upper arm, shoulder, or belly (only put 1% strength on belly, not 1.62%)</td> <td>Every morning</td> <td>Comes in different strengths. Pump bottle gives exact dose.</td> </tr> <tr> <td>Testim</td> <td>Gel put on the upper arm or shoulder</td> <td>Every morning</td> <td>Comes in 1-dose tubes. Some people notice a smell.</td> </tr> <tr> <td>Fortesta</td> <td>Gel put on thighs</td> <td>Every morning</td> <td>Pump bottle gives exact dose.</td> </tr> <tr> <td>Axiron</td> <td>Liquid put on armpits</td> <td>Every morning</td> <td>Pump bottle with applicator gives exact dose.</td> </tr> <tr> <td>Striant</td> <td>Sticky tablet&nbsp;stays on gums for 12 hours</td> <td>Twice a day</td> <td>Molds to the gums. Do not chew or swallow. Can irritate gums. </td> </tr> <tr> <td>Testopel</td> <td>Tiny pellets that are implanted under skin of the butt, belly wall, or thigh</td> <td>Every 3 to&nbsp;6 months</td> <td> <p>Implant is inserted&nbsp;through a cut on the skin under local anesthesia. It can only be done at certain doctor's offices or hospitals.&nbsp;Area where implant is given can become red and painful.</p> </td> </tr> <tr> <td>&nbsp;Aveed (testosterone undecanoate)</td> <td>&nbsp;Injection (shot) in butt</td> <td>Every 10 weeks (but second shot is done at 4 weeks)</td> <td>Shot is given only in certain doctor's offices or hospitals. Rare cases of lung problems or allergic reactions have happened soon after the shot was given. &nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A man might need androgen replacement if he has low levels of an androgen called \"testosterone.\" There are several different ones, but testosterone is the main androgen. There are different ways to give testosterone to men who need androgen replacement. Each brand is used a different way. Your doctor or nurse can give you the directions for the brand you use.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 86166 Version 4.0</div></div></div>"},"86167":{"type":"graphic_table","displayName":"Jet lag PI","title":"Tips for managing jet lag","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for managing jet lag</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">If you are traveling east</td> <td class=\"subtitle1\">If you are traveling west</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Before travel</strong></td> <td> <ul> <li>Starting 3 days before your trip, make your bedtime and wake time 30 minutes earlier each day. For example: <ul> <li>If you normally wake up at 7:00, try waking up at 6:30, then at 6:00, then at 5:30. </li> <li>If you normally go to bed at 11:00, try going to bed at 10:30, then at 10:00, then at 9:30. </li> </ul> </li> <li>To help with this, try to be around bright light within a few hours of waking up in the morning, and avoid lights (including electronics) around bedtime. </li> </ul> </td> <td> <ul> <li>Starting 3 days before your trip, make your bedtime and wake time 30 minutes later each day. For example: <ul> <li>If you normally wake up at 7:00, try waking up at 7:30, then at 8:00, then at 8:30. </li> <li>If you normally go to bed at 11:00, try going to bed at 11:30, then at 12:00, then at 12:30. </li> </ul> </li> <li>To help with this, try to be around bright light in the evening, and avoid bright light for the first few hours after waking up. </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>During travel</strong></td> <td> <ul> <li>Set your watch for the new time zone you will be in. </li> </ul> </td> <td> <ul> <li>Set your watch for the new time zone you will be in. </li> </ul> </td> </tr> <tr> <td> <ul> <li>To help your body start to adjust, do the following (based on what time it is in the place you are traveling to): <ul> <li>Avoid bright light in the early morning. On the plane, you can wear sunglasses and keep your window shades down to help with this. </li> <li>Get lots of bright light in the late morning and early afternoon. </li> </ul> </li> </ul> </td> <td> <ul> <li>To help your body start to adjust, do the following (based on what time it is in the place you are traveling to): <ul> <li>Get lots of bright light in the late afternoon and evening. </li> <li>Avoid bright light during the nighttime hours. On the plane, you can wear sunglasses, keep your window shades down, and avoid electronics to help with this. </li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Try to sleep when it is nighttime in the time zone you are traveling to. </li> <li>If you cannot sleep during this time, avoid light (especially during the second half of the night). Dark sunglasses can help with this. </li> </ul> </td> <td> <ul> <li>Try to sleep when it is nighttime in the time zone you are traveling to. </li> <li>Try to stay up until the time you would normally go to bed in the time zone you are traveling to. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Avoid medicines that might make you sleepy during your flight. </li> </ul> </td> <td> <ul> <li>Avoid medicines that might make you sleepy during your flight. </li> </ul> </td> </tr> <tr> <td rowspan=\"3\"><strong>On arrival</strong></td> <td> <ul> <li>Avoid early morning bright light. </li> <li>Get lots of bright light in the late morning and early afternoon. </li> </ul> </td> <td> <ul> <li>Avoid bright light at nighttime. </li> <li>Get lots of bright light in the late afternoon and evening. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If you are taking melatonin, take it at the time you want to go to bed. </li> <li>Falling asleep might be difficult the first few days. </li> </ul> </td> <td> <ul> <li>Melatonin is not helpful. </li> <li>Try to stay up to until the time you would normally go to bed. </li> <li>Staying asleep might be difficult the first few days. Avoid electronics if you wake up during the night or in the very early morning. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Short naps (less than 45 minutes) and caffeine might help you feel more awake. </li> </ul> </td> <td> <ul> <li>Short naps (less than 45 minutes) and caffeine might help you feel more awake. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86167 Version 2.0</div></div></div>"},"86168":{"type":"graphic_table","displayName":"Pegylated liposomal doxorubicin and carboplatin EOC","title":"Pegylated liposomal doxorubicin and carboplatin chemotherapy for epithelial ovarian cancer[1]","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pegylated liposomal doxorubicin and carboplatin chemotherapy for epithelial ovarian cancer[1]</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"4\">Cycle length: 28 days<br /> Total cycles: 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Carboplatin</strong></td> <td>AUC*=5 IV</td> <td>Dilute in 250 mL normal saline<sup>&#916;</sup> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Pegylated liposomal doxorubicin</strong></td> <td>30 mg/m<sup>2</sup> IV</td> <td>Dilute in 5 percent dextrose in water and administer over one hour<sup>&#9674;</sup>.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> No specific premedication regimen is recommended. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Both pegylated liposomal doxorubicin and carboplatin are irritants; avoid extravasation. Refer to \"UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated<sup>[1]</sup>. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> Doxorubicin, the active component of pegylated liposomal doxorubicin, is associated with cumulative dose-related cardiotoxicity, particularly left ventricular failure. The degree to which pegylation mitigates this risk is not known. Lifetime anthracycline dose exposure should be considered in assessing the calculated risks for cardiotoxicity. Assess baseline left ventricular ejection fraction (LVEF) prior to administration. Pegylated liposomal doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines<sup>[2]</sup>. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess CBC with differential prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess serum electrolytes and liver and renal function tests prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor cumulative pegylated liposomal doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for palmar-plantar erythrodysesthesias during treatment.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Liver or renal dysfunction:</strong> A lower starting dose of pegylated liposomal doxorubicin may be needed for patients with liver impairment. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula*. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> If the ANC &#8804;1500 cells/microL or platelets &#8804;75,000/microL on day 1 of each cycle, therapy should be delayed until counts recover. Reduce carboplatin dose to AUC* = 4 for subsequent cycles in patients who develop severe neutropenia (&#8804;500 cells/microL) or thrombocytopenia (&#8804;50,000 cells/microL)<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous and mucosal toxicity:</strong> For severe or cumulative cutaneous reactions (erythema and desquamation) and/or stomatitis, hold therapy until improved and then adjust pegylated liposomal doxorubicin dose<sup>[2]</sup>. Discontinue if toxicity persists. Refer to UpToDate topics on \"Oral toxicity associated with chemotherapy\" and \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.<br />* AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert Formula is total dose (mg) = (target AUC) x (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>◊</FONT> Pegylated liposomal doxorubicin should be infused initially at a rate of 1 mg/min to minimize risk of infusion reactions. If none are observed, increase rate of infusion to complete administration over one hour.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Pujade-Lauraine E, et al. J Clin Oncol 2010; 28:3323.</LI>&#xD;&#xA;<LI>Pegylated liposomal doxorubicin injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 13, 2012).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 13, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86168 Version 7.0</div></div></div>"},"86169":{"type":"graphic_picture","displayName":"Breast asymmetry","title":"Breast asymmetry","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Breast asymmetry</div><div class=\"cntnt\"><img style=\"width:598px; height:229px;\" src=\"images/PEDS/86169_Breastasymmetry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eighteen-year-old with breast asymmetry.</div><div class=\"graphic_reference\">Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86169 Version 7.0</div></div></div>"},"86170":{"type":"graphic_picture","displayName":"Juvenile breast hypertrophy","title":"Juvenile breast hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Juvenile breast hypertrophy</div><div class=\"cntnt\"><img style=\"width:598px; height:230px;\" src=\"images/PEDS/86170_Macromastia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86170 Version 8.0</div></div></div>"},"86171":{"type":"graphic_picture","displayName":"Tuberous breast deformity","title":"Tuberous breast deformity","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Tuberous breast deformity</div><div class=\"cntnt\"><img style=\"width:598px; height:230px;\" src=\"images/PEDS/86171_Tuberousbreastdeformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sixteen-year-old with bilateral tuberous breast deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86171 Version 7.0</div></div></div>"},"86172":{"type":"graphic_picture","displayName":"Supernumerary nipple","title":"Supernumerary nipple","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supernumerary nipple</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/PEDS/86172_Supernumerarynipple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supernumerary nipple (note that the supernumerary nipple occurs in the \"milk line\").</div><div class=\"graphic_reference\">Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86172 Version 7.0</div></div></div>"},"86178":{"type":"graphic_table","displayName":"Ann Arbor modification ENSAT staging ACC","title":"Ann Arbor modification of the ENSAT staging system for adrenocortical cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ann Arbor modification of the ENSAT staging system for adrenocortical cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">ENSAT</td> <td class=\"subtitle1\">Ann Arbor modification of ENSAT</td> </tr> <tr> <td><strong>Stage 1</strong></td> <td>T1, N0, M0</td> <td>Stage 1 + low-grade stage 2</td> </tr> <tr> <td><strong>Stage 2</strong></td> <td>T2, N0, M0</td> <td>High-grade stage 2 + low-grade stage 3</td> </tr> <tr> <td><strong>Stage 3</strong></td> <td>T3-4, N0, M0 T1-4, N1, M0</td> <td>High-grade stage 3</td> </tr> <tr> <td><strong>Stage 4</strong></td> <td>Any M1</td> <td>Stage 4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENSAT: European Network for the Study of Adrenal Tumors.</div><div class=\"graphic_reference\">Reproduced from: Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395:955. Copyright &copy; 2010; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 86178 Version 5.0</div></div></div>"},"86179":{"type":"graphic_table","displayName":"Atypical mole syndrome","title":"Atypical mole syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical mole syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome name</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sporadic syndromes</td> </tr> <tr> <td class=\"indent1\">Atypical mole syndrome</td> <td>Three or more of the following characteristics: <ol> <li>Two or more clinically atypical nevi </li> <li>&#62;100 nevi &#62;2 mm diameter or &#62;50 nevi if &#60;20 or &#62;50 years of age </li> <li>Nevi abnormally distributed (buttocks or dorsum of foot) </li> <li>Nevi in the anterior scalp </li> <li>Iris pigmented lesion(s) </li> </ol> </td> </tr> <tr> <td class=\"indent1\">Classical atypical mole syndrome</td> <td> <ol> <li>&#62;100 melanocytic nevi </li> <li>One or more nevi &#62;8 mm diameter </li> <li>One or more nevi with atypical features </li> </ol> </td> </tr> <tr> <td class=\"indent1\">B-K mole</td> <td>&#8805;10 mm diameter; irregular outline; haphazard mixture of tan, brown, black, and pink; small palpable dermal component</td> </tr> <tr> <td class=\"indent1\">B-K mole syndrome</td> <td>Fewer than 10 B-K moles to more than 100 moles prominent on the upper trunk and extremities; variability of mole size (5 to 15 mm diameter), outline, and color</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Familial syndromes</td> </tr> <tr> <td class=\"indent1\">Familial atypical mole syndrome</td> <td> <ol> <li>Two or more family members with atypical moles </li> <li>One or more family members with melanoma </li> </ol> </td> </tr> <tr> <td class=\"indent1\">Familial atypical multiple mole melanoma syndrome</td> <td> <ol> <li>Melanoma in two or more first- or second-degree relatives </li> <li>Many atypical nevi (often more than 50) </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Marghoob AA, Kovalyshyn I, Halpern AC. Management of Dysplastic Nevi and Melonomas. In: Surgery of the Skin, 2nd ed, Robinson JK (Ed), Elsevier 2010. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86179 Version 1.0</div></div></div>"},"86180":{"type":"graphic_picture","displayName":"Double duct sign in pancreatic cancer","title":"\"Double duct\" sign in a patient with pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">\"Double duct\" sign in a patient with pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:502px;\" src=\"images/GAST/86180_Doub_duc_pancrea_can.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) in a patient with adenocarcinoma in the head of the pancreas. The common bile duct is dilated proximal to a stricture (arrow). In addition, the pancreatic duct is dilated (arrowhead) due to obstruction by the tumor. The dilation of both the common bile duct and the pancreatic duct is known as the \"double duct\" sign, a finding that is highly suggestive of a malignancy.</div><div id=\"graphicVersion\">Graphic 86180 Version 2.0</div></div></div>"},"86182":{"type":"graphic_picture","displayName":"Proctocolectomy specimen","title":"Proctocolectomy specimen ","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Proctocolectomy specimen </div><div class=\"cntnt\"><img style=\"width:515px; height:207px;\" src=\"images/SURG/86182_Proctocolectomy_spec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the extracted colon specimen exteriorized through the Pfannenstiel incision. The total colectomy was performed using a laparoscopic assisted approach.</div><div class=\"graphic_reference\">Courtesy of Alessandro Fichera, MD, FACS, FASCRS.</div><div id=\"graphicVersion\">Graphic 86182 Version 1.0</div></div></div>"},"86184":{"type":"graphic_picture","displayName":"Darier mucosal","title":"Involvement of the oral mucosa in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Involvement of the oral mucosa in Darier disease</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86184_Darier_mucosal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86184 Version 5.0</div></div></div>"},"86185":{"type":"graphic_picture","displayName":"Darier plantar hyperkeratosis","title":"Plantar hyperkeratosis in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar hyperkeratosis in Darier disease</div><div class=\"cntnt\"><img style=\"width:377px; height:504px;\" src=\"images/DERM/86185_Darier_plntar_hyperkeratos.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86185 Version 5.0</div></div></div>"},"86186":{"type":"graphic_picture","displayName":"Darier plaques","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86186_Darier_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent, papular, hyperkeratotic lesions forming large, crusted plaques in a patient with Darier disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86186 Version 5.0</div></div></div>"},"86187":{"type":"graphic_picture","displayName":"Darier forehead","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86187_Darier_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86187 Version 5.0</div></div></div>"},"86188":{"type":"graphic_picture","displayName":"Darier keratotic papule","title":"Keratotic papules of Darier disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keratotic papules of Darier disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86188_Darier_keratotic_papule.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86188 Version 5.0</div></div></div>"},"86189":{"type":"graphic_picture","displayName":"Darier histopathology","title":"Histopathology of Darier disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of Darier disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86189_Darier_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic examination of lesional skin in Darier disease shows a suprabasal cleft containing acantholytic cells, eosinophilic dyskeratotic cells (corps ronds) in the epidermis and flattened parakeratotic cells (grains) in the stratum corneum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86189 Version 5.0</div></div></div>"},"86190":{"type":"graphic_table","displayName":"DDx FL path","title":"Differential diagnosis of follicular lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of follicular lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Follicular lymphoma</td> <td>Nodular growth pattern of follicle center cells (centrocytes and centroblasts). Tingible body macrophages usually absent.</td> <td> <p>Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA. Ki-67 low.</p> Cytoplasmic staining for BCL-2 protein is strongly positive in almost all grade I/II follicular lymphoma tumors</td> <td>No single chromosomal change is diagnostic. t(14;18) present in 85 percent. Abnormalities in 3q27 present in 5 to 15 percent.</td> </tr> <tr> <td>Reactive follicular hyperplasia</td> <td>Discrete follicles of varying sizes and shapes are separated from one another by interfollicular regions rich in T cells within the lymph node cortex. Prominent tingible body macrophages.</td> <td> <p>Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA. Ki-67 high</p> BCL-2 negative</td> <td>No specific genetic features</td> </tr> <tr> <td>Mantle cell lymphoma </td> <td>Monomorphous small to medium-sized B lymphocytes with irregular nuclei. No proliferation centers.</td> <td> <p>CD5+ and CD10&ndash;</p> The vast majority overexpress cyclin D1</td> <td>t(11;14)</td> </tr> <tr> <td>Diffuse large B cell lymphoma: T cell rich large B cell lymphoma subtype</td> <td>Infiltrating small cells (reactive T cells) are present with interspersed larger cells that resemble centroblasts</td> <td>Larger neoplastic cells express pan B-cell antigens (CD19, CD20, CD79a), and monoclonal surface membrane IgM. Smaller cells are reactive and express T cell antigens.</td> <td>Genetic abnormalities varied</td> </tr> <tr> <td>Marginal zone lymphoma</td> <td>May have a partially nodular pattern of growth</td> <td>&#62;95 percent CD10&ndash;</td> <td>Lacks t(11;14) and t(14;18)</td> </tr> <tr> <td>Histologic transformation to diffuse large B cell lymphoma</td> <td>Large, transformed B cells with prominent nucleoli and basophilic cytoplasm demonstrating a diffuse growth pattern and a high (&#62;40 percent) proliferation fraction</td> <td>Express pan B cell antigens (CD19, CD20, CD79a), CD45, and monoclonal surface membrane IgM. Some cases will demonstrate CD5.</td> <td>Often t(14;18) positive; various other genetic aberrations</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86190 Version 4.0</div></div></div>"},"86192":{"type":"graphic_picture","displayName":"Periorbital microcystic adnexal carcinoma","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86192_Periorbit_micro_adnex_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma presenting as a subtle papule beneath the eye.</div><div id=\"graphicVersion\">Graphic 86192 Version 2.0</div></div></div>"},"86193":{"type":"graphic_picture","displayName":"Periorbital microcystic adnexal carcinoma outlined","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86193_Peri_micrcyst_ad_carc_out.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma presenting as a subtle white papule beneath the eye. The palpable tumor is outlined.</div><div id=\"graphicVersion\">Graphic 86193 Version 1.0</div></div></div>"},"86194":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma on cheek","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:447px; height:504px;\" src=\"images/DERM/86194_Micro_adnex_carcin_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma presenting as a white-yellow plaque on the cheek.</div><div id=\"graphicVersion\">Graphic 86194 Version 1.0</div></div></div>"},"86195":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma on cheek outlined","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:501px;\" src=\"images/DERM/86195_Mic_adnex_carc_cheek_out.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma presenting as a white-yellow plaque on the cheek. The palpable tumor is outlined. Note the asymmetrical extension.</div><div id=\"graphicVersion\">Graphic 86195 Version 1.0</div></div></div>"},"86196":{"type":"graphic_picture","displayName":"Recurrent microcystic adnexal carcinoma","title":"Recurrent microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Recurrent microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/DERM/86196_Recur_micrcy_adnx_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recurrence of microcystic adnexal carcinoma in the site of previous excision. There are few clinical changes to suggest recurrence, except for extensive firmness to palpation around the skin graft (A). Tissue invasion by this recurrent microcystic adnexal carcinoma was more extensive than evident on clinical examination. Extensive surgical excision including resection of the underlying bone was required (B).</div><div id=\"graphicVersion\">Graphic 86196 Version 1.0</div></div></div>"},"86199":{"type":"graphic_diagnosticimage","displayName":"Ovarian torsion sonogram 2","title":"Ovarian torsion","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Ovarian torsion</div><div class=\"cntnt\"><img style=\"width:516px; height:247px;\" src=\"images/OBGYN/86199_Ovarian_tros_son_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">35-year-old woman with pelvic pain and torsion.<br />A) Transvaginal ultrasound shows an enlarged (7 cm) edematous appearing right ovary in the cul-de-sac.<br />B) Color Doppler shows normal arterial and venous waveforms. Torsion was confirmed at surgery.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 86199 Version 2.0</div></div></div>"},"86200":{"type":"graphic_diagnosticimage","displayName":"Ovarian torsion sonogram 3","title":"Ovarian torsion","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Ovarian torsion</div><div class=\"cntnt\"><img style=\"width:565px; height:418px;\" src=\"images/OBGYN/86200_Ovarian_tors_sono_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">32-year-old with right lower quandrant pain and right ovarian torsion.<br />(A) Transvaginal color Doppler ultrasound shows an enlarged edematous appearing right ovary without demonstrable flow.<br />(B) Transvaginal color Doppler ultrasound of the left ovary shows a normal sized ovary with normal flow.<br />(C) T2 weighted&nbsp;magnetic resonance&nbsp;image shows the enlarged edematous ovary with peripheral cysts.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 86200 Version 3.0</div></div></div>"},"86201":{"type":"graphic_diagnosticimage","displayName":"Multiple tortuous pelvic veins","title":"Multiple tortuous pelvic veins in a patient with chronic pelvic pain","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Multiple tortuous pelvic veins in a patient with chronic pelvic pain</div><div class=\"cntnt\"><img style=\"width:519px; height:211px;\" src=\"images/OBGYN/86201_Multi_tort_pelv_veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">48-year-old woman with chronic pelvic pain.<br />A) Transvaginal ultrasound image shows multiple tubular structures.<br />B) Color doppler of the same image shows flow in the tubular structures, compatible with multiple tortuous dilated pelvic veins.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 86201 Version 1.0</div></div></div>"},"86202":{"type":"graphic_diagnosticimage","displayName":"Breast MRI invasive cancer","title":"Breast MRI invasive cancer","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Breast MRI invasive cancer</div><div class=\"cntnt\"><img style=\"width:561px; height:426px;\" src=\"images/RADIOL/86202_Breast_MRI_invasive_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI reveals an invasive ductal cancer of the breast characterized as a dark mass on T2 (ringed by the circle) and as an enhancing mass on the post contrast T1 images (arrow) in the axial (B and D) and sagittal projections (C). The spiculations emanating from the mass (arrowheads) and heterogeneous enhancement are well demonstrated. The signal void (dashed arrow) represents a clip placed at time of ultrasound guided biopsy.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 86202 Version 3.0</div></div></div>"},"86203":{"type":"graphic_diagnosticimage","displayName":"Breast MRI extensive noninvasive cancer","title":"Breast MRI extensive noninvasive cancer","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Breast MRI extensive noninvasive cancer</div><div class=\"cntnt\"><img style=\"width:598px; height:328px;\" src=\"images/RADIOL/86203_Br_MRI_extens_noninv_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The screening mammogram of the breasts in the MLO (A) and CC views (B) reveal concerning extensive pleomorphic calcifications in the upper inner central right breast.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MLO: mediolateral oblique; CC: craniocaudad.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 86203 Version 2.0</div></div></div>"},"86204":{"type":"graphic_table","displayName":"Rx treatment obesity","title":"Drugs available as adjuncts to diet and exercise for treatment of obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs available as adjuncts to diet and exercise for treatment of obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Usual dosing (adults)</td> <td class=\"subtitle1\">US DEA schedule</td> <td class=\"subtitle1\">Adverse effects and precautions*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pancreatic lipase inhibitor approved for long-term use</td> </tr> <tr> <td class=\"indent1\">Orlistat</td> <td> <p>120 mg three times daily with fat-containing meals.</p> A reduced dose of 60 mg<sup>&#182;</sup> is an option for patients who do not tolerate 120 mg.</td> <td>Not a controlled substance</td> <td> <p>Cramps, flatulence, fecal incontinence, oily spotting, absorption of fat-soluble vitamins may be reduced. Rarely reported: severe liver injury, oxalate-kidney injury.</p> Contraindicated during pregnancy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Serotinin-2C receptor agonist approved for long-term use</td> </tr> <tr> <td class=\"indent1\">Lorcaserin</td> <td>10 mg twice daily; re-evaluate after 12 weeks.</td> <td>C-IV</td> <td> <p>Headache, dizziness, nausea, dry mouth, constipation (non-diabetic patients). Hypoglycemia, headache, back pain, cough (diabetic patients).</p> <p>Avoid in patients with severe hepatic or renal insufficiency (CrCl &#60;30 mL/min).</p> <p>Preferably avoid use with other serotoninergic agents (including most antidepressants, triptan anti-migraine medications, 5HT3-antagonist antiemetics, tramadol, dextromethorphan,&nbsp;and some muscle relaxants) due to risk of serotonin toxicity.</p> <p>Neuropsychiatric side effects and valvulopathy were not significantly increased in clinical trials, but few long-term safety data are available.</p> <p>Contraindicated with ergot derivatives (eg, ergotamine) and during pregnancy.</p> <p>May cause psychic dependence and/or euphoria at higher than recommended doses.</p> Possible increase in cancer risk based on murine model data.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combination of phentermine-topiramate approved for long-term use</td> </tr> <tr> <td class=\"indent1\">Phentermine-topiramate</td> <td> <p>Initial: 3.75 mg phentermine/23 mg topiramate once daily in the morning for 14 days.</p> <p>Then titrate based upon response: 7.5 mg phentermine/46 mg topiramate daily for 12 weeks, then 11.25 mg phentermine/69 mg topiramate daily for 14 days.</p> Maximum dose: 15 mg phentermine/92 mg topiramate daily; re-evaluate after 12 weeks.</td> <td>C-IV (due to phentermine component)</td> <td> <p>Dry mouth, taste disturbance, constipation, paraesthesias, depression, anxiety, elevated heart rate, cognitive disturbances, insomnia (higher dose).</p> <p>Abuse potential due to phentermine component.</p> <p>Topiramate is teratogenic (increased risk of oral cleft defects, T1); negative pregnancy test prior to and during treatment and two forms of contraception necessary for women of child-bearing potential.</p> <p>Actions of topiramate component include inhibition of carbonic anhydrase; rarely metabolic acidosis and kidney stones may result from renal bicarbonate loss.</p> <p>Maximum dose with moderate hepatic or renal impairment (CrCl &#60;50 mL/min) 7.5 mg phentermine/46 mg topiramate once daily.</p> <p>Upon discontinuation, tapering of dose over at least one week using every other day dosing is recommended.</p> Contraindicated during pregnancy, hyperthyroidism, glaucoma, patients taking MAO inhibitors.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combination of bupropion-naltrexone approved for long-term use</td> </tr> <tr> <td class=\"indent1\">Bupropion-naltrexone</td> <td> <p>Week 1: One tablet (8 mg naltrexone/90 mg bupropion) once daily.</p> <p>Week 2: One tablet twice daily.</p> <p>Week 3: Two tablets in morning and one tablet in evening.</p> <p>Week 4: Two tablets twice daily.</p> Maximum daily dose: Four tablets (32 mg naltrexone/360 mg bupropion); re-evaluate after 12 weeks.</td> <td>Not a controlled substance</td> <td> <p>Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth.</p> <p>Transient increase in blood pressure (1 to 2 mmHg on average) during initial 12 weeks of treatment; heart rate may also be increased.</p> Contraindicated in patients with uncontrolled hypertension, seizure disorder, eating disorder, use of other bupropion-containing products, chronic opioid use, use within 14 days of MAO inhibitors, pregnancy, or breastfeeding.<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">GLP-1 agonist approved for long-term use</td> </tr> <tr> <td class=\"indent1\">Liraglutide&nbsp;</td> <td> <p>Initial: 0.6 mg subcutaneously daily.</p> <p>Increase at weekly intervals (1.2, 1.8, 2.4 mg) until recommended dose of 3 mg daily; re-evaluate after 16 weeks.<sup>&#9674;</sup></p> </td> <td>Not a controlled substance</td> <td> <p>Nausea, vomiting, diarrhea, constipation, hypoglycemia in patients with T2DM (more common if used in conjunction with diabetes medications known to cause hypoglycemia), injection site reactions, increased lipase, increased heart rate.&nbsp;Rarely reported: pancreatitis, gallbladder disease, renal impairment, suicidal thoughts.</p> <p>Advise patients to avoid dehydration in relation to GI side effects.</p> <p>Monitor blood glucose in diabetic patients and adjust co-administered sulfonylureas (eg, reduce&nbsp;dose by 50 percent)&nbsp;and other anti-diabetic medications as needed to prevent potentially severe hypoglycemia.</p> <p>Causes a modest delay of gastric emptying.</p> <p>Use is not recommended in severe renal impairment (CrCl &#60;30 mL/min), severe hepatic impairment, or children/adolescents &#8804;18 years and adults &#8805;75 years; safety and efficacy data are lacking.</p> <p>Possible increase in thyroid cancer risk based on murine model data.</p> <p>Contraindicated in pregnancy and in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Noradrenergic sympathomimetic drugs approved for short-term use</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Benzphetamine</td> <td>Initial: 25 mg once daily; may titrate up to 25 to 50 mg one to three times daily.</td> <td rowspan=\"2\">C-III</td> <td rowspan=\"9\"> <p>Applies to all sympathomimetic agents:</p> <p>Due to their side effects and potential for abuse, we suggest <strong>not</strong> prescribing sympathomimetics for weight loss.</p> <p>If prescribed, limit to short-term (&#8804;12 weeks) use.</p> <p>Adverse effects include increase in heart rate, blood pressure, insomnia, dry mouth, constipation, nervousness.</p> <p>Abuse potential due to amphetamine-like effects.</p> <p>May counteract effect of blood pressure medications.</p> <p>Avoid in patients with heart disease, poorly controlled hypertension, pulmonary hypertension, or history of addiction or drug abuse.</p> Contraindicated in patients with a history of CVD, hyperthyroidism, glaucoma, MAO inhibitor-therapy, agitated states, pregnancy, or breast feeding.</td> </tr> <tr> <td>Maximum dose: 50 mg three times daily.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Diethylpropion</td> <td>Immediate release: 25 mg three times daily before meals.</td> <td rowspan=\"2\">C-IV</td> </tr> <tr> <td>Controlled release: 75 mg every morning.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Phentermine</td> <td>Immediate release: 15 to 37.5 mg daily or divided twice-daily.</td> <td rowspan=\"2\">C-IV</td> </tr> <tr> <td>Orally disintegrating tablet (ODT): 15 to 37.5 mg once daily in the morning.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Phendimetrazine</td> <td>Immediate release: 17.5 to 35 mg two or three times daily, one hour before meals.</td> <td rowspan=\"3\">C-III</td> </tr> <tr> <td>Maximum dose: 70 mg three times daily.</td> </tr> <tr> <td>Sustained release: 105 mg daily in the morning.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CrCl: creatinine clearance; CVD: cardiovascular disease (arrhythmias, congestive heart failure, coronary artery disease, stroke, uncontrolled hypertension); GI: gastrointestinal; GLP-1: glucagon-like peptide 1; MAO inhibitors: monamine oxidase inhibitors; T1: first trimester pregnancy; T2DM: type 2 diabetes mellitus; US DEA: United States Drug Enforcement Agency; FDA: US Food and Drug Administration.<br />* Applies to all drugs except orlistat: May increase risk of hypoglycemia in type 2 diabetics. For additional information on potential interactions of anti-obesity drugs with other medications, use Lexi-Interact program included with UpToDate.<br />¶ Orlistat 60 mg is available without a prescription in the United States and some other countries.<br />Δ FDA recommends warning young adults (age 18 to 24 years) of the risk of becoming suicidal during initial treatment of psychiatric disorders with any antidepressant.<br />◊ According to United States labeling, if weight loss is not ≥4 percent after 16 weeks or 3 mg/week is not tolerated, discontinue use. Labeling in the European Union recommends discontinuation of use if weight loss is not ≥5 percent after 12 weeks of 3 mg/week.</div><div class=\"graphic_reference\">Courtesy of authors.<br />With additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li><a href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=\"_blank\">dailymed.nlm.nih.gov/dailymed/index.cfm</a> (Accessed October 8, 2014).</li>&#xD;&#xA;    <li>Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95:1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86204 Version 13.0</div></div></div>"},"86205":{"type":"graphic_picture","displayName":"Neoplastic C-cell hyperplasia","title":"Neoplastic C-cell hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Neoplastic C-cell hyperplasia</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/ENDO/86205_Neoplas_C-cell_hyper.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">C-cell hyperplasia and microcarcinomas in a 5-year-old boy with the Cys634Arg mutation. The expanding C-cell masses disrupt the basal membrane surrounding individual thyroid follicles (arrows).</div><div class=\"graphic_reference\">Reproduced from: Expert Review of Endocrinology &amp; Metabolism, September 2009, Vol. 4, No. 5, Pages 443-465 with permission of Expert Reviews Ltd.</div><div id=\"graphicVersion\">Graphic 86205 Version 2.0</div></div></div>"},"86206":{"type":"graphic_picture","displayName":"MTC surgical specimen","title":"Medullary thyroid cancer: Surgical specimen","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Medullary thyroid cancer: Surgical specimen</div><div class=\"cntnt\"><img style=\"width:511px; height:199px;\" src=\"images/ENDO/86206_MTC_surgical_specimen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathological specimen of bilateral and multicentric medullary thyroid cancer.</div><div class=\"graphic_reference\">Reproduced from: Expert Review of Endocrinology &amp; Metabolism, September 2009, Vol. 4, No. 5, Pages 443-465 with permission of Expert Reviews Ltd.</div><div id=\"graphicVersion\">Graphic 86206 Version 1.0</div></div></div>"},"86207":{"type":"graphic_picture","displayName":"Pheo surgical specimen","title":"Pheochromocytoma: Surgical specimen","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Pheochromocytoma: Surgical specimen</div><div class=\"cntnt\"><img style=\"width:513px; height:185px;\" src=\"images/ENDO/86207_Pheo_surgical_spec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multinodular pheochromocytoma: General view and cross section. A rim of cortical tissue can be seen at the top.</div><div class=\"graphic_reference\">Reproduced from: Expert Review of Endocrinology &amp; Metabolism, September 2009, Vol. 4, No. 5, Pages 443-465 with permission of Expert Reviews Ltd.</div><div id=\"graphicVersion\">Graphic 86207 Version 1.0</div></div></div>"},"86216":{"type":"graphic_picture","displayName":"Bullous lupus erythematosus chest","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/RHEUM/86216_Bullous_lupus_eryth_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple blisters and erosions&nbsp;are present on the chest of this patient with bullous systemic lupus erythematosus.<BR></div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD.</div><div id=\"graphicVersion\">Graphic 86216 Version 1.0</div></div></div>"},"86217":{"type":"graphic_picture","displayName":"Bullous lupus erythematosus pathology","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:540px; height:359px;\" src=\"images/RHEUM/86217_Bullous_lupus_eryth_pathol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subepidermal blister with a predominantly neutrophilic dermal infiltrate.</div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD.</div><div id=\"graphicVersion\">Graphic 86217 Version 1.0</div></div></div>"},"86222":{"type":"graphic_table","displayName":"Contributors to fatigue in patients with advanced cancer","title":"Potential contributors to fatigue in patients with advanced cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential contributors to fatigue in patients with advanced cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cancer-related symptoms including pain, psychological symptoms (anxiety, depression), dyspnea, nausea, anorexia/cachexia, and insomnia </td> </tr> <tr> <td>Cancer treatment-related (cytotoxic therapy, radiotherapy, bioimmunotherapy)</td> </tr> <tr> <td>Anemia</td> </tr> <tr> <td>Mood disorders</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td>Deconditioning</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr> <td>Dehydration</td> </tr> <tr> <td>Neuroendocrine alterations (eg, testosterone deficiency in men with advanced cancer)</td> </tr> <tr> <td>Polypharmacy</td> </tr> <tr> <td>Comorbidities (Renal, hepatic, cardiac)</td> </tr> <tr> <td>Autonomic dysfunction</td> </tr> <tr> <td>Tumor byproducts, inflammatory cytokines</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86222 Version 1.0</div></div></div>"},"86223":{"type":"graphic_picture","displayName":"Oral chronic graft-versus-host disease","title":"Oral chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:388px; height:290px;\" src=\"images/ONC/86223_Oral_chron_graft_vs_host.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominent reticular oral chronic graft-versus-host disease of the left buccal mucosa.</div><div class=\"graphic_reference\">Courtesy of Nathaniel Treister, DMD, DMSc.</div><div id=\"graphicVersion\">Graphic 86223 Version 2.0</div></div></div>"},"86225":{"type":"graphic_table","displayName":"Prevention of dental caries in high-risk individuals","title":"Prevention of dental caries in high-risk individuals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of dental caries in high-risk individuals</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Rationale</td> <td class=\"subtitle1\">Directions</td> </tr> <tr> <td>Oral hygiene and non-cariogenic diet</td> <td>Decreases the substrate available for cariogenic bacteria </td> <td> <p>Brush teeth at least twice daily using soft-bristled toothbrush</p> <p>Daily use of dental floss</p> <p>Restrict the amount of refined carbohydrates in daily meals</p> Avoid sugary and acidic beverages</td> </tr> <tr> <td>Fluoride products </td> <td>Increases tooth surface resistance to acids and acts as a reservoir for remineralization of early caries</td> <td> <p>Fluoride toothpaste should be used twice/day</p> <p>Fluoride gel in tray should be applied daily</p> Fluoride varnish can be professionally applied up to four time per year</td> </tr> <tr> <td>Calcium-phosphate based remineralizing agents</td> <td> <p>Casein phosphopeptide - amorphous calcium phosphate (CPP-ACP) product provide a source of calcium and phosphate</p> Facilitates remineralization of early carious lesions</td> <td>Use daily with fluoride</td> </tr> <tr> <td>Xylitol products</td> <td>Unlike sucrose or fructose, xylitol is not utilized by <em>S.mutans</em> as a source of energy</td> <td> <p>Use xylitol-containing products (gum, candy) three to five times per day</p> Fluoride toothpaste with at least 10 percent xylitol should be used twice/day</td> </tr> <tr> <td>Routine dental visits</td> <td> <p>Caries screening through clinical examination and bitewing radiographs</p> <p>Restoration of carious lesions</p> <p>Professional dental cleaning</p> Fluoride varnish application</td> <td> <p>Recall visits every six months</p> <p>Bitewings radiographs annually, or more frequent if high caries risk</p> Dental caries should be treated as soon as identified</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Nathaniel Treister, DMD, DMSc.</div><div id=\"graphicVersion\">Graphic 86225 Version 2.0</div></div></div>"},"86226":{"type":"graphic_table","displayName":"NIH consensus criteria for diagnosis of GVHD","title":"National Institutes of Health consensus criteria for the diagnosis of oral chronic graft-versus-host disease (GVHD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Institutes of Health consensus criteria for the diagnosis of oral chronic graft-versus-host disease (GVHD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic (sufficient to establish the diagnosis of chronic GVHD)</td> <td class=\"subtitle1\">Distinctive (seen in chronic GVHD, but insufficient alone to establish a diagnosis of chronic GVHD)</td> </tr> <tr> <td class=\"centered\"> <p>Lichen-type features</p> <p>Hyperkeratotic plaques</p> <p>Restriction of mouth opening from sclerosis</p> </td> <td class=\"centered\"> <p>Xerostomia</p> <p>Mucoceles</p> <p>Mucosal atrophy</p> <p>Pseudomembranes</p> Ulcers</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.</div><div id=\"graphicVersion\">Graphic 86226 Version 1.0</div></div></div>"},"86227":{"type":"graphic_table","displayName":"Mean effect size symptom rating PMDD","title":"Mean effect sizes and symptom ratings by premenstrual dysphoric disorder symptom or functioning measure and perimenstrual interval in 864 participants in the community sample","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean effect sizes and symptom ratings by premenstrual dysphoric disorder symptom or functioning measure and perimenstrual interval in 864 participants in the community sample</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Symptom*</td> <td class=\"subtitle1\" colspan=\"2\">Symptom rating<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"4\">Effect size<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">Day of peak</td> <td class=\"subtitle2\">Mean rating at peak</td> <td class=\"subtitle2\">(&ndash;6, &ndash;1)</td> <td class=\"subtitle2\">(&ndash;5, 1)</td> <td class=\"subtitle2\">(&ndash;4, 2)</td> <td class=\"subtitle2\">(&ndash;3, 3)</td> </tr> <tr> <td>Physical symptoms, eg, bloating</td> <td class=\"centered\">1</td> <td class=\"centered\">2.87</td> <td class=\"centered\">0.33</td> <td class=\"centered\">0.49</td> <td class=\"centered\">0.58</td> <td class=\"centered\">0.62</td> </tr> <tr> <td>Food cravings</td> <td class=\"centered\">1</td> <td class=\"centered\">1.84</td> <td class=\"centered\">0.24</td> <td class=\"centered\">0.27</td> <td class=\"centered\">0.29</td> <td class=\"centered\">0.31</td> </tr> <tr> <td>Low sex drive</td> <td class=\"centered\">1</td> <td class=\"centered\">1.9</td> <td class=\"centered\">0.21</td> <td class=\"centered\">0.27</td> <td class=\"centered\">0.29</td> <td class=\"centered\">0.29</td> </tr> <tr> <td>Mood swings</td> <td class=\"centered\">1</td> <td class=\"centered\">1.83</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.26</td> <td class=\"centered\">0.28</td> <td class=\"centered\">0.29</td> </tr> <tr> <td>Change in appetite</td> <td class=\"centered\">1</td> <td class=\"centered\">1.85</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.23</td> <td class=\"centered\">0.24</td> </tr> <tr> <td>Suddenly sad or tearful</td> <td class=\"centered\">2</td> <td class=\"centered\">1.7</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.18</td> <td class=\"centered\">0.22</td> <td class=\"centered\">0.23</td> </tr> <tr> <td>Suddenly irritable</td> <td class=\"centered\">1</td> <td class=\"centered\">1.93</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.21</td> <td class=\"centered\">0.22</td> </tr> <tr> <td>Sensitive to rejection</td> <td class=\"centered\">1</td> <td class=\"centered\">1.74</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.18</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.2</td> </tr> <tr> <td>Irritability that stayed with me</td> <td class=\"centered\">1</td> <td class=\"centered\">1.72</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.19</td> <td class=\"centered\">0.18</td> </tr> <tr> <td>Easily upset</td> <td class=\"centered\">1</td> <td class=\"centered\">1.86</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.17</td> <td class=\"centered\">0.18</td> <td class=\"centered\">0.18</td> </tr> <tr> <td>Symptoms interfered with getting things done at work</td> <td class=\"centered\">1</td> <td class=\"centered\">1.66</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.18</td> <td class=\"centered\">0.2</td> </tr> <tr> <td>Felt \"on edge\"</td> <td class=\"centered\">1</td> <td class=\"centered\">1.73</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.17</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Depressed mood</td> <td class=\"centered\">1</td> <td class=\"centered\">1.72</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.18</td> </tr> <tr> <td>Symptoms interfered with relationships at home</td> <td class=\"centered\">1</td> <td class=\"centered\">1.6</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Wanted to be alone</td> <td class=\"centered\">1</td> <td class=\"centered\">1.86</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.16</td> <td class=\"centered\">0.16</td> </tr> <tr> <td>Felt distractible</td> <td class=\"centered\">1</td> <td class=\"centered\">1.62</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Symptoms interfered with relationships at work</td> <td class=\"centered\">1</td> <td class=\"centered\">1.63</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.16</td> </tr> <tr> <td>Felt \"out of control\"</td> <td class=\"centered\">1</td> <td class=\"centered\">1.41</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.16</td> </tr> <tr> <td>Increased interpersonal conflict</td> <td class=\"centered\">3</td> <td class=\"centered\">1.61</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Feelings of tension</td> <td class=\"centered\">1</td> <td class=\"centered\">2.12</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.15</td> </tr> <tr> <td>No energy</td> <td class=\"centered\">1</td> <td class=\"centered\">2.25</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.18</td> </tr> <tr> <td>Easily fatigued</td> <td class=\"centered\">1</td> <td class=\"centered\">2.18</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Agitated</td> <td class=\"centered\">1</td> <td class=\"centered\">1.92</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Negative thoughts about myself</td> <td class=\"centered\">1</td> <td class=\"centered\">1.61</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Time missed from work</td> <td class=\"centered\">1</td> <td class=\"centered\">NA</td> <td class=\"centered\">0.06</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Overeating</td> <td class=\"centered\">1</td> <td class=\"centered\">1.71</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.15</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Symptoms interfered with social activities</td> <td class=\"centered\">1</td> <td class=\"centered\">1.62</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.15</td> </tr> <tr> <td>Felt restless</td> <td class=\"centered\">1</td> <td class=\"centered\">1.74</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Felt suddenly angry</td> <td class=\"centered\">1</td> <td class=\"centered\">1.68</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.11</td> </tr> <tr> <td>Arguments with people</td> <td class=\"centered\">1</td> <td class=\"centered\">1.36</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.12</td> </tr> <tr> <td>Felt \"keyed up\"</td> <td class=\"centered\">1</td> <td class=\"centered\">1.59</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.11</td> </tr> <tr> <td>Decreased interest in usual activities</td> <td class=\"centered\">1</td> <td class=\"centered\">1.63</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Symptoms interfered with getting things done at home</td> <td class=\"centered\">1</td> <td class=\"centered\">1.75</td> <td class=\"centered\">0.06</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.12</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Trouble sleeping</td> <td class=\"centered\">1</td> <td class=\"centered\">1.87</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Less productive at home</td> <td class=\"centered\">1</td> <td class=\"centered\">1.89</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Difficulty concentrating</td> <td class=\"centered\">1</td> <td class=\"centered\">1.81</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Less productive at work</td> <td class=\"centered\">1</td> <td class=\"centered\">1.12</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.11</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Symptoms interfered with getting things done at school</td> <td class=\"centered\">1</td> <td class=\"centered\">1.52</td> <td class=\"centered\">&ndash;0.04</td> <td class=\"centered\">0.06</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.14</td> </tr> <tr> <td>Avoided social activities</td> <td class=\"centered\">1</td> <td class=\"centered\">1.53</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.1</td> </tr> <tr> <td>Anger that stayed with me</td> <td class=\"centered\">1</td> <td class=\"centered\">1.51</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.09</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Felt hopeless</td> <td class=\"centered\">1</td> <td class=\"centered\">1.48</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.09</td> </tr> <tr> <td>Slept too much</td> <td class=\"centered\">1</td> <td class=\"centered\">1.49</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Felt lonely</td> <td class=\"centered\">1</td> <td class=\"centered\">1.62</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Felt anxious</td> <td class=\"centered\">1</td> <td class=\"centered\">1.97</td> <td class=\"centered\">0.02</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Felt guilty</td> <td class=\"centered\">1</td> <td class=\"centered\">1.48</td> <td class=\"centered\">0.03</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.04</td> </tr> <tr> <td>Felt overwhelmed</td> <td class=\"centered\">1</td> <td class=\"centered\">1.91</td> <td class=\"centered\">0.01</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.05</td> </tr> <tr> <td>Time missed from class</td> <td class=\"centered\">1</td> <td class=\"centered\">NA</td> <td class=\"centered\">0.11</td> <td class=\"centered\">&ndash;1.01</td> <td class=\"centered\">0.03</td> <td class=\"centered\">0.06</td> </tr> <tr> <td>Symptoms interfered with relationships at school</td> <td class=\"centered\">1</td> <td class=\"centered\">1.64</td> <td class=\"centered\">0.09</td> <td class=\"centered\">&ndash;0.02</td> <td class=\"centered\">&ndash;0.05</td> <td class=\"centered\">0.01</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.<br />* Symptoms are presented in descending order of severity and change during the last four days before and the first two days of the menstrual period.<br />¶ Ratings are on a six-point scale: 1 indicates not at all; 2, minimal; 3, mild; 4, moderate; 5, severe; and 6, extreme.<br />Δ Effect size measures the increase in symptom endorsement during the perimenstrual interval compared with a nonmenstrual interval adjusted for the standard deviation of symptom endorsement during the entire cycle. The interval (–6, –1) indicates six days before through one day before menses; (–5, 1), five days before through the first day of menses; (–4, 2), four days before through the first two days of menses; and –3, 3), three days before through the first three days of menses.</div><div class=\"graphic_reference\">Reproduced with permission from: Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder. Arch Gen Psychiatry 2012; 69:300. Copyright &copy; 2012 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86227 Version 10.0</div></div></div>"},"86228":{"type":"graphic_table","displayName":"Assessment tools for fatigue in patients with serious illness","title":"Assessment tools for fatigue in patients with cancer and/or other serious life-threatening conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment tools for fatigue in patients with cancer and/or other serious life-threatening conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Fatigue severity scale</td> </tr> <tr> <td>2. Fatigue questionnaire</td> </tr> <tr> <td>3. Multidimensional fatigue inventory</td> </tr> <tr> <td>4. Multidimensional fatigue symptom inventory</td> </tr> <tr> <td>5. Revised Piper fatigue scale</td> </tr> <tr> <td>6. Revised Schwartz cancer fatigue scale</td> </tr> <tr> <td>7. Brief fatigue inventory</td> </tr> <tr> <td>8. Multidimensional assessment of fatigue</td> </tr> <tr> <td>9. Fatigue symptom inventory</td> </tr> <tr> <td>10. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</td> </tr> <tr> <td>&nbsp;11. Functional Assessment of Cancer Therapy-Fatigue (FACT-F)</td> </tr> <tr> <td>12. Edmonton Symptom Assessment Scale (ESAS)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86228 Version 2.0</div></div></div>"},"86230":{"type":"graphic_figure","displayName":"Life cycle of echinococcosis","title":"Life cycle of echinococcosis","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Life cycle of echinococcosis</div><div class=\"cntnt\"><img style=\"width:600px; height:452px;\" src=\"images/ID/86230_Life_cycle_echinococcosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Causal agents: Human echinococcosis (hydatidosis, or hydatid disease) is caused by the larval stages of cestodes (tapeworms) of the genus <EM>Echinococcus</EM>. <EM>Echinococcus granulosus</EM> causes cystic echinococcosis, the form most frequently encountered; <EM>E. multilocularis</EM> causes alveolar echinococcosis; <EM>E. vogeli</EM> causes polycystic echinococcosis; and <EM>E. oligarthrus</EM> is an extremely rare cause of human echinococcosis.<BR>The adult <EM>Echinococcus granulosus</EM> (3 to 6 mm long) <STRONG>(1)</STRONG> resides in the small bowel of the definitive hosts, dogs, or other canids. Gravid proglottids release eggs <STRONG>(2)</STRONG> that are passed in the feces. After ingestion by a suitable intermediate host (under natural conditions: sheep, goat, swine, cattle, horses, camel), the egg hatches in the small bowel and releases an oncosphere <STRONG>(3)</STRONG> that penetrates the intestinal wall and migrates through the circulatory system into various organs, especially the liver and lungs. In these organs, the oncosphere develops into a cyst <STRONG>(4)</STRONG> that enlarges gradually, producing protoscolices and daughter cysts that fill the cyst interior. The definitive host becomes infected by ingesting the cyst-containing organs of the infected intermediate host. After ingestion, the protoscolices <STRONG>(5)</STRONG> evaginate, attach to the intestinal mucosa <STRONG>(6)</STRONG>, and develop into adult stages <STRONG>(1)</STRONG> in 32 to 80 days. The same life cycle occurs with <EM>E. multilocularis</EM> (1.2 to 3.7 mm), with the following differences: the definitive hosts are foxes, and to a lesser extent dogs, cats, coyotes, and wolves; the intermediate host are small rodents; and larval growth (in the liver) remains indefinitely in the proliferative stage, resulting in invasion of the surrounding tissues. With <EM>E. vogeli</EM> (up to 5.6 mm long), the definitive hosts are bush dogs and dogs; the intermediate hosts are rodents; and the larval stage (in the liver, lungs, and other organs) develops both externally and internally, resulting in multiple vesicles. <EM>E. oligarthrus</EM> (up to 2.9 mm long) has a life cycle that involves wild felids as definitive hosts and rodents as intermediate hosts. Humans become infected by ingesting eggs <STRONG>(Δ)</STRONG>, with resulting release of oncospheres <STRONG>(◊)</STRONG> in the intestine and the development of cysts <STRONG>(*)</STRONG> in various organs.<BR><EM>E. granulosus</EM> occurs practically worldwide, and more frequently in rural, grazing areas where dogs ingest organs from infected animals. <EM>E. multilocularis</EM> occurs in the northern hemisphere, including central Europe and the northern parts of Europe, Asia, and North America. <EM>E. vogeli</EM> and <EM>E. oligarthrus</EM> occur in Central and South America.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Echinococcosis. Available at: <A href=\"http://www.cdc.gov/dpdx/echinococcosis/index.html\">http://www.cdc.gov/dpdx/echinococcosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 86230 Version 2.0</div></div></div>"},"86231":{"type":"graphic_table","displayName":"General approach to treatment of fatigue in palliative care","title":"General approach to treatment of fatigue in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General approach to treatment of fatigue in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Treatment of the underlying cause</td> </tr> <tr> <td>Anemia - Red blood cell transfusion or an erythropoiesis stimulating agent, most useful in patients receiving chemotherapy who have severe anemia</td> </tr> <tr> <td>Deconditioning - exercise</td> </tr> <tr> <td>Depression&nbsp;- antidepressants </td> </tr> <tr> <td>Hypogonadism - testosterone replacement therapy&nbsp;</td> </tr> <tr> <td>Infections - antibiotics</td> </tr> <tr> <td>Dehydration - intravenous or subcutaneous fluids</td> </tr> <tr> <td>Hypoxia - oxygen,&nbsp;if hypoxemic (eg,&nbsp;oxygen saturation &#60;90 percent by pulse oximetry)</td> </tr> <tr> <td>Metabolic and endocrine disorders - correction of disorder (eg, thyroid or testosterone replacement)</td> </tr> <tr> <td>Insomnia - sleep hygiene, brief trial of short-acting hypnotics in refractory cases </td> </tr> <tr> <td>Pain - NSAIDs, opioids</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of the symptom</td> </tr> <tr> <td>Established therapies - glucocorticoids, megestrol acetate </td> </tr> <tr> <td>Less well established therapies - methylphenidate, modafinil, American Ginseng</td> </tr> <tr> <td>Alternative therapies - melatonin, fish oil, yoga, and meditation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86231 Version 2.0</div></div></div>"},"86234":{"type":"graphic_picture","displayName":"Cardiac auscultation supine and leaning forward","title":"Cardiac auscultation supine and leaning forward","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Cardiac auscultation supine and leaning forward</div><div class=\"cntnt\"><img style=\"width:513px; height:213px;\" src=\"images/CARD/86234_Card_auscul_sup_lean.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Auscultation of the pericardium: To elicit pericardial rubs, the patient is invited to lean forward (A) or rest on elbows and knees (B). Both physical maneuvers increase the contact of visceral and parietal pericardium.</div><div class=\"graphic_reference\">Reproduced from: Heart, Imazio M. Pericardial involvement in systemic inflammatory diseases, 97:1882, Copyright © 2011, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 86234 Version 1.0</div></div></div>"},"86236":{"type":"graphic_figure","displayName":"Continuous bronchodilator nebulization in children","title":"Continuous beta agonist nebulization set-up for face mask delivery in children","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Continuous beta agonist nebulization set-up for face mask delivery in children</div><div class=\"cntnt\"><img style=\"width:502px; height:652px;\" src=\"images/ALLRG/86236_Continuous-bronchodilator-nebulizations-in-children.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilute the calculated albuterol dose per hour with 0.9 percent normal saline for inhalation to a final volume of 20 mL. Set the pump to nebulize continuously at 20 mL per hour, with a driving oxygen flow rate set at 8 to 10 mL per minute. The pump should be labeled \"for respiratory use only\" to minimize the risk of inadvertent intravenous administraion.</div><div id=\"graphicVersion\">Graphic 86236 Version 4.0</div></div></div>"},"86246":{"type":"graphic_table","displayName":"Colposcopy terminology","title":"2011 International Federation of Cervical Pathology and Colposcopy colposcopic terminology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2011 International Federation of Cervical Pathology and Colposcopy colposcopic terminology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Section</td> <td class=\"subtitle1\">Pattern</td> </tr> <tr> <td rowspan=\"3\">General assessment</td> <td>Adequate or inadequate for the reason (eg, cervix obscured by inflammation, bleeding, scar)</td> </tr> <tr> <td>Squamocolumnar junction visibility: completely visible, partially visible, not visible</td> </tr> <tr> <td>Transformation zone types 1, 2, 3</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Normal colposcopic findings</td> <td>Original squamous epithelium: mature, atrophic</td> </tr> <tr> <td>Columnar epithelium, ectopy/ectropion</td> </tr> <tr> <td>Metaplastic squamous epithelium, nabothian cysts, crypt (gland) openings</td> </tr> <tr> </tr> <tr> <td>Deciduosis in pregnancy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Abnormal colposcopic findings</td> <td>General principles</td> </tr> <tr> <td>Location of the lesion: inside or outside the transformation zone, location of the lesion by clock position</td> </tr> <tr> <td>Size of the lesion: number of cervical quadrants the lesion covers</td> </tr> <tr> <td>Size of the lesion as percentage of cervix</td> </tr> <tr> <td>Grade 1 (minor): fine mosaic; fine punctation; thin acetowhite epithelium; irregular, geographic border</td> </tr> <tr> <td>Grade 2 (major): sharp border, inner border sign, ridge sign, dense acetowhite epithelium, coarse mosaic, coarse punctation, rapid appearance of acetowhitening, cuffed crypt (gland) openings</td> </tr> <tr> <td>Nonspecific: leukoplakia (keratosis, hyperkeratosis), erosion</td> </tr> <tr> <td>Lugol's staining (Schiller's test): stained or nonstained</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Suspicious for invasion</td> <td>Atypical vessels</td> </tr> <tr> <td>Additional signs: fragile vessels, irregular surface, exophytic lesion, necrosis, ulceration (necrotic), tumor or gross neoplasm</td> </tr> <tr class=\"divider_top\"> <td>Miscellaneous findings</td> <td>Congenital transformation zone, condyloma, polyp (ectocervical or endocervical), inflammation, stenosis, congenital anomaly, posttreatment consequence, endometriosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Bornstein J, Bentley J, Bosze P, et al. 2011 Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012; 120:166. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86246 Version 5.0</div></div></div>"},"86251":{"type":"graphic_diagnosticimage","displayName":"TB of the spine Pott's disease","title":"Tuberculosis of the spine (Pott's disease)","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Tuberculosis of the spine (Pott's disease)</div><div class=\"cntnt\"><img style=\"width:461px; height:492px;\" src=\"images/ID/86251_TB_of the spine_Pott_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI)&nbsp;with T1-weighted fat-saturated image showing anterior vertebral body destruction with relative sparing of adjacent discs and an abscess spreading beneath the anterior longitudinal ligament.</div><div class=\"graphic_reference\">Courtesy of Denis Spelman, MBBS, FRACP, FRCPA, MPH.</div><div id=\"graphicVersion\">Graphic 86251 Version 4.0</div></div></div>"},"86252":{"type":"graphic_diagnosticimage","displayName":"TB of the spine Pott's disease 2","title":"Tuberculosis of the spine (Pott's disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis of the spine (Pott's disease)</div><div class=\"cntnt\"><img style=\"width:301px; height:421px;\" src=\"images/ID/86252_TB_spine_Pott_disease_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI) of 17-year-old fisherman showing tuberculous infection of adjacent thoracic vertebrae with intervening disc destruction and an anterior paraspinal abscess.</div><div class=\"graphic_reference\">Courtesy of Malcolm McDonald, PhD, FRACP, FRCPA.</div><div id=\"graphicVersion\">Graphic 86252 Version 4.0</div></div></div>"},"86253":{"type":"graphic_diagnosticimage","displayName":"TB of the spine Pott's disease 3","title":"Tuberculosis of the spine (Pott's disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis of the spine (Pott's disease)</div><div class=\"cntnt\"><img style=\"width:336px; height:412px;\" src=\"images/ID/86253_TB_spine_Pott_disease_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI) of 17-year-old fisherman (coronal section) showing a large tuberculous paraspinal abscess and pleural involvement.</div><div class=\"graphic_reference\">Courtesy of Malcolm McDonald, PhD, FRACP, FRCPA.</div><div id=\"graphicVersion\">Graphic 86253 Version 4.0</div></div></div>"},"86254":{"type":"graphic_diagnosticimage","displayName":"Post fixation spinal TB","title":"Post-surgical drainage and fixation of spinal tuberculosis (Pott's disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-surgical drainage and fixation of spinal tuberculosis (Pott's disease)</div><div class=\"cntnt\"><img style=\"width:267px; height:504px;\" src=\"images/ID/86254_Post_fix_spinal_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of 17-year-old fisherman&nbsp;following surgical drainage and spinal fixation.</div><div class=\"graphic_reference\">Courtesy of Malcolm McDonald, PhD, FRACP, FRCPA.</div><div id=\"graphicVersion\">Graphic 86254 Version 3.0</div></div></div>"},"86255":{"type":"graphic_picture","displayName":"Paragard IUD PI","title":"Paragard IUD","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Paragard IUD</div><div class=\"cntnt\"><img style=\"width:468px; height:287px;\" src=\"images/PI/86255_Paragard_IUD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The copper-releasing intrauterine device (IUD) is called Paragard. It is inserted into the uterus to prevent pregnancy.</div><div id=\"graphicVersion\">Graphic 86255 Version 3.0</div></div></div>"},"86256":{"type":"graphic_figure","displayName":"Arterial stent PI","title":"Arterial stent","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Arterial stent</div><div class=\"cntnt\"><img style=\"width:457px; height:289px;\" src=\"images/PI/86256_HeartstentPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A stent is a tiny metal tube that helps prop open an artery (blood vessel). Most stents are coated with a medicine that helps keep the artery from getting narrow or blocked again.</div><div id=\"graphicVersion\">Graphic 86256 Version 2.0</div></div></div>"},"86257":{"type":"graphic_figure","displayName":"Poisonous spiders PI","title":"Poisonous spiders ","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Poisonous spiders </div><div class=\"cntnt\"><img style=\"width:513px; height:369px;\" src=\"images/PI/86257_Poisonous_spiders_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most spiders are not dangerous to people. But these 4 spiders can cause painful bites that can also cause other serious symptoms.<br />A) Black widow.<br />B) Brown widow.<br />C) False black widow.<br />D) Female recluse.<br /></div><div id=\"graphicVersion\">Graphic 86257 Version 1.0</div></div></div>"},"86258":{"type":"graphic_table","displayName":"Dangerous spiders table PI","title":"Dangerous spiders: Where they are found and what they look like","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dangerous spiders: Where they are found and what they look like</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Where they are found in the world</td> <td class=\"subtitle1\">Common name/species name</td> <td class=\"subtitle1\">What they look like</td> <td class=\"subtitle1\">Where they live</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Widows</td> </tr> <tr> <td class=\"indent1\">Southeastern United States (Maryland, Southern Ohio and lower states)</td> <td>Southern black widow<br /> <em>L. mactans</em></td> <td rowspan=\"2\">Shiny black spider with some form of red on body</td> <td rowspan=\"6\"> <p>Clutter around homes, gardens, sheds, garages</p> Rarely indoors</td> </tr> <tr> <td class=\"indent1\">Western half of the United States from Canada to Mexico</td> <td>Western black widow<br /> <em>L. hesperus</em></td> </tr> <tr> <td class=\"indent1\"> <p>New Zealand (coastal areas)</p> <p>Australia (coastal areas)</p> Japan (Osaka prefecture)</td> <td>Australian red back<br /> <em>L. hasselti</em></td> <td>Shiny black body with red stripe on back </td> </tr> <tr> <td class=\"indent1\">South America</td> <td><em>L. curacaviensis</em></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Mediterranean</td> <td>Black hag, black wolf<br /> <em>L. tredecimguttatus</em></td> <td>13 red dots on back of body, no red hourglass</td> </tr> <tr> <td class=\"indent1\">Worldwide and in United States (from South Carolina to Texas and California)</td> <td> <p>Brown widow </p> <p><em>L. geometricus</em></p> <p>(can bite humans, but mild)</p> </td> <td>White stripes on a tan body with orange hourglass. Can vary a lot in color, from cream to almost black. &nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">False black widows</td> </tr> <tr> <td class=\"indent1\"> <p>United States: Pacific coast and Colorado</p> <p>Canada: British Columbia</p> <p>Australia</p> </td> <td> <p>False black widow</p> <p><em>S. grossa</em></p> </td> <td rowspan=\"2\"> <p>Similar shape to widows</p> <p>Chocolate brown color with tan stripes or markings on body</p> DO NOT have red markings</td> <td rowspan=\"2\"> <p>Clutter around homes</p> <p>Also indoors (in cupboards and other dark, quiet places)</p> </td> </tr> <tr> <td class=\"indent1\">Europe</td> <td> <p><em>S. paykulliana</em></p> <em>S. grossa</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Recluses</td> </tr> <tr> <td class=\"indent1\">United States: Mid-west and Southern states extending westward </td> <td>Brown recluse<br /> <em>L. reclusa</em></td> <td rowspan=\"4\"> <p>Ordinary-looking brown spiders</p> <p>3 pairs of eyes (6 total)</p> <p>Body and legs are the same color</p> Legs have very fine hairs</td> <td rowspan=\"4\"> <p>Mostly inside homes: attics, basements, cupboards</p> Outdoors: in rock piles and under tree bark, NOT in live plants</td> </tr> <tr> <td class=\"indent1\">Worldwide inside buildings</td> <td>Mediterranean recluse<br /> <em>L. rufescens</em></td> </tr> <tr> <td class=\"indent1\">South America (Brazil, Chile, others)</td> <td rowspan=\"2\"> <p>Chilean recluse </p> <p><em>L. laeta</em></p> <p><em>L. intermedia</em></p> <em>L. gaucho</em></td> </tr> <tr> <td class=\"indent1\">Isolated reports in South Africa, Australia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Phoneutria</td> </tr> <tr> <td class=\"indent1\">South America</td> <td> <p>Brazilian wandering spider</p> <p><em>P. nigriventer</em></p> <p><em>P. keyserlingi</em></p> <em>P. fera</em></td> <td> <p>Large (almost 4-inch [95 millimeter]&nbsp;leg span)</p> Very hairy</td> <td> <p>Might hide under household items during the day</p> Found in cities in piles of clutter, trees and other plants, or garbage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Australian funnel web</td> </tr> <tr> <td class=\"indent1\">Australia: Southeastern coastal regions (including Sydney and Brisbane)</td> <td> <p>Australian funnel web spider</p> <p><em>Atrax robustus</em></p> 5 species of Hadronyche</td> <td> <p>Large spider (1-inch [25&nbsp;millimeter] body)</p> Shiny black body</td> <td>Moist areas, such as basements</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86258 Version 1.0</div></div></div>"},"86259":{"type":"graphic_picture","displayName":"Heat rash PI","title":"Heat rash (prickly heat)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heat rash (prickly heat)</div><div class=\"cntnt\"><img style=\"width:393px; height:511px;\" src=\"images/PI/86259_Heat_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A heat rash can cause&nbsp;bumps that look like small pimples (see picture A)&nbsp;or clusters of tiny bubbles under the skin (see picture B).</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 86259 Version 1.0</div></div></div>"},"86264":{"type":"graphic_picture","displayName":"Junctional EB Herlitz 1","title":"Junctional epidermolysis bullosa (JEB), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized severe</div><div class=\"cntnt\"><img style=\"width:333px; height:502px;\" src=\"images/DERM/86264_Junctional_EB_Herlitz_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized blistering, crusted erosions, and extensive areas of denudation in generalized severe JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86264 Version 2.0</div></div></div>"},"86266":{"type":"graphic_diagnosticimage","displayName":"US post tib tendon RA","title":"Transverse ultrasonograpy of the posterior tibial tendon in a patient with rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Transverse ultrasonograpy of the posterior tibial tendon in a patient with rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:513px; height:189px;\" src=\"images/RHEUM/86266_US_post_tib_ten_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows a grey-scale transverse sonogram of the posterior tibial tendon (T) of a patient with rheumatoid arthritis as it passes near the medial malleolus (M) and talus (Ta). The tendon sheath is distended with fluid (arrowheads). The right panel shows a power Doppler sonogram of the same patient. Both pictures show an extensive inflammation of both the tendon and the tendon sheath.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86266 Version 2.0</div></div></div>"},"86267":{"type":"graphic_picture","displayName":"Junctional epidermolysis bullosa Herlitz 2","title":"Junctional epidermolysis bullosa, generalized severe","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa, generalized severe</div><div class=\"cntnt\"><img style=\"width:576px; height:382px;\" src=\"images/DERM/86267_JunctionalEBHerlitz2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized blistering, crusted erosions, and extensive areas of denudation in generalized severe JEB.</div><div class=\"graphic_footnotes\">JEB: junctional epidermolysis bullosa.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86267 Version 4.0</div></div></div>"},"86268":{"type":"graphic_diagnosticimage","displayName":"PIP synovitis US in RA","title":"Ultrasound image of synovitis of a proximal interphalangeal joint in a patient with rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of synovitis of a proximal interphalangeal joint in a patient with rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:512px; height:199px;\" src=\"images/RHEUM/86268_PIP_synovitis_US_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows synovitis (arrowheads) of the third proximal interphalangeal joint (curved arrow) from the dorsal view in a patient with rheumatoid arthritis. Right panel shows positive power Doppler synovitis in the third proximal interphalangeal joint of the same patient.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86268 Version 1.0</div></div></div>"},"86269":{"type":"graphic_picture","displayName":"Junctional EB Herlitz 3","title":"Junctional epidermolysis bullosa (JEB), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized severe</div><div class=\"cntnt\"><img style=\"width:576px; height:385px;\" src=\"images/DERM/86269_Junctional_EB_Herlitz_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blisters, crusted erosions, and large denuded areas in generalized severe JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86269 Version 2.0</div></div></div>"},"86270":{"type":"graphic_picture","displayName":"Junctional EB Herlitz 4","title":"Junctional epidermolysis bullosa (JEB), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized severe</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86270_Junctional_EB_Herlitz_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive areas of denudation in generalized severe JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86270 Version 2.0</div></div></div>"},"86271":{"type":"graphic_picture","displayName":"Junctional EB Herlitz 5","title":"Junctional epidermolysis bullosa (JEB), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized severe</div><div class=\"cntnt\"><img style=\"width:466px; height:471px;\" src=\"images/DERM/86271_Junctional_EB_Herlitz_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail erosions with periungual granulomatous tissue and incipient onycholysis in generalized severe JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86271 Version 2.0</div></div></div>"},"86272":{"type":"graphic_diagnosticimage","displayName":"Contrast-enhanced CT of appendiceal mucocele","title":"Contrast-enhanced computed tomography (CT) of appendiceal mucocele","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced computed tomography (CT) of appendiceal mucocele</div><div class=\"cntnt\"><img style=\"width:598px; height:301px;\" src=\"images/GAST/86272_Cont_enh_CT_append_mucocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low attenuation, encapsulated, elongated mass.<BR>(B) Impingement of cecal lumen by mass.</div><div class=\"graphic_reference\">Courtesy of Louis-Michel Wong Kee Song, MD.</div><div id=\"graphicVersion\">Graphic 86272 Version 1.0</div></div></div>"},"86274":{"type":"graphic_picture","displayName":"Appendiceal mucocele","title":"Appendiceal mucocele","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Appendiceal mucocele</div><div class=\"cntnt\"><img style=\"width:455px; height:596px;\" src=\"images/GAST/86274_Appendiceal_mucocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Surgically resected specimen showing dilated appendix.<br />(B) Gross pathology of a mucinous cystadenoma.</div><div class=\"graphic_reference\">Courtesy of Richard Devine, MD, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 86274 Version 1.0</div></div></div>"},"86275":{"type":"graphic_figure","displayName":"Volume responsiveness to guide fluid therapy","title":"Volume responsiveness to guide fluid therapy","html":"<div class=\"graphic\"><div style=\"width: 659px\" class=\"figure\"><div class=\"ttl\">Volume responsiveness to guide fluid therapy</div><div class=\"cntnt\"><img style=\"width:639px; height:474px;\" src=\"images/ANEST/86275_Vol_respons_guide_flu_ther.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frank-Starling relationship with corresponding respiratory variations in the arterial pressure waveform. High respiratory variation in the arterial pressure or in the plethysmographic waveforms indicates that the patient is on the steep portion of the Frank-Starling relationship. Low variation indicates that the patient is on the plateau. Cardiac output maximization concepts aim at increasing cardiac output until it reaches the plateau of the Frank-Starling relationship. This goal, as demonstrated on this figure, could be achieved by minimizing respiratory variation in arterial pressure or plethysmographic waveform.</div><div class=\"graphic_footnotes\">* Arterial waveform obtained from invasive arterial monitoring.</div><div class=\"graphic_reference\">Modified with permission from: Rinehart J, Liu N, Alexander B, Cannesson M. Closed-Loop Systems in Anesthesia: Is There a Potential for Closed-Loop Fluid Management and Hemodynamic Optimization? Anesth Analg 2012; 114:130. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86275 Version 6.0</div></div></div>"},"86276":{"type":"graphic_figure","displayName":"Rocker sole shoe","title":"Rocker sole shoe","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Rocker sole shoe</div><div class=\"cntnt\"><img style=\"width:482px; height:297px;\" src=\"images/SURG/86276_Rocker-sole-shoe.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86276 Version 2.0</div></div></div>"},"86277":{"type":"graphic_table","displayName":"Prognostic factors in chronic intestinal pseudo-obstruction","title":"Prognostic factors in chronic intestinal pseudo-obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic factors in chronic intestinal pseudo-obstruction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Poor outcome</td> </tr> <tr> <td>Myopathy</td> </tr> <tr> <td>Early/acute onset</td> </tr> <tr> <td>Urinary involvement</td> </tr> <tr> <td>Malrotation</td> </tr> <tr> <td>Short bowel syndrome</td> </tr> <tr> <td>Surgery</td> </tr> <tr> <td>Total parenteral nutrition (TPN)</td> </tr> <tr> <td class=\"sublist1_start\">Findings on small intestinal manometry:</td> </tr> <tr> <td class=\"sublist1\">Hypomotility</td> </tr> <tr> <td class=\"sublist1\">Absence of MMCs</td> </tr> <tr> <td class=\"sublist1\">Intestinal phasic and tonic pressure \"bursts\"</td> </tr> <tr> <td class=\"sublist1\">Inadequate intestinal response to a meal (fed pattern)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Good outcome</td> </tr> <tr> <td>Gender (male)</td> </tr> <tr> <td>No vagal dysfunction or sympathetic dysfunction</td> </tr> <tr> <td>Clinical response to cisapride</td> </tr> <tr> <td>Normal bowel diameter</td> </tr> <tr> <td>Findings on small intestinal manometry: presence of MMCs, motor response to octreotide</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMCs: migrating motor complexes.</div><div class=\"graphic_reference\">Data from: Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc 2010; 42:15.</div><div id=\"graphicVersion\">Graphic 86277 Version 1.0</div></div></div>"},"86279":{"type":"graphic_diagnosticimage","displayName":"Colonic ischemia on computed tomography","title":"Colonic ischemia on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Colonic ischemia on computed tomography</div><div class=\"cntnt\"><img style=\"width:598px; height:358px;\" src=\"images/RADIOL/86279_Colonic_ischemia_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the abdomen is from a 72-year-old female who presented with acute abdominal pain. Image A is an axial projection through the cecum, and image B shows the cecum and ascending colon reformatted in the coronal plane. The images show an accumulation of air within the wall of the cecum (arrows), a finding that is characteristic of pneumatosis coli. Associated radiolologic findings include the lack of formed stool in the colon reflecting loss of mucosal function, thickening of the peritoneum and lateral conal fascia (arrowhead), and ascites (dashed arrow). No portal venous air was evident. In the appropriate clinical setting, the findings are highly suggestive of acute ischemia of the large bowel.</div><div class=\"graphic_footnotes\">CT: computed tomography. </div><div id=\"graphicVersion\">Graphic 86279 Version 4.0</div></div></div>"},"86280":{"type":"graphic_picture","displayName":"Facial findings following strangulation attempt","title":"Facial findings following strangulation attempt","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Facial findings following strangulation attempt</div><div class=\"cntnt\"><img style=\"width:264px; height:393px;\" src=\"images/PC/86280_Strangulation_findings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left subconjunctival hemorrhage is a sign after strangulation.</div><div class=\"graphic_reference\">Courtesy of Amy Weil, MD, FACP.</div><div id=\"graphicVersion\">Graphic 86280 Version 2.0</div></div></div>"},"86281":{"type":"graphic_picture","displayName":"Collagen type III glomerulopathy","title":"Collagen type III glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Collagen type III glomerulopathy</div><div class=\"cntnt\"><img style=\"width:513px; height:193px;\" src=\"images/NEPH/86281_Coll_III_glomerulopth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Light microscopy showing mesangial expansion and thickened capillary walls (hematoxylin and eosin stain).<BR>(B) Electron microscopy showing subendothelial expansion with collagen fibrils.</div><div class=\"graphic_reference\">Courtesy of Dr. Lynn Cornell, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.</div><div id=\"graphicVersion\">Graphic 86281 Version 1.0</div></div></div>"},"86283":{"type":"graphic_table","displayName":"Montreal classification for Crohn disease","title":"Montreal classification for Crohn disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Montreal classification for Crohn disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Age at diagnosis</td> </tr> <tr> <td class=\"indent1\">A1 below 16 years</td> </tr> <tr> <td class=\"indent1\">A2 between 17 and 40 years</td> </tr> <tr> <td class=\"indent1\">A3 above 40 years</td> </tr> <tr> <td class=\"subtitle1_single\">Location</td> </tr> <tr> <td class=\"indent1\">L1 ileal</td> </tr> <tr> <td class=\"indent1\">L2 colonic</td> </tr> <tr> <td class=\"indent1\">L3 ileocolonic</td> </tr> <tr> <td class=\"indent1\">L4 isolated upper disease*</td> </tr> <tr> <td class=\"subtitle1_single\">Behavior</td> </tr> <tr> <td class=\"indent1\">B1 nonstricturing, nonpenetrating</td> </tr> <tr> <td class=\"indent1\">B2 stricturing</td> </tr> <tr> <td class=\"indent1\">B3 penetrating</td> </tr> <tr> <td class=\"indent1\">p perianal disease modifier<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* L4 is a modifier that can be added to L1-L3 when concomitant upper gastrointestinal disease is present.<br />¶ \"p\" is added to B1-B3 when concomitant perianal disease is present.</div><div class=\"graphic_reference\">Reproduced from: Gut, Satsangi J, Silverberg MS, Vermere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, 55:749-53, copyright &copy; 2006, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 86283 Version 8.0</div></div></div>"},"86284":{"type":"graphic_table","displayName":"Montreal classification of severity of ulcerative colitis","title":"Montreal classification of severity of ulcerative colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Montreal classification of severity of ulcerative colitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Severity</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>S0</td> <td>Clinical remission</td> <td>Asymptomatic</td> </tr> <tr> <td>S1</td> <td>Mild UC</td> <td>Passage of four or fewer stools/day (with or without blood), absence of any systemic illness, and normal inflammatory markers (ESR)</td> </tr> <tr> <td>S2</td> <td>Moderate UC</td> <td>Passage of more than four stools per day but with minimal signs of systemic toxicity</td> </tr> <tr> <td>S3</td> <td>Severe UC</td> <td>Passage of at least six bloody stools daily, pulse rate of at least 90 beats per minute, temperature of at least 37.5&#176;C, haemoglobin of less than 10.5 g/dL, and ESR of at least 30 mm/hour</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UC: ulcerative colitis; ESR: erythrocyte sedimentation rate.</div><div class=\"graphic_reference\">Reproduced from: Gut, Satsangi J, Silverberg MS, Vermere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, 55:749-53, copyright © 2006, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 86284 Version 4.0</div></div></div>"},"86308":{"type":"graphic_table","displayName":"Clinical COPD Questionnaire","title":"Clinical COPD Questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical COPD Questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1\" colspan=\"8\">Please <em>circle</em> the number of the response that best describes how you have been feeling during the <em>past week</em>.<br /> (Only <em>one</em> response for each question)</td> </tr> <tr> <td class=\"sublist1_start\">On average, <strong>during the past week</strong>, how often did you feel:</td> <td class=\"centered sublist1_start\">Never</td> <td class=\"centered sublist1_start\">Hardly ever</td> <td class=\"centered sublist1_start\">A few times</td> <td class=\"centered sublist1_start\">Several times</td> <td class=\"centered sublist1_start\">Many times</td> <td class=\"centered sublist1_start\">A great many times</td> <td class=\"centered sublist1_start\">Almost all the time</td> </tr> <tr> <td class=\"indent1\">1. Short of breath <strong>at rest</strong>?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">2. Short of breath <strong>doing physical activities</strong>?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">3. <strong>Concerned</strong> about getting a cold or your breathing getting worse?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">4. <strong>Depressed (down)</strong> because of your breathing problems?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"8\">In general, <strong>during the past week</strong>, how much of the time:</td> </tr> <tr> <td class=\"indent1\">5. Did you <strong>cough</strong>?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">6. Did you <strong>produce phlegm</strong>?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"sublist1_start\">On average, <strong>during the past week</strong>, how limited were you in these activities <strong>because of your breathing problems</strong>:</td> <td class=\"centered sublist1_start\">Not limited at all</td> <td class=\"centered sublist1_start\">Very slightly limited</td> <td class=\"centered sublist1_start\">Slightly limited</td> <td class=\"centered sublist1_start\">Moderately limited</td> <td class=\"centered sublist1_start\">Very limited</td> <td class=\"centered sublist1_start\">Extremely limited</td> <td class=\"centered sublist1_start\">Totally limited/or unable to do</td> </tr> <tr> <td class=\"indent1\">7. <strong>Strenuous physical activities</strong> (such as climbing stairs, hurrying, doing sports)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">8. <strong>Moderate physical activities</strong> (such as walking, housework, carrying things)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">9. <strong>Daily activities at home</strong> (such as dressing, washing yourself)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">10. <strong>Social activities</strong> (such as talking, being with children, visiting friends/relatives)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CCQ Questionnaire calculation of scores:<br /><UL>&#xD;&#xA;<LI>CCQ total score = (item 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10)/10</LI>&#xD;&#xA;<LI>Symptom = (item 1 + 2 + 5 + 6)/4</LI>&#xD;&#xA;<LI>Functional state = (item 7 + 8 + 9 + 10)/4</LI>&#xD;&#xA;<LI>Mental state = (item 3 + 4)/2.</LI></UL></div><div class=\"graphic_reference\">Reproduced with permission from: van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1:13. Copyright &copy; 2003 Thys van der Molen. The Clinical COPD Questionnaire is copyrighted. It may not be changed, translated, or sold (paper or software) without permission of Thys van der Molen. The CCQ is available for all clinical purposes without charge in 62 languages on <a href=\"http://www.ccq.nl/\" target=\"_blank\">www.ccq.nl</a>.</div><div id=\"graphicVersion\">Graphic 86308 Version 2.0</div></div></div>"},"86309":{"type":"graphic_table","displayName":"Panitumumab monotherapy CRC","title":"Panitumumab monotherapy for metastatic, K-ras wild type colorectal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Panitumumab monotherapy for metastatic, K-ras wild type colorectal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 2 weeks.<br /> <strong>Duration:</strong> Continue until disease progression or unacceptable toxicity. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr class=\"divider_bottom\"> <td>Panitumumab</td> <td>6 mg/kg IV</td> <td>Dilute to total volume 100 mL with normal saline.* Administer over 60 minutes<sup>&#182;</sup> using a low-protein-binding 0.2 micron or 0.22 micron in-line filter.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine premedication not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each dose. Monitor calcium, magnesium and potassium levels weekly for eight weeks after completion of therapy and institute appropriate treatment as needed.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for skin rash and for evidence of keratitis or ulcerative keratitis. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess for signs/symptoms of pulmonary toxicity. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Ocular toxicities</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt or discontinue panitumumab for acute or worsening keratitis.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Reduce infusion rate by 50% for mild or moderate (grade 1 and 2) reactions and terminate the infusion for severe infusion reactions. Depending on the severity and/or persistence of the reaction, permanently discontinue panitumumab.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dermatologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold therapy for severe or intolerable toxicity; may resume at 50% of dose if toxicity improves and escalate dose as tolerated for subsequent infusions.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Permanently discontinue panitumumab in patients developing pulmonary fibrosis/interstitial lung disease.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Doses higher than 1000 mg should be diluted to 150 mL with normal saline and administered over 90 rather than 60 minutes.<br />¶ If initial dose is well tolerated, subsequent doses can be administered over 30 minutes.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Van Cutsem E, et al. J Clin Oncol 2007; 25:1658.</LI>&#xD;&#xA;<LI>Panitumumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 8, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86309 Version 9.0</div></div></div>"},"86311":{"type":"graphic_table","displayName":"FOLFIRI plus panitumumab for colorectal cancer","title":"FOLFIRI plus panitumumab chemotherapy for K-ras wild-type metastatic colorectal cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFIRI plus panitumumab chemotherapy for K-ras wild-type metastatic colorectal cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Panitumumab</strong></td> <td>6 mg/kg IV</td> <td>Dilute to total volume 100 mL* with normal saline (NS) and administer over 60 minutes<sup>&#916;</sup> using a low-protein-binding 0.2 micron or 0.22 micron in-line filter.</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Irinotecan</strong></td> <td>180<sup>&#9674;</sup> mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water (D5W)<sup>&#167;</sup> and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection) after panitumumab; may be given concurrently with leucovorin via y-site connection.</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Leucovorin</strong><sup>&#165;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL D5W and administer over two hours; may give concurrent with irinotecan via y-site connection.</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Slow intravenous push over five minutes (administer immediately after leucovorin).</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Days 1 and 15</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Routine premedication not indicated. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not justified (risk of febrile neutropenia with this regimen was 2 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of FU and irinotecan may be needed for patients with baseline hepatic impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes (including magnesium, calcium, and potassium) and liver and renal function prior to each dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for skin rash and for evidence of keratitis or ulcerative keratitis.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for signs or symptoms of pulmonary toxicity.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Delay treatment until absolute neutrophil count is &#62;1500 cells/microL and the platelet count is &#62;100,000/microL. United States Prescribing Information suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle<sup>[3]</sup>. A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m<sup>2</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle<sup>[3]</sup>. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dermatologic toxicity:</strong> Severe dermatologic reactions, such as acneiform rash, require delayed administration of panitumumab and/or dose reduction. Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor&nbsp;(EGFR) inhibitors\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Permanently discontinue panitumumab in patients developing pulmonary fibrosis/interstitial lung disease<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2<sup>[2]</sup>. Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution<sup>[4]</sup>. Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle<sup>[3]</sup>. For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial. Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* Doses higher than 1000 mg should be diluted to 150 mL with NS and administered over 90 rather than 60 minutes.<br />&Delta; If the first panitumumab dose is well tolerated, subsequent infusions can be given over 30 minutes.<br /><span class=\"lozenge\">&loz;</span> A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".<br />&sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />&yen; Leucovorin dose is given for d,l-racemic mixture<sup>[5]</sup>. Use half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Peeters M, et al. J Clin Oncol 2010; 28:4706.</LI>&#xD;&#xA;<LI>Panitumumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 8, 2012).</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86311 Version 8.0</div></div></div>"},"86312":{"type":"graphic_picture","displayName":"Vulvar varicosity","title":"Vulvar varicosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar varicosity</div><div class=\"cntnt\"><img style=\"width:237px; height:318px;\" src=\"images/OBGYN/86312_Vulvar_varicosity.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Natasha R Johnson, MD.</div><div id=\"graphicVersion\">Graphic 86312 Version 1.0</div></div></div>"},"86313":{"type":"graphic_table","displayName":"Challenge with sulfite solution","title":"Challenge with sulfite solution for patients reporting asthmatic reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Challenge with sulfite solution for patients reporting asthmatic reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td><strong>Step 1 (placebo dose)</strong></td> <td>10 mL vehicle solution.* Have patient swish for several seconds&nbsp;and swallow.</td> <td>Measure FEV<sub>1</sub> prior to dose and if patient develops symptoms. If no reaction after 30 minutes, proceed to step 2.</td> </tr> <tr> <td><strong>Steps 2 through 4 (active doses)</strong></td> <td>Give 10 mL vehicle* containing: 10, 50, and then 100 mg potassium metabisulfite.</td> <td>Measure FEV<sub>1</sub> prior to each dose and if patient develops symptoms. Allow 30 minutes between doses. If no reaction after last dose, proceed to step 5.</td> </tr> <tr> <td><strong>Step 5 (placebo dose)</strong></td> <td>Give one 10 mL dose of vehicle solution*. Have patient swish and swallow.</td> <td>Measure FEV<sub>1</sub> prior to each dose and if patient develops symptoms. If no reaction, observe for 30 minutes after last dose.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Asthmatic reactions to sulfite solutions occur quickly.&nbsp;A 30-minute interval is adequate for observation after each dose. Each dose should be swished in the mouth for several seconds and then swallowed. If the patient reacts to an active dose, then the challenge is stopped and deemed positive. Protocol courtesy of Ronald A Simon, MD.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.<br />* Vehicle solution is lemonade made on day of challenge from sulfite-free commercial crystalized lemonade mix or from fresh lemons.</div><div id=\"graphicVersion\">Graphic 86313 Version 4.0</div></div></div>"},"86315":{"type":"graphic_diagnosticimage","displayName":"Long head biceps tendon US in RA","title":"Sonogram of the long head of the biceps tendon in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Sonogram of the long head of the biceps tendon in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:611px; height:216px;\" src=\"images/RHEUM/86315_Long_head_biceps_tend_US_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows an anterior transverse sonogram of the long head of the biceps tendon in a patient with rheumatoid arthritis. Fluid (arrowheads) is present inside the distended biceps tendon sheath. The biceps tendon itself shows signs of partial tear (curved arrow). The right panel shows power Doppler signals of the biceps tendon sheath.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86315 Version 1.0</div></div></div>"},"86316":{"type":"graphic_diagnosticimage","displayName":"Shoulder bursitis US PMR","title":"Sonogram of shoulder bursitis in polymyalgia rheumatica","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Sonogram of shoulder bursitis in polymyalgia rheumatica</div><div class=\"cntnt\"><img style=\"width:618px; height:243px;\" src=\"images/RHEUM/86316_Shoulder_bursitis_US_PMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows an anterior longitudinal sonogram of the shoulder in a patient with polymyalgia rheumatica. Fluid is present within the distended subacromial-subdeltoid bursa (*). The right panel shows an anterior transverse sonogram of the same shoulder, with power Doppler signals indicating active inflammation of the bursal sheaths (arrows).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86316 Version 1.0</div></div></div>"},"86319":{"type":"graphic_picture","displayName":"Embedded earring with infection","title":"Embedded earring with infection after helical piercing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Embedded earring with infection after helical piercing</div><div class=\"cntnt\"><img style=\"width:309px; height:504px;\" src=\"images/EM/86319_Embed_earring_w_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note crusted discharge and surrounding erythema and swelling at the piercing through the upper portion of the helix (arrow).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86319 Version 1.0</div></div></div>"},"86320":{"type":"graphic_picture","displayName":"Cauliflower ear deformity from infected piercing","title":"Cauliflower ear deformity from infected piercing of the fossa trangularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cauliflower ear deformity from infected piercing of the fossa trangularis</div><div class=\"cntnt\"><img style=\"width:342px; height:504px;\" src=\"images/EM/86320_Cauliflow_ear_def_inf_pier.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86320 Version 1.0</div></div></div>"},"86321":{"type":"graphic_diagnosticimage","displayName":"CT pyelograms ureter and renal pelvis tumors","title":"CT pyelograms showing tumor involving the ureters and the renal pelvis","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">CT pyelograms showing tumor involving the ureters and the renal pelvis</div><div class=\"cntnt\"><img style=\"width:610px; height:445px;\" src=\"images/ONC/86321_CT_pylgrm_urtr_rnl_plvs_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT pyelograms showing tumor involving the ureters (panel A) and the renal pelvis (panel B). The tumor is depicted by the arrows in each.</div><div class=\"graphic_reference\">Courtesy of Dr. Jerome P Richie.</div><div id=\"graphicVersion\">Graphic 86321 Version 1.0</div></div></div>"},"86322":{"type":"graphic_figure","displayName":"Gastric attachments","title":"Gastric attachments","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gastric attachments</div><div class=\"cntnt\"><img style=\"width:468px; height:438px;\" src=\"images/SURG/86322_Gastric_attachments.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86322 Version 1.0</div></div></div>"},"86323":{"type":"graphic_algorithm","displayName":"Acute gastric volvulus","title":"Acute gastric volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute gastric volvulus</div><div class=\"cntnt\"><img style=\"width:421px; height:611px;\" src=\"images/SURG/86323_Acutegastricvolvulus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy. <br />* Typically laparoscopic. If surgery is required to decompress the stomach, the findings at surgery will determine choice of repair plus gastropexy versus gastropexy alone.<br />¶ Open or laparoscopic.<br />Δ If unsuccessful, the patient will need surgery for decompression.</div><div id=\"graphicVersion\">Graphic 86323 Version 4.0</div></div></div>"},"86324":{"type":"graphic_picture","displayName":"Insect in the external auditory canal","title":"Insect in the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Insect in the external auditory canal</div><div class=\"cntnt\"><img style=\"width:471px; height:498px;\" src=\"images/EM/86324_Insect_exter_audit_canal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a tick (black arrow) in the external auditory ear canal and immediately adjacent to the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86324 Version 1.0</div></div></div>"},"86325":{"type":"graphic_picture","displayName":"Penetrating ear foreign body","title":"Tympanic membrane perforation from a penetrating foreign body of the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane perforation from a penetrating foreign body of the external auditory canal</div><div class=\"cntnt\"><img style=\"width:474px; height:504px;\" src=\"images/EM/86325_Penet_ear_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows a postero-superior perforation (arrow) of the tympanic membrane of the right ear caused by a pencil point. Injury in this location can cause permanent hearing loss.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86325 Version 1.0</div></div></div>"},"86326":{"type":"graphic_picture","displayName":"Febrile ulceronecrotic Mucha-Habermann disease","title":"Febrile ulceronecrotic Mucha-Habermann disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Febrile ulceronecrotic Mucha-Habermann disease</div><div class=\"cntnt\"><img style=\"width:337px; height:504px;\" src=\"images/DERM/86326_Feb_ulcer_mucha_haber_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic nodules in febrile ulceronecrotic Mucha-Habermann disease.</div><div id=\"graphicVersion\">Graphic 86326 Version 1.0</div></div></div>"},"86328":{"type":"graphic_diagnosticimage","displayName":"Gooseneck deformity of AV canal defect","title":"Gooseneck deformity of atrioventricular (AV) canal defect","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gooseneck deformity of atrioventricular (AV) canal defect</div><div class=\"cntnt\"><img style=\"width:504px; height:343px;\" src=\"images/PEDS/86328_Gse_defm_AV_canal_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic image from subcostal location demonstrating the gooseneck deformity that results from elongation and narrowing of the left ventricular outflow tract (arrow) in AV canal defects. The superior bridging leaflet is seen \"scooping out\" the subaortic region during diastole.</div><div class=\"graphic_footnotes\">Ao: aorta; LV: left ventricle; RA: right atrium; S: superior; I: inferior; R: right; L: left.</div><div id=\"graphicVersion\">Graphic 86328 Version 1.0</div></div></div>"},"86329":{"type":"graphic_figure","displayName":"Rastelli classification of AV canal defects","title":"Rastelli classification of atrioventricular canal defects","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Rastelli classification of atrioventricular canal defects</div><div class=\"cntnt\"><img style=\"width:464px; height:208px;\" src=\"images/PEDS/86329_Rast_class_AV_can_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Rastelli type A: The most common type, in which the superior bridging leaflet is committed to the left ventricle&nbsp;with&nbsp;chordal attachments to the crest of the ventricular septum.<BR>(B) Rastelli type B: The least common type, in which the superior bridging leaflet extends into the right ventricle.<BR>(C) Rastelli type C: In this form, the superior bridging leaflet is even larger and has no chordal attachment to the interventricular septum, referred to as “free floating.” It is found in combination with other cardiac defects, such as tetralogy of Fallot, transposition of the great arteries, and heterotaxy syndromes.</div><div class=\"graphic_footnotes\">SB: superior bridging leaflet; AL: anterior leaflet; RLL: right lateral leaflet; IB: inferior bridging leaflet; LLL: left lateral leaflet.</div><div id=\"graphicVersion\">Graphic 86329 Version 1.0</div></div></div>"},"86330":{"type":"graphic_diagnosticimage","displayName":"Fetal echocardiogram AV canal defect","title":"Fetal echocardiogram of atrioventricular canal defect","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fetal echocardiogram of atrioventricular canal defect</div><div class=\"cntnt\"><img style=\"width:504px; height:397px;\" src=\"images/PEDS/86330_Fet_echo_AV_canal_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal echocardiogram with common atrioventricular valve (AVV) separating a common atrium (CA) and ventricles.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; R: right; L: left; I: inferior; S: superior.</div><div id=\"graphicVersion\">Graphic 86330 Version 2.0</div></div></div>"},"86331":{"type":"graphic_diagnosticimage","displayName":"2-D echocardiogram of AV canal defect","title":"Two-dimensional echocardiograms of atrioventricular canal defect","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Two-dimensional echocardiograms of atrioventricular canal defect</div><div class=\"cntnt\"><img style=\"width:515px; height:186px;\" src=\"images/PEDS/86331_2D_echo_AV_canal_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional, four-chamber view of (A) balanced and (B) unbalanced complete atrioventricular (AV) canal defect. <br />(A) Balanced AV canal defect with large atrial (*) and ventricular (**) components separated by common atrioventricular valve (arrow). <br />(B) Unbalanced AV canal defect with right ventricular dominance, and hypoplastic left atrium and left ventricle.</div><div class=\"graphic_footnotes\">RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle; S: superior; I: inferior; R: right; L: left.</div><div id=\"graphicVersion\">Graphic 86331 Version 1.0</div></div></div>"},"86332":{"type":"graphic_table","displayName":"Manifestations of gender based violence","title":"Manifestations of gender-based violence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manifestations of gender-based violence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The family</td> </tr> <tr> <td class=\"subtitle2_left\">Physical</td> </tr> <tr> <td class=\"indent1\">Murder, battering, genital mutilation, infanticide, deprivation of food, medical care, reproductive coercion/control</td> </tr> <tr> <td class=\"subtitle2_left\">Sexual</td> </tr> <tr> <td class=\"indent1\">Rape, incest</td> </tr> <tr> <td class=\"subtitle2_left\">Emotional</td> </tr> <tr> <td class=\"indent1\">Confinement, forced marriage, threat of reprisals</td> </tr> <tr> <td class=\"subtitle1_single\">The community (social reference)</td> </tr> <tr> <td class=\"subtitle2_left\">Physical</td> </tr> <tr> <td class=\"indent1\">Battery, physical chastisement, reproductive coercion/control, pernicious traditional practices</td> </tr> <tr> <td class=\"subtitle2_left\">Sexual assault</td> </tr> <tr> <td class=\"indent1\">Rape, harassment</td> </tr> <tr> <td class=\"subtitle2_left\">Workplace</td> </tr> <tr> <td class=\"indent1\"> <p>Sexual aggression: Harassment, intimidation</p> <p>Commercialized: Sex trafficking, prostitution</p> </td> </tr> <tr> <td class=\"subtitle1_single\">The state</td> </tr> <tr> <td class=\"subtitle2_left\">Political</td> </tr> <tr> <td class=\"indent1\">llegitimate detention, forced sterilization, forced pregnancies, tolerating gender violence</td> </tr> <tr> <td class=\"subtitle2_left\">Custodial (military/police)</td> </tr> <tr> <td class=\"indent1\"> <p>Child soldiers</p> Rape, torture</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: United Nations Population Fund Country Technical Services Team (CST). Violence against women: Issues and legislative responses in East and South-East Asia and the Pacific. UNFPA 2000. Updated information from the UNFPA is available at: <A spellcheck=true href=\"http://asiapacific.unfpa.org/en/publications/policy-and-programme-guidance-hiv-and-gender-based-violence\" target=_blank>http://asiapacific.unfpa.org/en/publications/policy-and-programme-guidance-hiv-and-gender-based-violence</A>.</div><div id=\"graphicVersion\">Graphic 86332 Version 2.0</div></div></div>"},"86333":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram of AV canal defect demonstrating common AV valve","title":"Echocardiogram of AV canal defect demonstrating common AV valve","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of AV canal defect demonstrating common AV valve</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/PEDS/86333_Echo_AV_can_def_com_AV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional enface view of common atrioventricular (AV) valve in a patient with an AV canal defect. The superior bridging leaflet is committed to the left ventricle with attachments to the ventricular septum (asterisk).</div><div class=\"graphic_footnotes\">AL: anterior leaflet; IB: inferior bridging leaflet; LLL: left lateral leaflet; RLL: right lateral leaflet; SB: superior bridging leaflet; VS: ventricular septum; A/R: anterior/rightward; S: superior.</div><div id=\"graphicVersion\">Graphic 86333 Version 1.0</div></div></div>"},"86334":{"type":"graphic_diagnosticimage","displayName":"Doppler echo of AV canal defect with AV valve regurgitation","title":"Doppler echocardiogram of atrioventricular (AV) canal defect with AV valve regurgitation","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Doppler echocardiogram of atrioventricular (AV) canal defect with AV valve regurgitation</div><div class=\"cntnt\"><img style=\"width:555px; height:354px;\" src=\"images/PEDS/86334_Dop_ech_AV_can_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional color-flow Doppler four-chamber image across common AV valve in systole in a patient with an AV canal defect. In the right panel, color Doppler image demonstrates right AV valve regurgitation (asterisk), left AV valve regurgitation (double asterisk) and left-to-right shunting (arrow).</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; RA: right atrium; LA: left atrium; R: right; S: superior.</div><div id=\"graphicVersion\">Graphic 86334 Version 3.0</div></div></div>"},"86335":{"type":"graphic_diagnosticimage","displayName":"Echo of AV canal defect and elongated LVOT","title":"Echocardiogram of atrioventricular canal defect with elongated left ventricular outflow tract","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of atrioventricular canal defect with elongated left ventricular outflow tract</div><div class=\"cntnt\"><img style=\"width:504px; height:384px;\" src=\"images/PEDS/86335_Echo_AV_can_def_LVOT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram in a patient with atrioventricular canal defect and left ventricular outflow tract (LVOT) elongation but without obstruction, as the Doppler detects no flow acceleration (normal blue color).</div><div class=\"graphic_footnotes\">R: right; L: left; S: superior; I: inferior.</div><div id=\"graphicVersion\">Graphic 86335 Version 2.0</div></div></div>"},"86336":{"type":"graphic_waveform","displayName":"ECG AV canal defect","title":"Electrocardiogram in a patient with atrioventricular (AV) canal defect","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in a patient with atrioventricular (AV) canal defect</div><div class=\"cntnt\"><img style=\"width:590px; height:296px;\" src=\"images/PEDS/86336_ECG_AV_canal_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in a patient with atrioventricular (AV) canal defect with a characteristic leftward and superior QRS axis.</div><div id=\"graphicVersion\">Graphic 86336 Version 2.0</div></div></div>"},"86337":{"type":"graphic_figure","displayName":"Repair of complete AV canal defect","title":"Surgical techniques for repair of complete atrioventricular canal defect","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Surgical techniques for repair of complete atrioventricular canal defect</div><div class=\"cntnt\"><img style=\"width:739px; height:400px;\" src=\"images/PEDS/86337_One_repair_com_AV_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) One-patch repair: Prosthetic patch material is placed to close the ventricular and atrial communications. The common atrioventricular (AV) valve is divided and re-attached to the patch.<br />(Panel B) Two-patch repair: Prosthetic patch material is used to close the ventricular septal defect, and the common AV valve is sutured to the top of the patch. The atrial component is closed with a pericardial patch that is sutured to the common AV valve and ventricular patch.<br />(Panel C) Modified (simplified) single-patch repair: The common AV valve is directly sutured to the crest of the ventricular septum. Pericardium is used to close the atrial component and is sutured to the crest of the ventricular septum, separating the common AV valve into right and left components.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle; LAVV: left atrioventricular valve; RAVV: right atrioventricular valve.</div><div class=\"graphic_reference\">Reproduced from: Calkoen EE, Hazekamp MG, Blom NA, et al. Atrioventricular septal defect: From embryonic development to long-term follow-up. Int J Cardiol 2016; 202:784. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86337 Version 2.0</div></div></div>"},"86338":{"type":"graphic_figure","displayName":"Embryology of AV canal defects","title":"Embryology of atrioventricular (AV) canal defects","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Embryology of atrioventricular (AV) canal defects</div><div class=\"cntnt\"><img style=\"width:594px; height:520px;\" src=\"images/PEDS/86338_EmbryAVcanaldef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the embryologic development of the atrioventricular canal region and the spectrum of atrioventricular septal defects (AVSD), including partial, transitional, complete, and intermediate forms. Types A, B, and C refer to the Rastelli classification based on the anatomy of the superior bridging leaflet (please refer to the topic review on the clinical manifestations of atrioventricular canal defects).</div><div class=\"graphic_footnotes\">A: anterior leaflet; AB: anterior bridging leaflet; DDCC: dextrodorsal conus cushion; IEC: inferior endocardial cushion; LEC: lateral endocardial cushion; P: posterior leaflet; PB: posterior bridging leaflet; S: septal leaflet; SEC: superior endocardial cushion; L: lateral leaflet.</div><div class=\"graphic_reference\">Reproduced with permission from: Cetta F, Minich LL, Edwards WD, et al. Atrioventricular septal defects. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86338 Version 6.0</div></div></div>"},"86339":{"type":"graphic_picture","displayName":"Urine sediment showing a hyaline cast","title":"Urine sediment showing a hyaline cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing a hyaline cast</div><div class=\"cntnt\"><img style=\"width:343px; height:387px;\" src=\"images/NEPH/86339_Urine_sediment_hyaline_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative photomicrographs of unstained elements in urine.</div><div class=\"graphic_reference\">Reproduced from: Brunzel NA. Fundamentals of urine and body fluid analysis, 2nd ed, WB Saunders, Philadelphia, 2004. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86339 Version 1.0</div></div></div>"},"86341":{"type":"graphic_figure","displayName":"Cerumen or ear foreign body removal by irrigation","title":"Cerumen or ear foreign body removal by irrigation","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Cerumen or ear foreign body removal by irrigation</div><div class=\"cntnt\"><img style=\"width:484px; height:538px;\" src=\"images/EM/86341_Cerumenearforebodyremov.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringing cerumen or a foreign body from the auditory canal with an intravenous catheter attached to a 20 mL syringe. The irrigating stream is directed at the posterosuperior wall of the external auditory canal.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuerst RS. Removal of cerumen impaction. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86341 Version 7.0</div></div></div>"},"86346":{"type":"graphic_figure","displayName":"Different forms of AV canal defects","title":"Different forms of atrioventricular canal defects","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Different forms of atrioventricular canal defects</div><div class=\"cntnt\"><img style=\"width:546px; height:356px;\" src=\"images/PEDS/86346_DiffformAVcanaldef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic and physiologic similarities between the different forms of atrioventricular septal defect (AVSD) are illustrated. Complete AVSDs have one annulus with large interatrial and interventricular communications. Intermediate defects (one annulus, two orifices) are a subtype of complete AVSD. Complete AVSDs have physiology of ventricular septal defects (VSD) and atrial septal defects (ASD). In contrast, partial AVSDs have physiology of ASDs. Transitional defects are a form of complete AVSD in which a small insignificant inlet VSD is present, and as a result the physiology is more similar to that of a partial defect. Partial defects and the intermediate form of complete AVSD share a similar anatomic feature: a tongue of tissue divides the common atrioventricular valve into distinct right and left orifices.</div><div class=\"graphic_footnotes\">LA: left atrium; LPV: left pulmonary vein; LV: left ventricle; RA: right atrium; RPV: right pulmonary vein; RV: right ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from: Cetta F, Minich LL, Edwards WD, et al. Atrioventricular septal defects. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86346 Version 8.0</div></div></div>"},"86348":{"type":"graphic_picture","displayName":"Urine sediment renal tubular and epithelial cell cast","title":"Urine sediment showing renal tubular epithelial cells and a fragmented epithelial cell cast","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing renal tubular epithelial cells and a fragmented epithelial cell cast</div><div class=\"cntnt\"><img style=\"width:504px; height:404px;\" src=\"images/NEPH/86348_Urin_sed_ren_tub_frag_e.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This slide shows renal tubular cells (arrows) found in the urine, together with a fragment of&nbsp;a tubular epithelial cell cast&nbsp;(arrowhead). The tubular cells are characterized by one central nucleus and many cytoplasmic granules.</div><div class=\"graphic_reference\">Reproduced with permission from: Fogazzi GB, Verdesca S. An album of urinary microscopy images in a clinical context. NDT-Educational. Available at:&nbsp;<A style=\"FONT-STYLE: italic\" href=\"http://www.ndt-educational.org/fogazzislide20071part.htm\" target=_blank>http://www.ndt-educational.org/fogazzislide20071part.htm</A> (Accessed September 5, 2012). Copyright © 2012 Giovanni B Fogazzi, MD.</div><div id=\"graphicVersion\">Graphic 86348 Version 1.0</div></div></div>"},"86350":{"type":"graphic_picture","displayName":"Headlamp for ear foreign body removal","title":"Headlamp for ear foreign body removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Headlamp for ear foreign body removal</div><div class=\"cntnt\"><img style=\"width:353px; height:306px;\" src=\"images/EM/86350_Headlamp_ear_for_body_rem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use of a head lamp permits the use of both hands to brace and immobilize the head during removal of an external auditory canal foreign body that is near the tympanic membrane. A metal operating ear speculum is also used to direct light and to protect the lining of the ear canal during the procedure.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86350 Version 2.0</div></div></div>"},"86351":{"type":"graphic_picture","displayName":"Equipment for removal of ear foreign bodies","title":"Equipment for removal of foreign bodies from the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Equipment for removal of foreign bodies from the external auditory canal</div><div class=\"cntnt\"><img style=\"width:504px; height:367px;\" src=\"images/EM/86351_Equip_rem_ear_foreign_bod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pictured are a head lamp and from top to bottom: a Schuknecht foreign body remover, right-angle Day hook, and alligator forceps.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86351 Version 1.0</div></div></div>"},"86352":{"type":"graphic_picture","displayName":"Papoose restraint for ear or nose foreign body removal","title":"Papoose restraint for ear or nose foreign body removal","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Papoose restraint for ear or nose foreign body removal</div><div class=\"cntnt\"><img style=\"width:502px; height:144px;\" src=\"images/EM/86352_Papoo_rest_ear_for_bod_rem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prior to removal of the foreign body from the external auditory canal or nose, the child is restrained in the supine position using either a papoose board (pictured) or a sheet wrap. The head is then held by an assistant. For removal of ear foreign bodies, the affected ear is turned up as shown.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86352 Version 2.0</div></div></div>"},"86353":{"type":"graphic_figure","displayName":"Removal of killed insect from the ear","title":"Removal of killed insect from the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Removal of killed insect from the external auditory canal</div><div class=\"cntnt\"><img style=\"width:538px; height:344px;\" src=\"images/EM/86353_Removal_of_killed_insect_from_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the insect is killed by instilling mineral oil, 95 percent ethanol, or 1 percent lidocaine, it is removed under direct visualization using alligator forceps.</div><div class=\"graphic_reference\">Adapted from illustration by Glenn Isaacson MD</div><div id=\"graphicVersion\">Graphic 86353 Version 2.0</div></div></div>"},"86354":{"type":"graphic_figure","displayName":"Removal of foam rubber from the ear","title":"Removal of foam rubber from the external ear canal","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Removal of foam rubber from the external ear canal</div><div class=\"cntnt\"><img style=\"width:538px; height:342px;\" src=\"images/EM/86354_Removal_of_foam_rubber_from_the_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft objects, such as foam rubber,&nbsp;and those with irregular surfaces may be removed with&nbsp;Lucae bayonet (pictured) or alligator forceps</div><div class=\"graphic_reference\">Adapted from illustration by Glenn Isaacson MD</div><div id=\"graphicVersion\">Graphic 86354 Version 2.0</div></div></div>"},"86355":{"type":"graphic_figure","displayName":"Removal of round ear foreign body","title":"Removal of a spherical external auditory canal foreign body","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Removal of a spherical external auditory canal foreign body</div><div class=\"cntnt\"><img style=\"width:540px; height:342px;\" src=\"images/EM/86355_Removal_of_round_ear_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A right angle hook is carefully advanced beyond the spherical bead and slowly withdrawn.</div><div class=\"graphic_reference\">Adapted from illustration by&nbsp;Glenn Isaacson MD</div><div id=\"graphicVersion\">Graphic 86355 Version 2.0</div></div></div>"},"86356":{"type":"graphic_picture","displayName":"Schuknecht foreign body remover","title":"Schuknecht foreign body remover","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Schuknecht foreign body remover</div><div class=\"cntnt\"><img style=\"width:504px; height:362px;\" src=\"images/EM/86356_Schuknecht_for_body_rem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suction attaches to the bottom of the red handle to permit removal of freely mobile spherical foreign bodies from the external auditory canal or nasal cavity.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86356 Version 2.0</div></div></div>"},"86357":{"type":"graphic_figure","displayName":"Removal of spherical ear foreign body","title":"Removal of spherical external auditory canal foreign body using a Schuknecht foreign body remover","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Removal of spherical external auditory canal foreign body using a Schuknecht foreign body remover</div><div class=\"cntnt\"><img style=\"width:538px; height:344px;\" src=\"images/EM/86357_Removal_of_spherical_ear_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Schuknecht foreign body remover is attached to the mobile round foreign body and suction is applied for extraction.</div><div class=\"graphic_reference\">Adapted from: Illustration by Glenn Isaacson MD.</div><div id=\"graphicVersion\">Graphic 86357 Version 3.0</div></div></div>"},"86360":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion radiograph","title":"Right-sided pneumonia with pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Right-sided pneumonia with pleural effusion</div><div class=\"cntnt\"><img style=\"width:513px; height:375px;\" src=\"images/PEDS/86360_Pleural_effusion_radio.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dwight A Powell, MD.</div><div id=\"graphicVersion\">Graphic 86360 Version 1.0</div></div></div>"},"86361":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion CT","title":"Computed tomography: Left-sided pneumonia with pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Computed tomography: Left-sided pneumonia with pleural effusion</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/PEDS/86361_Pleural_effusion_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dwight A Powell, MD.</div><div id=\"graphicVersion\">Graphic 86361 Version 1.0</div></div></div>"},"86362":{"type":"graphic_diagnosticimage","displayName":"Necrotizing pneumonia","title":"Computed tomography: Left-sided <EM>Streptococcus pneumoniae </EM>necrotizing pneumonia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Computed tomography: Left-sided <EM>Streptococcus pneumoniae </EM>necrotizing pneumonia</div><div class=\"cntnt\"><img style=\"width:504px; height:371px;\" src=\"images/PEDS/86362_Necrotizingpneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy William J Barson, MD.</div><div id=\"graphicVersion\">Graphic 86362 Version 2.0</div></div></div>"},"86363":{"type":"graphic_diagnosticimage","displayName":"Mycoplasma pneumoniae radiograph","title":"Plain radiograph: <EM>Mycoplasma pneumoniae </EM>pneumonia","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Plain radiograph: <EM>Mycoplasma pneumoniae </EM>pneumonia</div><div class=\"cntnt\"><img style=\"width:513px; height:263px;\" src=\"images/PEDS/86363_M_pneumoniae_radio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse bilateral interstitial infiltrates with <em>M. pneumoniae</em> infection.</div><div class=\"graphic_reference\">Courtesy of Dwight A Powell, MD.</div><div id=\"graphicVersion\">Graphic 86363 Version 3.0</div></div></div>"},"86364":{"type":"graphic_figure","displayName":"Anatomy for central neck dissection","title":"Anatomy for central neck dissection","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Anatomy for central neck dissection</div><div class=\"cntnt\"><img style=\"width:503px; height:585px;\" src=\"images/SURG/86364_Central_neck_dissection.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86364 Version 1.0</div></div></div>"},"86365":{"type":"graphic_figure","displayName":"Lateral neck dissection anatomy","title":"Lateral neck dissection anatomy","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Lateral neck dissection anatomy</div><div class=\"cntnt\"><img style=\"width:486px; height:520px;\" src=\"images/SURG/86365_Lateral_neck_dissection.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86365 Version 1.0</div></div></div>"},"86372":{"type":"graphic_picture","displayName":"Bullous pemphigoid direct immunofluorescence 400X","title":"Linear IgG basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgG basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/DERM/86372_Bull_pemp_dir_immun_400x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence microscopy of perilesional skin from a patient with bullous pemphigoid reveals characteristic linear IgG basement membrane zone staining.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86372 Version 2.0</div></div></div>"},"86373":{"type":"graphic_picture","displayName":"Bullous pemphigoid direct immunofluorescence 200X","title":"Direct immunofluorescence microscopy of bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence microscopy of bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86373_Bull_pem_dir_immun_200x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence microscopy reveals linear IgG and C3 basement membrane zone staining (IgG shown here). 200 X.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86373 Version 1.0</div></div></div>"},"86374":{"type":"graphic_picture","displayName":"Epidermolysis bullosa acquisita split skin immunofluorescence","title":"Serum IgG basement membrane zone antibodies localizing to the dermal side of split skin substrate in epidermolysis bullosa acquisita by indirect immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serum IgG basement membrane zone antibodies localizing to the dermal side of split skin substrate in epidermolysis bullosa acquisita by indirect immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86374_Epid_bull_acqu_skin_immun.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear IgG antibody staining on the dermal side of basement membrane zone-split skin substrate characteristic of epidermolysis bullosa acquisita. This pattern also is referred to as staining the floor of the blister, and&nbsp;may be found in bullous lupus erythematosus and two subsets of pemphigoid, namely, anti-laminin 332 and anti-laminin gamma-1 pemphigoid.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86374 Version 3.0</div></div></div>"},"86376":{"type":"graphic_figure","displayName":"Diagram of prepuce","title":"Diagram of prepuce","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Diagram of prepuce</div><div class=\"cntnt\"><img style=\"width:512px; height:381px;\" src=\"images/OBGYN/86376_Prepuce.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86376 Version 1.0</div></div></div>"},"86377":{"type":"graphic_figure","displayName":"Diagram of circumcised penis","title":"Diagram of circumcised penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of circumcised penis</div><div class=\"cntnt\"><img style=\"width:431px; height:414px;\" src=\"images/OBGYN/86377_Circumcised_penis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86377 Version 2.0</div></div></div>"},"86383":{"type":"graphic_figure","displayName":"The effects of various therapies and treatment in diabetic dogs","title":"The effects of various therapies and methods of treatment in diabetic dogs","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">The effects of various therapies and methods of treatment in diabetic dogs</div><div class=\"cntnt\"><img style=\"width:460px; height:704px;\" src=\"images/NEPH/86383_Eff_var_ther_trt_diab_dog.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This graph shows the effects of various antihypertensive therapies on afferent and efferent arteriolar tone in unilaterally nephrectonized diabetic hypertensive dogs.<br />(B) This graph shows the effects of an ace inhibitor or calcium blocker on mesangial matrix proliferation in diabetic dogs.</div><div class=\"graphic_footnotes\">* p &lt;0.05 compared to control.<BR>Δ p &lt;0.05 compared to DM alone.<BR><FONT class=lozenge>◊</FONT> p &lt;0.01 compared to DM.</div><div class=\"graphic_reference\">(A) Adapted by permission from Macmillan Publishers Ltd: Kidney International. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/ki/index.html\" target=_blank>http://www.nature.com/ki/index.html</A>. Copyright © 1993.<BR>(B) Adapted by permission from Macmillan Publishers Ltd: Kidney International. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46:161. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/ki/index.html\" target=_blank>http://www.nature.com/ki/index.html</A>. Copyright © 1994.</div><div id=\"graphicVersion\">Graphic 86383 Version 2.0</div></div></div>"},"86390":{"type":"graphic_picture","displayName":"EB simplex localized 1","title":"Friction-induced bullae in epidermolysis bullosa simplex (EBS)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Friction-induced bullae in epidermolysis bullosa simplex (EBS)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86390_EB_simplex_localized_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blisters and erosions on mechanically exposed hands in localized EBS.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86390 Version 2.0</div></div></div>"},"86391":{"type":"graphic_picture","displayName":"EB simplex localized 2","title":"Epidermolysis bullosa simplex (EBS), localized","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa simplex (EBS), localized</div><div class=\"cntnt\"><img style=\"width:576px; height:397px;\" src=\"images/DERM/86391_EB_simplex_localized_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partly hemorrhagic blisters and erosions on mechanically exposed hands in localized EBS.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86391 Version 2.0</div></div></div>"},"86392":{"type":"graphic_picture","displayName":"EB simplex Dowling-Meara 1","title":"Epidermolysis bullosa simplex (EBS), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa simplex (EBS), generalized severe</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86392_EB_simplex_Dowling_Meara_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical herpetiform distribution of cutaneous lesions, including blisters, erosions, crusts, and atrophic scars, in generalized severe EBS.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86392 Version 3.0</div></div></div>"},"86393":{"type":"graphic_picture","displayName":"EB simplex Dowling-Meara 2","title":"Epidermolysis bullosa simplex (EBS), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa simplex (EBS), generalized severe</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86393_EB_simplex_Dowling_Meara_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical herpetiform distribution of cutaneous lesions, including&nbsp;blisters, erosions, crusts, and atrophic scars, in generalized severe EBS.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86393 Version 3.0</div></div></div>"},"86395":{"type":"graphic_figure","displayName":"Cases of NSF reported to the USFDA AERS","title":"The number of cases of nephrogenic systemic fibrosis reported to the US Food and Drug Administration, adverse events reporting system","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">The number of cases of nephrogenic systemic fibrosis reported to the US Food and Drug Administration, adverse events reporting system</div><div class=\"cntnt\"><img style=\"width:614px; height:222px;\" src=\"images/NEPH/86395_Cas_NSF_repor_USFDA_AERS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The number of cases reported to the US Food and Drug Administration's adverse events reporting system declined in 2011.</div><div class=\"graphic_reference\">Courtesy of Dr. Ira Krefting, FDA presented at: 5th Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and Allied Fibrotic Disorders. May 20, 2011 at the Yale University School of Medicine, New Haven, CT.</div><div id=\"graphicVersion\">Graphic 86395 Version 1.0</div></div></div>"},"86396":{"type":"graphic_table","displayName":"EB extracutaneous complications","title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa (EB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extracutaneous manifestations and complications of inherited epidermolysis bullosa (EB)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organ system</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Predominant EB subtypes</td> </tr> <tr> <td rowspan=\"7\">Nail apparatus<sup>[1]</sup></td> <td>Peri- or subungual blistering, hemorrhages and nail bed hyperkeratosis with onycholysis, onychomadesis; periodic nail shedding and regrowth with progressive onychodystrophy (EBS, JEB, DEB) +/- onychogryphosis (EBS, JEB)</td> <td rowspan=\"7\">Severe EBS subtypes (excluding localized EBS, EBS migratory circinate, EBS with pyloric atresia); most JEB patients; DEB</td> </tr> <tr> <td>Paronychia-like lesions and nail loss with nail bed erosions and development of sub- and periungual granulation tissue soon after birth (JEB-H and LOC-syndrome)</td> </tr> <tr> <td>Complete nail loss, nail bed and matrix scarring, mitten deformity (DEB)</td> </tr> <tr> <td>Thin, brittle, short atrophic nails due to nail matrix damage by repetitive blistering (JEB, DEB)</td> </tr> <tr> <td>Few nails affected in localized DEB</td> </tr> <tr> <td>Autosomal dominant trait of toenail onychodystrophy in a child may be sign of DEB</td> </tr> <tr> <td>Parrot beak nail deformity from recurrent blistering in distal fingers resulting in soft tissue and bone reabsorption with nail bending around shortened fingertip (KS)</td> </tr> <tr> <td rowspan=\"7\">Hair</td> <td>Increased hair and skin fragility due to deficient stabilization of the upper permanent portion of the follicle (infundibulum, isthmus, bulge region) to the surrounding connective tissues (DEB)</td> <td rowspan=\"7\">EBS, JEB, DEB</td> </tr> <tr> <td>Cicatricial alopecia secondary to blistering (JEB, DEB) or infection involving interfollicular epidermis and upper portion of hair follicle</td> </tr> <tr> <td>Transient, reversible telogen effluvium due to anemia or sepsis</td> </tr> <tr> <td>Sparse, short, dry, curly, woolly hair; hypotrichosis</td> </tr> <tr> <td>Absent eyebrows and eyelashes (ectodermal dysplasia-skin fragility syndrome) </td> </tr> <tr> <td>Complete absence of hair, eyebrows, eyelashes, vellus hairs (lethal acantholytic EBS)</td> </tr> <tr> <td>Secondary scarring alopecia (JEB with pyloric atresia)</td> </tr> <tr> <td rowspan=\"5\">Eye<sup>[2]</sup></td> <td>Red watery eyes, photophobia, ocular pain; conjunctival injection, edema, blisters; subconjunctival hemorrhage, blepharoconjunctivitis (sgRDEB, RDEB-I), exposure keratopathy</td> <td rowspan=\"5\">sgRDEB, RDEB-O, JEB-H, JEB-nH</td> </tr> <tr> <td>Corneal bullae, erosion, ulceration, abrasions, pitting, opacities, scars; peripheral corneal vascularization, corneal pannus formation, limbal broadening, cornea plana, sclerocornea, cataracts</td> </tr> <tr> <td>Eyelid blisters or ectropion with exuberant granulation tissue (JEB-H), eyelid scarring, pseudopterygium, symblepharon (JEB, RDEB), ankyloblepharon</td> </tr> <tr> <td>Lacrimal duct obstruction (RDEB-I, JEB-H)</td> </tr> <tr> <td>Refractive errors, amblyopia, strabismus, lens subluxation, posterior vitreous detachment, impaired vision (sgRDEB, RDEB-I), blindness (sgRDEB)<sup>[2,3]</sup></td> </tr> <tr> <td rowspan=\"12\">Oral cavity<sup>[4]</sup></td> <td><strong>Soft tissues</strong></td> <td rowspan=\"12\">sgRDEB, JEB, severe subtypes of EBS</td> </tr> <tr> <td class=\"indent1\">Mucosal fragility, blistering, ulceration, mostly localized (EBS)</td> </tr> <tr> <td class=\"indent1\">Significant involvement and oral scarring (EBS-DM)</td> </tr> <tr> <td class=\"indent1\">Variable blistering and ulceration; exuberant perioral granulation tissue resulting in a reduction of the oral opening (microstomia) and loss of tissue mobility in lips and perioral tissues (JEB-H)</td> </tr> <tr> <td class=\"indent1\">Involvement from mild to severe; extreme fragility evident shortly after birth with inability to suckle (sgRDEB, RDEB-O)</td> </tr> <tr> <td class=\"indent1\">Restricted oral aperture, ankyloglossia, obliteration of vestibules, loss of lingual papillae, ablated palatal rugae; intraoral keratocysts (milia), elevated risk for intraoral squamous cell carcinoma (sgRDEB)<sup>[5]</sup></td> </tr> <tr> <td class=\"indent1\">Early onset periodontal disease, gingival inflammation and hyperplasia; sometimes severe oral blistering in neonates and infants, decreasing with age (KS)</td> </tr> <tr> <td><strong>Hard tissues</strong></td> </tr> <tr> <td class=\"indent1\">Normal dentition, caries risk not increased (EBS)</td> </tr> <tr> <td class=\"indent1\">Enamel lesions including pitting, horizontal hypoplastic bands, white mottled enamel, generalized hypoplasia, abnormal tooth eruption; increased risk of dental caries (JEB)</td> </tr> <tr> <td class=\"indent1\">Normal enamel (type VII collagen not expressed by ameloblasts); excessive dental caries, extensive tooth plaque formation and bacterial inoculation (DEB)</td> </tr> <tr> <td class=\"indent1\">Normal dentition; risk of dental caries unknown (KS)</td> </tr> <tr> <td rowspan=\"7\">Gastrointestinal tract<sup>[3]</sup></td> <td>Painful esophageal blistering, erosions, scarring, web formation, stenosis, strictures; hiatus hernia, abnormal esophageal peristalsis, atony, spontaneous perforation (sgRDEB)</td> <td rowspan=\"7\">sgRDEB, RDEB-I, JEB-H</td> </tr> <tr> <td>Gastroesophageal reflux disease common in more severe forms (RDEB, JEB-H, EBS-DM, JEB-nH) and prominent in pediatric populations; peptic ulcer disease</td> </tr> <tr> <td>Malabsorption, diarrhea; protein losing enteropathy; irritable bowel disease; inflammatory bowel disease (EBS, DEB<sup>[6]</sup>); diverticular disease; megacolon; colon perforation and peritonitis</td> </tr> <tr> <td>Rectal tears, prolapse, strictures; perianal fistulae; hemorrhoids, intussusception; megarectum</td> </tr> <tr> <td>Constipation</td> </tr> <tr> <td>Anemia, deficiencies of specific nutrients and vitamins (iron, selenium, zinc, vitamins A, B6, B12, C, D), hypoalbuminemia, osteoporosis/osteopenia</td> </tr> <tr> <td>Hypercatabolic state with failure to thrive (sgRDEB, JEB-H, EBS-DM, JEB-nH, RDEB-I; RDEB-O)</td> </tr> <tr> <td rowspan=\"9\">Genitourinary tract<sup>[3]</sup></td> <td>Dysuria</td> <td rowspan=\"9\">JEB-H, RDEB</td> </tr> <tr> <td>Blistering, fibrosis and scarring of glans penis; urethral meatal stenosis (RDEB); chronic inflammation of detrusor muscles secondary to exposure of denuded tissues to urine</td> </tr> <tr> <td>Urethral diverticula, penile and bulbar urethral strictures, hypospadias, epispadias</td> </tr> <tr> <td>Erosion or ulcerations on labia (RDEB-I), partial fusion of labia, narrowing of vaginal vestibule; urinary reflux into vagina and filling of uterine cavity</td> </tr> <tr> <td>Macroscopic blisters within the bladder, bladder edema, bladder cystitis, reduced bladder capacity, thickened bladder wall, bladder exstrophy</td> </tr> <tr> <td>Microscopic cleft formation within bladder, renal pelvis, ureter</td> </tr> <tr> <td>Urinary retention, stenosis or obstruction of the ureterovesical junction, ureteral fibrosis and stenosis, ureteral reflux with posterior urethral valves, hydroureter, hydronephrosis, renal pelvis stenosis, pyelocaliectasis, ureterectasis</td> </tr> <tr> <td>Pyelonephritis, poststreptococcal, IgA, mesangial glomerulonephritis (RDEB); renal amyloidosis (RDEB), recurrent urinary tract infections, recurrent urosepsis</td> </tr> <tr> <td>Renal insufficiency and failure (sgRDEB)</td> </tr> <tr> <td rowspan=\"12\">Ear, nose, throat, and upper airway<sup>[3]</sup></td> <td><strong>Ear</strong></td> <td rowspan=\"12\">JEB (including LOC syndrome), RDEB</td> </tr> <tr> <td class=\"indent1\">Trauma induced blistering, erosions, crusting on auricle and external auditory canal; secondary microbial colonization and infections (JEB), scarring/stenosis (DEB); auricular milia formation (DEB)</td> </tr> <tr> <td class=\"indent1\">Otitis media and externa (JEB-H)</td> </tr> <tr> <td class=\"indent1\">Bilateral sensorineural deafness (RDEB, RDEB-I)</td> </tr> <tr> <td><strong>Nose</strong></td> </tr> <tr> <td class=\"indent1\">Erosions, crusting, around nares and within nostrils; rhinitis</td> </tr> <tr> <td class=\"indent1\">Granulation tissue (JEB-H) resulting in airway narrowing and repeated bleeding</td> </tr> <tr> <td class=\"indent1\">No increased frequency of atopy among any EB subtype<sup>[7]</sup></td> </tr> <tr> <td><strong>Oropharynx</strong></td> </tr> <tr> <td class=\"indent1\">Blisters, erosions, scarring, stenosis (JEB; DEB)</td> </tr> <tr> <td><strong>Larynx, trachea</strong></td> </tr> <tr> <td class=\"indent1\">Blisters, erosions, inflammation and soft tissue edema, scar formation along luminal surfaces including vocal cords (hoarse cry or voice; stridor); cysts; webbing, stenosis, strictures; complete or partial luminal occlusion secondary to exuberant granulation tissue with secondary aspiration pneumonitis or acute airway occlusion (JEB-H, LOC)</td> </tr> <tr> <td rowspan=\"3\">Musculoskeletal system and heart<sup>[8]</sup></td> <td>Pseudosyndactyly and total encasement of digits (sgRDEB; RDEB-I; infrequently in DDEB, cicatricial JEB, EBS-DM); contractures of hands (adduction contractures of thumb), feet, popliteal and antecubital fossae, and axillary vaults; progressive functional disability (difficulties in weight bearing, standing, walking; reduced fine manipulative skill; loss of digital prehension); muscle atrophy; bone absorption</td> <td rowspan=\"3\">sgRDEB, RDEB-I</td> </tr> <tr> <td>Osteopenia, osteoporosis (RDEB) consequent to restricted mobility and weight-bearing activity (painful skin wounds, contractures); impaired nutritional intake despite greater requirements (calcium, vitamin D, anemia); reduced sunlight exposure (restricted outdoor activities, extensive bandaging); induction of catabolic osteoclastic activity by proinflammatory cytokines in the course of chronic inflammation and chronic skin infection</td> </tr> <tr> <td>Cardiomyopathy (sgRDEB; rarely RDEB-O; JEB) due to malnutrition and micronutrient (selenium and carnitine) deficiency<sup>[9]</sup>, chronic anemia, transfusion-associated iron overload, viral myocarditis; precipitating or exacerbating cardiotoxic medications (amitriptyline, cisapride); may present in early childhood</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBS: epidermolysis bullosa simplex; EBS-DM: epidermolysis bullosa simplex Dowling-Meara; EBS-MD: epidermolysis bullosa simplex with muscular dystrophy; JEB: junctional epidermolysis bullosa; JEB-H: junctional epidermolysis bullosa Herlitz; JEB-nH: junctional epidermolysis bullosa non-Herlitz; LOC syndrome: laryngo-oculo-cutaneous syndrome; DEB: dystrophic epidermolysis bullosa; RDEB: recessive dystrophic epidermolysis bullosa; DDEB: dominant dystrophic epidermolysis bullosa; sgRDEB: severe generalized dystrophic epidermolysis bullosa; RDEB-O: other severe generalized epidermolysis bullosa; RDEB-I: inverse recessive dystrophic epidermolysis bullosa; KS: Kindler syndrome.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Tosti A, de Farias DC, Murrell DF. Nail involvement in epidermolysis bullosa. Dermatol Clin 2010; 28:153.</li>&#xD;&#xA;    <li>Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin 2010; 28:143.</li>&#xD;&#xA;    <li>Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61:367.</li>&#xD;&#xA;    <li>Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol Clin 2010; 28:159.</li>&#xD;&#xA;    <li>Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience,1986-2006. J Am Acad Dermatol 2009; 60:203.</li>&#xD;&#xA;    <li>Shah N, Freeman E, Martinez A, et al. Histopathological features of gastrointestinal mucosal biopsy specimens in children with epidermolysis bullosa. J Clin Pathol 2007; 60:843.</li>&#xD;&#xA;    <li>Fine JD, Johnson LB, Weiner M, Suchindran C. Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. Laryngoscope 2007; 117:1652.</li>&#xD;&#xA;    <li>Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009; 61:387.</li>&#xD;&#xA;    <li>Lara-Corrales I, Mellerio JE, Martinez AE, et al. Dilated cardiomyopathy in epidermolysis bullosa: a retrospective, multicenter study. Pediatr Dermatol 2010; 27:238.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86396 Version 4.0</div></div></div>"},"86399":{"type":"graphic_picture","displayName":"Junctional EB non-Herlitz","title":"Junctional epidermolysis bullosa (JEB), generalized intermediate","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized intermediate</div><div class=\"cntnt\"><img style=\"width:576px; height:383px;\" src=\"images/DERM/86399_Junctional_EB_non_Herlitz.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive erosions on the leg and foot of a newborn with generalized intermediate JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86399 Version 3.0</div></div></div>"},"86400":{"type":"graphic_picture","displayName":"JEB non-Herlitz adults 1","title":"Junctional epidermolysis bullosa (JEB), generalized intermediate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized intermediate</div><div class=\"cntnt\"><img style=\"width:330px; height:503px;\" src=\"images/DERM/86400_JEB_non_Herlitz_adults_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonhealing erosions, partly hemorrhagic crusts, and skin atrophy with stellate scars predominant in adults with generalized intermediate JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86400 Version 2.0</div></div></div>"},"86401":{"type":"graphic_picture","displayName":"JEB non-Herlitz adults 2","title":"Junctional epidermolysis bullosa (JEB), generalized intermediate in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized intermediate in adults</div><div class=\"cntnt\"><img style=\"width:318px; height:447px;\" src=\"images/DERM/86401_JEB_non_Herlitz_adults_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense blisters, nonhealing erosions, partly hemorrhagic crusts, and skin atrophy with stellate scars predominant in adults with generalized intermediate JEB.</div><div id=\"graphicVersion\">Graphic 86401 Version 3.0</div></div></div>"},"86402":{"type":"graphic_picture","displayName":"JEB non-Herlitz adult nails","title":"Junctional epidermolysis bullosa (JEB), generalized intermediate","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized intermediate</div><div class=\"cntnt\"><img style=\"width:576px; height:363px;\" src=\"images/DERM/86402_JEB_non_Herlitz_adult_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychodystrophy in an adult individual with generalized intermediate&nbsp;JEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86402 Version 2.0</div></div></div>"},"86403":{"type":"graphic_picture","displayName":"Nail biopsy specimen orientation","title":"Longitudinal sectioning of a nail biopsy specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal sectioning of a nail biopsy specimen</div><div class=\"cntnt\"><img style=\"width:405px; height:363px;\" src=\"images/DERM/86403_Nail_bio_spec_orient.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86403 Version 2.0</div></div></div>"},"86404":{"type":"graphic_picture","displayName":"Nail fold biopsy Freer elevator","title":"Nail fold biopsy using a Freer elevator","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Nail fold biopsy using a Freer elevator</div><div class=\"cntnt\"><img style=\"width:574px; height:386px;\" src=\"images/DERM/86404_Nail_fld_bpsy_usng_Fre_lvtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of Informa Healthcare, from An Atlas of Diseases of the Nail, Rich P, Scher RK, New York, 2003; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 86404 Version 4.0</div></div></div>"},"86405":{"type":"graphic_picture","displayName":"Complete nail plate avulsion","title":"Complete nail plate avulsion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Complete nail plate avulsion</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86405_Comp_nail_plate_avulsion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86405 Version 1.0</div></div></div>"},"86406":{"type":"graphic_algorithm","displayName":"Proposed genetic testing algorithm for pts with PCC or PGL","title":"Proposed genetic testing algorithm for patients with pheochromocytoma/paraganglioma based on clinical features","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Proposed genetic testing algorithm for patients with pheochromocytoma/paraganglioma based on clinical features</div><div class=\"cntnt\"><img style=\"width:546px; height:403px;\" src=\"images/ONC/86406_Prop_gen_test_algo_PCC_PGL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed genetic testing algorithm for patients with paraganglioma based upon the clinical features of the tumor(s). Genes are listed after descending priority from top to bottom.</div><div class=\"graphic_footnotes\"><EM>VHL</EM>: von Hippel-Lindau gene; <EM>NF1</EM>: neurofibromatosis type 1 gene; <EM>RET</EM>: rearranged during transfection gene; <EM>SDHD</EM>: succinate dehydrogenase subunit D gene; <EM>SDHAF2</EM>:&nbsp;succinate dehydrogenase&nbsp;complex assembly factor 2 gene; SDHx: succinate dehydrogenase complex genes; <EM>SDHC</EM>: succinate dehydrogenase subunit C gene; <EM>SDHB</EM>: succinate dehydrogenase subunit B gene; <EM>SDHA</EM>: succinate dehydrogenase subunit A gene; <EM>MAX</EM>: MYC-associated factor X gene.<br />* If using sequential testing, if a mutation is identified at any point in the testing algorithm, no further testing should be performed.</div><div id=\"graphicVersion\">Graphic 86406 Version 4.0</div></div></div>"},"86407":{"type":"graphic_figure","displayName":"Paragangliomas origin and location","title":"Paragangliomas classified according to their origin and location","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Paragangliomas classified according to their origin and location</div><div class=\"cntnt\"><img style=\"width:466px; height:592px;\" src=\"images/ONC/86407_Paragangliom_orig_loca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paragangliomas have their origin in cells derived from the embryological neuroectoderm. There are four types of paragangliomas<SUP>[1,2]</SUP>: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Branchiomeric group: In the region of the embryological branchiomeres (jugulotympanic ganglion, carotid body, laryngeal ganglia, subclavian ganglion, aorticopulmonary ganglion). There is a close relationship with blood vessels.<BR></LI>&#xD;&#xA;<LI>Intravagal group: In the region of the parasympathetic nerves (jugular ganglion, nodose ganglion). They have their origin within the perineurium.<BR></LI>&#xD;&#xA;<LI>Aortosympathetic group: In the region of the sympathetic nerves of the aorta.<BR></LI>&#xD;&#xA;<LI>Visceral autonomic group: in the nervous system of the heart, digestive tract, liver hilus, and bladder.</LI></UL></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Kleinsasser O. Das Glomus laryngicum inferior. Ein bisher unbekanntes, nichtchromaffines Paraganglion vom Bau der sog. Carotisdrüse im menschlichen Kehlkopf. European Archives of Oto-Rhino-Laryngology 1964; 184:214.</LI>&#xD;&#xA;<LI>Glenner GG, Grimley PM. Tumors of the Extra-Adrenal Paraganglion System. Bethesda, MD: Armed Forces Institute of Pathology, 1974.</LI></OL>Reproduced from: Lips C, Lentjes E, Höppener J, et al. Familial paragangliomas. Hered Cancer Clin Pract 2006; 4:169. Copyright © 2006 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 86407 Version 3.0</div></div></div>"},"86409":{"type":"graphic_table","displayName":"ENETS staging system for pancreatic NETS","title":"ENETS staging system for pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ENETS staging system for pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">TNM</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">T - primary tumor</td> </tr> <tr> <td colspan=\"4\"><em>For any T, add (m) for multiple tumors</em></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to pancreas and size &#60;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor limited to the pancreas and size 2-4 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor limited to the pancreas and size &#62;4 cm or invading duodenum or bile duct</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or superior mesenteric artery)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">N - regional lymph nodes</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph node cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">M - distant metastases</td> </tr> <tr> <td class=\"indent1\">MX</td> <td colspan=\"3\">Distant metastasis cannot be assessed</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Stage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Disease stages</td> </tr> <tr> <td class=\"indent1\">Stage I</td> <td class=\"centered\">T1</td> <td class=\"centered\">N0</td> <td class=\"centered\">M0</td> </tr> <tr> <td class=\"indent1\">Stage IIa</td> <td class=\"centered\">T2</td> <td class=\"centered\">N0</td> <td class=\"centered\">M0</td> </tr> <tr> <td class=\"indent1\">Stage IIb</td> <td class=\"centered\">T3</td> <td class=\"centered\">N0</td> <td class=\"centered\">M0</td> </tr> <tr> <td class=\"indent1\">Stage IIIa</td> <td class=\"centered\">T4</td> <td class=\"centered\">N0</td> <td class=\"centered\">M0</td> </tr> <tr> <td class=\"indent1\">Stage IIIb</td> <td class=\"centered\">Any T</td> <td class=\"centered\">N1</td> <td class=\"centered\">M0</td> </tr> <tr> <td class=\"indent1\">Stage IV</td> <td class=\"centered\">Any T</td> <td class=\"centered\">Any N</td> <td class=\"centered\">M1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, nodes, metastasis.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sobin LH, Wittekind C (Eds). TNM classification of malignant tumours. Wiley-Liss, New York, 2002.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Rindi G, Kloppel H, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395. Copyright &copy; 2006; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 86409 Version 4.0</div></div></div>"},"86410":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance images pediatric appendicitis","title":"Axial and coronal magnetic resonance images showing appendicitis in a child","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Axial and coronal magnetic resonance images showing appendicitis in a child</div><div class=\"cntnt\"><img style=\"width:602px; height:291px;\" src=\"images/EM/86410_Mag_res_img_pdtrc_appndcts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial (A) and coronal (B) images show an enlarged and inflamed appendix (arrows). These are noncontrast T-2 images obtained from a three Tesla magnet.</div><div class=\"graphic_reference\">Courtesy of George A Taylor, MD.</div><div id=\"graphicVersion\">Graphic 86410 Version 1.0</div></div></div>"},"86412":{"type":"graphic_figure","displayName":"ICF model","title":"International classification of functioning, disability, and health (ICF) model","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">International classification of functioning, disability, and health (ICF) model</div><div class=\"cntnt\"><img style=\"width:376px; height:298px;\" src=\"images/PC/86412_ICF_model.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Towards a Common Language for Functioning, Disability, and Health: ICF - The International Classification of Functioning, Disability and Health. World Health Organization, Geneva, Switzerland, 2002. Copyright &copy; 2002. Available at: <a href=\"http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf\">http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf</a>. (Accessed September 11, 2012.)</div><div id=\"graphicVersion\">Graphic 86412 Version 1.0</div></div></div>"},"86413":{"type":"graphic_table","displayName":"Member roles and functions for rehab team","title":"Primary roles and functions of members of the multidisciplinary rehabilitation team","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary roles and functions of members of the multidisciplinary rehabilitation team</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Discipline</td> <td class=\"subtitle1\">Evaluation and treatment methods</td> <td class=\"subtitle1\">Targeted aspect of the disablement process</td> </tr> <tr> <td>Assistive Technology Provider (ATP*)</td> <td>Determine need for assistive technology and optimal technology to best meet needs</td> <td> <p>Activities</p> Participation</td> </tr> <tr> <td>Dietician</td> <td> <p>Assess nutritional status</p> Alter diet to maximize nutrition</td> <td>Health condition</td> </tr> <tr> <td>Hand therapist<sup>&#182;</sup></td> <td> <p>Exercise</p> <p>Physical modalities (heat, ultrasound, etc.)</p> Fabrication of splints</td> <td>Impairment (upper extremity)</td> </tr> <tr> <td>Medical provider<sup>&#916;</sup></td> <td> <p>Assess health conditions</p> Treat health conditions (medications, surgery)</td> <td>Health condition</td> </tr> <tr> <td>Nursing</td> <td> <p>Assessment of physical condition</p> <p>Wound care and medication management</p> <p>Evaluate self-care skills</p> <p>Evaluate family and home care factors</p> <p>Self-care training</p> Patient and family education</td> <td> <p>Health condition</p> <p>Impairment</p> <p>Activities</p> Contextual factors (especially social)</td> </tr> <tr> <td>Occupational therapist</td> <td> <p>Evaluate self-care skills and other activities of daily living</p> <p>Home safety evaluation</p> <p>Self-care skills training</p> <p>Recommendations for assistive technology</p> <p>Fabrication of splints</p> Treatment of upper extremity deficits</td> <td> <p>Impairment (upper extremity)</p> <p>Activities</p> <p>Participation</p> Contextual factors (especially environment)</td> </tr> <tr> <td>Physical therapist </td> <td> <p>Assessment of range of motion and strength</p> <p>Assessment of gait and mobility</p> <p>Exercise training</p> Treatment with physical modalities (heat, cold, ultrasound, massage, electrical stimulation)</td> <td> <p>Impairment (lower extremity, back, shoulder)</p> Activities (mobility)</td> </tr> <tr> <td>Prosthetist</td> <td>Fabricate prosthetic limbs and other prosthetic devices (eg, prosthetic eye)</td> <td>Impairment</td> </tr> <tr> <td>Psychologist/psychiatrist</td> <td> <p>Assessment of mental and emotional function</p> Treatment of mental/emotional disorder (medication, counseling)</td> <td> <p>Health condition</p> <p>Impairment (psychological)</p> Context (personal)</td> </tr> <tr> <td>Recreation therapist</td> <td> <p>Assess leisure skills and interests</p> Involve patients in recreational activities to maintain social roles</td> <td>Participation</td> </tr> <tr> <td>Speech/language therapist</td> <td> <p>Assessment of all aspects of communication</p> <p>Assessment of swallowing disorders</p> <p>Treatment of communications deficits</p> Recommendations for alterations of diet and positioning to treat dysphagia</td> <td> <p>Impairment</p> Participation</td> </tr> <tr> <td>Social worker</td> <td> <p>Evaluation of family and home care factors</p> <p>Assessment of psychosocial factors</p> <p>Counseling</p> Liaison with the community</td> <td> <p>Participation</p> Context (social)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Successful completion of a certifying exam offered by the Rehabilitation Engineering and Assistive Technology Society of North America.<br />¶ Occupational or physical therapist who has complete additional training and passed a national certification exam in hand therapy.<br />Δ Depending on the settings, the medical provider may be a physician such as a physical medicine and rehabilitation specialist (\"physiatrist\"), neurologist, orthopedic surgeon, or geriatrician and/or mid-level practitioners such as nurse practitioner or physician assistant.</div><div id=\"graphicVersion\">Graphic 86413 Version 2.0</div></div></div>"},"86414":{"type":"graphic_table","displayName":"Comparison of mobility aids","title":"Attributes for selection of particular mobility aids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Attributes for selection of particular mobility aids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Body weight supported</td> <td class=\"subtitle1\">Unilateral/bilateral support</td> <td class=\"subtitle1\">Balance required</td> <td class=\"subtitle1\">Coordination needed</td> <td class=\"subtitle1\">Arm strength needed</td> </tr> <tr> <td><strong>Cane</strong></td> <td class=\"centered\">Minimal (10 to 15 percent)</td> <td class=\"centered\">Unilateral</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> </tr> <tr> <td><strong>Two-wheel walker</strong></td> <td class=\"centered\">Moderate (15 to 30 percent)</td> <td class=\"centered\">Bilateral</td> <td class=\"centered\">Moderate</td> <td class=\"centered\">Moderate</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td><strong>Four-wheel walker</strong></td> <td class=\"centered\">Moderate (15 to 30 percent)</td> <td class=\"centered\">Bilateral</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td><strong>Crutches, swing-through motion</strong></td> <td class=\"centered\">Full (100 percent)</td> <td class=\"centered\">Unilateral</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> <td class=\"centered\">Excellent</td> </tr> <tr> <td><strong>Crutches, alternating motion</strong></td> <td class=\"centered\">Partial (30 to 50 percent)</td> <td class=\"centered\">Bilateral</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> <td class=\"centered\">Good</td> </tr> <tr> <td><strong>Manual wheelchair</strong></td> <td class=\"centered\">Full (100 percent)</td> <td class=\"centered\">Bilateral</td> <td class=\"centered\">Minimal</td> <td class=\"centered\">Minimal-moderate*</td> <td class=\"centered\">Minimal-good*</td> </tr> <tr> <td><strong>Power wheelchair/scooter</strong></td> <td class=\"centered\">Full (100 percent)</td> <td class=\"centered\">Bilateral</td> <td class=\"centered\">Minimal-moderate<sup>&#182;</sup></td> <td class=\"centered\">Moderate</td> <td class=\"centered\">Minimal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Amount of coordination and arm strength for manual wheelchair depends on if it is self-propelled or propelled by another person.<br />&#182; Good sitting balance is required for a scooter but may not be required for a power wheelchair.</div><div id=\"graphicVersion\">Graphic 86414 Version 3.0</div></div></div>"},"86415":{"type":"graphic_table","displayName":"Medicare coverage of medical equipment and prosthetic items","title":"Medicare coverage of durable medical equipment and prosthetic and orthotic items","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicare coverage of durable medical equipment and prosthetic and orthotic items</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">What Medicare covers</td> <td class=\"subtitle1\">What the patient pays</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Durable medical equipment</td> </tr> <tr> <td class=\"indent1\">Air-fluidized beds</td> <td rowspan=\"18\">The patient pays 20% of the Medicare-approved amount after paying Medicare Part B deductible for the year. Medicare pays the other 80%. The Medicare-approved amount is the lower of the actual charge for the item or the fee Medicare sets for the item. However, the amount the patient pays may vary because Medicare pays for different kinds of durable medical equipment in different ways. Some equipment may be able to be rented or purchased.</td> </tr> <tr> <td class=\"indent1\">Blood glucose monitors</td> </tr> <tr> <td class=\"indent1\">Bone growth (or osteogenesis) stimulators</td> </tr> <tr> <td class=\"indent1\">Canes (except white canes for the blind)</td> </tr> <tr> <td class=\"indent1\">Bedside commode</td> </tr> <tr> <td class=\"indent1\">Crutches</td> </tr> <tr> <td class=\"indent1\">Home oxygen equipment and supplies</td> </tr> <tr> <td class=\"indent1\">Hospital beds</td> </tr> <tr> <td class=\"indent1\">Infusion pumps and some medicines used in them</td> </tr> <tr> <td class=\"indent1\">Lymphedema pumps/pneumatic compression devices</td> </tr> <tr> <td class=\"indent1\">Nebulizers and some medicines used in them </td> </tr> <tr> <td class=\"indent1\">Patient lifts</td> </tr> <tr> <td class=\"indent1\">Scooters and power wheelchairs</td> </tr> <tr> <td class=\"indent1\">Traction equipment </td> </tr> <tr> <td class=\"indent1\">Transcutaneous electronic nerve stimulators (TENS)</td> </tr> <tr> <td class=\"indent1\">Ventilators or respiratory assist devices</td> </tr> <tr> <td class=\"indent1\">Walkers</td> </tr> <tr> <td class=\"indent1\">Wheelchairs (manual and power)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Prosthetic&nbsp;and orthotic items</td> </tr> <tr> <td class=\"indent1\">Arm, leg, back, and neck braces</td> <td rowspan=\"6\">Patient pays 20% of the Medicare-approved amount after paying Medicare Part B deductible for the year. Medicare pays the other 80%.</td> </tr> <tr> <td class=\"indent1\">Artificial limbs and eyes</td> </tr> <tr> <td class=\"indent1\">Breast prostheses (including a surgical brassiere) after a mastectomy</td> </tr> <tr> <td class=\"indent1\">Ostomy supplies for people who have had a colostomy, ileostomy, or urinary ostomy (per physician order)</td> </tr> <tr> <td class=\"indent1\">Prosthetic devices needed to replace an internal body part or function (eg, Foley urinary catheter)</td> </tr> <tr> <td class=\"indent1\">Therapeutic shoes or inserts for people with diabetes who have severe diabetic foot disease (prescribed by the doctor treating the diabetes or a podiatrist, and provided by doctor or other qualified individual such as a podiatrist)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Medicare. Your Medicare Coverage: Durable medical equipment (DME) coverage. Available at: <A href=\"https://www.medicare.gov/coverage/durable-medical-equipment-coverage.html\">https://www.medicare.gov/coverage/durable-medical-equipment-coverage.html</A> (Access on November 2, 2016).</LI>&#xD;&#xA;<LI>Medicare. Your Medicare Coverage: Prosthetic devices. Available at: <A href=\"https://www.medicare.gov/coverage/prosthetic-devices.html\">https://www.medicare.gov/coverage/prosthetic-devices.html</A> (Accessed on November 2, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 86415 Version 5.0</div></div></div>"},"86416":{"type":"graphic_table","displayName":"Criteria for OT and PT in acute hospital setting","title":"Criteria to identify patients able to participate in occupational therapy/physical therapy treatment in the acute hospital setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria to identify patients able to participate in occupational therapy/physical therapy treatment in the acute hospital setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Health characteristic</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td rowspan=\"3\">Cognition</td> <td>Able to follow one-step commands</td> </tr> <tr> <td>Oriented to person</td> </tr> <tr> <td>Remember one of three items</td> </tr> <tr> <td rowspan=\"7\">Hemodynamic</td> <td>Mean arterial pressure 65 to 110 mmHg&nbsp;(resting systolic blood pressure 85 to 160 mmHg, and &#60;200&nbsp;mmHg with exertion)</td> </tr> <tr> <td>Heart rate 40 to 130 beats per minute</td> </tr> <tr> <td>Respiratory rate 5 to 40 breaths per minute</td> </tr> <tr> <td>Oxygen saturation &#8805;88%, with or without supplemental O<sub>2</sub> and at rest or with activity</td> </tr> <tr> <td>Change in vital signs with activity &#60;20%</td> </tr> <tr> <td>Hematocrit &#62;25%</td> </tr> <tr> <td>No unstable angina (eg, change in ECG with activity)</td> </tr> <tr> <td>Musculoskeletal stability</td> <td>Fracture/open wounds require explicit clinician guidance with regards to physical activity (eg, weightbearing status, orthoses/braces, etc.)</td> </tr> <tr> <td>Pain</td> <td>No acute exacerbation of pain during OT/PT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; OT: occupational therapy; PT: physical therapy.</div><div id=\"graphicVersion\">Graphic 86416 Version 2.0</div></div></div>"},"86417":{"type":"graphic_table","displayName":"Medicare qualifying conditions for inpatient rehab facility","title":"Medicare qualifying medical conditions for inpatient rehabilitation facility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicare qualifying medical conditions for inpatient rehabilitation facility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Stroke</td> </tr> <tr> <td>Spinal cord injury</td> </tr> <tr> <td>Congenital deformity</td> </tr> <tr> <td>Amputation</td> </tr> <tr> <td>Major multiple trauma</td> </tr> <tr> <td>Femur fracture (hip fracture)</td> </tr> <tr> <td>Brain injury</td> </tr> <tr> <td>Neurologic disorders (including multiple sclerosis, muscular dystrophy, Parkinson disease)</td> </tr> <tr> <td>Burns</td> </tr> <tr> <td>Active polyarticular rheumatoid/psoriatic arthritis and seronegative arthritides, with qualifiers</td> </tr> <tr> <td>Systemic vasculitides with joint inflammation, with qualifiers</td> </tr> <tr> <td>Severe or advanced osteoarthritis involving&nbsp;two or more major weightbearing joints, with qualifiers</td> </tr> <tr> <td>Hip or knee joint replacement, or both, with qualifiers</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: CMS Manual System. Pub. 100-04, Medicare Claims Processing, Transmittal 347. Department of Health and Human Services, Centers for Medicare and Medicaid Services 2005. Available at:&nbsp;<A style=\"FONT-STYLE: italic\" href=\"https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R347CP.pdf\" target=_blank>https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R347CP.pdf</A> (Accessed September 11, 2012).</div><div id=\"graphicVersion\">Graphic 86417 Version 4.0</div></div></div>"},"86418":{"type":"graphic_picture","displayName":"Koilonychia 1","title":"Koilonychia (spoon nail) associated with iron deficiency","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Koilonychia (spoon nail) associated with iron deficiency</div><div class=\"cntnt\"><img style=\"width:500px; height:374px;\" src=\"images/DERM/86418_Koilonychia_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo courtesy of Moise L Levy, MD. Reproduced with permission from: Chung EK, Boom JA, Datto GA, Matz PS. Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86418 Version 2.0</div></div></div>"},"86419":{"type":"graphic_picture","displayName":"Koilonychia 2","title":"Koilonychia (spoon nail) associated with iron deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Koilonychia (spoon nail) associated with iron deficiency</div><div class=\"cntnt\"><img style=\"width:282px; height:504px;\" src=\"images/DERM/86419_Koilonychia_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86419 Version 1.0</div></div></div>"},"86420":{"type":"graphic_picture","displayName":"Splinter hemorrhages 1","title":"Splinter hemorrhages of the great toe","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Splinter hemorrhages of the great toe</div><div class=\"cntnt\"><img style=\"width:504px; height:428px;\" src=\"images/DERM/86420_Splinter_hemorrages_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trauma-induced splinter hemorrhages are typically located in the distal nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86420 Version 2.0</div></div></div>"},"86421":{"type":"graphic_picture","displayName":"Nail plate post-surgery","title":"Nail plate replacement after nail bed surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail plate replacement after nail bed surgery</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86421_Nail_plate_post_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whenever possible, the nail plate is put back in place after nail bed biopsy to protect the wound and act as a biologic dressing. The nail plate can be taped or sutured in place.</div><div id=\"graphicVersion\">Graphic 86421 Version 2.0</div></div></div>"},"86422":{"type":"graphic_picture","displayName":"AITL arborizing blood vessels","title":"Angioimmunoblastic T cell lymphoma with arborizing blood vessels","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Angioimmunoblastic T cell lymphoma with arborizing blood vessels</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/HEME/86422_AITLarborizbloodvessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy shows effacement of normal architecture by arborizing blood vessels and large tumor cells with clear cytoplasm. H&amp;E, x20.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86422 Version 6.0</div></div></div>"},"86423":{"type":"graphic_picture","displayName":"AITL high power","title":"Angioimmunoblastic T cell lymphoma with polymorphous infiltrate","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Angioimmunoblastic T cell lymphoma with polymorphous infiltrate</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/HEME/86423_AITLhighpower.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Higher magnification shows an area with mixed cellularity. H&amp;E, x60.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86423 Version 6.0</div></div></div>"},"86424":{"type":"graphic_picture","displayName":"AITL CD3","title":"Angioimmunoblastic T cell lymphoma around high endothelial venules","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Angioimmunoblastic T cell lymphoma around high endothelial venules</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/HEME/86424_AITLCD3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD3 stain, immunoperoxidase, x20.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86424 Version 6.0</div></div></div>"},"86425":{"type":"graphic_picture","displayName":"AITL CD21","title":"Angioimmunoblastic T cell lymphoma dendritic meshwork","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Angioimmunoblastic T cell lymphoma dendritic meshwork</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/HEME/86425_AITLCD21.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A follicular dendritic meshwork is demonstrated by CD21 staining. Immunoperoxidase, x20.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86425 Version 6.0</div></div></div>"},"86426":{"type":"graphic_table","displayName":"MMRC dyspnea scale","title":"Modified Medical Research Council (MMRC) dyspnea scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Medical Research Council (MMRC) dyspnea scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description of breathlessness</td> </tr> <tr> <td class=\"centered\">0</td> <td>I only get breathless with strenuous exercise</td> </tr> <tr> <td class=\"centered\">1</td> <td>I get short of breath when hurrying on level ground or walking up a slight hill</td> </tr> <tr> <td class=\"centered\">2</td> <td>On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace</td> </tr> <tr> <td class=\"centered\">3</td> <td>I stop for breath after walking about 100 yards or after a few minutes on level ground</td> </tr> <tr> <td class=\"centered\">4</td> <td>I am too breathless to leave the house or I am breathless when dressing</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. British Medical Journal 1959; 2:257.</div><div id=\"graphicVersion\">Graphic 86426 Version 1.0</div></div></div>"},"86427":{"type":"graphic_diagnosticimage","displayName":"Radiograph blastic lytic and mixed metastases","title":"Radiograph blastic lytic and mixed metastases","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Radiograph blastic lytic and mixed metastases</div><div class=\"cntnt\"><img style=\"width:596px; height:319px;\" src=\"images/RADIOL/86427_Xray_blast_lytic_mix_metast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images are from different patients and reflect different patterns of metastatic bone disease on plain radiograph. Arrowheads indicate lytic disease and arrows indicate blastic disease. Image A is a lateral skull radiograph from a patient with prostate carcinoma and shows two well defined blastic metastases (arrows). Image B is a lateral skull radiograph from a patient with lytic metastatic disease, revealing a poor zone of transition between the lytic lesion and the normal surrounding bone (arrowheads). Image C is from a patient with multiple myeloma and also shows lytic disease. The size of the lesions appear to be more uniform and have characteristic salt and pepper appearance. The lateral examination of the spine (D) is a patient with blastic metastases to the thoracic spine (single arrow). Image E is a patient with lung carcinoma and has a lytic lesion in the right greater trochanter (arrowhead). The metallic T-shaped structure in the pelvis is an IUD. The patient displayed in image F is a patient with treated breast carcinoma with both lytic (arrowhead) and blastic disease (arrow) in the neck of the left femur.</div><div class=\"graphic_footnotes\">IUD: intrauterine device.</div><div class=\"graphic_reference\">Images A, B, and C reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition, Lippincott Williams &amp; Wilkins, Philadelphia, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86427 Version 5.0</div></div></div>"},"86428":{"type":"graphic_diagnosticimage","displayName":"MRI neurogenic TOS","title":"MRI of neurogenic thoracic outlet syndrome","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">MRI of neurogenic thoracic outlet syndrome</div><div class=\"cntnt\"><img style=\"width:515px; height:309px;\" src=\"images/NEURO/86428_MRI_neurogenic_TOS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right brachial plexus magnetic resonance neurography. Coronal and axial T1-weighted images (A, B) and coronal fat-suppressed T2-weighted neurographic image (C) reveal a thick fibrous band (arrows in A and B) causing distortion and edema of the right brachial plexus (arrowheads in A and C). Oblique coronal fat-suppressed T2-weighted neurographic image (D) further illustrates a selective thickening of C8 root (arrowheads).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Luigetti M, Capone F, Di Lazzaro V. Teaching NeuroImages: Neurogenic thoracic outlet syndrome. Neurology 2012; 79:e11. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86428 Version 6.0</div></div></div>"},"86429":{"type":"graphic_picture","displayName":"Hanging bronchoscopes","title":"Bronchoscopes hung upright to prevent the accumulation of moisture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopes hung upright to prevent the accumulation of moisture</div><div class=\"cntnt\"><img style=\"width:254px; height:590px;\" src=\"images/PULM/86429_Hanging_bronchoscopes.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86429 Version 1.0</div></div></div>"},"86430":{"type":"graphic_diagnosticimage","displayName":"CT scan fasciola hepatica","title":"Computed tomography (CT) scan of <em>Fasciola hepatica</em>","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) scan of <em>Fasciola hepatica</em></div><div class=\"cntnt\"><img style=\"width:577px; height:507px;\" src=\"images/RADIOL/86430_CT_scan_fasciola_hepatica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the liver reveals a focal cluster of variably sized hypodense lesions surrounding the porta hepatis in segment IV and V. The lesions are noted in image A and magnified in B. The lesions (double arrow) are round to oval in shape and are associated with regional adenopathy (arrow). In addition, characteristic linear tracts extending along the portal triads are noted in image C and magnified in D (arrowheads). The tracts reflect the migration of the parasites. The findings are characteristic of <EM>Fasciola hepatica</EM>.</div><div id=\"graphicVersion\">Graphic 86430 Version 3.0</div></div></div>"},"86431":{"type":"graphic_figure","displayName":"Heineke-Mikulicz strictureplasty","title":"Heineke-Mikulicz strictureplasty","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Heineke-Mikulicz strictureplasty</div><div class=\"cntnt\"><img style=\"width:538px; height:531px;\" src=\"images/SURG/86431_H-M_strictureplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A full-thickness longitudinal incision is made along the antimesenteric border of the stricture for approximately one to two centimeters beyond the stricture.<br />(B1) The lumen is closed in one layer transversely.<br />(B2) If the surgeon prefers, the lumen can be closed in two layers.<br />(C) The resulting diameter of the bowel is sufficient to relieve the obstruction and preserve the length of bowel.</div><div id=\"graphicVersion\">Graphic 86431 Version 3.0</div></div></div>"},"86432":{"type":"graphic_picture","displayName":"Button battery removed from the nose","title":"Button battery removed from the nose","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Button battery removed from the nose</div><div class=\"cntnt\"><img style=\"width:472px; height:504px;\" src=\"images/EM/86432_Button_battery_remove_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This button battery was removed from the nose and shows necrotic tissue attached to the negative pole.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86432 Version 2.0</div></div></div>"},"86433":{"type":"graphic_picture","displayName":"Foam rubber foreign body in the nose","title":"Foam rubber foreign body in the nose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foam rubber foreign body in the nose</div><div class=\"cntnt\"><img style=\"width:409px; height:401px;\" src=\"images/EM/86433_Foam_rubber_fore_body_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy view of foam rubber in the nose with associated white mucoid discharge.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86433 Version 1.0</div></div></div>"},"86434":{"type":"graphic_diagnosticimage","displayName":"Radio-opaque nasal foreign body","title":"Radio-opaque nasal foreign body","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Radio-opaque nasal foreign body</div><div class=\"cntnt\"><img style=\"width:504px; height:413px;\" src=\"images/EM/86434_Radio_opaq_nas_for_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal computed tomography image shows a radio-opaque nasal foreign body (yellow arrow) in a child with suspected sinusitis.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86434 Version 1.0</div></div></div>"},"86435":{"type":"graphic_figure","displayName":"Common locations of nasal foreign bodies","title":"Common locations of nasal foreign bodies","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Common locations of nasal foreign bodies</div><div class=\"cntnt\"><img style=\"width:526px; height:404px;\" src=\"images/EM/86435_Common_locations_of_nasal_foreign_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal foreign bodies are typically located on the floor of the nasal passage near the inferior turbinate or superiorly in the nasal cavity just anterior to the middle turbinate.<BR></div><div id=\"graphicVersion\">Graphic 86435 Version 1.0</div></div></div>"},"86437":{"type":"graphic_picture","displayName":"Magnets as nasal foreign bodies","title":"Magnets as nasal foreign bodies","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magnets as nasal foreign bodies</div><div class=\"cntnt\"><img style=\"width:504px; height:399px;\" src=\"images/EM/86437_Magnet_nasal_for_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 13 year old boy&nbsp;placed flashing-light magnetic-backed earrings on both alae. The magnets subsequently attached across the nasal septum high in the anterior nasal cavity. One battery is visualized here (dotted box).</div><div class=\"graphic_reference\">Reproduced with permission from: Starke L. Easy removal of nasal magnets. Pediatr Emerg Care 2005; 21:598. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86437 Version 4.0</div></div></div>"},"86438":{"type":"graphic_picture","displayName":"Cherry pit with secretions in the nose","title":"Cherry pit with secretions in the nose","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Cherry pit with secretions in the nose</div><div class=\"cntnt\"><img style=\"width:597px; height:425px;\" src=\"images/EM/86438_Cherry_pit_secretions_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nasal foreign body (cherry pit) was placed into the left nasal cavity by a six-year-old child (A). After suctioning (B), the cherry pit was located on the floor of the nasal passage adjacent to the inferior turbinate.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86438 Version 1.0</div></div></div>"},"86439":{"type":"graphic_figure","displayName":"EPT plot of achalasia subtypes in the Chicago Classification","title":"Esophageal pressure topography plot of achalasia subtypes in the Chicago Classification","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Esophageal pressure topography plot of achalasia subtypes in the Chicago Classification</div><div class=\"cntnt\"><img style=\"width:598px; height:248px;\" src=\"images/GAST/86439_EPT_achalasia_sub_Chig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In each case, the 30 mmHg isobaric contour is highlighted in black and there is impaired EGJ relaxation evident by the EGJ never relaxing to less than 30 mmHg in any panel. With type I achalasia, there is minimal contractile activity between the UES and EGJ. Type II is defined by &ge;20 percent of swallows (supine posture, 5 mL water) with panesophageal pressurization to &ge;30 mmHg. With type III, there is &ge;20 percent of swallows with either premature contractions or fragments of peristalsis.</div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction; UES: upper esophageal sphincter.</div><div class=\"graphic_reference\">Original figure modified for this publication. Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135:1526. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86439 Version 2.0</div></div></div>"},"86440":{"type":"graphic_figure","displayName":"EPT phenotypes of abnormal propagation","title":"Esophageal pressure topography phenotypes of abnormal propagation","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Esophageal pressure topography phenotypes of abnormal propagation</div><div class=\"cntnt\"><img style=\"width:600px; height:304px;\" src=\"images/GAST/86440_EPT_phen_abnorm_propag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A illustrates a premature contraction defined by a DL of &lt;4.5 s with a normal IRP, the defining feature of DES in the Chicago classification. In this example the CFV is also markedly abnormal with the upper limit of normal being 9 cm/s. Panel B also illustrates a premature contraction, but in this case the CFV is normal. In Panel C, there is a normal DL but rapid CFV. Note how this is associated with a large (5.5 cm) break in the 30 mmHg isobaric contour and an otherwise normal appearing fragment of peristalsis. Panel C is categorized as borderline motor function in the Chicago classification whereas this would have been defined as DES utilizing conventional manometric criteria.</div><div class=\"graphic_footnotes\">DES: distal esophageal spasm; UES: upper esophageal sphincter; CDP: contractile deceleration point; EGJ: esophagogastric junction; CFV: contractile front velocity; DL: distal latency.</div><div class=\"graphic_reference\">Original figure modified for this publication. Pandolfino JE, Roman S, Carlson D, et al. Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology 2011; 141:469. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86440 Version 2.0</div></div></div>"},"86441":{"type":"graphic_figure","displayName":"DCI thresholds on EPT","title":"Distal contractile integral thresholds on esophageal pressure topography for normal hypertensive peristalsis and hypercontractile esophagus","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Distal contractile integral thresholds on esophageal pressure topography for normal hypertensive peristalsis and hypercontractile esophagus</div><div class=\"cntnt\"><img style=\"width:462px; height:280px;\" src=\"images/GAST/86441_DCI_thresholds_EPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DCI threshold for hypercontractility is &gt;8000 mmHg&bull;s&bull;cm (panel B). Note that the IRP and DL are normal. The criteria for jackhammer esophagus indicate that 20 percent (two) test swallows have a hypercontractile pattern.</div><div class=\"graphic_footnotes\">DCI: distal contractile integral; UES: upper esophageal sphincter; EGJ: esophagogastric junction; s: seconds; IRP: integrated relaxation pressure; DL: distal latency.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008; 103:27. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 86441 Version 4.0</div></div></div>"},"86442":{"type":"graphic_picture","displayName":"Pediculosis corporis hyperpigmentation","title":"Pediculosis corporis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pediculosis corporis</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86442_Pediculosis_corpor_hyperpig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriations and prominent hyperpigmentation in a patient with pediculosis corporis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86442 Version 3.0</div></div></div>"},"86443":{"type":"graphic_picture","displayName":"Pediculosis humanus humanus","title":"Pediculosis humanus humanus (human body louse)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pediculosis humanus humanus (human body louse)</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/DERM/86443_Pediculus_humanus_human.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo provided by B. Thomas Photo Research.</div><div id=\"graphicVersion\">Graphic 86443 Version 1.0</div></div></div>"},"86444":{"type":"graphic_diagnosticimage","displayName":"HRCT NTM lung disease","title":"High resolution computed tomography of nontuberculous mycobacterial pulmonary disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">High resolution computed tomography of nontuberculous mycobacterial pulmonary disease</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/PEDS/86444_HRCTNTMlungdisease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seventeen-year-old patient with cystic fibrosis and sputum culture positive for <EM>Mycobacterium avium</EM>-<EM>intracellulare</EM> in association with declining pulmonary function and weight loss. Note the multiple bilateral nodular opacities distributed in a bronchovascular pattern (arrows). Moderate bronchiectasis is demonstrated by dilated airways and bronchial wall thickening (arrowheads).</div><div class=\"graphic_reference\">Courtesy Sheldon L Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 86444 Version 3.0</div></div></div>"},"86445":{"type":"graphic_picture","displayName":"Nasal foreign body positive pressure technique","title":"Nasal foreign body positive pressure technique","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Nasal foreign body positive pressure technique</div><div class=\"cntnt\"><img style=\"width:470px; height:500px;\" src=\"images/EM/86445_Nas_for_body_press_tech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For removing anterior foreign bodies, having the child blow the nose with the opposite nostril occluded is frequently successful.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86445 Version 1.0</div></div></div>"},"86446":{"type":"graphic_algorithm","displayName":"Selecting gait aid","title":"Determining which gait aid to prescribe for issues of endurance, balance, or weightbearing","html":"<div class=\"graphic\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">Determining which gait aid to prescribe for issues of endurance, balance, or weightbearing</div><div class=\"cntnt\"><img style=\"width:816px; height:1012px;\" src=\"images/PC/86446_Selecting_gait_aid_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When more than one gait aid is listed in a box, they are listed in order of increasing support. Comorbid conditions would influence which gait aid to chose when more than one option is available and/or would influence use of a more supportive device (eg, some with a little impairment in endurance plus a little impairment in balance might require a wheelchair for community mobility but be able to use a walker at home).</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmondary disease; HF: heart failure.</div><div id=\"graphicVersion\">Graphic 86446 Version 2.0</div></div></div>"},"86449":{"type":"graphic_figure","displayName":"US pertussis cases by age 2012","title":"Incidence of confirmed and probable pertussis among persons aged ≤19 years, by patient age and vaccines received — National Notifiable Diseases Surveillance System, United States, January 1–June 14, 2012","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Incidence of confirmed and probable pertussis among persons aged ≤19 years, by patient age and vaccines received — National Notifiable Diseases Surveillance System, United States, January 1–June 14, 2012</div><div class=\"cntnt\"><img style=\"width:556px; height:398px;\" src=\"images/PEDS/86449_US_pertussis_case_age_2012.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acellular vaccines (DTaP) replaced whole-cell vaccines (DTwP) for the 4<sup>th</sup> and 5<sup>th</sup> doses in 1992 and all five doses of the childhood series in 1997. Tdap was recommended for adolescents aged 11 to 12 years in 2006. Thus, all children aged &le;14 years are likely to have received acellular vaccines for the complete childhood series. Adolescents aged 15 years were born during a transition year from whole-cell to acellular vaccines for the childhood series. Adolescents aged &ge;16 years received whole-cell vaccines for the first three doses, and acellular vaccines for the 4<sup>th</sup> and 5<sup>th</sup> doses.</div><div class=\"graphic_footnotes\">DTaP: diphtheria and tetanus toxoids and acellular pertussis; DTwP: diphtheria and tetanus toxoids and whole-cell pertussis; Tdap: tetanus and reduced diphtheria toxoids and acellular pertussis.<br />* Ages during which the Advisory Committee on Immunization Practices recommends that specified vaccine doses be administered.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Pertussis epidemic - Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517.</div><div id=\"graphicVersion\">Graphic 86449 Version 1.0</div></div></div>"},"86450":{"type":"graphic_picture","displayName":"Items for nasal foreign body removal","title":"Instruments and topical anesthetic for nasal foreign body removal","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Instruments and topical anesthetic for nasal foreign body removal</div><div class=\"cntnt\"><img style=\"width:590px; height:440px;\" src=\"images/EM/86450_Items_nasal_foreign_bod_rem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The headlamp frees both hands for instrumentation. When dosing the lidocaine and oxymetazoline mixture ensure no more than&nbsp;1 mg/kg (0.1 mL per kg of the 2 percent lidocaine mixture) is administered. Instruments pictured from top to bottom: right angle Day hook,&nbsp;Lucae bayonet forceps, alligator forceps.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesty of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86450 Version 3.0</div></div></div>"},"86456":{"type":"graphic_table","displayName":"HAT characteristics","title":"Characteristics of African trypanosomiasis species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of African trypanosomiasis species</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>T. b. gambiense</em></td> <td class=\"subtitle1\"><em>T. b. rhodesiense</em></td> </tr> <tr> <td><strong>Geographic distribution</strong></td> <td>West, Central Africa</td> <td>East Africa</td> </tr> <tr> <td><strong>Fly species</strong></td> <td>Glossina palpalis</td> <td>Glossina morsitans</td> </tr> <tr> <td><strong>Fly habitat</strong></td> <td>Humid; river habitat</td> <td>Dry; savannah and woodland habitat</td> </tr> <tr> <td><strong>Primary host</strong></td> <td>Humans</td> <td>Animals</td> </tr> <tr> <td><strong>Nature of clinical infection</strong></td> <td>Chronic</td> <td>Acute</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86456 Version 2.0</div></div></div>"},"86457":{"type":"graphic_table","displayName":"Treatment of HAT","title":"Treatment of African trypanosomiasis in adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of African trypanosomiasis in adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\"><em>Trypanosoma brucei gambiense</em></td> <td class=\"subtitle1\" colspan=\"2\"><em>Trypanosoma brucei rhodesiense</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Early infection</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Preferred</td> </tr> <tr> <td class=\"indent1\">Pentamidine</td> <td>4 mg/kg/day IM or IV (over&nbsp;two hours) for&nbsp;7 days</td> <td>Suramin</td> <td>100 to 200 mg (test dose) IV, then 20 mg/kg (max 1 g) IV on days 1, 3, 7, 14, and 21</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Alternative</td> </tr> <tr> <td class=\"indent1\">Suramin</td> <td>100 to 200 mg (test dose) IV, then 20 mg/kg (max 1 g) IV on days 1, 3, 7, 14, and 21</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Late infection</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Preferred</td> </tr> <tr> <td class=\"indent1\"> <p>Eflornithine</p> <p><strong>PLUS</strong></p> Nifurtimox</td> <td> <p>200 mg/kg every 12 hours IV (over&nbsp;one hour) for&nbsp;7 days</p> <p><strong>PLUS</strong></p> 5 mg/kg orally every 8 hours for 10 days</td> <td>Melarsoprol*</td> <td>2.2 mg/kg/day IV for 10 days</td> </tr> <tr> <td class=\"indent1\">Eflornithine</td> <td>100 mg/kg IV every 6 hours for 14 days</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Alternative</td> </tr> <tr> <td class=\"indent1\">Melarsoprol*</td> <td>2.2 mg/kg/day IV for 10 days</td> <td>Melarsoprol*</td> <td>Three series of 3.6 mg/kg/day IV&nbsp;for&nbsp;3&nbsp;days spaced by intervals of&nbsp;7 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscularly; IV: intravenously.<br />* Melarsoprol should be coadministered with prednisolone 1 mg/kg per day (up to 40 mg/kg per day), beginning one to two days before therapy and continued until therapy is completed.</div><div id=\"graphicVersion\">Graphic 86457 Version 3.0</div></div></div>"},"86459":{"type":"graphic_picture","displayName":"Bow-legs PI","title":"Bow-legs in children with rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bow-legs in children with rickets</div><div class=\"cntnt\"><img style=\"width:252px; height:207px;\" src=\"images/PI/86459_Bow_legs_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Babies and children who don't get enough vitamin D can get a condition called \"rickets\" that makes legs bend to the side.</div><div id=\"graphicVersion\">Graphic 86459 Version 1.0</div></div></div>"},"86464":{"type":"graphic_picture","displayName":"Chronic eosinophilic pneumonia HRCT","title":"Chronic eosinophilic pneumonia HRCT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic eosinophilic pneumonia HRCT</div><div class=\"cntnt\"><img style=\"width:380px; height:595px;\" src=\"images/PULM/86464_Chron_eosino_pneumonia_HRCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) high resolution computed tomography images from a patient with chronic eosinophilic pneumonia (CEP). The findings include bilateral, upper lobe predominant, and peripheral consolidative and ground-glass opacities. In CEP, lung involvement is bilateral 75 percent of the time and confined to the upper lobe in 50 percent. While these findings are \"classic,\" it should be recognized that the chest imaging findings in most cases of CEP are not classic.</div><div class=\"graphic_reference\">Courtesy of David A Lynch, MD.</div><div id=\"graphicVersion\">Graphic 86464 Version 2.0</div></div></div>"},"86465":{"type":"graphic_diagnosticimage","displayName":"Chronic eosinophilic pneumonia CXR","title":"Chronic eosinophilic pneumonia chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Chronic eosinophilic pneumonia chest radiograph</div><div class=\"cntnt\"><img style=\"width:540px; height:528px;\" src=\"images/PULM/86465_Chron_eosino_pneumonia_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic findings of chronic eosinophilic pneumonia (CEP) as seen on a&nbsp;conventional chest radiograph. The findings include bilateral, upper lobe predominant, and&nbsp;peripheral consolidative and ground-glass opacities. In CEP, lung involvement is bilateral in&nbsp;75 percent and confined to the upper lobe in&nbsp;50 percent. While these findings are \"classic,\" it should be recognized that the chest imaging findings in most cases of CEP are not classic.</div><div class=\"graphic_reference\">Courtesy of David A Lynch, MD.</div><div id=\"graphicVersion\">Graphic 86465 Version 4.0</div></div></div>"},"86466":{"type":"graphic_diagnosticimage","displayName":"Coil embolization type II aortic endoleak","title":"Coil embolization type II aortic endoleak","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coil embolization type II aortic endoleak</div><div class=\"cntnt\"><img style=\"width:427px; height:481px;\" src=\"images/SURG/86466_Embolized_type_II_endoleak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coil embolization of type II&nbsp;aortic endoleak is performed by obliterating the nidus of the endoleak at its junction with the AAA sac, as well as the inflow vessel (arrow). Care is taken to avoid obliteration of the sigmoidal, rectal, and colic branches of the inferior mesenteric artery.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 86466 Version 3.0</div></div></div>"},"86467":{"type":"graphic_figure","displayName":"Hypoglossal palsy ICA dissection","title":"Isolated hypoglossal nerve palsy due to internal carotid artery dissection","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Isolated hypoglossal nerve palsy due to internal carotid artery dissection</div><div class=\"cntnt\"><img style=\"width:513px; height:583px;\" src=\"images/NEURO/86467_Hypogloss_palsy_ICA_dissect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The patient's tongue deviated to the left.<br />(B) T1-weighted MRI demonstrates narrowing of the lumen and intramural hematoma in the left internal carotid artery.<br />(C) True fast MRI with steady-state precession reveals the anatomic juxtaposition of the hypoglossal nerve (arrowhead) and the dissected internal carotid artery (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Okunomiya T, Kageyama T, Suenaga T. Teaching NeuroImages: Isolated hypoglossal nerve palsy due to internal carotid artery dissection. Neurology 2012; 79:e37. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86467 Version 4.0</div></div></div>"},"86468":{"type":"graphic_table","displayName":"ASFA apheresis indications (2016)","title":"American Society for Apheresis 2016 indications for therapeutic apheresis and cytapheresis procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society for Apheresis 2016 indications for therapeutic apheresis and cytapheresis procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"64%\"></colgroup><colgroup span=\"3\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">Indication</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">Modality</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">Category</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">Evidence</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\">Acute disseminated encephalomyelitis: Steroid refractory</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr&#233; syndrome)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary treatment </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>After intravenous immune globulin </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Acute liver failure</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td>TPE-HV</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent1\">Age-related macular degeneration, dry</td> <td>Rheopheresis</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Amyloidosis, systemic</td> <td>Beta2-microglobulin column</td> <td>II</td> <td>2B</td> </tr> <tr> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">ANCA-associated rapidly progressive glomerulonephritis (granulomatosis with polyangiitis [Wegener's]; microscopic polyangiitis)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dialysis dependent </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dialysis independent </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Diffuse alveolar hemorrhage </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Anti-glomerular basement membrane disease (Goodpasture's syndrome)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dialysis dependent and no diffuse alveolar hemorrhage </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dialysis independent </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Diffuse alveolar hemorrhage </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Atopic (neuro-) dermatitis (atopic eczema), recalcitrant</td> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Autoimmune hemolytic anemia</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Severe cold agglutinin disease </li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Severe warm autoimmune hemolytic anemia </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Babesiosis, severe</td> <td>RBC exchange</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Burn shock resuscitation</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Cardiac transplantation</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cellular/recurrent rejection </li> </ul> </td> <td>ECP</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Desensitization </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prophylaxis for rejection </li> </ul> </td> <td>ECP</td> <td>II</td> <td>2A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Treatment of antibody-mediated rejection </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Cardiomyopathy, dilated idiopathic (NYHA functional class II-IV)</td> <td>IA</td> <td>II</td> <td>1B</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Catastrophic antiphospholipid syndrome (APS)</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Chronic focal encephalitis (Rasmussen encephalitis)</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Chronic inflammatory demyelinating polyradiculoneuropathy</td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Coagulation factor inhibitors</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Alloantibody </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Autoantibody </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>1C</td> </tr> <tr> <td class=\"indent1\">Complex regional pain syndrome, chronic</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Cryoglobulinemia: Severe/symptomatic</td> <td>TPE</td> <td>II</td> <td>2A</td> </tr> <tr> <td>IA</td> <td>II</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Cutaneous T cell lymphoma; mycosis fungoides; S&#233;zary syndrome</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Erythrodermic </li> </ul> </td> <td>ECP</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Non-erythrodermic </li> </ul> </td> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Dermatomyositis/polymyositis</td> <td>TPE</td> <td>IV</td> <td>2B</td> </tr> <tr> <td>ECP</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Drug overdose or poisoning</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Encephalitis associated with <em>N</em>-methyl D-aspartate receptor antibodies</td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\">Envenomation</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Erythrocytosis, secondary</td> <td>Erythrocytapheresis</td> <td>III</td> <td>1C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Erythropoietic porphyria, liver disease</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Familial hypercholesterolemia</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Heterozygotes </li> </ul> </td> <td>LDL apheresis</td> <td>II</td> <td>1A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Homozygotes </li> </ul> </td> <td>LDL apheresis</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Homozygotes with small blood volume </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Focal segmental glomerulosclerosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Recurrent in transplanted kidney </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Steroid-resistant, in native kidney </li> </ul> </td> <td>LDL apheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Graft-versus-host disease</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute (skin or non-skin) </li> </ul> </td> <td>ECP</td> <td>II</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic (skin or non-skin) </li> </ul> </td> <td>ECP</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent1\">Hashimoto's encephalopathy: Steroid-responsive encephalopathy associated with autoimmune thyroiditis</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Hemolysis, elevated liver function tests, and low platelets (HELLP) syndrome</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Antepartum </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Postpartum </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Hematopoietic cell transplantation, HLA desensitization</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Hematopoietic cell transplantation, major ABO incompatibility (recipient has anti-A or anti-B antibodies)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Stem cells from bone marrow </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Stem cells from peripheral blood </li> </ul> </td> <td>TPE</td> <td>II</td> <td>2B</td> </tr> <tr> <td class=\"indent1\">Hematopoietic cell transplantation, minor ABO incompatibility (donor has anti-A or anti-B antibodies), stem cells from peripheral blood</td> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Hemophagocytic lymphocytosis (HLH); macrophage activating syndrome</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Henoch-Sch&#246;nlein purpura: Crescentic or severe extrarenal disease</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Heparin-induced thrombocytopenia (HIT): Pre-cardiopulmonary bypass or with thrombosis</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Hereditary hemochromatosis</td> <td>Erythrocytapheresis</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Hyperleukocytosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prophylactic or secondary </li> </ul> </td> <td>Leukocytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Symptomatic </li> </ul> </td> <td>Leukocytapheresis</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent1\">Hypertriglyceridemic pancreatitis</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Immune thrombocytopenia (ITP): Refractory</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Immunoglobin A nephropathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic progressive </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Crescentic </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Crohn disease </li> </ul> </td> <td>Adsorptive cytapheresis</td> <td>III</td> <td>1B</td> </tr> <tr> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ulcerative colitis (UC) </li> </ul> </td> <td>Adsorptive cytapheresis</td> <td>III/II</td> <td>1B/2B</td> </tr> <tr> <td class=\"indent1\">Lambert-Eaton myasthenic syndrome</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Lipoprotein (a) hyperlipoproteinemia</td> <td>LDL apheresis</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Liver transplantation, ABO incompatible</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Desensitization, deceased donor; or living donor, antibody-mediated rejection (includes ABO and HLA) </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Desensitization, living donor </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lung transplantation</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Allograft rejection (bronchiolitis obliterans syndrome) </li> </ul> </td> <td>ECP</td> <td>II</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Antibody-mediated rejection or desensitization </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Malaria, severe*</td> <td>RBC exchange</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Monoclonal gammopathies with hyperviscosity</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prophylaxis for rituximab </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Treatment of symptoms </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Acute central nervous system inflammatory demyelinating disease </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic progressive </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\">Mushroom poisoning</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Moderate-severe </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pre-thymectomy </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\">Myeloma cast nephropathy</td> <td>TPE</td> <td>II</td> <td>2B</td> </tr> <tr> <td class=\"indent1\">Neonatal lupus, cardiac</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Nephrogenic systemic fibrosis</td> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Neuromyelitis optica spectrum disorders</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Maintenance </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Paraneoplastic neurologic syndromes</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Paraproteinemic demyelinating neuropathies/chronic acquired demyelinating polyneuropathies</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Anti-MAG neuropathy </li> </ul> </td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>IgA, IgG </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>IgA, IgG, IgM </li> </ul> </td> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>IgM </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Multifocal motor neuropathy </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Multiple myeloma </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) exacerbation</td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Pemphigus vulgaris, severe</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Peripheral vascular diseases</td> <td>LDL apheresis</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Phytanic acid storage disease (Refsum disease)</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td>LDL apheresis</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera</td> <td>Erythrocytapheresis</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\">Post-transfusion purpura</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy associated with natalizumab</td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent1\">Pruritus due to hepatobiliary disease, treatment resistant</td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Psoriasis</td> <td>ECP</td> <td>III</td> <td>2B</td> </tr> <tr> <td>Lymphocytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Psoriasis, disseminated pustular</td> <td>Adsorptive cytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Pure red cell aplasia</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">RBC alloimmunization in pregnancy, prior to intrauterine transfusion availability</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Renal transplantation, ABO compatible</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Antibody-mediated rejection or desensitization, living donor </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td>IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Deceased donor, desensitization </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Renal transplantation, ABO incompatible</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Antibody-mediated rejection </li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td>IA</td> <td>II</td> <td>1B</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Deceased donor, group A2/A2B into group B recipient </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>1B</td> </tr> <tr> <td>IA</td> <td>IV</td> <td>1B</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Living donor, desensitization </li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td>IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class=\"indent1\">Rh(D) exposure from RH(D)-positive RBCs, prevention of alloimmunization</td> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Scleroderma (systemic sclerosis)</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>ECP</td> <td>III</td> <td>2A</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Sensorineural hearing loss, sudden</td> <td>LDL apheresis</td> <td>III</td> <td>2A</td> </tr> <tr> <td>Rheopheresis</td> <td>III</td> <td>2A</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Sepsis with multiorgan failure</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Sickle cell disease</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute chest syndrome, severe </li> </ul> </td> <td>RBC exchange</td> <td>II</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute stroke </li> </ul> </td> <td>RBC exchange</td> <td>I</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Multi-organ failure, pregnancy, priapism, recurrent vaso-occlusive pain episodes, splenic or hepatic sequestration or intrahepatic cholestasis </li> </ul> </td> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Preoperative </li> </ul> </td> <td>RBC exchange</td> <td>III</td> <td>2A</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prevention of transfusional iron overload or prophylaxis for primary or secondary stroke </li> </ul> </td> <td>RBC exchange</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent1\">Stiff-person syndrome</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Sydenham chorea, severe</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Nephritis </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Severe (eg, cerebritis, diffuse alveolar hemorrhage) </li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Thrombocytosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Secondary or prophylaxis </li> </ul> </td> <td>Thrombocytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Symptomatic </li> </ul> </td> <td>Thrombocytapheresis</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Thrombotic microangiopathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Coagulation-mediated: <em>THBD</em> mutation </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Complement-mediated: Complement factor gene mutations </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Complement-mediated: Factor H autoantibodies </li> </ul> </td> <td>TPE</td> <td>I</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Complement-mediated: Membrane cofactor protein (<em>MCP</em>) mutations </li> </ul> </td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Drug-associated: Calcineurin inhibitors </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Drug-associated: Clopidogrel </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Drug-associated: Gemcitabine or quinine </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Drug-associated: Ticlopidine<sup>&#182;</sup> </li> </ul> </td> <td>TPE</td> <td>I</td> <td>2B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hematopoietic stem cell transplant-associated </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Shiga toxin-mediated, absence of severe neurologic symptoms </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>1C</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Shiga toxin-mediated, with severe neurologic symptoms </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td>IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Shiga toxin-mediated, Streptococcus pneumonia </li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura (TTP): Acquired, autoimmune</td> <td>TPE</td> <td>I</td> <td>1A</td> </tr> <tr> <td class=\"indent1\">Thyroid storm</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Toxic epidermal necrolysis, refractory</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Vasculitis</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <ul> <li>Beh&#231;et's disease </li> </ul> </td> <td>Adsorption granulocytapheresis</td> <td>II</td> <td>1C</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Eosinophilic granulomatosis with polyangiitis (EGPA) </li> </ul> </td> <td>TPE</td> <td>III</td> <td>1B</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hepatitis B virus-associated polyarteritis nodosa (HBV-PAN) </li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Idiopathic polyarteritis nodosa (PAN) </li> </ul> </td> <td>TPE</td> <td>IV</td> <td>1B</td> </tr> <tr> <td class=\"indent1\">Voltage-gated potassium channel antibodies</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class=\"indent1\">Wilson disease, fulminant</td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Category</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Category I: Disorders for which apheresis is accepted as first-line therapy, either as a standalone treatment or in conjunction with other therapies.</LI>&#xD;&#xA;<LI>Category II: Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other therapies.</LI>&#xD;&#xA;<LI>Category III: Disorders for which the optimum role of apheresis therapy is not established.</LI>&#xD;&#xA;<LI>Category IV: Disorders for which published evidence demonstrates or suggests apheresis to be ineffective or harmful.</LI></UL><STRONG>Evidence</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Evidence grade 1: Strong recommendation.</LI>&#xD;&#xA;<LI>Evidence grade 2: Weak recommendation.</LI>&#xD;&#xA;<LI>Evidence quality A: High-quality evidence.</LI>&#xD;&#xA;<LI>Evidence quality B: Moderate-quality evidence.</LI>&#xD;&#xA;<LI>Evidence quality C: Low-quality or very low-quality evidence.</LI></UL><STRONG>Refer to UpToDate topics on individual conditions for specific treatment recommendations.</STRONG> Due to UpToDate styling and alphabetization, the order of diseases in this table may differ from the original source publication.</div><div class=\"graphic_footnotes\">ANCA: anti-neutrophil cytoplasmic autoantibody; ECP: extracorporeal photopheresis; HLA: human leukocyte antigen; IA: immunoadsorption; LDL: low density lipoprotein; MAG: myelin-associated glycoprotein; NYHA: New York Heart Association; RBC: red blood cell; TPE: therapeutic plasma exchange; TPE-HV: high volume therapeutic plasma exchange.<br />* UpToDate authors do not use RBC exchange for severe malaria.<br />&para; UpToDate authors consider this entity (thrombotic microangiopathy [TMA] in the setting of ticlopidine) to be acquired autoimmune thrombotic thrombocytopenic purpura (TTP) rather than drug-induced TMA because the patients had severe ADAMTS13 deficiency.</div><div class=\"graphic_reference\">Adapted from: Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice&mdash;evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue. J Clin Apher 2016; 31:149. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/jca.21470/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1002/jca.21470/abstract</a>. Copyright &copy; 2016. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 86468 Version 9.0</div></div></div>"},"86471":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris with islands of sparing","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86471_Pityr_rubr_pil_islands_spar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large orange-red plaques and islands of spared skin in pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86471 Version 3.0</div></div></div>"},"86472":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris follicular papules","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:540px; height:406px;\" src=\"images/DERM/86472_Pityr_rubr_pil_foll_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular papules and red-orange plaques in pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86472 Version 3.0</div></div></div>"},"86473":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris islands of sparing close view","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86473_Pityr_rubr_pil_isl_spar_clo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous scaly plaques and islands of spared skin in pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86473 Version 3.0</div></div></div>"},"86474":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris plantar hyperkeratosis","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86474_Pityr_rubr_pil_plant_hyper.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plantar hyperkeratosis in pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86474 Version 3.0</div></div></div>"},"86475":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris follicular papules in dark skin","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:540px; height:406px;\" src=\"images/DERM/86475_Pityr_rubr_pil_fol_pap_dark.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic follicular papules in pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86475 Version 3.0</div></div></div>"},"86476":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris face and scalp involvement","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/DERM/86476_Pityr_rubr_pil_face_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and scale are present on the face and scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86476 Version 3.0</div></div></div>"},"86478":{"type":"graphic_picture","displayName":"Perforating dermatosis","title":"Acquired reactive perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acquired reactive perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:332px;\" src=\"images/DERM/86478_Perforatingdermatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple dome-shaped, umbilicated papules with a central keratinous plug in a patient with acquired perforating dermatosis.</div><div id=\"graphicVersion\">Graphic 86478 Version 5.0</div></div></div>"},"86479":{"type":"graphic_picture","displayName":"Phototoxic eruption","title":"Phototoxic eruption","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Phototoxic eruption</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86479_Phototoxic_eruption_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bright red, confluent rash on the \"V\" of the neck of a patient with drug-induced photosensitivity reaction.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86479 Version 6.0</div></div></div>"},"86482":{"type":"graphic_picture","displayName":"Epidermolysis bullosa acquisita scarring","title":"Epidermolysis bullosa acquisita","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa acquisita</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86482_Epid_bullosa_acquisita_scar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarring and milia on the dorsal hands in epidermolysis bullosa acquisita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86482 Version 3.0</div></div></div>"},"86484":{"type":"graphic_picture","displayName":"Solar lentigo back","title":"Solar lentigines","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Solar lentigines</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86484_Solar_lentigo_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solar lentigines typically present as small, well-circumscribed, brown macules on sun-exposed areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86484 Version 6.0</div></div></div>"},"86486":{"type":"graphic_picture","displayName":"Callus new","title":"Callus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Callus</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86486_Callus_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86486 Version 3.0</div></div></div>"},"86487":{"type":"graphic_picture","displayName":"Molluscum dermatitis","title":"Molluscum dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum dermatitis</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/DERM/86487_Molluscum_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eczematous plaques surround lesions of molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86487 Version 3.0</div></div></div>"},"86488":{"type":"graphic_picture","displayName":"Nasal foreign body removal without speculum","title":"Nasal foreign body removal without speculum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nasal foreign body removal without speculum</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/EM/86488_Nas_for_bod_rem_wout_spec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the cooperative patient, the clinician can visualize the nasal foreign body using a head lamp by pushing up on the tip of the nose with the patient sitting upright.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86488 Version 1.0</div></div></div>"},"86489":{"type":"graphic_figure","displayName":"Removal of nasal foreign body using a nasal speculum","title":"Removal of nasal foreign body using a nasal speculum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of nasal foreign body using a nasal speculum</div><div class=\"cntnt\"><img style=\"width:404px; height:332px;\" src=\"images/EM/86489_Remnasforbdynasspec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insert the speculum as shown in the figure to avoid injury to the nasal septum with epistaxis.</div><div class=\"graphic_reference\">Reproduced with permission from: Bennett JE. Nasal foreign body removal. In: Textbook of Pediatric Emergency Procedures, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86489 Version 6.0</div></div></div>"},"86490":{"type":"graphic_figure","displayName":"Removal of nasal foreign body foam rubber","title":"Removal of nasal foreign body - foam rubber","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Removal of nasal foreign body - foam rubber</div><div class=\"cntnt\"><img style=\"width:504px; height:228px;\" src=\"images/EM/86490_Rem_nas_for_bod_foam_rub.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foam rubber may be grasped by alligator, Lucae (pictured here), or Gruenwald nasal dressing forceps and removed.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86490 Version 1.0</div></div></div>"},"86491":{"type":"graphic_figure","displayName":"Nasal foreign body removal button battery","title":"Nasal foreign body removal - button battery","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Nasal foreign body removal - button battery</div><div class=\"cntnt\"><img style=\"width:498px; height:329px;\" src=\"images/EM/86491_Nas_for_bod_rem_butt_batt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right angle hook is advanced behind the button battery and then pulled forward to remove it.</div><div class=\"graphic_reference\">Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86491 Version 1.0</div></div></div>"},"86492":{"type":"graphic_figure","displayName":"Nasal foreign body removal with a balloon catheter","title":"Nasal foreign body removal with a balloon catheter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nasal foreign body removal with a balloon catheter</div><div class=\"cntnt\"><img style=\"width:504px; height:282px;\" src=\"images/EM/86492_Nas_for_bod_rem_balloon_cat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The catheter (5 to 8 French Foley or Fogarty balloon catheter) is lubricated with 2 percent lidocaine jelly and advanced past the object. The balloon is then inflated with 2 to 3 mL of air, and the catheter is withdrawn from the nose with the object.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86492 Version 1.0</div></div></div>"},"86494":{"type":"graphic_table","displayName":"Colonoscopy surveillance and screening intervals","title":"United States Multi-Society Task Force on Colorectal Cancer recommendations for surveillance and screening intervals in individuals with baseline average risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States Multi-Society Task Force on Colorectal Cancer recommendations for surveillance and screening intervals in individuals with baseline average risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Baseline colonoscopy: most advanced finding(s)</td> <td class=\"subtitle1\">Recommended surveillance interval (years)</td> <td class=\"subtitle1\">Quality of evidence supporting the recommendation</td> <td class=\"subtitle1\">New evidence stronger than 2006</td> </tr> <tr> <td>No polyps</td> <td>10</td> <td>Moderate</td> <td>Yes</td> </tr> <tr> <td>Small (&#60;10 mm) hyperplastic polyps in rectum or sigmoid</td> <td>10</td> <td>Moderate</td> <td>No</td> </tr> <tr> <td>1 to 2 small (&#60;10 mm) tubular adenomas</td> <td>5 to 10</td> <td>Moderate</td> <td>Yes</td> </tr> <tr> <td>3 to 10 tubular adenomas</td> <td>3</td> <td>Moderate</td> <td>Yes</td> </tr> <tr> <td>&#62;10 adenomas</td> <td>&#60;3</td> <td>Moderate</td> <td>No</td> </tr> <tr> <td>One or more tubular adenomas &#8805;10 mm</td> <td>3</td> <td>High</td> <td>Yes</td> </tr> <tr> <td>One or more villous adenomas</td> <td>3</td> <td>Moderate</td> <td>Yes</td> </tr> <tr> <td>Adenoma with HGD</td> <td>3</td> <td>Moderate</td> <td>No</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Serrated lesions</td> </tr> <tr> <td class=\"sublist1\">Sessile serrated polyp(s) &#60;10 mm with no dysplasia</td> <td class=\"sublist_other\">5</td> <td class=\"sublist_other\">Low</td> <td class=\"sublist_other\">NA</td> </tr> <tr> <td class=\"sublist1\"> <p>Sessile serrated polyp(s) &#8805;10 mm</p> <p><strong>OR</strong></p> <p>Sessile serrated polyp with dysplasia</p> <p><strong>OR</strong></p> <p>Traditional serrated adenoma</p> </td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">Low</td> <td class=\"sublist_other\">NA</td> </tr> <tr> <td>Serrated polyposis syndrome*</td> <td>1</td> <td>Moderate</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The recommendations assume that the baseline colonoscopy was complete and adequate and that all visible polyps were completely removed.</div><div class=\"graphic_footnotes\">HGD: high-grade dysplasia; NA: not applicable.<BR>* Based on the World Health Organization definition of serrated polyposis syndrome, with one of the following criteria: (1) at least five serrated polyps proximal to sigmoid, with two or more ≥10 mm; (2) any serrated polyps proximal to sigmoid with family history of serrated polyposis syndrome; and (3) &gt;20 serrated polyps of any size throughout the colon.</div><div class=\"graphic_reference\">Reproduced from: Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143:844. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86494 Version 1.0</div></div></div>"},"86495":{"type":"graphic_table","displayName":"Polyp surveillance after first surveillance colonoscopy","title":"United States Multi-Society Task Force on Colorectal Cancer recommendations for polyp surveillance after first surveillance colonoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States Multi-Society Task Force on Colorectal Cancer recommendations for polyp surveillance after first surveillance colonoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Baseline colonoscopy</td> <td class=\"subtitle1\">First surveillance</td> <td class=\"subtitle1\">Interval for second surveillance (years)</td> </tr> <tr> <td rowspan=\"3\">LRA</td> <td>HRA</td> <td>3</td> </tr> <tr> <td>LRA</td> <td>5</td> </tr> <tr> <td>No adenoma</td> <td>10</td> </tr> <tr> <td rowspan=\"3\">HRA</td> <td>HRA</td> <td>3</td> </tr> <tr> <td>LRA</td> <td>5</td> </tr> <tr> <td>No adenoma</td> <td>5*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LRA: low risk adenoma; HRA: high risk adenoma.<br />* If the findings on the second surveillance are negative, there is insufficient evidence to make a recommendation.</div><div class=\"graphic_reference\">Reproduced from: Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143:844. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86495 Version 2.0</div></div></div>"},"86496":{"type":"graphic_figure","displayName":"Smooth nasal foreign bodies avoid forceps","title":"Smooth nasal foreign bodies: avoid forceps","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Smooth nasal foreign bodies: avoid forceps</div><div class=\"cntnt\"><img style=\"width:504px; height:280px;\" src=\"images/EM/86496_Sm_nas_for_bd_av_for.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Attempts at removing a smooth intranasal foreign body with forceps will often push these objects deeper into the nasal cavity. A right angle hook should be used instead.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 86496 Version 1.0</div></div></div>"},"86497":{"type":"graphic_figure","displayName":"Junctional ectopic rhythm","title":"Junctional ectopic rhythm","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Junctional ectopic rhythm</div><div class=\"cntnt\"><img style=\"width:590px; height:135px;\" src=\"images/CARD/86497_Junct_ectopic_rhythm_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this tracing of junctional ectopic rhythm, the QRS complexes are narrow and have a rate faster than the P waves. This is an example of atrioventricular dissociation. No retrograde P waves are seen since there is retrograde VA block.</div><div id=\"graphicVersion\">Graphic 86497 Version 1.0</div></div></div>"},"86499":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus indirect immunofluorescence bladder","title":"Paraneoplastic pemphigus ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus </div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/86499_Paraneo_pemphig_imm_blad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect immunofluorescence microscopy demonstrates deposition of IgG intercellularly and at the basement membrane zone. The substrate is murine bladder. 100X.</div><div id=\"graphicVersion\">Graphic 86499 Version 1.0</div></div></div>"},"86500":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus indirect immunofluorescence esophagus","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86500_Paraneo_pemph_immun_esoph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect immunofluorescence microscopy demonstrates deposition of IgG intercellularly and at the basement membrane zone. The substrate is monkey esophagus. 200X.</div><div id=\"graphicVersion\">Graphic 86500 Version 1.0</div></div></div>"},"86501":{"type":"graphic_table","displayName":"Normal serum potassium levels in children","title":"Normal serum potassium levels in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal serum potassium levels in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Range (mEq/L or mmol/L)</td> </tr> <tr> <td class=\"centered\">Premature infant</td> <td class=\"centered\">4 to 6.5</td> </tr> <tr> <td class=\"centered\">Newborn</td> <td class=\"centered\">3.7 to 5.9</td> </tr> <tr> <td class=\"centered\">Infant</td> <td class=\"centered\">4.1 to 5.3</td> </tr> <tr> <td class=\"centered\">Child &#62;1 year old</td> <td class=\"centered\">3.5 to 5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Local laboratory reference ranges for normal may vary depending on laboratory and assay technique. Clinical implications of variation from normal or reference range levels must be considered individually.</div><div id=\"graphicVersion\">Graphic 86501 Version 2.0</div></div></div>"},"86503":{"type":"graphic_figure","displayName":"Light chain amyloidosis survival by hematologic response","title":"Survival curves for patients with systemic light chain amyloidosis stratified by hematologic response at six months","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Survival curves for patients with systemic light chain amyloidosis stratified by hematologic response at six months</div><div class=\"cntnt\"><img style=\"width:571px; height:394px;\" src=\"images/HEME/86503_Lgt_chn_amyld_surv_hem_res.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients in this international case series from seven centers were analyzed for survival at three months after beginning therapy based on metrics for hematologic response assessed at six months. In this series, 43.6 percent received oral melphalan and dexamethasone (MDex), 11.4 percent SCT, 22 percent immunomodulatory agent-based therapy, and 3 percent bortezomib and dexamethasone. Response criteria are CR (immunofixation negative and FLC normal); very good PR (very good partial; reduction in the dFLC to &lt;40 mg/L); PR (partial; reduction in the dFLC by &gt;50 percent); and NR (no response; less than PR).<sup>[1]</sup></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Palladini G, Dispenzieri A, Gertz MA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116:1364a.</LI></OL>Reprinted by permission from Macmillan Publishers Ltd: Leukemia, Comenzo RL, Reece D, Palladini G, Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, advance online publication, 15 May 2012 (DOI: 10.1038/leu.2012.100). Copyright © 2012. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/leu/index.html\" target=_blank>http://www.nature.com/leu/index.html</A>.</div><div id=\"graphicVersion\">Graphic 86503 Version 1.0</div></div></div>"},"86505":{"type":"graphic_figure","displayName":"Light chain amyloidosis survival by NT-proBNP response","title":"Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months</div><div class=\"cntnt\"><img style=\"width:532px; height:398px;\" src=\"images/HEME/86505_Lgt_chn_amy_surv_proBNP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the international series of 816 patients from seven centers, staging cardiac biomarkers were available for 53 percent (432/816). Of these, 24 percent were stage 1 (both NT-proBNP p &le;332 ng/L and cardiac troponin T (cTnT) p &le;0.035 ng/mL or cTnI p &le;0.1 ng/mL), 52 percent stage 2 (NT-proBNP &gt;332 ng/L or cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL), and 24 percent stage 3 (both NT-proBNP &gt;332 ng/L and cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL). In these survival curves, results for 377 patients with baseline NT-proBNP greater than or equal to 650 ng/L are shown according to NT-proBNP response or progression at six months.<sup>[1]</sup></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Palladini G, Dispenzieri A, Gertz MA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116:1364a.</LI></OL>Reprinted by permission from Macmillan Publishers Ltd: Leukemia, Comenzo RL, Reece D, Palladini G, Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, advance online publication, 15 May 2012 (DOI: 10.1038/leu.2012.100). Copyright © 2012. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/leu/index.html\" target=_blank>http://www.nature.com/leu/index.html</A>.</div><div id=\"graphicVersion\">Graphic 86505 Version 1.0</div></div></div>"},"86506":{"type":"graphic_picture","displayName":"SDRIFE","title":"Symmetrical drug-related intertriginous and flexural exanthem (SDRIFE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Symmetrical drug-related intertriginous and flexural exanthem (SDRIFE)</div><div class=\"cntnt\"><img style=\"width:271px; height:504px;\" src=\"images/DERM/86506_SDRIFE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply demarcated erythema in the gluteal/perianal area in a patient with SDRIFE. Note the involvement of the popliteal folds.</div><div id=\"graphicVersion\">Graphic 86506 Version 3.0</div></div></div>"},"86507":{"type":"graphic_figure","displayName":"Molecular targets in NSCLC","title":"Molecular targets in non-small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Molecular targets in non-small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:581px; height:362px;\" src=\"images/ONC/86507_Molecular_targ_NSCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathways for molecularly targeted therapy in non-small cell lung cancer.</div><div class=\"graphic_reference\">Original, courtesy of Dr. Joel Neal.</div><div id=\"graphicVersion\">Graphic 86507 Version 1.0</div></div></div>"},"86508":{"type":"graphic_diagnosticimage","displayName":"MRI vestibular Schwannoma","title":"MRI vestibular Schwannoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI vestibular Schwannoma</div><div class=\"cntnt\"><img style=\"width:418px; height:508px;\" src=\"images/RADIOL/86508_MRI_vestibular_Schwannoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 30-year-old female presented with hearing loss on the right and has findings consistent with an acoustic neuroma on the following MRI images. The T1 weighted image without contrast (A) shows a mass centered in the right internal auditory canal (arrow). It is isointense to the brain parenchyma. Following gadolinium the Schwannoma enhances homogeneously and has the classic \"ice cream cone\" shape (arrowhead). The high resolution T2 weighted image, shows loss of the normal fluid signal in the internal auditory canal which can be appreciated on the left side. The mass (green overlay) projects into the cerebellopontine angle cistern (dashed arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 86508 Version 2.0</div></div></div>"},"86509":{"type":"graphic_picture","displayName":"Exanthematous drug eruption - Back","title":"Exanthematous (morbilliform) drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exanthematous (morbilliform) drug eruption</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/DERM/86509_Exanthem_drug_erupt_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Profuse eruption of macules and papules on the back of a patient with exanthematous drug eruption.</div><div id=\"graphicVersion\">Graphic 86509 Version 4.0</div></div></div>"},"86511":{"type":"graphic_figure","displayName":"Drug eruption chronology","title":"Chronology of drug eruptions","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Chronology of drug eruptions</div><div class=\"cntnt\"><img style=\"width:494px; height:338px;\" src=\"images/DRUG/86511_Drug_erupt_chronology.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approximate onset and evolution of uncomplicated drug-induced exanthemas with probable T-cell-mediated pathophysiology in previously sensitized individuals. The height of the lines reflects acuity, their ends the approximate duration. In newly sensitized individuals, typically exanthems develop between the 8<SUP>th</SUP> and 12<SUP>th</SUP> day (red dashed line).</div><div class=\"graphic_footnotes\">SDRIFE: Symmetrical drug-related intertriginous and flexural exanthem</div><div class=\"graphic_reference\">Reproduced with permission from: Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy 2012; 97:79. Copyright &copy; 2012 S. Karger AG. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86511 Version 5.0</div></div></div>"},"86512":{"type":"graphic_diagnosticimage","displayName":"Superior mesenteric arterty angioplasty and stent","title":"Superior mesenteric arterty angioplasty and stent","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Superior mesenteric arterty angioplasty and stent</div><div class=\"cntnt\"><img style=\"width:510px; height:598px;\" src=\"images/RADIOL/86512_Super_mesen_art_angio_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arteriogram (A) shows filling of the jejunal, ileal, ileocolic, right colic, and middle colic arteries. There is a small amount of retrograde filling of the celiac axis via the pancreaticoduodenal arcade. The stenosis of the SMA is not visible on this view. A steep right anterior oblique view of the SMA (B) shows a short segment stenosis of the proximal SMA at its origin (thick white arrow). A stent has been positioned in the proximal SMA (C) in the region of the stenosis (thin white arrow) and expanded using a balloon. A selective SMA arteriogram (D) postangioplasty shows significant improvement in the severity of the stenosis following stent placement (white arrowhead).&nbsp;</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 86512 Version 2.0</div></div></div>"},"86513":{"type":"graphic_table","displayName":"Exanthematous drug eruption ddx","title":"Differential diagnosis of exanthematous (maculopapular) drug eruptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of exanthematous (maculopapular) drug eruptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Viral exanthems</td> </tr> <tr> <td class=\"indent1\">Measles (rubeola)</td> <td>The \"brick-red\" maculopapular rash often begins on the head and neck area and spreads centrifugally. Patients also complain of fever, cough, coryza, and conjunctivitis. Koplik's spots, tiny punctate elevated white buccal mucosa lesions located adjacent to the lower molars, are pathognomonic of measles and can precede the rash by 24 to 48 hours.</td> </tr> <tr> <td class=\"indent1\">Rubella</td> <td>The rash resembles measles, but the patient does not appear to be sick; prominent postauricular, posterior cervical, and/or suboccipital adenopathy also assists in the diagnosis</td> </tr> <tr> <td class=\"indent1\">Erythema infectiosum or \"fifth disease\" (human parvovirus B19)</td> <td>Children, unlike adults, often develop a characteristic rash with a \"slapped cheeks\" appearance</td> </tr> <tr> <td class=\"indent1\">Roseola infantum or exanthem subitum (human herpesvirus 6 or 7)</td> <td>Primarily seen in infants and young children, is characterized by high fever for three to four days, followed by generalized maculopapular rash that spreads from the trunk to the extremities but spares the face</td> </tr> <tr> <td class=\"indent1\">Infectious mononucleosis (Epstein-Barr virus or cytomegalovirus)</td> <td>Maculopapular rash, usually occurring after administration of ampicillin, in older children, adolescents, or young adults with pharyngitis, fever, lymphadenopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HIV infection</td> <td>A transient, maculopapular, nonpruritic rash, located on the trunk or face, may occur in the acute retroviral syndrome, two to four weeks after the primary HIV infection. Fever, sore throat, malaise, headache, lymphadenopathy, and mucocutaneous ulceration are accompanying symptoms.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Bacterial exanthems</td> </tr> <tr> <td class=\"indent1\">Scarlet fever</td> <td>Coarse, sandpaper-like, erythematous, blanching rash, occurring most commonly in the setting of pharyngitis from group A streptococcus infection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mycoplasma infection</td> <td>Mild erythematous maculopapular or vesicular rash, most commonly accompanying respiratory tract infections. Rarely, erythema multiforme or Stevens-Johnson syndrome.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Maculopapular rash associated with autoimmune connective tissue disease</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis and adult-onset Still disease</td> <td>Evanescent, salmon pink maculopapular rash occurring with fever. The rash predominantly involves the trunk and extremities, but can also involve the palms, soles, and occasionally the face.</td> </tr> <tr> <td class=\"indent1\">Acute cutaneous lupus erythematosus</td> <td>Widespread morbilliform eruption often focused over the extensor aspects of the arms and hands. Typically precipitated or exacerbated by exposure to UV light.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86513 Version 4.0</div></div></div>"},"86514":{"type":"graphic_algorithm","displayName":"Intimate partner violence screening algorithm","title":"Asking caregivers about intimate partner victimization at pediatric visits","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Asking caregivers about intimate partner victimization at pediatric visits</div><div class=\"cntnt\"><img style=\"width:566px; height:1036px;\" src=\"images/PEDS/86514_Intmtprtnrvlncscrngalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm should be used in conjunction with the UpToDate topic on childhood exposure to intimate partner violence.</div><div class=\"graphic_footnotes\">IPV: intimate partner violence.<br />* Risk factors for maternal IPV include: being a woman between 20 and 34 years of age; maternal disability; history of physical injury during pregnancy; mother directly or indirectly refers to IPV; alcohol or substance abuse in the home; maternal history of depression, anxiety, or suicidality; having a child with alleged or confirmed child maltreatment; not following through with recommended treatments for self or child(ren); chronically missing appointments for self or child(ren).<br />¶ Refer to UpToDate content on intimate partner violence and childhood exposure to intimate partner violence for additional details.<br />Δ The <A href=\"http://www.cdc.gov/violenceprevention/pdf/ipv/ipvandsvscreening.pdf\" target=_blank>Centers for Disease Control and Prevention (CDC)</A> provides a summary of screening instruments.<br /><FONT class=lozenge>◊</FONT> Other causes of toxic stress include: physical abuse; bullying/severe teasing; sexual abuse; medical care trauma; animal attack; motor vehicle accident; removal from the home by Child Protective Services; witness to violence in the home; witness to violence in the community; incarceration of a caregiver; loss of a parent due to death, divorce, deportation, deployment. A <A href=\"http://www.ifapa.org/pdf_docs/ACES_Handout.pdf\" target=_blank>patient information handout</A> related to toxic stress is available through the Community &amp; Family Services Division of the Spokane Health District. Additional resources related to toxic stress are available through the <A spellcheck=true href=\"https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/resilience/Pages/ACEs-and-Toxic-Stress.aspx\" target=_blank>American Academy of Pediatrics</A> and the <A href=\"http://www.cdc.gov/violenceprevention/childmaltreatment/essentials.html\" target=_blank>CDC</A>.<br />§ Assessment of safety and lethality is a difficult and uncertain process and cannot predict if an IPV perpetrator will harm or kill his or her partner. <A href=\"https://www.dangerassessment.org/DA.aspx\" target=_blank>Danger assessment</A> is a tool for assessing safety provided by the Johns Hopkins School of Nursing. Scenarios that are that are most concern for risk of harm include: the victim is trying to leave the relationship; alcohol or drug use; access to weapons; escalating violence; history of nonfatal strangulation; threats of homicide or suicide. Refer to UpToDate content on intervention and management of intimate partner violence for additional details.<br />¥ Examples of indications to contact law enforcement/security include: perpetrator has threatened to kill the caregiver/patient and has a weapon; the caregiver/patient has injuries and the perpetrator is on site; the clinician is concerned for the safety of the patient, patient's parent, clinic staff, or self.</div><div class=\"graphic_reference\">Courtesy of Kathleen M Franchek-Roa, MD.<br /><br />Additional data from:<br /><OL>&#xD;&#xA;<LI>Futures Without Violence. Available at: <A href=\"http://www.futureswithoutviolence.org/\" target=_blank>www.futureswithoutviolence.org</A> (Accessed on March 14, 2016).</LI></OL><br /></div><div id=\"graphicVersion\">Graphic 86514 Version 4.0</div></div></div>"},"86515":{"type":"graphic_table","displayName":"Drug eruptions clin manifestations and chronology","title":"Clinical manifestations and chronology of cutaneous drug reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations and chronology of cutaneous drug reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical manifestation</td> <td class=\"subtitle1\">Chronology</td> <td class=\"subtitle1\">Morphology and localization</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Urticaria</strong></td> <td> <p>Immediate</p> <p>Minutes to two hours</p> <p>Rapid change and resolution of single lesions (&#60;24 hours)</p> </td> <td> <p>Urticarial wheals, pale swelling surrounded by erythematous border</p> <p>Pruritus</p> <p>Trunk, face, mucosae, or generalized</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Angioedema</strong></td> <td> <p>Immediate to delayed</p> <p>Minutes up to six hours</p> <p>Resolution 24 to 72 hours</p> </td> <td> <p>Pale swelling</p> <p>Dysesthesia, pain</p> <p>Face, lips, eye lids, mucosa, male genitals</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Maculopapular exanthem</strong></td> <td> <p>Delayed</p> <p>Typically 6 to 24 hours</p> <p>Peak at 48 to 72 hours</p> <p>Resolution one week</p> </td> <td> <p>Macules, papules</p> <p>Confluence, desquamation</p> <p>Trunk, proximal extremities, or disseminated</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fixed drug eruption</strong></td> <td> <p>Delayed</p> <p>Typically 30 minutes to 8 hours</p> <p>Resolution 7 to 10 days</p> </td> <td> <p>Erythematous or lilac macule or plaque, central bulla/erosion, permanent hyperpigmentation, burning, pruritus</p> <p>Fixed (identical site)</p> <p>Acral or mucosal localization</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pustular exanthem (AGEP)</strong></td> <td> <p>Delayed</p> <p>Typically 6 to 12 hours up to 48 hours</p> <p>Resolution one week</p> </td> <td> <p>Confluent erythema, pinpoint nonfollicular pustules, pruritus, massive desquamation</p> <p>Folds, trunk, or generalized</p> </td> </tr> <tr> <td><strong>Vesicobullous exanthems</strong></td> <td> <p>Delayed</p> <p>Typically 24 to 48 hours</p> <p>Resolution several weeks</p> </td> <td> <p>Macules, bullae, epidermolysis, mucositis</p> <p>Initially painful skin</p> <p>Trunk, face, or generalized</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original table modified for this publication. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94:711. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86515 Version 2.0</div></div></div>"},"86517":{"type":"graphic_figure","displayName":"Talus and calcaneous - medial and lateral views","title":"Talus and calcaneous: Medial and lateral views","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Talus and calcaneous: Medial and lateral views</div><div class=\"cntnt\"><img style=\"width:534px; height:627px;\" src=\"images/EM/86517_Talus_calcan_med_lat_views.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Oatis CA. Kinesiology. The Mechanics and Pathomechanics of Human Movement. Baltimore: Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86517 Version 2.0</div></div></div>"},"86518":{"type":"graphic_diagnosticimage","displayName":"MRI retracted hamstring complete avulsion","title":"MRI of retracted hamstring following complete avulsion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of retracted hamstring following complete avulsion</div><div class=\"cntnt\"><img style=\"width:437px; height:455px;\" src=\"images/RADIOL/86518_MRI_retract_hamstr_avulsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 57-year-old male who was involved in a water skiing injury. The MRI of the thigh using a fast STIR sequence in the coronal plane (A, B) and proton density with fat saturation in the sagittal plane (C, D) demonstrate a completely detached and retracted hamstring injury. The retracted hamstring tendon is seen as redundant low signal structures distally (arrow). The retracted tendon is remote and detached from its insertion site at the ischial tuberosity (small arrowhead). A seroma (large arrowhead) is seen as a large high intensity homogeneous signal. Clot within the seroma (dashed arrow) is seen as intermediate signal.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 86518 Version 2.0</div></div></div>"},"86522":{"type":"graphic_table","displayName":"Comparison clinical features epidemic dysentery cholera","title":"Comparison of clinical features of epidemic dysentery and cholera","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of clinical features of epidemic dysentery and cholera</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Epidemic dysentery</td> <td class=\"subtitle1\">Cholera</td> </tr> <tr> <td><strong>Causative organism</strong></td> <td><em>Shigella dysenteriae</em> type 1</td> <td> <p><em>Vibrio cholerae</em> O1</p> (<em>Vibrio cholerae</em> O139)</td> </tr> <tr> <td><strong>Infective dose</strong></td> <td>10 to 100 organisms </td> <td>1000 to 1,000,000 organisms</td> </tr> <tr> <td><strong>Clinical features</strong></td> <td> <p>Bloody diarrhea</p> <p>Abdominal cramps</p> <p>Fever</p> Rectal pain</td> <td> <p>Watery diarrhea</p> <p>Dehydration</p> Vomiting</td> </tr> <tr> <td><strong>Complications</strong></td> <td> <p>Seizures</p> <p>Rectal prolapse</p> <p>Hemolytic-uremic syndrome</p> Sepsis</td> <td> <p>Severe hypovolemia/shock</p> Electrolyte abnormalities</td> </tr> <tr> <td><strong>Treatment</strong></td> <td>Antibiotics</td> <td>Rehydration</td> </tr> <tr> <td><strong>Transmission</strong></td> <td> <p>Food and water</p> Person-to-person</td> <td>Food and water</td> </tr> <tr> <td><strong>Case fatality rate</strong></td> <td> <p>10 to 20 percent (untreated)</p> 5 percent (treated)</td> <td> <p>40 percent (untreated)</p> &#60;1 percent (treated)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.</div><div id=\"graphicVersion\">Graphic 86522 Version 1.0</div></div></div>"},"86523":{"type":"graphic_diagnosticimage","displayName":"Chronic pulmonary histoplasmosis chest x-ray","title":"Chronic cavitary pulmonary histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic cavitary pulmonary histoplasmosis</div><div class=\"cntnt\"><img style=\"width:433px; height:504px;\" src=\"images/ID/86523_Chron_pulm_histoplas_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray showing multiple cavities in a patient with chronic pulmonary histoplasmosis.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 86523 Version 1.0</div></div></div>"},"86524":{"type":"graphic_picture","displayName":"Histoplasma in macrophage","title":"Histoplasma capsulatum within a macrophage","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histoplasma capsulatum within a macrophage</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/ID/86524_Histoplasma_in_macrophage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Touch preparation from a lung biopsy stained with Giemsa showing <EM>Histoplasma capsulatum</EM> within a macrophage.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 86524 Version 2.0</div></div></div>"},"86525":{"type":"graphic_table","displayName":"Pathogens causing adult diarrhea developing world","title":"Common pathogens causing diarrhea in adults in the developing world","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common pathogens causing diarrhea in adults in the developing world</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td rowspan=\"8\"><strong>Acute watery diarrhea</strong></td> <td>Enterotoxigenic <em>Escherichia coli</em> (ETEC)</td> <td>Most common cause of acute watery diarrhea</td> </tr> <tr> <td><em>Vibrio cholerae</em> O1 or O139</td> <td>&nbsp;</td> </tr> <tr> <td>Norovirus</td> <td>Vomiting may be a prominent feature</td> </tr> <tr> <td>Campylobacter species</td> <td>&nbsp;</td> </tr> <tr> <td>Nontyphoidal <em>Salmonella enterica</em></td> <td>&nbsp;</td> </tr> <tr> <td>Aeromonas species</td> <td>&nbsp;</td> </tr> <tr> <td>Enteroaggregative <em>Escherichia coli</em> (EAEC)</td> <td>&nbsp;</td> </tr> <tr> <td>Enterotoxigenic <em>Bacteroides fragilis</em></td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"><strong>Acute bloody diarrhea</strong></td> <td>Shigella species</td> <td>Most common cause of acute bloody diarrhea</td> </tr> <tr> <td>Campylobacter species</td> <td>&nbsp;</td> </tr> <tr> <td>Enteroinvasive <em>Escherichia coli</em> (EIEC)</td> <td>&nbsp;</td> </tr> <tr> <td>Enterohemorrhagic <em>Escherichia coli</em> (EHEC)</td> <td>&nbsp;</td> </tr> <tr> <td>Nontyphoidal <em>Salmonella enterica</em></td> <td>Rare&nbsp;</td> </tr> <tr> <td><em>Entamoeba histolytica</em></td> <td>&nbsp;</td> </tr> <tr> <td><em>Schistosoma mansoni</em></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.</div><div id=\"graphicVersion\">Graphic 86525 Version 1.0</div></div></div>"},"86526":{"type":"graphic_table","displayName":"Composition hypoosmolar ORS","title":"Composition of hypo-osmolar oral rehydration solution (per one liter of clean water)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of hypo-osmolar oral rehydration solution (per one liter of clean water)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sodium chloride (NaCl)</td> <td>2.6 g</td> </tr> <tr> <td>Sodium citrate</td> <td>2.9 g</td> </tr> <tr> <td>Potassium chloride (KCl)</td> <td>1.5 g</td> </tr> <tr> <td>Glucose</td> <td>13.5 g </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.</div><div id=\"graphicVersion\">Graphic 86526 Version 1.0</div></div></div>"},"86528":{"type":"graphic_table","displayName":"Potential complications of acute diarrheal disease in adults","title":"Potential complications of acute diarrheal disease in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential complications of acute diarrheal disease in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Associated bacterial agent</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Bacteremia</td> <td>Shigella species, Nontyphoidal S<em>almonella enterica</em>, <em>Campylobacter fetus</em></td> <td>Particular concern in HIV-infected individuals</td> </tr> <tr> <td>Hemolytic-uremic syndrome</td> <td>Shigella species, Shiga toxin-producing <em>Escherichia coli</em></td> <td>Shiga toxins are responsible for damage to endothelial cells and hemolytic-uremic syndrome</td> </tr> <tr> <td>Guillain-Barr&#233; syndrome</td> <td><em>Campylobacter jejuni</em></td> <td>&nbsp;</td> </tr> <tr> <td>Reactive arthritis</td> <td>Campylobacter species, Salmonella species, <em>Shigella flexneri</em></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.</div><div id=\"graphicVersion\">Graphic 86528 Version 1.0</div></div></div>"},"86529":{"type":"graphic_algorithm","displayName":"Approach to fluid management in adult with hypovolemia","title":"Approach to fluid management in adult with hypovolemia","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Approach to fluid management in adult with hypovolemia</div><div class=\"cntnt\"><img style=\"width:500px; height:461px;\" src=\"images/ID/86529_Appfluidmanadultdehyd.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ORS: oral rehydration salts.</div><div class=\"graphic_reference\">Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.</div><div id=\"graphicVersion\">Graphic 86529 Version 3.0</div></div></div>"},"86530":{"type":"graphic_picture","displayName":"Peripheral blood MCL","title":"Peripheral blood smear of mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear of mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/HEME/86530_PeripheralbloodMCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows many lymphoma cells with variable sizes, irregular configuration, high nuclear-cytoplasm ratio, and prominent nucleoli. Wright-Giemsa stain, 60x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86530 Version 7.0</div></div></div>"},"86531":{"type":"graphic_picture","displayName":"Blastoid variant MCL","title":"Blastoid variant of mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Blastoid variant of mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:576px; height:416px;\" src=\"images/HEME/86531_BlastoidvariantMCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blastoid variant of mantle cell lymphoma reveals medium-sized lymphoid cells with large irregular nuclei and a dispersed chromatin pattern. Nucleoli are seen in a few tumor cells. Hematoxylin and eosin, 60x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86531 Version 6.0</div></div></div>"},"86532":{"type":"graphic_picture","displayName":"Nodular type MCL","title":"Nodular type of mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nodular type of mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:576px; height:425px;\" src=\"images/HEME/86532_NodulartypeMCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular type of mantle cell lymphoma shows multiple nodules with irregular margins. Hematoxylin and eosin, 10x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86532 Version 6.0</div></div></div>"},"86533":{"type":"graphic_picture","displayName":"Diffuse type MCL","title":"Diffuse type of mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Diffuse type of mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:476px; height:355px;\" src=\"images/HEME/86533_DiffusetypeMCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse type of mantle cell lymphoma shows diffuse infiltration of small lymphoid cells with slightly irregular nuclear configuration. Multiple pink histiocytes (white arrow) are present. Hematoxylin and eosin, 60x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86533 Version 6.0</div></div></div>"},"86534":{"type":"graphic_table","displayName":"PASS scoring scale for pheochromocytoma of the adrenal gland","title":"PASS scoring scale for pheochromocytoma of the adrenal gland","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PASS scoring scale for pheochromocytoma of the adrenal gland</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Score if present<br /> (number of points assigned)</td> </tr> <tr> <td>Large nests or diffuse growth (&#62;10 percent of tumor volume)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Central (middle of large nests) or confluent tumor necrosis (not degenerative change)</td> <td class=\"centered\">2</td> </tr> <tr> <td>High cellularity</td> <td class=\"centered\">2</td> </tr> <tr> <td>Cellular monotony</td> <td class=\"centered\">2</td> </tr> <tr> <td>Tumor cell spindling (even if focal)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Mitotic figures &#62;3/10 HPF</td> <td class=\"centered\">2</td> </tr> <tr> <td>Atypical mitotic figure(s)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Extension into adipose tissue</td> <td class=\"centered\">2</td> </tr> <tr> <td>Vascular invasion</td> <td class=\"centered\">1</td> </tr> <tr> <td>Capsular invasion</td> <td class=\"centered\">1</td> </tr> <tr> <td>Profound nuclear pleomorphism</td> <td class=\"centered\">1</td> </tr> <tr> <td>Nuclear hyperchromasia</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"><strong>Total: 20</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PASS: Pheochromocytoma of the Adrenal gland Scaled Score; HPF: high-powered field.</div><div class=\"graphic_reference\">Reproduced with permission from: Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002; 26:551. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86534 Version 5.0</div></div></div>"},"86535":{"type":"graphic_table","displayName":"MIPI","title":"Mantle cell lymphoma international prognostic index (MIPI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mantle cell lymphoma international prognostic index (MIPI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">ECOG performance status</td> <td class=\"subtitle1\">LDH:ULN ratio</td> <td class=\"subtitle1\">WBC (10<sup>9</sup>/L)</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">&#60;50</td> <td class=\"centered\">0 to 1</td> <td class=\"centered\">&#60;0.67</td> <td class=\"centered\">&#60;6.7</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">50 to 59</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.67 to 0.99</td> <td class=\"centered\">6.7 to 9.9</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">60 to 69</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">1.00 to 1.49</td> <td class=\"centered\">10.0 to 14.9</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">&#8805;70</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8805;1.50</td> <td class=\"centered\">&#8805;15.00</td> </tr> <tr> <td colspan=\"5\">One to three points is given for each of the above characteristics present in the patient with MCL, for a total score ranging from zero to 12. When applied to a study of long term survival in 455 patients with MCL diagnosed between 1996 and 2004, the following three risk groups and their corresponding median and five-year survivals were as follows:</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"2\">Score</td> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\">Median survival</td> <td class=\"subtitle1\">Five-year OS</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">0 to 3 points</td> <td class=\"centered\">Low risk</td> <td class=\"centered\">Not reached</td> <td class=\"centered\">60 percent</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">4 to 5 points</td> <td class=\"centered\">Intermediate risk</td> <td class=\"centered\">58 months</td> <td class=\"centered\">35 percent</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">6 to 12 points</td> <td class=\"centered\">High risk</td> <td class=\"centered\">37 months</td> <td class=\"centered\">20 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; ULN: upper limit of normal; WBC: white blood cells; MCL: mantle cell lymphoma; OS: overall survival.</div><div class=\"graphic_reference\">This research was originally published in Blood. Modified from: Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558. Copyright © 2008 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 86535 Version 1.0</div></div></div>"},"86536":{"type":"graphic_table","displayName":"Diagnostic criteria for diffuse panbronchiolitis","title":"Diagnostic criteria for diffuse panbronchiolitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for diffuse panbronchiolitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Noninvasive</td> </tr> <tr> <td class=\"indent1\">Persistent cough, sputum, and exertional dyspnea</td> </tr> <tr> <td class=\"indent1\">History or current symptoms of chronic sinusitis</td> </tr> <tr> <td class=\"indent1\">Bilateral, diffuse, small nodular shadows on a plain chest radiograph or centrilobular micronodules on chest CT images</td> </tr> <tr> <td class=\"indent1\">Coarse crackles</td> </tr> <tr> <td class=\"indent1\">FEV<sub>1</sub>/FVC less than 70 percent and PaO<sub>2</sub> less than 80 mmHg (10.64 kPa)</td> </tr> <tr> <td class=\"indent1\">Titer of cold agglutinins of 64 or greater</td> </tr> <tr> <td class=\"subtitle1_single\">Lung biopsy</td> </tr> <tr> <td class=\"indent1\">Lung biopsy showing inflammation centered on the respiratory bronchioles with a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages, also known as foam cells*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>/FVC: forced expiratory volume in one second/forced vital capacity; PaO<sub>2</sub>: arterial tension for oxygen.<br />* In regions where diffuse panbronchiolitis is endemic (eg, East Asia), a lung biopsy is not needed if the patient fulfills the first three criteria and at least two of the second three.</div><div class=\"graphic_reference\">Data from: Kudoh S, Keicho N. Diffuse panbronchiolitis. Clin Chest Med 2012; 33:297.</div><div id=\"graphicVersion\">Graphic 86536 Version 2.0</div></div></div>"},"86537":{"type":"graphic_table","displayName":"Mode of presentation of paragangliomas","title":"Mode of presentation of benign paragangliomas, stratified by tumor location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mode of presentation of benign paragangliomas, stratified by tumor location</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mode of presentation</td> <td class=\"subtitle1\">Patients with tumors in head or neck<br /> (n = 161)*</td> <td class=\"subtitle1\">Patients with tumors below neck<br /> (n = 81)*</td> <td class=\"subtitle1\">Patients with multicentric tumors above and below the neck<br /> (n = 6)*</td> </tr> <tr> <td>Headaches</td> <td class=\"centered\">7</td> <td class=\"centered\">26</td> <td class=\"centered\">50</td> </tr> <tr> <td>Palpitations</td> <td class=\"centered\">6</td> <td class=\"centered\">21</td> <td class=\"centered\">50</td> </tr> <tr> <td>Perspiration</td> <td class=\"centered\">5</td> <td class=\"centered\">25</td> <td class=\"centered\">50</td> </tr> <tr> <td>Pallor</td> <td class=\"centered\">2</td> <td class=\"centered\">12</td> <td class=\"centered\">17</td> </tr> <tr> <td>Orthostasis</td> <td class=\"centered\">4</td> <td class=\"centered\">6</td> <td class=\"centered\">0</td> </tr> <tr> <td>Neck mass</td> <td class=\"centered\">55</td> <td class=\"centered\">1</td> <td class=\"centered\">33</td> </tr> <tr> <td>Cranial nerve palsies</td> <td class=\"centered\">16</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Incidentalomas on imaging studies<sup>&#182;</sup></td> <td class=\"centered\">10</td> <td class=\"centered\">6</td> <td class=\"centered\">17</td> </tr> <tr> <td>Unexpected finding on pathology after operation for an indeterminate mass<sup>&#916;</sup></td> <td class=\"centered\">1</td> <td class=\"centered\">27</td> <td class=\"centered\">0</td> </tr> <tr> <td>Tinnitus</td> <td class=\"centered\">18</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Pulsatile mass in ear</td> <td class=\"centered\">9</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Decreased hearing</td> <td class=\"centered\">8</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Pain localized to chest, abdomen</td> <td class=\"centered\">0</td> <td class=\"centered\">21</td> <td class=\"centered\">0</td> </tr> <tr> <td>Abdominal mass</td> <td class=\"centered\">0</td> <td class=\"centered\">4</td> <td class=\"centered\">0</td> </tr> <tr> <td>Gastrointestinal hemorrhage</td> <td class=\"centered\">0</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td>Intracranial hemorrhage</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> </tr> <tr> <td>Cardiomyopathy</td> <td class=\"centered\">0</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td>Generalized weakness</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td>Preeclampsia in pregnancy</td> <td class=\"centered\">0</td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> </tr> <tr> <td>Weight loss</td> <td class=\"centered\">0</td> <td class=\"centered\">5</td> <td class=\"centered\">0</td> </tr> <tr> <td>Intraoperative lability of blood pressure</td> <td class=\"centered\">0</td> <td class=\"centered\">4</td> <td class=\"centered\">0</td> </tr> <tr> <td>Hypertension</td> <td class=\"centered\">42</td> <td class=\"centered\">64</td> <td class=\"centered\">67</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These numbers include patients with single tumors and also the six patients with multiple tumors above and below the neck.<br />¶&nbsp;Tumors incidentally discovered on imaging studies and suspected to be paragangliomas prior to surgery.<br />Δ Unexpected tumors found to be paragangliomas on pathological examination for indeterminate mass.</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson D, Kundva YC, Ebersold MJ, et al. Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86:5210. Copyright &copy; 2001 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 86537 Version 2.0</div></div></div>"},"86538":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis direct immunofluorescence","title":"Direct immunofluorescence microscopy in dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence microscopy in dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86538_Derm_herp_dir_immunofluor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence microscopy of a perilesional specimen from a patient with dermatitis herpetiformis demonstrates granular deposits of IgA within the papillary dermis.</div><div id=\"graphicVersion\">Graphic 86538 Version 1.0</div></div></div>"},"86539":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis direct immunofluorescence linear","title":"Direct immunofluorescence microscopy in dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence microscopy in dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/DERM/86539_Derm_herpeti_dir_im_lin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although granular deposits of IgA within the papillary dermis are the classic direct immunofluorescence findings in dermatitis herpetiformis, granular deposits of IgA along the basement membrane zone may also be seen.</div><div id=\"graphicVersion\">Graphic 86539 Version 1.0</div></div></div>"},"86540":{"type":"graphic_table","displayName":"Adverse effects of dapsone","title":"Adverse effects of dapsone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse effects of dapsone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse effect</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Hemolysis</td> <td>Common</td> <td>Usually a compensated hemolysis but can be severe. Need to monitor with routine complete blood counts.</td> </tr> <tr class=\"divider_bottom\"> <td>Agranulocytosis</td> <td>Uncommon</td> <td>Can be severe and life-threatening. Usually occurs in the first few months of treatment.</td> </tr> <tr class=\"divider_bottom\"> <td>Methemoglobinemia</td> <td>Common</td> <td>Usually asymptomatic. Symptomatic methemoglobinemia (cardiopulmonary symptoms) should be evaluated and requires alteration of dose or discontinuation of dapsone.</td> </tr> <tr class=\"divider_bottom\"> <td>Hypersensitivity syndrome (DRESS)</td> <td>Rare</td> <td>Life-threatening. Fever, lymphadenopathy, eosinophilia, flu-like symptoms, hepatitis, morbilliform skin eruption. Immediately discontinue dapsone.</td> </tr> <tr> <td>Peripheral neuropathy</td> <td>Uncommon</td> <td>Usually seen in patients with high daily doses of dapsone and high cumulative doses. Can be motor, sensory, or mixed neuropathy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DRESS: drug rash with eosinophilia and systemic symptoms.</div><div id=\"graphicVersion\">Graphic 86540 Version 2.0</div></div></div>"},"86541":{"type":"graphic_table","displayName":"Concentrations of food additives used for skin testing","title":"Concentrations of food additives used for skin testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concentrations of food additives used for skin testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food additive </td> <td class=\"subtitle1\">Preparation of epicutaneous skin&nbsp;test solution</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>Gelatin</td> <td>Dissolve 1 teaspoon (5 grams) of gelatin powder (plain or flavored) in 5 mL normal saline</td> <td>Vaccine allergy practice parameter. Kelso JM, Li JT. Practice Parameters: Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103:1.</td> </tr> <tr> <td>Carmine</td> <td>Make 10% solution of carmine powder in phosphate buffered saline, agitate at 4&#176;C&nbsp;for&nbsp;two hours. Dialyze against purified water and filter through 0.22 micron filter.</td> <td>Anibarro B, Seoane J, Vila C, et al. Occupational asthma induced by inhaled carmine among butchers. Int J Occup Med Environ Health 2003; 16:133.</td> </tr> <tr> <td>Annato</td> <td>Additive containing food (Gouda cheese) and a commercial preparation of annato dye, diluted 1000-fold was used</td> <td>Ebo DG, Ingelbrecht S, Bridts CH, et al. Allergy for cheese; evidence for an IgE-mediated reaction from the natural dye annatto. Allergy 2009; 64:1558.</td> </tr> <tr> <td>Guar gum</td> <td>Additive containing food (a meal substitute) and guar gum preparation (no details provided)</td> <td>Papanikolaou I, Stenger R, Bessot JC, et al. Anaphylactic shock to guar gum (food additive E412) contained in a meal substitute. Allergy 2007; 62:822.</td> </tr> <tr> <td>Psyllium</td> <td>Extract commercially available</td> <td>&nbsp;</td> </tr> <tr> <td>Carrageenan</td> <td>0.4% weight/volume sodium carrageenan</td> <td>Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy. J Allergy Clin Immunol 1995 (5 part 1):933.</td> </tr> <tr> <td>Potassium metabisulfite</td> <td>Maximum concentration of 1 mg/mL</td> <td>Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev&nbsp;Allergy 1990; 8:159.</td> </tr> <tr> <td>Yeast (saccharomyces cerevisiae)</td> <td>Extract commercially available</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;Erythritol</td> <td>2 mg/mL, 20 mg/mL, and 200 mg/mL in distilled water</td> <td>Shirao K, Inoue M, Tokuda R, et&nbsp;al. \"Bitter Sweet\": A child case of erythritol-induced anaphylaxis. Allergol Int 2013; 62:269.&nbsp;</td> </tr> <tr> <td>Carob bean gum</td> <td>Carob gum at 5 mg/mL and 25 mg/mL; can&nbsp;use raw carob gum, boiled carob gum, and carob bean extract for skin testing also</td> <td>Alarcon,&nbsp;E, del Pozo MD, Bartolome B, et al. J Investig Allergol Clin Immunol 2011; 21:77.&nbsp;&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Concentrations of food additives used for epicutaneous (prick-puncture) skin testing in published studies.</div><div id=\"graphicVersion\">Graphic 86541 Version 5.0</div></div></div>"},"86543":{"type":"graphic_figure","displayName":"Ultrasound-guided breast biopsy PI","title":"Ultrasound-guided breast biopsy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Ultrasound-guided breast biopsy</div><div class=\"cntnt\"><img style=\"width:512px; height:629px;\" src=\"images/PI/86543_Ultrasound-guided_breast_biopsy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During an ultrasound-guided breast biopsy, the doctor uses an ultrasound, which uses sound waves, to create a picture of your breast. It lets the doctor see where to place the needle for the biopsy.</div><div id=\"graphicVersion\">Graphic 86543 Version 1.0</div></div></div>"},"86544":{"type":"graphic_figure","displayName":"Stereotactic breast biopsy PI","title":"Stereotactic breast biopsy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Stereotactic breast biopsy</div><div class=\"cntnt\"><img style=\"width:503px; height:482px;\" src=\"images/PI/86544_Stereotactic_breast_biopsy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a stereotactic breast biopsy, you lie face down on a table with your breast through a hole. Your breast is pressed between 2 metal plates, just like it would be during a mammogram. The machine takes X-rays from different angles. The images let the doctor see where to place the needle for the biopsy.</div><div id=\"graphicVersion\">Graphic 86544 Version 1.0</div></div></div>"},"86545":{"type":"graphic_figure","displayName":"Sentinel node biopsy PI","title":"Sentinel node biopsy for breast cancer","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Sentinel node biopsy for breast cancer</div><div class=\"cntnt\"><img style=\"width:511px; height:680px;\" src=\"images/PI/86545_Sentinel_node_biopsy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a sentinel node biopsy for cancer, a doctor:<br /><ol>&#xD;&#xA;    <li>Injects a blue dye and/or a radioactive substance near the tumor.</li>&#xD;&#xA;    <li>If a radioactive substance is used, the doctor uses a probe that detects radiation to find the sentinel lymph nodes. If a blue dye is used, the sentinel lymph node turns blue.</li>&#xD;&#xA;    <li>The doctor then removes the sentinel lymph node for testing.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86545 Version 4.0</div></div></div>"},"86549":{"type":"graphic_picture","displayName":"Corona phlebectasia","title":"Corona phlebectasia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Corona phlebectasia</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/SURG/86549_Corona_phlebectasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corona phlebectasia is&nbsp;a 'crown' of telangiectasias and/or reticular veins around the ankle</div><div id=\"graphicVersion\">Graphic 86549 Version 1.0</div></div></div>"},"86550":{"type":"graphic_picture","displayName":"Morbilliform drug eruption histo","title":"Histopathologic features of exanthematous (morbilliform) drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of exanthematous (morbilliform) drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:357px;\" src=\"images/DERM/86550_Morbillif_drug_erupt_hist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The histologic features of morbilliform drug eruptions are typically those of an interface dermatitis with scattered dyskeratotic keratinocytes along the dermoepidermal junction. There is also a superficial perivascular lymphocytic infiltrate with scattered eosinophils and mild papillary edema.</div><div class=\"graphic_reference\">Reproduced with permission from: Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30:352. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86550 Version 5.0</div></div></div>"},"86551":{"type":"graphic_figure","displayName":"Mitochondrial pathways in congenital sideroblastic anemias","title":"Mitochondrial pathways in the erythroblast and associated genetic defects in congenital sideroblastic anemias","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Mitochondrial pathways in the erythroblast and associated genetic defects&nbsp;in congenital sideroblastic anemias</div><div class=\"cntnt\"><img style=\"width:482px; height:566px;\" src=\"images/HEME/86551_Mitochondrial_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on sideroblastic anemias for additional information on pathophysiology and diagnostic testing.</div><div class=\"graphic_footnotes\">A38 (white text in green shape): SLC25A38; CoA: coenzyme A; ALA: 5-aminolevulinic acid; CP'gen III: coproporphyrinogen III; PPIX: protoporphyrin IX; Fe: iron; MFRN1 (white text in blue shape): mitoferrin 1; Fe-S: iron-sulfur; ABCB7 (white text in purple shape): mitochondrial transporter for cytosolic Fe-S cluster maturation; Thiamine-P-P: thiamine pyrophosphate; tRNA: transfer RNA; mt: mitochondrial; ALAS2: 5-aminolevulinate synthase; SLC25A38: mitochondrial amino acid carrier protein; GLRX5: glutaredoxin 5; HSPA9: heat shock protein family A member 9; FECH: ferrochelatase; PUS1: pseudouridine synthase; YARS2: tyrosyl-tRNA synthetase; LARS2: leucyl-tRNA synthase; NDUFB11: NADH:ubiquinone oxidoreductase subunit B11; mtDNA: mitochondrial DNA; MLASA: Myopathy, lactic acidosis, and sideroblastic anemia; MTATP6: ATP synthase 6; SLC19A2: high affinity thiamine transporter.</div><div id=\"graphicVersion\">Graphic 86551 Version 3.0</div></div></div>"},"86552":{"type":"graphic_picture","displayName":"Exanthematous drug eruption dark skin","title":"Exanthematous (morbilliform) drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Exanthematous (morbilliform) drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86552_Exanth_drug_erupt_dark.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous small, discrete papules on the back of a patient with exanthematous drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86552 Version 5.0</div></div></div>"},"86555":{"type":"graphic_picture","displayName":"Urine sediment showing a broad cast","title":"Urine sediment showing a broad cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing a broad cast</div><div class=\"cntnt\"><img style=\"width:351px; height:385px;\" src=\"images/NEPH/86555_Urine_sediment_broad_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Ringsrud KM, Linne JJ. Urinalysis and Body Fluids: A Colortext and Atlas, Mosby, Amsterdam 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86555 Version 1.0</div></div></div>"},"86556":{"type":"graphic_algorithm","displayName":"Proposed classification of MPGN","title":"Proposed classification of MPGN","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Proposed classification of MPGN</div><div class=\"cntnt\"><img style=\"width:872px; height:527px;\" src=\"images/NEPH/86556_PropclassificationMPGN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MPGN: membranoproliferative glomerulonephritis; Ig: immunoglobulin; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic-uremic syndrome; C3GN: C3 glomerulonephritis; DDD: dense deposit disease.<br />* In rare cases, patients with MPGN caused by monoclonal gammopathy may present with isolated C3 deposits with no staining for immunoglobulins by routine immunofluorescence staining. Immunofluorescence of formalin-fixed paraffin embedded tissue after protease digestion may reveal the presence of masked glomerular monoclonal immunoglobulin deposits.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366:1119.</li>&#xD;&#xA;    <li>Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012.</li>&#xD;&#xA;</ol>&#xD;&#xA;Algorithm created by Sanjeev Sethi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86556 Version 3.0</div></div></div>"},"86557":{"type":"graphic_table","displayName":"Clinical and laboratory features of severe drug eruptions","title":"Clinical and laboratory features of severe drug eruptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory features of severe drug eruptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Rash morphology</td> <td class=\"subtitle1\">Localization</td> <td class=\"subtitle1\">Timing</td> <td class=\"subtitle1\">Internal organ involvement</td> <td class=\"subtitle1\">Systemic signs</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr class=\"divider_bottom\"> <td>DHS/DRESS</td> <td> <p>Maculopapular exanthem</p> <p>Erythroderma</p> Facial edema</td> <td> <p>Generalized</p> Mucosal involvement infrequent</td> <td>&#62;14 days</td> <td> <p>Lymphadenopathy</p> <p>Hepatitis</p> <p>Pneumonitis</p> Nephritis</td> <td> <p>Fever</p> <p>Malaise</p> Fatigue</td> <td> <p>Eosinophilia, atypical lymphocytes</p> Abnormal liver, renal function tests</td> </tr> <tr class=\"divider_bottom\"> <td>AGEP</td> <td> <p>Widespread erythema</p> <p>Erythroderma</p> Pustules (small, numerous)</td> <td> <p>Generalized, rarely flexural</p> Mucosal involvement rare</td> <td>&#60;3 days</td> <td>Possible but rare</td> <td>High fever (&#62;38&#176;C)</td> <td>Leukocytosis with neutrophilia (&#62;7000/mm<sup>3</sup>)</td> </tr> <tr> <td>SJS/TEN</td> <td> <p>Dusky red, coalescent macular exanthem</p> <p>Atypical target lesions</p> <p>Bullous lesions</p> <p>Epidermal necrosis (&#60;10% in SJS, 10 to 30% in SJS/TEN, &#62;30% in TEN)</p> Nikolsky sign (ready removal of the epidermis with slight tangential pressure)</td> <td> <p>Disseminated</p> Mucosal involvement nearly in all cases (stomatitis, conjunctivitis)</td> <td>4 to 21 days</td> <td>Pneumonitis</td> <td> <p>Fever</p> <p>Malaise</p> <p>Fatigue</p> <p>Sore throat</p> Dysphagia, photophobia</td> <td> <p>Lymphopenia</p> Epidermal necrosis on skin biopsy with full thickness loss of epidermis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DHS/DRESS: drug hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms; AGEP: acute generalized exanthematous pustulosis; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Scherer K, Bircher A. Adverse drug reactions and the skin--from trivial to fire signal. Internist (Berl) 2009; 50:171.</li>&#xD;&#xA;    <li>Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94:711.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86557 Version 6.0</div></div></div>"},"86559":{"type":"graphic_picture","displayName":"Angioedema lip PI","title":"Angioedema of the lips","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angioedema of the lips</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/PI/86559_Angioedema_lip_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angioedema causes puffiness of the tissues under the skin, often in the face. This photo shows angioedema of the lips.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86559 Version 3.0</div></div></div>"},"86565":{"type":"graphic_table","displayName":"Symptoms and findings for patients with jugular foramen tumors","title":"Symptoms and findings for patients with jugular foramen tumors of different types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and findings for patients with jugular foramen tumors of different types</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Paraganglioma, %</td> <td class=\"subtitle1\">Schwannoma, %</td> <td class=\"subtitle1\">Meningioma, %</td> <td class=\"subtitle1\">All, %</td> </tr> <tr> <td>Pulsatile tinnitus</td> <td class=\"centered\">89.6</td> <td class=\"centered\">55.6</td> <td class=\"centered\">71.4</td> <td class=\"centered\">84.3</td> </tr> <tr> <td>Hearing loss</td> <td class=\"centered\">80.6</td> <td class=\"centered\">55.6</td> <td class=\"centered\">57.1</td> <td class=\"centered\">75.9</td> </tr> <tr> <td>Hoarseness</td> <td class=\"centered\">28.4</td> <td class=\"centered\">55.6</td> <td class=\"centered\">57.1</td> <td class=\"centered\">34.9</td> </tr> <tr> <td>Dizziness</td> <td class=\"centered\">20.9</td> <td class=\"centered\">33.3</td> <td class=\"centered\">26.6</td> <td class=\"centered\">22.9</td> </tr> <tr> <td>Vertigo</td> <td class=\"centered\">16.4</td> <td class=\"centered\">33.3</td> <td class=\"centered\">0.0</td> <td class=\"centered\">16.9</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">16.4</td> <td class=\"centered\">44.4</td> <td class=\"centered\">14.3</td> <td class=\"centered\">19.3</td> </tr> <tr> <td>Swallowing problem</td> <td class=\"centered\">13.4</td> <td class=\"centered\">22.2</td> <td class=\"centered\">14.3</td> <td class=\"centered\">14.5</td> </tr> <tr> <td>Aural fullness</td> <td class=\"centered\">12.1</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">9.8</td> </tr> <tr> <td>Otalgia</td> <td class=\"centered\">10.5</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">8.4</td> </tr> <tr> <td>Unsteadiness</td> <td class=\"centered\">7.5</td> <td class=\"centered\">11.1</td> <td class=\"centered\">14.3</td> <td class=\"centered\">8.4</td> </tr> <tr> <td>Dysphagia</td> <td class=\"centered\">6.0</td> <td class=\"centered\">1.1</td> <td class=\"centered\">14.3</td> <td class=\"centered\">6.0</td> </tr> <tr> <td>Discharge</td> <td class=\"centered\">6.0</td> <td class=\"centered\">22.2</td> <td class=\"centered\">0.0</td> <td class=\"centered\">7.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Signs</td> </tr> <tr> <td class=\"indent1\">Retrotympanic mass</td> <td class=\"centered\">91.0</td> <td class=\"centered\">11.1</td> <td class=\"centered\">42.9</td> <td class=\"centered\">78.3</td> </tr> <tr> <td class=\"indent1\">Vocal cord paralysis</td> <td class=\"centered\">11.9</td> <td class=\"centered\">11.1</td> <td class=\"centered\">42.8</td> <td class=\"centered\">13.3</td> </tr> <tr> <td class=\"indent1\">Shoulder weakness</td> <td class=\"centered\">9.0</td> <td class=\"centered\">22.2</td> <td class=\"centered\">28.6</td> <td class=\"centered\">12.0</td> </tr> <tr> <td class=\"indent1\">Absent&nbsp;gag reflex</td> <td class=\"centered\">7.5</td> <td class=\"centered\">33.3</td> <td class=\"centered\">26.6</td> <td class=\"centered\">12.0</td> </tr> <tr> <td class=\"indent1\">Glossal atrophy</td> <td class=\"centered\">9.0</td> <td class=\"centered\">11.1</td> <td class=\"centered\">28.6</td> <td class=\"centered\">10.8</td> </tr> <tr> <td class=\"indent1\">Facial nerve dysfunction</td> <td class=\"centered\">3.0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">2.4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Fayad JN, Keles B, Brackmann DE. Jugular foramen tumors: clinical characteristics and treatment outcomes. Otol Neurotol 2010; 31:299. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86565 Version 5.0</div></div></div>"},"86566":{"type":"graphic_table","displayName":"Classification of tumor extent head and neck paragangliomas","title":"Classifications of tumor severity and extent for head and neck paragangliomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifications of tumor severity and extent for head and neck paragangliomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Fisch classification<sup>[1,2]</sup></td> </tr> <tr> <td class=\"indent1\">Class A</td> <td>Tumors that arise along the tympanic plexus on the cochlear promontory</td> </tr> <tr> <td class=\"indent1\">Class B</td> <td>Tumors with invasion of hypotympanon; cortical bone over jugular bulb intact</td> </tr> <tr> <td class=\"indent1\">Class C<sub>1</sub></td> <td>Tumors with encroachment of the carotid foramen, but no invasion of the carotid artery</td> </tr> <tr> <td class=\"indent1\">Class C<sub>2</sub></td> <td>Tumors with destruction of the vertical carotid canal</td> </tr> <tr> <td class=\"indent1\">Class C<sub>3</sub></td> <td>Tumors that invade the horizontal portion of the carotid canal, but do not reach the foramen lacerum</td> </tr> <tr> <td class=\"indent1\">Class C<sub>4</sub></td> <td>Tumors with growth to foramen lacerum and along the carotid artery and the cavernous sinus</td> </tr> <tr> <td class=\"indent1\">Class De<sub>1/2</sub></td> <td>Tumors with intracranial but only extradural extension; De<sub>1/2</sub> according to displacement of dura (De<sub>1</sub> = less than 2 cm, De<sub>2</sub> = more than 2 cm)</td> </tr> <tr> <td class=\"indent1\">Class Di<sub>1/2/3</sub></td> <td>Tumors with intracranial and intradural extension; Di<sub>1/2/3</sub> according to depth of invasion into posterior cranial fossa (Di<sub>1</sub> = less than 2 cm, Di<sub>2</sub> = between 2 and 4 cm, Di<sub>3</sub> = more than 4 cm</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Jackson/Glasscock classification<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">Type 1</td> <td>Small tumor involving the jugular bulb, middle ear, and mastoid process</td> </tr> <tr> <td class=\"indent1\">Type 2</td> <td>Extending under internal auditory canal; may have intracranial extension</td> </tr> <tr> <td class=\"indent1\">Type 3</td> <td>Extending into petrous apex; may have intracranial extension</td> </tr> <tr> <td class=\"indent1\">Type 4</td> <td>Extending beyond petrous apex into clivus or infratemporal fossa; may have intracranial extension</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fisch U, Mattox D. Microsurgery of the skull base. Thieme, Stuttgart-New York, 1988, page 149.</li>&#xD;&#xA;    <li>Boedeker CC. Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg 2011; 10:Doc03.</li>&#xD;&#xA;    <li>Jackson CG, Glasscock ME 3rd, Harris PF. Glomus Tumors. Diagnosis, classification, and management of large lesions. Arch Otolaryngol 1982; 108:401.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86566 Version 2.0</div></div></div>"},"86568":{"type":"graphic_table","displayName":"Risks and benefits of enteral feeding tubes","title":"Risks and benefits of enteral feeding tubes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risks and benefits of enteral feeding tubes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Timing of tube insertion</td> </tr> <tr> <td class=\"subtitle2_left\">Prophylactic</td> </tr> <tr> <td class=\"indent1\">More effective weight maintenance</td> </tr> <tr> <td class=\"indent1\">Decreased need for additional hospitalization</td> </tr> <tr> <td class=\"indent1\">Better quality of life</td> </tr> <tr> <td class=\"subtitle2_left\">Reactive</td> </tr> <tr> <td class=\"indent1\">Feeding tube avoided if unnecessary</td> </tr> <tr> <td class=\"indent1\">Decreased risk of delayed dysphagia</td> </tr> <tr> <td class=\"indent1\">Less prolonged use of enteral feeding</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding tube</td> </tr> <tr> <td class=\"subtitle2_left\">Nasogastric </td> </tr> <tr> <td class=\"indent1\">Easier to insert</td> </tr> <tr> <td class=\"indent1\">Decreased risk of serious complications </td> </tr> <tr> <td class=\"indent1\">Lower costs</td> </tr> <tr> <td class=\"indent1\">Potentially shorter duration of tube dependency</td> </tr> <tr> <td class=\"indent1\">Pharyngoesophageal dilatation less likely to be required</td> </tr> <tr> <td class=\"subtitle2_left\">Percutaneous endoscopic gastrostomy</td> </tr> <tr> <td class=\"indent1\">More comfortable than a nasogastric tube</td> </tr> <tr> <td class=\"indent1\">Less likely to be displaced</td> </tr> <tr> <td class=\"indent1\">More effective weight maintenance</td> </tr> <tr> <td class=\"indent1\">Improved quality of life</td> </tr> <tr> <td class=\"indent1\">Unlimited duration of use possible</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adopted from Koyfman SA, Adelstein DJ. Enteral Feeding Tubes in Patients Undergoing Definitive Chemoradiation Therapy for Head-and-Neck Cancer: A&nbsp;Critical Review Int J. Radiat Oncol Bio Phys 2012: 84:581.</div><div id=\"graphicVersion\">Graphic 86568 Version 1.0</div></div></div>"},"86570":{"type":"graphic_table","displayName":"Trastuzumab plus cape and cis HER2 adv EG cancers","title":"Trastuzumab plus capecitabine and cisplatin for HER2-overexpressing advanced esophagogastric cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trastuzumab plus capecitabine and cisplatin for HER2-overexpressing advanced esophagogastric cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><sup></sup>Cycle length: 21 days.<br /> Duration of therapy: 6 cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Cisplatin</strong></td> <td>80 mg/m<sup>2</sup> IV</td> <td> <p>Dilute in 250 mL normal saline (NS)* and administer over 30 minutes or at a rate of 1 mg/min. Do not administer with aluminum needles or sets.</p> Alternative: Dilute in 2000 mL 5 percent dextrose in 1/2 or 1/3 NS containing 37.5 g of mannitol and infuse over a six to eight hour period<sup>[2]</sup>. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr> <td><strong>Capecitabine</strong><sup>&#916;</sup></td> <td>1000 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily; swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets<sup>&#9674;</sup>.</td> <td>Days 1 through 14</td> </tr> <tr> <td><strong>Trastuzumab<sup></sup></strong><sup>&#167;</sup></td> <td>8 mg/kg IV loading dose</td> <td>Dilute in 250 mL NS and administer over 90 minutes. <strong>Do not</strong> mix with 5 percent dextrose in water (D5W) and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1, cycle 1 only</td> </tr> <tr> <td><strong>Trastuzumab<sup></sup></strong><sup>&#167;</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes. <strong>Do not</strong> mix D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 of every subsequent cycle, starting with cycle 2<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of cisplatin<sup>[2]</sup>. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> HIGH (&#62;90 percent risk of emesis); prophylaxis for acute and delayed nausea and emesis through days 1 to 4 is warranted. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". According to the National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines, cisplatin doses &#62;50 mg/m<sup>2</sup> are considered of high emetic risk. While it is true the capecitabine given on days 2 through 14 is low risk, it may be confusing to practitioners to state that antiemetic risk is only high on day 1, since the period of nausea may last for several days.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Routine prophylaxis not indicated for cisplatin. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated (estimated risk of febrile neutropenia is 5 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline renal dysfunction:</strong> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. A lower starting dose of capecitabine may be needed for patients with renal impairment. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiopulmonary issues:</strong> Trastuzumab is associated with cardiotoxicity; assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with baseline LVEF less than 50 percent were excluded from this study<sup>[1]</sup>. Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease<sup>[3]</sup>. Refer to UpToDate topics on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each new treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each new treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for infusion reactions, especially during the first two courses of trastuzumab.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) due to capecitabine. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Hold new course of treatment until absolute neutrophil count is &#8805;1500/microL and platelet count is &#8805;100,000/microL<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Nephrotoxicity:</strong> Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced (or switch to carboplatin) if &#60;60 mL/min. While this is clinically appropriate, there is not a specific reference in the United States Prescribing Information outlining a change to carboplatin based on creatinine clearance of &#60;60 mL/min.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> Assess LVEF at least every three months during trastuzumab<sup>[3]</sup>. The United States Prescribing Information recommends withholding trastuzumab for at least four weeks for LVEF &#8805;16 percent decrease from baseline or LVEF below lower limit of normal and &#8805;10 percent decrease from baseline; repeat LVEF assessment every four weeks. May resume trastuzumab treatment if LVEF returns to normal limits within four to eight weeks and remains at &#8804;15 percent decrease from baseline value. Discontinue permanently for persistent (&#62;8 weeks) LVEF decline or for &#62;3 incidents of treatment interruption for cardiomyopathy. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurologic toxicity:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hand-foot syndrome and diarrhea/stomatitis:</strong> Hold capecitabine for grade 3 toxicity, and following recovery, reduce the dose by 25 percent for recurrent grade 2 or worse toxicity. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Other toxicity (including hepatotoxicity):</strong> Recommended dose modification guidelines for capecitabine are listed in the United States Prescribing Information<sup>[4]</sup>.&nbsp;<span style=\"color: black;\">For the first, second, and third occurrence of grade 2 toxicity, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75 percent of the starting dose; third occurrence, 50 percent of the starting dose)</span><span style=\"color: black;\"><sup>[4]</sup>. For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75 percent of the starting dose; second occurrence, 50 percent of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50 percent of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for first recurrence of grade 4 toxicity.</span></p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Doses of capecitabine omitted for toxicity are not replaced or restored; instead the patient should resume with the next planned treatment cycle<sup>[4]</sup>.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />◊ Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.<br />§&nbsp;High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic \"HER2 and predicting response to therapy in breast cancer\".<br />¥&nbsp;In the original trial, cisplatin and capecitabine were stopped after six 21-day cycles, and trastuzumab alone continued on day 1 every 21 days until disease progression<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bang J, et al. Lancet 2010; 376:687.</li>&#xD;&#xA;    <li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on June 7, 2012).</li>&#xD;&#xA;    <li>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 7, 2012).</li>&#xD;&#xA;    <li>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 7, 2012).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86570 Version 15.0</div></div></div>"},"86571":{"type":"graphic_table","displayName":"Trastuzumab plus FU and cis HER2 adv EG cancers","title":"Trastuzumab plus fluorouracil and cisplatin for HER2-overexpressing* advanced esophagogastric cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trastuzumab plus fluorouracil and cisplatin for HER2-overexpressing* advanced esophagogastric cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.<br /> Duration of therapy: 6 cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Cisplatin</strong></td> <td>80 mg/m<sup>2</sup> IV</td> <td> <p>Dilute in 250 mL normal saline (NS)<sup>&#916;</sup> and administer over 30 minutes or at a rate of 1 mg/min. Do not administer with aluminum needles or sets.</p> Alternative: Dilute in 2000 mL 5 percent dextrose in 1/2 or 1/3 NS containing 37.5 g of mannitol and infuse over a six to eight hour period<sup>[2]</sup>. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>800 mg/m<sup>2</sup> per day IV</td> <td>Dilute in 500 to 1000 mL 5 percent dextrose in water (D5W) and administer as continuous infusion over 24 hours per day.</td> <td>Days 1 through 5</td> </tr> <tr> <td><strong>Trastuzumab</strong></td> <td>8 mg/kg IV loading dose</td> <td>Dilute in 250 mL NS and administer over 90 minutes. DO NOT mix with D5W and DO NOT infuse as an IV push or bolus.</td> <td>Day 1, cycle 1 only</td> </tr> <tr> <td><strong>Trastuzumab</strong></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes. DO NOT mix D5W and DO NOT infuse as an IV push or bolus.</td> <td>Day 1 of each subsequent cycle, starting with cycle 2<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of cisplatin<sup>[2]</sup>. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> HIGH (&#62;90 percent risk of emesis); prophylaxis for acute and delayed nausea and emesis through days 1 to 4 is warranted. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". According to the National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines, cisplatin doses &#62;50 mg/m<sup>2</sup> are considered of high emetic risk. While it is true the FU given on days 2 through 5 is low risk, it may be confusing to practitioners to state that antiemetic risk is only high on day 1, since the period of nausea may last for several days.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Routine prophylaxis not indicated for cisplatin or fluorouracil. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated (estimated risk of febrile neutropenia with this regimen is 5 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiopulmonary issues:</strong> Trastuzumab is associated with cardiotoxicity; assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with baseline LVEF less than 50 percent were excluded from this study<sup>[1]</sup>. Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease<sup>[3]</sup>. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each new treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each new treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for infusion reactions, especially during the first two courses of trastuzumab.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) due to FU. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Hold new course of treatment until absolute neutrophil count is &#8805;1500 cells/microL and platelet count is &#8805;100,000/microL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold FU for grade 2 or worse diarrhea and restart at a lower dose after complete resolution. <strong>NOTE:</strong> Severe diarrhea and mucositis after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Nephrotoxicity:</strong> Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced (or switch to carboplatin) if &#60;60 mL/min. While this is clinically appropriate, there is not a specific reference in the United States Prescribing Information outlining a change to carboplatin based on creatinine clearance of &#60;60 mL/min.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> Assess LVEF at least every three months during trastuzumab<sup>[3]</sup>. The United States Prescribing Information recommends withholding trastuzumab for at least four weeks for LVEF &#8805;16 percent decrease from baseline or LVEF below lower limit of normal and &#8805;10 percent decrease from baseline; repeat LVEF assessment every four weeks. May resume trastuzumab treatment if LVEF returns to normal limits within four to eight weeks and remains at &#8804;15 percent decrease from baseline value. Discontinue permanently for persistent (&#62;8 weeks) LVEF decline or for &#62;3 incidents of treatment interruption for cardiomyopathy. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurologic toxicity:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment<sup>[2]</sup>. Refer to UpToDate topic on \"<span style=\"font-size: 11pt; font-family: calibri,sans-serif;\">Overview of neurologic complications of platinum-based chemotherapy</span>\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Palmar-plantar erythrodysesthesia:</strong> Hold FU for &#8805;grade 2 palmar plantar erythrodysesthesia. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>◊</FONT> In the original trial, cisplatin and FU were stopped after six 21-day cycles, and trastuzumab alone continued on day 1 every 21 days until disease progression<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Bang J, et al. Lancet 2010; 376:687.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on June 7, 2012).</LI>&#xD;&#xA;<LI>Trastuzumab injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 7, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86571 Version 10.0</div></div></div>"},"86574":{"type":"graphic_algorithm","displayName":"Selecting IGRA or TST","title":"Choice of IGRA versus TST for diagnosis of latent tuberculosis infection in children","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Choice of IGRA versus TST for diagnosis of latent&nbsp;tuberculosis infection in children</div><div class=\"cntnt\"><img style=\"width:584px; height:586px;\" src=\"images/ID/86574_SelectingIGRAorTST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An algorithm for the use of the TST and IGRAs in children. Entry into the algorithm assumes that the child has at least one risk factor for TB infection.</div><div class=\"graphic_footnotes\">IGRA: interferon-gamma release assay; TST: tuberculin skin test; BCG: Bacillus Calmette-Guerin vaccine; NTM: nontuberculous mycobacteria.<br />* Criteria A: High clinical suspicion for TB disease and/or high risk for infection, progression, or poor outcome.<br />&para; Criteria B: Additional evidence needed to ensure adherence and/or child healthy and at low risk and/or NTM suspected.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 134, Pages e1763-73, Copyright © 2014 by the AAP.</div><div id=\"graphicVersion\">Graphic 86574 Version 12.0</div></div></div>"},"86575":{"type":"graphic_table","displayName":"Differential diagnosis of pulsatile tinnitus","title":"Differential diagnosis of pulsatile tinnitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pulsatile tinnitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">General</td> <td class=\"subtitle1\">Hypervascular/hyperamic</td> <td class=\"subtitle1\">Arterial</td> <td class=\"subtitle1\">Venous</td> </tr> <tr> <td> <p>Hyperthyroidism</p> <p>Anemia</p> <p>Pregnancy</p> Cardiac murmur</td> <td> <p>Acute otitis media</p> <p>Otosclerosis</p> <p>Paget disease</p> <p>Cholesteatoma</p> <p>Tympanic paraganglioma</p> <p>Jugular paraganglioma</p> <p>Hemangioma</p> Amputation neuroma</td> <td> <p>Stenosis of ICA</p> <p>Fibromuscular dysplasia of vertebral artery</p> <p>Arteriovenous fistulas</p> <p>Aneurysms</p> <p>Arterial ectasias</p> <p>Aberrant ICA</p> <p>Persistant stapedial artery</p> Persistant primitive trigeminal artery (artery trigeminalis)</td> <td> <p>Anomalies of jugular</p> <p>Bulb and other venous malformations of the temporal bone (eg, large emissary veins)</p> <p>Benign intracranial hypertension</p> <p>Intracranial tumor</p> Hydrocephalus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICA: internal carotid artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Boedeker CC. Paragangliomas and paraganglioma syndromes. Laryngorhinootologie 2011; 90 Suppl 1:S56. Copyright &copy; 2011 Thieme Publishers. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86575 Version 3.0</div></div></div>"},"86576":{"type":"graphic_diagnosticimage","displayName":"MRI carotid body paraganglioma","title":"MRI carotid body paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">MRI carotid body paraganglioma</div><div class=\"cntnt\"><img style=\"width:613px; height:243px;\" src=\"images/ONC/86576_MRI_CBT_paraganglioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CBT (class I): The axial T1-weighted MRI with contrast medium shows a CBT in typical location. Splaying of the left carotid bifurcation without any surrounding of the carotid vessels (arrows).<br />(B) CBT (class II): Axial T1-weighted MRI with contrast showing a right-sided CBT partially surrounding the internal and external carotid artery (arrows).<br />(C) CBT (class III): A large left-sided CBT intimately surrounding the carotid vessels (arrow) (axial T1 weighted MRI with contrast).</div><div class=\"graphic_footnotes\">CBT: carotid body tumor; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Modified with permission from: Boedeker CC. Paragangliomas and paraganglioma syndromes. Laryngorhinootologie 2011; 90 Suppl 1:S56. Copyright &copy; 2011 Thieme Publishers. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86576 Version 3.0</div></div></div>"},"86582":{"type":"graphic_picture","displayName":"Epidermal nevus - inguinal","title":"Epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epidermal nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/DERM/86582_Epidermal_nevus_inguinal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A verrucous, brown, linear plaque is present in the inguinal crease.</div><div id=\"graphicVersion\">Graphic 86582 Version 2.0</div></div></div>"},"86583":{"type":"graphic_picture","displayName":"Horizontal shoulder abduction prone","title":"Horizontal shoulder abduction while prone","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Horizontal shoulder abduction while prone</div><div class=\"cntnt\"><img style=\"width:516px; height:202px;\" src=\"images/EM/86583_Horiz_should_abduc_prone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Start by lying on your stomach with your arm hanging straight down. Lift your arm&nbsp;to your side&nbsp;over&nbsp;a 2 second&nbsp;count until it is perpendicular with your torso, and then, slowly, lower your arm back to the starting position over a 4 second count. Repeat the movement 25 times&nbsp;to complete&nbsp;one set.&nbsp;Perform two sets on each side.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86583 Version 1.0</div></div></div>"},"86584":{"type":"graphic_diagnosticimage","displayName":"CT scan and ultrasound of pararenal paraganglioma","title":"CT scan and ultrasound of pararenal paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">CT scan and ultrasound of pararenal paraganglioma</div><div class=\"cntnt\"><img style=\"width:603px; height:524px;\" src=\"images/RADIOL/86584_CT_scan_US_pararen_paragang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan performed on a 40-year-old female to assess a large pelvic mass confirmed the presence of a fibroid (arrow in A and coronal reconstruction in B) with the incidental finding of a pararenal mass (small arrowhead in A and B). The ultrasound (C) shows an isoechoic almost homogeneous mass (large arrowhead) impinging on the hilum of the kidney and causing mild hydronephrosis (dashed arrowhead). The Doppler ultrasound (D) shows minimal vascularity in the mass (thick arrow). The patient had elevated metanephrines and a diagnosis of paraganglioma was proven surgically.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86584 Version 2.0</div></div></div>"},"86585":{"type":"graphic_table","displayName":"Rates of cutaneous drug reactions","title":"Rates of cutaneous reactions to drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of cutaneous reactions to drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Rate (percent) of allergic cutaneous reactions</td> </tr> <tr> <td>Amoxicillin</td> <td>1.2-5.1</td> </tr> <tr> <td>Ampicillin</td> <td>3.3</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> <td>2.1-3.4</td> </tr> <tr> <td>Semisynthetic penicillins</td> <td>2.1</td> </tr> <tr> <td>Penicillin G</td> <td>1.9</td> </tr> <tr> <td>Cephalosporins</td> <td>1.5</td> </tr> <tr> <td>Erythromycin</td> <td>2.0</td> </tr> <tr> <td>Gentamicin</td> <td>0.5</td> </tr> <tr> <td>Doxycycline</td> <td>0.5</td> </tr> <tr> <td>Fluoroquinolones</td> <td>0.1-1.6</td> </tr> <tr> <td>Furosemide</td> <td>0.05</td> </tr> <tr> <td>Allopurinol</td> <td>0.8</td> </tr> <tr> <td>Metoclopramide</td> <td>0.3</td> </tr> <tr> <td>Heparin sodium</td> <td>0.1</td> </tr> <tr> <td>Barbiturates</td> <td>0.4</td> </tr> <tr> <td>Nitrazepam</td> <td>0.2</td> </tr> <tr> <td>Diazepam</td> <td>0.04</td> </tr> <tr> <td>Lamotrigine</td> <td>0.6</td> </tr> <tr> <td>Carbamazepine</td> <td>0.3</td> </tr> <tr> <td>Maprotiline</td> <td>0.2</td> </tr> <tr> <td>Escitalopram</td> <td>0.2</td> </tr> <tr> <td>Tricyclic/tetracyclic antidepressants</td> <td>0.07</td> </tr> <tr> <td>SSRIs</td> <td>0.05</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRIs: selective serotonin reuptake inhibitors.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.</li>&#xD;&#xA;    <li>van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.</li>&#xD;&#xA;    <li>Kulthanan K, Chularojanamontri L, Manapajon A, et al. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22:155.</li>&#xD;&#xA;    <li>Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009; 70:1258.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86585 Version 2.0</div></div></div>"},"86586":{"type":"graphic_picture","displayName":"Y exercise for scapular stabilizers","title":"\"Y\" exercise for scapular stabilizers","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">\"Y\" exercise for scapular stabilizers</div><div class=\"cntnt\"><img style=\"width:517px; height:202px;\" src=\"images/EM/86586_Y_exer_scap_stabilizers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Y\" exercises are performed with the elbows extended and the thumbs pointing up. Flex your shoulders in a plane at approximately a 45 degree angle from&nbsp;your body until the arm or arms are in line with the body. Hold the position for one second, and then slowly return the arms to the starting position.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86586 Version 1.0</div></div></div>"},"86587":{"type":"graphic_picture","displayName":"Seated row","title":"Seated row exercise","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Seated row exercise</div><div class=\"cntnt\"><img style=\"width:468px; height:326px;\" src=\"images/EM/86587_Seated_row.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While seated, grasp the handle of a pulley bar directly in front of you and, while maintaining an erect posture, gradually pull the bar straight to your belly, hold for one second, and then return the bar to the starting position.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86587 Version 1.0</div></div></div>"},"86588":{"type":"graphic_picture","displayName":"Close-grip pull-down","title":"Close-grip pull-down exercise","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Close-grip pull-down exercise</div><div class=\"cntnt\"><img style=\"width:489px; height:326px;\" src=\"images/EM/86588_Close_grip_pull_down.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While seated, grasp the handle of a pulley bar directly in front of you and, while maintaining an erect posture, gradually pull the bar straight to your belly, hold for one second, and then return the bar to the starting position.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86588 Version 1.0</div></div></div>"},"86589":{"type":"graphic_picture","displayName":"I exercise for scapula stability","title":"\"I\" exercise for scapular stabilizers","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">\"I\" exercise for scapular stabilizers</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/EM/86589_I_exer_scapula_stabil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"I\" exercises begin with the involved arm hanging straight down from the shoulder. Keeping the elbows straight, extend your shoulders until the arms are pointing straight down and are adjacent to your torso. Hold this position for one second, and then slowly return the arms to the starting position.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86589 Version 1.0</div></div></div>"},"86590":{"type":"graphic_picture","displayName":"Defect following nail unit excision","title":"Defect following en bloc nail unit excision","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Defect following en bloc nail unit excision</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/DERM/86590_Def_foll_nail_unit_excisn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Phoebe Rich, MD.</div><div id=\"graphicVersion\">Graphic 86590 Version 2.0</div></div></div>"},"86591":{"type":"graphic_picture","displayName":"Glomus tumor excision","title":"Excision of subungual glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Excision of subungual glomus tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86591_Glomus_tumor_excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Phoebe Rich, MD.</div><div id=\"graphicVersion\">Graphic 86591 Version 2.0</div></div></div>"},"86592":{"type":"graphic_picture","displayName":"T exercise for scapular stabilizers with resistance","title":"\"T\" exercise for scapular stabilizers with resistance","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">\"T\" exercise for scapular stabilizers with resistance</div><div class=\"cntnt\"><img style=\"width:515px; height:189px;\" src=\"images/EM/86592_T_exc_scap_stabili_resis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"T\" exercises are performed keeping the elbows extended. Raise your arms straight to the side (combination of shoulder extension and abduction) until they are perpendicular to and in the same plane as the torso. Hold the position for one second, and then, slowly return the arms to the starting position.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86592 Version 1.0</div></div></div>"},"86594":{"type":"graphic_picture","displayName":"DEB1","title":"Recessive dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Recessive dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:576px; height:382px;\" src=\"images/DERM/86594_DEB1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large nonhealing erosions and ulcers in generalized severe recessive dystrophic epidermolysis bullosa.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86594 Version 2.0</div></div></div>"},"86595":{"type":"graphic_picture","displayName":"DEB2","title":"Recessive dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Recessive dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:576px; height:384px;\" src=\"images/DERM/86595_DEB2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86595 Version 1.0</div></div></div>"},"86596":{"type":"graphic_picture","displayName":"DEB3","title":"Recessive dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Recessive dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:588px; height:440px;\" src=\"images/DERM/86596_DEB3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, nonhealing erosions and ulcers with partly impetiginized crusts in&nbsp;generalized severe recessive DEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86596 Version 2.0</div></div></div>"},"86597":{"type":"graphic_picture","displayName":"DEB4","title":"Dominant dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Dominant dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:576px; height:382px;\" src=\"images/DERM/86597_DEB4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions, crusts, and atrophic scarring on knees in dominant dystrophic EB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86597 Version 1.0</div></div></div>"},"86598":{"type":"graphic_picture","displayName":"Mitten deformity","title":"Pseudosyndactyly (mitten deformity) in generalized severe recessive dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudosyndactyly (mitten deformity) in&nbsp;generalized severe recessive dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:345px; height:455px;\" src=\"images/DERM/86598_Mitten_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudosyndactyly (mitten deformity) of hands (top) and feet (bottom) with skin atrophy, loss of nails (anonychia), shortening of distal phalanges, and severe contractures in&nbsp;generalized severe recessive DEB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86598 Version 2.0</div></div></div>"},"86599":{"type":"graphic_picture","displayName":"DEB squamous cell carcinoma 1","title":"Squamous cell carcinoma in generalized severe dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma in&nbsp;generalized severe dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86599_DEB_squamous_cell_carcin_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Squamous cell carcinoma on the elbow of a patient with&nbsp;generalized severe recessive DEB. Clinically, squamous cell carcinoma may masquerade as a nonhealing wound. Although histopathology is often well differentiated, the tumor is often extremely aggressive.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86599 Version 2.0</div></div></div>"},"86600":{"type":"graphic_picture","displayName":"DEB squamous cell carcinoma 2","title":"Squamous cell carcinoma in generalized severe recessive dystrophic epidermolysis bullosa (DEB)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma in&nbsp;generalized severe recessive dystrophic epidermolysis bullosa (DEB)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86600_DEB_squamous_cell_carcin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Squamous cell carcinoma on the elbow of a patient with&nbsp;generalized severe recessive DEB. Clinically, squamous cell carcinoma may masquerade as a nonhealing wound. Although histopathology is often well differentiated, the tumor is often extremely aggressive.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86600 Version 2.0</div></div></div>"},"86601":{"type":"graphic_picture","displayName":"EB nevi 1","title":"Epidermolysis bullosa nevi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa nevi</div><div class=\"cntnt\"><img style=\"width:333px; height:501px;\" src=\"images/DERM/86601_EB_nevi_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermolysis bullosa nevus presenting with bizarre protrusions and satellite lesions in an area of extensive blistering.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86601 Version 1.0</div></div></div>"},"86603":{"type":"graphic_picture","displayName":"EB nevi 2","title":"Epidermolysis bullosa nevi","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa nevi</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86603_EB_nevi_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermolysis bullosa nevus typically tracing the outline of a preexisting blister.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86603 Version 1.0</div></div></div>"},"86604":{"type":"graphic_picture","displayName":"EB nevi 3","title":"Epidermolysis bullosa nevi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa nevi</div><div class=\"cntnt\"><img style=\"width:329px; height:502px;\" src=\"images/DERM/86604_EB_nevi_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical flat, stippled epidermolysis bullosa nevus in a 13-year-old patient with dystrophic epidermolysis bullosa.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86604 Version 2.0</div></div></div>"},"86605":{"type":"graphic_picture","displayName":"EB nevi dermoscopy","title":"Dermoscopic image of an epidermolysis bullosa (EB) nevus","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of an epidermolysis bullosa (EB)&nbsp;nevus</div><div class=\"cntnt\"><img style=\"width:586px; height:465px;\" src=\"images/DERM/86605_EB_nevi_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopic image of an EB nevus on the thumb of a five-year-old boy with&nbsp;EBS, autosomal recessive,&nbsp;with muscular dystrophy showing an atypical pigment network, irregular dots and globules, and homogeneous white and reddish areas (multicomponent pattern).</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86605 Version 2.0</div></div></div>"},"86607":{"type":"graphic_picture","displayName":"EB nevi 5","title":"Epidermolysis bullosa nevi","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa nevi</div><div class=\"cntnt\"><img style=\"width:576px; height:376px;\" src=\"images/DERM/86607_EB_nevi_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular components arising within an EB nevus in a 35-year-old patient with junctional EB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86607 Version 1.0</div></div></div>"},"86608":{"type":"graphic_picture","displayName":"EB nevi 6","title":"Unpigmented epidermolysis bullosa nevi","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Unpigmented epidermolysis bullosa nevi</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/86608_EB_nevi_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two unpigmented \"shagreen\" EB nevi on the chest and the upper arm of a 65-year-old patient with junctional EB.</div><div class=\"graphic_reference\">Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</div><div id=\"graphicVersion\">Graphic 86608 Version 1.0</div></div></div>"},"86620":{"type":"graphic_table","displayName":"Hay Ison criteria for diagnosis of bacterial vaginosis","title":"Hay Ison criteria for diagnosis of bacterial vaginosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hay Ison criteria for diagnosis of bacterial vaginosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Grade 0: No bacteria present</td> </tr> <tr> <td>Grade 1: Lactobacillus morphotypes predominate</td> </tr> <tr> <td>Grade 2: Mixed flora with some lactobacilli present, but gardnerella or mobiluncus morphotypes also present</td> </tr> <tr> <td>Grade 3*: Predominantly gardnerella and/or mobiluncus morphotypes. Few or absent lactobacilli.</td> </tr> <tr> <td>Grade 4: Gram-positive cocci predominate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Grade 3 is diagnostic of bacterial vaginosis.</div><div class=\"graphic_reference\">Source: Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect 2002; 78:413.</div><div id=\"graphicVersion\">Graphic 86620 Version 1.0</div></div></div>"},"86621":{"type":"graphic_picture","displayName":"Skin nodule associated with Staphyloccoccus aureus infection","title":"Skin nodule associated with Staphyloccoccus aureus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin nodule associated with Staphyloccoccus aureus infection</div><div class=\"cntnt\"><img style=\"width:384px; height:504px;\" src=\"images/EM/86621_Skin_nod_ass_Staph_aur_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sheldon Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 86621 Version 1.0</div></div></div>"},"86622":{"type":"graphic_diagnosticimage","displayName":"Incidental Meckels on CT scan","title":"Incidental Meckels on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Incidental Meckels on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:335px;\" src=\"images/RADIOL/86622_Incid_Meckels_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidental note of a noninflamed Meckel's diverticulum (arrow) in the axial view (A) and coronal reconstruction (B) of the abdominal CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86622 Version 2.0</div></div></div>"},"86623":{"type":"graphic_figure","displayName":"Ileostomy PI","title":"Ileostomy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Ileostomy</div><div class=\"cntnt\"><img style=\"width:512px; height:672px;\" src=\"images/PI/86623_Ileostomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows an ileostomy. To make an ileostomy, a doctor makes a small opening in the belly. This opening is called a \"stoma.\" Then he or she connects the small intestine to the stoma. Bowel movements exit the body through the stoma. They go into a bag that is attached to the skin.</div><div id=\"graphicVersion\">Graphic 86623 Version 2.0</div></div></div>"},"86624":{"type":"graphic_table","displayName":"Medicines for treating atrial fibrillation PI","title":"Medicines for treating atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines for treating atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of medicine</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Sample US brand names</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Heart rate control medicines</td> <td class=\"sublist1_start\" colspan=\"2\">Beta-blockers including:</td> </tr> <tr> <td class=\"indent1\">Metoprolol</td> <td>Toprol XL</td> </tr> <tr> <td class=\"indent1\">Atenolol</td> <td>Tenormin</td> </tr> <tr> <td class=\"indent1\">Carvedilol</td> <td>Coreg</td> </tr> <tr> <td class=\"indent1\">Bisoprolol</td> <td>Zebeta</td> </tr> <tr> <td class=\"indent1\">Nadolol</td> <td>Corgard</td> </tr> <tr> <td>Diltiazem</td> <td>Cardizem, Cartia XT, Tiazac</td> </tr> <tr> <td>Verapamil</td> <td>Calan, Isoptin SR, Verelan</td> </tr> <tr class=\"divider_bottom\"> <td>Digoxin</td> <td>Lanoxin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Anti-clotting medicines</td> <td>Warfarin</td> <td>Coumadin, Jantoven</td> </tr> <tr> <td>Dabigatran</td> <td>Pradaxa</td> </tr> <tr> <td>Rivaroxaban</td> <td>Xarelto</td> </tr> <tr> <td>Apixaban</td> <td>Eliquis</td> </tr> <tr class=\"divider_bottom\"> <td>Edoxaban</td> <td>Savaysa</td> </tr> <tr> <td rowspan=\"6\">Heart rhythm control medicines</td> <td>Amiodarone</td> <td>Cordarone, Pacerone</td> </tr> <tr> <td>Dronedarone</td> <td>Multaq</td> </tr> <tr> <td>Dofetilide</td> <td>Tikosyn</td> </tr> <tr> <td>Sotalol</td> <td>Betapace AF</td> </tr> <tr> <td>Flecainide</td> <td>Tambocor</td> </tr> <tr> <td>Propafenone</td> <td>Rythmol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86624 Version 4.0</div></div></div>"},"86626":{"type":"graphic_table","displayName":"Allergy causes and symptoms PI","title":"Causes and symptoms of common allergies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and symptoms of common allergies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of allergy</td> <td class=\"subtitle1\">Caused by</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr> <td rowspan=\"2\">Seasonal allergies (also called hay fever)</td> <td>Pollen from trees, grasses, or weeds</td> <td rowspan=\"5\"> <ul> <li>Stuffy nose, runny nose, or sneezing a lot </li> <li>Itchy or red eyes, sore throat, or itching of the throat or ears </li> <li>Waking up at night or trouble sleeping, which can lead to feeling tired during the day </li> <li>Asthma symptoms (wheezing or noisy breathing, coughing, a tight feeling in the chest, and shortness of breath) </li> </ul> </td> </tr> <tr> <td>Mold spores that grow when the weather is humid, wet, or damp</td> </tr> <tr> <td rowspan=\"3\">Indoor allergies</td> <td><span style=\"color: black;\">Mold spores</span></td> </tr> <tr> <td><span style=\"color: black;\">Animals, such as cats and dogs</span></td> </tr> <tr> <td><span style=\"color: black;\">Insects, such as dust mites and cockroaches</span></td> </tr> <tr> <td><span style=\"color: black;\">Insect allergies</span></td> <td><span style=\"color: black;\">Stings from honeybees, yellow jackets, hornets, wasps, and fire ants</span></td> <td rowspan=\"4\"> <ul> <li>Red, hot, skin especially on your face (flushing) </li> <li>Red, raised patches of skin that are very itchy (hives) </li> <li>Swelling of the face, eyelids, mouth, tongue, hands, and feet (angioedema) </li> <li>Asthma symptoms (wheezing or noisy breathing, coughing, a tight feeling in the chest, and shortness of breath) </li> <li>Nausea and vomiting </li> <li>Feeling lightheaded or like you might pass out </li> </ul> </td> </tr> <tr> <td>Food allergies </td> <td>Milk and foods that contain milk such as ice cream or butter (called dairy foods); eggs, wheat, soy, peanuts, tree nuts, (such as almonds or cashews); fish, shellfish (such as shrimp or oysters)</td> </tr> <tr> <td>Medicine allergies </td> <td>Penicillin (most common)&nbsp;or other medicines </td> </tr> <tr> <td>Latex allergy</td> <td>Gloves and other medical supplies that contain latex, condoms, balloons</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86626 Version 3.0</div></div></div>"},"86627":{"type":"graphic_picture","displayName":"Kerion in tinea capitis","title":"Kerion in tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Kerion in tinea capitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86627_Kerion_tinea_capitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A boggy plaque with pustules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86627 Version 4.0</div></div></div>"},"86628":{"type":"graphic_picture","displayName":"Tinea capitis - black dot","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86628_Tinea_capitis_black_dot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A round patch of alopecia with overlying scale and \"black dots\" at the sites of follicular openings is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86628 Version 5.0</div></div></div>"},"86629":{"type":"graphic_diagnosticimage","displayName":"Bladder paraganglioma","title":"Bladder paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bladder paraganglioma</div><div class=\"cntnt\"><img style=\"width:540px; height:436px;\" src=\"images/RADIOL/86629_Bladder_paraganglioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T2 weighted MRI of the pelvis in the coronal plane shows a T2 bright lesion (arrow) surrounded by T2 bright urine (arrowhead). The diagnosis of urinary bladder paraganglioma was proven surgically.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 86629 Version 2.0</div></div></div>"},"86631":{"type":"graphic_diagnosticimage","displayName":"Paraganglioma of the Organ of Zuckerkandl","title":"CT scan and octreotide scan of an organ of Zuckerkandl paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">CT scan and octreotide scan of an organ of Zuckerkandl paraganglioma</div><div class=\"cntnt\"><img style=\"width:496px; height:576px;\" src=\"images/RADIOL/86631_Paragangl_Organ_Zuckerkandl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images demonstrate an organ of Zuckerkandl paraganglioma (arrows) that extends from the just above the region of the inferior mesenteric artery (arrowhead, A) to the aortic bifurcation (dashed arrow, image C) for 12 cm. Images A, B, and C depict contrast-enhanced CT scan images of the same patient as seen in the axial, sagittal, and coronal planes, respectively. The affinity of the paraganglioma for octreotide is shown in the indium labeled nuclear medicine scan (image D). The mass is well defined with absent or delayed central contrast enhancement on the CT scans (images A, B, and C).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86631 Version 2.0</div></div></div>"},"86633":{"type":"graphic_table","displayName":"Classification criteria for SLE","title":"Classification criteria for systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification criteria for systemic lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">ACR criteria for the classification of systemic lupus erythematosus<sup>[1,2]</sup></td> <td class=\"subtitle1\" colspan=\"2\">SLICC criteria for the classification of systemic lupus erythematosus<sup>[3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"2\">(4 of 11 criteria)*</td> <td class=\"centered\" colspan=\"2\">(4 of 17 criteria, including at least one clinical criterion and one immunologic criterion;<sup>&#182;</sup> <strong>OR</strong> biopsy-proven lupus nephritis<sup>&#916;</sup>)</td> </tr> <tr> <td class=\"subtitle2\">Criterion</td> <td class=\"subtitle2\">Definition</td> <td class=\"subtitle2\">Criterion</td> <td class=\"subtitle2\">Definition</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Clinical criteria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Malar rash</td> <td>Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds</td> <td rowspan=\"2\">Acute cutaneous lupus</td> <td rowspan=\"2\">Lupus malar rash (do not count if malar discoid); bullous lupus; toxic epidermal necrolysis variant of SLE; maculopapular lupus rash; photosensitive lupus rash (in the absence of dermatomyositis); <strong>OR</strong> subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Photosensitivity</td> <td>Skin rash as a result of unusual reaction to sunlight, by patient history or clinician observation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Discoid rash</td> <td>Erythematosus raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions</td> <td>Chronic cutaneous lupus</td> <td>Classic discoid rash; localized (above the neck); generalized (above and below the neck); hypertrophic (verrucous) lupus; lupus panniculitis (profundus); mucosal lupus; lupus erythematosus tumidus; chilblains lupus; <strong>OR</strong> discoid lupus/lichen planus overlap</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Nonscarring alopecia</td> <td>Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as alopecia areata, drugs, iron deficiency, and androgenic alopecia)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oral ulcers</td> <td>Oral or nasopharyngeal ulceration, usually painless, observed by a clinician</td> <td>Oral or nasal ulcers</td> <td>Palate, buccal, tongue, <strong>OR </strong>nasal ulcers (in the absence of other causes, such as vasculitis, Beh&#231;et's disease, infection [herpesvirus], inflammatory bowel disease, reactive arthritis, and acidic foods)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Arthritis</td> <td class=\"divider_bottom\" rowspan=\"2\">Nonerosive arthritis involving two or more peripheral joints, characterized by tenderness, swelling, or effusion</td> <td class=\"divider_bottom\" rowspan=\"2\">Joint disease</td> <td>Synovitis involving two or more joints, characterized by swelling or effusion <strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Tenderness in two or more joints and at least 30 minutes of morning stiffness</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Serositis</td> <td>Pleuritis &ndash; Convincing history of pleuritic pain or rubbing heard by a clinician or evidence of pleural effusion <strong>OR</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">Serositis</td> <td>Typical pleurisy for more than one day, pleural effusions, or pleural rub, <strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Pericarditis &ndash; Documented by ECG, rub, or evidence of pericardial effusion</td> <td>Typical pericardial pain (pain with recumbency improved by sitting forward) for more than one day, pericardial effusion, pericardial rub, or pericarditis by electrocardiography in the absence of other causes, such as infection, uremia, and Dressler's syndrome</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Renal disorder</td> <td>Persistent proteinuria greater than 500 mg/24 hours or greater than 3+ if quantitation not performed <strong>OR</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">Renal</td> <td>Urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500 mg protein/24 hours, <strong>OR</strong> </td> </tr> <tr class=\"divider_bottom\"> <td>Cellular casts &ndash; May be red cell, hemoglobin, granular, tubular, or mixed</td> <td>Red blood cell casts</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neurologic disorder</td> <td>Seizures <strong>OR</strong> psychosis &ndash; In the absence of offending drugs or known metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)</td> <td>Neurologic</td> <td>Seizures; psychosis; mononeuritis multiplex (in the absence of other known causes, such as primary vasculitis); myelitis; peripheral or cranial neuropathy (in the absence of other known causes, such as primary vasculitis, infection, and diabetes mellitus); <strong>OR</strong> acute confusional state (in the absence of other causes, including toxic/metabolic, uremia, drugs)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Hematologic disorder</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Hemolytic anemia &ndash; With reticulocytosis <strong>OR</strong></p> <p>Leukopenia &ndash; Less than 4000/mm<sup>3</sup> total on two or more occasions <strong>OR</strong></p> <p>Lymphopenia &ndash; Less than 1500/mm<sup>3</sup> on two or more occasions <strong>OR</strong></p> Thrombocytopenia &ndash; Less than 100,000/mm<sup>3</sup> (in the absence of offending drugs)</td> <td>Hemolytic anemia</td> <td>Hemolytic anemia</td> </tr> <tr> <td rowspan=\"2\">Leukopenia or lymphopenia</td> <td>Leukopenia (&#60;4000/mm<sup>3</sup> at least once) (in the absence of other known causes, such as Felty's syndrome, drugs, and portal hypertension), <strong>OR</strong></td> </tr> <tr> <td>Lymphopenia (&#60;1000/mm<sup>3</sup> at least once) (in the absence of other known causes, such as glucocorticoids, drugs, and infection)</td> </tr> <tr class=\"divider_bottom\"> <td>Thrombocytopenia</td> <td>Thrombocytopenia (&#60;100,000/mm<sup>3</sup>) at least once in the absence of other known causes, such as drugs, portal hypertension, and thrombotic thrombocytopenic purpura</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Immunologic criteria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ANA</td> <td>An abnormal titer of&nbsp;ANA by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with \"drug-induced lupus\" syndrome</td> <td>ANA</td> <td>ANA level above laboratory reference range</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Immunologic disorders</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Anti-DNA &ndash; Antibody to native DNA in abnormal titer <strong>OR</strong></p> <p>Anti-Sm &ndash; Presence of antibody to Sm nuclear antigen <strong>OR</strong></p> Positive finding of antiphospholipid antibody based on an abnormal serum level of IgG or IgM anticardiolipin antibodies, on a positive test result for lupus anticoagulant using a standard method, or on a false-positive serologic test for syphilis known to be positive for at least six months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test</td> <td>Anti-dsDNA</td> <td>Anti-dsDNA antibody level above laboratory reference range (or &#62;twofold the reference range if tested by ELISA)</td> </tr> <tr> <td>Anti-Sm</td> <td>Presence of antibody to Sm nuclear antigen</td> </tr> <tr class=\"divider_bottom\"> <td>Antiphospholipid</td> <td>Antiphospholipid antibody positivity as determined by any of the following: Positive test result for lupus anticoagulant; false-positive test result for rapid plasma reagin; medium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM); or positive test result for anti-beta 2-glycoprotein I (IgA, IgG, or IgM)</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Low complement</td> <td>Low C3; low C4; <strong>OR </strong>low CH50</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Direct Coombs' test</td> <td>Direct Coombs' test in the absence of hemolytic anemia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACR: American College of Rheumatology; SLICC: Systemic Lupus International Collaborating Clinics; SLE: systemic lupus erythematosus; ECG: electrocardiogram; ANA: antinuclear antibodies; Anti-Sm: anti-Smith antibody; IgG: immunoglobulin G; IgM: immunoglobulin M; Anti-dsDNA: anti-double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A.<br />* For the ACR criteria, no distinction is made between clinical and immunologic criteria in determining whether the required number has been met. The classification is based upon 11 criteria. For the purpose of identifying patients in clinical studies, a person is said to have SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.<br />¶ For the SLICC criteria, criteria are cumulative and need not be presently concurrently. A patient is classified as having SLE if he or she satisfies four of the clinical and immunologic criteria used in the SLICC classification criteria, including at least one clinical criterion and one immunologic criterion.<br />Δ Alternatively, according to the SLICC criteria, a patient is classified as having SLE if he or she has biopsy-proven nephritis compatible with SLE in the presence of ANAs or anti-dsDNA antibodies.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.</LI>&#xD;&#xA;<LI>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40:1725.</LI>&#xD;&#xA;<LI>Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.</LI></OL></div><div id=\"graphicVersion\">Graphic 86633 Version 8.0</div></div></div>"},"86641":{"type":"graphic_picture","displayName":"Fixed drug eruption histo 1","title":"Histologic features of fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Histologic features of fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:584px; height:198px;\" src=\"images/DERM/86641_Fixed_drug_eruption_histo_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;A small number of lymphocytes adhering to the epidermis seen in the resting lesional skin (H &amp; E stain; ×66).<br />(B) Absence of lymphocytes in the epidermis of the adjacent uninvolved perilesional skin (H &amp; E stain; x66).</div><div class=\"graphic_reference\">Reproduced with permission from: Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201. Copyright &copy; 2007 John Libbey Eurotext. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86641 Version 3.0</div></div></div>"},"86642":{"type":"graphic_picture","displayName":"Fixed drug eruption histo 2","title":"Fixed drug eruption (FDE): Immunohistochemical staining of a resting lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption (FDE): Immunohistochemical staining of a resting lesion</div><div class=\"cntnt\"><img style=\"width:267px; height:514px;\" src=\"images/DERM/86642_Fix_drug_erup_hist_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraepidermal CD8+ T cells abundantly identified in a resting FDE lesion but are absent in nonlesional skin (immunoperoxidase stain).<br />(A) Nonlesional skin.<br />(B) Resting FDE lesion.<br />(C) Lesional skin.</div><div id=\"graphicVersion\">Graphic 86642 Version 4.0</div></div></div>"},"86643":{"type":"graphic_picture","displayName":"Fixed drug eruption histo 3","title":"Intraepidermal CD8+ T cells in fixed drug eruption (FDE)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Intraepidermal CD8+ T cells in fixed drug eruption (FDE)</div><div class=\"cntnt\"><img style=\"width:513px; height:351px;\" src=\"images/DERM/86643_Fix_drug_erupt_histo_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In situ activation of intraepidermal CD8+ T cells after clinical challenge with the causative drug (immunoperoxidase stain). Numerous intraepidermal CD8+ T cells are seen along the basal layer in the resting FDE lesion before challenge. Three hours after challenge, most of the CD8+ T cells are distributed in the lower half of the epidermis. At 24 hours, the density of CD8+ T cells declines because some undergo apoptosis at the site of extensive epidermal damage.<br />(A) Before.<br />(B) 3 hours.<br />(C) 24 hours.</div><div id=\"graphicVersion\">Graphic 86643 Version 4.0</div></div></div>"},"86644":{"type":"graphic_picture","displayName":"Fixed drug eruption before after","title":"Fixed drug eruption (FDE): Lesion reactivation upon challenge with the causative drug","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption (FDE): Lesion reactivation upon challenge with the causative drug</div><div class=\"cntnt\"><img style=\"width:596px; height:256px;\" src=\"images/DERM/86644_Fix_drug_erupt_before_after.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical resting hyperpigmented FDE lesions before and after clinical challenge with the causative drug: erythematous macules develop only in the pigmented lesions. The surrounding skin is unaffected.</div><div class=\"graphic_reference\">Reproduced with permission from: Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201. Copyright &copy; 2007 John Libbey Eurotext. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86644 Version 1.0</div></div></div>"},"86645":{"type":"graphic_picture","displayName":"Bullous fixed drug eruption","title":"Generalized bullous fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Generalized bullous fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86645_Bullfixeddrugerupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread red&nbsp;patches with overlying, large, flaccid bullae in a patient with generalized fixed drug eruption, an extremely rare clinical variant of FDE.</div><div class=\"graphic_footnotes\">FDE: fixed drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86645 Version 6.0</div></div></div>"},"86646":{"type":"graphic_figure","displayName":"Pleural fluid triglycerides in chylothorax","title":"Pleural fluid triglyceride values in chylothorax","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Pleural fluid triglyceride values in chylothorax</div><div class=\"cntnt\"><img style=\"width:573px; height:425px;\" src=\"images/PULM/86646_Pleural_fluid_trig_chyloth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleural fluid total triglyceride values in 74 patients with chylothorax. Boxes show interquartile ranges, and error bars represent highest and lowest values. The mean &plusmn; SD total triglyceride level was 728 &plusmn; 797 mg/dL (median, 483.5 mg/dL; interquartile range, 200 to 936 mg/dL). Individual data points are displaced horizontally to avoid overlap.</div><div class=\"graphic_footnotes\">SI conversion factor: To convert total triglyceride values to mmol/L, multiply by 0.0113.</div><div class=\"graphic_reference\">Reproduced from: Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009; 84:129. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86646 Version 2.0</div></div></div>"},"86649":{"type":"graphic_table","displayName":"PREMODA criteria","title":"PREsentation et MODe d’Accouchement (PREMODA) study criteria for selecting women at low risk with planned vaginal breech birth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PREsentation et MODe d’Accouchement (PREMODA) study criteria for selecting women at low risk with planned vaginal breech birth</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Normal pelvimetry by x-ray or computed tomography</td> </tr> <tr> <td>No hyperextension of the fetal head on ultrasound examination</td> </tr> <tr> <td>Estimated fetal weight 2500 to 3800 grams</td> </tr> <tr> <td>Frank breech presentation</td> </tr> <tr> <td>Continuous use of electronic fetal heart rate monitoring during labor</td> </tr> <tr> <td>Patient's written informed consent for vaginal breech birth</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Guideline (2000) of the Collège National des Gynécologues et Obstétriciens Français, available at&nbsp;<A href=\"http://www.cngof.fr/\">http://www.cngof.fr</A>.</div><div id=\"graphicVersion\">Graphic 86649 Version 3.0</div></div></div>"},"86650":{"type":"graphic_picture","displayName":"Erythema dyschromicum perstans","title":"Erythema dyschromicum perstans (ashy dermatosis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erythema dyschromicum perstans (ashy dermatosis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86650_Eryth_dyschromicum_perst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymptomatic gray/blue macules on the trunk and proximal extremities are characteristics of erythema dyschromicum perstans (ashy dermatosis), an acquired hypermelanosis of unknown etiology.</div><div class=\"graphic_reference\">Image created by Jeffrey Callen, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86650 Version 5.0</div></div></div>"},"86651":{"type":"graphic_picture","displayName":"Fixed drug eruption multiple","title":"Multiple (generalized) fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple (generalized) fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86651_Fixed_drug_erupt_multi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized fixed drug eruption is an uncommon variant characterized by multiple and disseminated brown macules or plaques involving the trunk and extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86651 Version 5.0</div></div></div>"},"86652":{"type":"graphic_table","displayName":"Clinical signs symptoms HAT","title":"Clinical signs and symptoms of human African trypanosomiasis in travelers and immigrants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical signs and symptoms of&nbsp;human African trypanosomiasis in travelers and immigrants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Travelers</td> <td class=\"subtitle1\">Immigrants</td> <td class=\"subtitle1\" rowspan=\"2\">Fisher test p-value</td> </tr> <tr> <td class=\"subtitle2\"> <p><em>T. b. rhodesiense</em></p> <p><span class=\"centered\">n = 42</span></p> Percent</td> <td class=\"subtitle2\"> <p><em>T. b. gambiense</em></p> <p>n = 14</p> Percent</td> <td class=\"subtitle2\"> <p><em>T. b. gambiense</em></p> <p>n = 14</p> Percent</td> </tr> <tr> <td><strong>Personality change</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">14.3</td> <td class=\"centered\">0.075</td> </tr> <tr> <td><strong>Hallucinations</strong></td> <td class=\"centered\">4.8</td> <td class=\"centered\">0</td> <td class=\"centered\">21.4</td> <td class=\"centered\">0.102</td> </tr> <tr> <td><strong>Depression</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">21.4</td> <td class=\"centered\">0.013</td> </tr> <tr> <td><strong>Tremor</strong></td> <td class=\"centered\">4.9</td> <td class=\"centered\">14.3</td> <td class=\"centered\">21.4</td> <td class=\"centered\">0.131</td> </tr> <tr> <td><strong>Abnormal reflexes</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">7.7</td> <td class=\"centered\">23.1</td> <td class=\"centered\">0.012</td> </tr> <tr> <td><strong>Reduced level of consciousness</strong></td> <td class=\"centered\">2.5</td> <td class=\"centered\">0</td> <td class=\"centered\">42.9</td> <td class=\"centered\">0.0001</td> </tr> <tr> <td><strong>Extrapyramidal symptoms</strong></td> <td class=\"centered\">2.5</td> <td class=\"centered\">0</td> <td class=\"centered\">14.3</td> <td class=\"centered\">0.202</td> </tr> <tr> <td><strong>Sensory deficit</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">7.7</td> <td class=\"centered\">14.3</td> <td class=\"centered\">0.064</td> </tr> <tr> <td><strong>Motor deficit</strong></td> <td class=\"centered\">0*</td> <td class=\"centered\">15.4*</td> <td class=\"centered\">64.3</td> <td class=\"centered\"> <p>0.001</p> 0.0115*</td> </tr> <tr> <td><strong>Daytime somnolence</strong></td> <td class=\"centered\">4.8</td> <td class=\"centered\">0</td> <td class=\"centered\">46.2</td> <td class=\"centered\">0.001</td> </tr> <tr> <td><strong>Nighttime insomnia</strong></td> <td class=\"centered\">7.1</td> <td class=\"centered\">21.4</td> <td class=\"centered\">0</td> <td class=\"centered\">0.168</td> </tr> <tr> <td><strong>Daytime somnolence and nighttime insomnia</strong></td> <td class=\"centered\">2.6</td> <td class=\"centered\">7.1</td> <td class=\"centered\">23.1</td> <td class=\"centered\">0.034</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Significant difference between <EM>Trypanosoma brucei gambiense </EM>and <EM>Trypanosoma brucei rhodesiense</EM> in travelers.</div><div class=\"graphic_reference\">Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright © 2011 Public Library of Science.</div><div id=\"graphicVersion\">Graphic 86652 Version 2.0</div></div></div>"},"86653":{"type":"graphic_figure","displayName":"HAT in endemic and nonendemic populations","title":"HAT in endemic and nonendemic populations (traveler)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">HAT in endemic and nonendemic populations (traveler)</div><div class=\"cntnt\"><img style=\"width:542px; height:572px;\" src=\"images/ID/86653_HAT_endemic_nonendemic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 14 patients, more than one country was estimated to be country of infection: Kenya or Tanzania: 7; Cameroon or Congo: 2; Nigeria or Gabon: 1; Zambia or Botswana: 1; Zambia, Zimbabwe, or Tanzania: 1; Namibia, Mozambique, or Malawi: 1; East Africa: 1 (these patients are not counted in the figure). The black line divides the endemic regions of <em>Trypanosoma brucei gambiense</em> and <em>Trypanosoma brucei rhodesiense</em> HAT.</div><div class=\"graphic_footnotes\">HAT: human African trypanosomiasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright &copy; 2011 Public Library of Science.</div><div id=\"graphicVersion\">Graphic 86653 Version 2.0</div></div></div>"},"86654":{"type":"graphic_table","displayName":"Laboratory parameters HAT","title":"Laboratory parameters of human African trypanosomiasis ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory parameters of human African trypanosomiasis </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Travelers</td> <td class=\"subtitle1\">Immigrants</td> <td class=\"subtitle1\" rowspan=\"2\">Fisher test p-value</td> </tr> <tr> <td class=\"subtitle2\"><em>Trypanosoma brucei&nbsp;rhodesiense</em></td> <td class=\"subtitle2\"><em>Trypanosoma brucei&nbsp;gambiense</em></td> <td class=\"subtitle2\"><em>Trypanosoma brucei&nbsp;gambiense</em></td> </tr> <tr> <td><strong>Elevated inflammatory parameter</strong>*</td> <td class=\"centered\">8/8 = 100 percent</td> <td class=\"centered\">8/9&nbsp;= 88.9 percent</td> <td class=\"centered\">6/6 = 100 percent</td> <td class=\"centered\">1.000</td> </tr> <tr> <td><strong>WBC &#60;3.5x10<sup>3</sup>/mm<sup>3</sup></strong></td> <td class=\"centered\">15/43 = 34.9 percent</td> <td class=\"centered\">3/7 = 42.9 percent</td> <td class=\"centered\">1/12 = 8.3 percent</td> <td class=\"centered\">0.164</td> </tr> <tr> <td><strong>WBC &#62;9.06x10<sup>3</sup>/mm<sup>3</sup> </strong></td> <td class=\"centered\">5/43 = 11.6 percent</td> <td class=\"centered\">2/7 = 28.6 percent</td> <td class=\"centered\">3/12 = 25 percent</td> <td class=\"centered\">0.289</td> </tr> <tr> <td><strong>Hb &#60;12 g/dL (female)&nbsp;and &#60;13.3 g/dL (male)</strong></td> <td class=\"centered\">18/34 = 52.9 percent</td> <td class=\"centered\">8/9 = 88.9 percent</td> <td class=\"centered\">11/11 = 100 percent</td> <td class=\"centered\"> <p>0.003</p> 0.0489</td> </tr> <tr> <td><strong>Platelets &#60;165 000/mm<sup>3</sup></strong></td> <td class=\"centered\">37/42 = 88.1 percent</td> <td class=\"centered\">3/5 = 60 percent</td> <td class=\"centered\">5/8 = 62.5 percent</td> <td class=\"centered\">0.082</td> </tr> <tr> <td><strong>Elevated liver enzymes<sup>&#182;</sup></strong></td> <td class=\"centered\">31/35 = 80.7 percent</td> <td class=\"centered\">1/3 = 33.3 percent</td> <td class=\"centered\">0/3 = 0 percent</td> <td class=\"centered\">0.005</td> </tr> <tr> <td><strong>Total bilirubin &#62;1.3 mg/dL</strong></td> <td class=\"centered\">17/22 = 77.3 percent</td> <td class=\"centered\">No data</td> <td class=\"centered\">0/2 = 0 percent</td> <td class=\"centered\">0.076</td> </tr> <tr> <td><strong>Creatinin &#62;0.9 mg/dL (female) and &#62;1.2 (male)</strong></td> <td class=\"centered\">24/29 = 82.8 percent</td> <td class=\"centered\">0/3 = 0 percent</td> <td class=\"centered\">0/4 = 0 percent</td> <td class=\"centered\"> <p>0.0016</p> 0.001</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal reference of value out of Harrison's Online (http://www.accessmedicine.com/popup.aspx?alD=2904606).</div><div class=\"graphic_footnotes\">WBC: white blood cell; Hb: hemoglobin.<br />* At least one of the following parameters was elevated: C-reactive protein (CRP) &gt;3.0 mg/L; erythrocyte sedimentation rate female &gt;20 mm/h, male &gt;15 mm/h.<br />¶&nbsp;At least one of the following parameters was elevated: alanin aminotransferase (SGOT, ALAT) &gt;7 to 41 U/I; aspartate aminotransferase (SGPT, ASAT) &gt;12 to 38 U/I; alkaline phosphatase (ALP) &gt;60 to 170 U/I.</div><div class=\"graphic_reference\">Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright © 2011 Public Library of Science.</div><div id=\"graphicVersion\">Graphic 86654 Version 3.0</div></div></div>"},"86655":{"type":"graphic_picture","displayName":"Emergency thoracotomy tray","title":"Emergency thoracotomy tray","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Emergency thoracotomy tray</div><div class=\"cntnt\"><img style=\"width:756px; height:562px;\" src=\"images/SURG/86655_Emergency_thoracotomy_tray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Long curved Mayo scissors<br />(B) Needle holder<br />(C) Sternal retractor<br />(D) Lebsche sternal chisel<br />(E) Coarctation clamp<br />(F) Angled aortic clamp<br />(G) Curved aortic clamp<br />(H) Long curved Metzenbaum scissors<br />(I) Mallet<br />(J) Rib cutter<br />(K) Scalpel holder<br />(L) Long tissue forceps</div><div id=\"graphicVersion\">Graphic 86655 Version 1.0</div></div></div>"},"86656":{"type":"graphic_table","displayName":"Instruments for emergency thoracotomy","title":"Instruments for emergency thoracotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instruments for emergency thoracotomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&nbsp;Sterile drapes and towels</td> </tr> <tr> <td>&nbsp;Scalpel holder and #10 or #20 blade</td> </tr> <tr> <td>&nbsp;Mayo scissors (curved)&nbsp;</td> </tr> <tr> <td>&nbsp;Trauma shears</td> </tr> <tr> <td>&nbsp;Rib spreader (Finochietto retractor)</td> </tr> <tr> <td>&nbsp;Long Metzenbaum scissors</td> </tr> <tr> <td>&nbsp;Gigli saw</td> </tr> <tr> <td>&nbsp;Lebsche knife</td> </tr> <tr> <td>&nbsp;Laparotomy sponges and gauze pads</td> </tr> <tr> <td>&nbsp;Long tissue forceps (smooth and toothed)</td> </tr> <tr> <td>&nbsp;Aortic cross clamp (Satinsky or Debakey aortic clamp)</td> </tr> <tr> <td>&nbsp;Teflon pledgets</td> </tr> <tr> <td>&nbsp;Needle holders (long and short)</td> </tr> <tr> <td>&nbsp;Suture scissors</td> </tr> <tr> <td>&nbsp;Suture material (prolene, silk)</td> </tr> <tr> <td>&nbsp;Assorted hemostats (curved and straight)</td> </tr> <tr> <td>&nbsp;Chest tube</td> </tr> <tr> <td>&nbsp;Balloon (Foley) catheter (5 cc balloon)</td> </tr> <tr> <td>&nbsp;Skin stapler</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86656 Version 1.0</div></div></div>"},"86658":{"type":"graphic_table","displayName":"Weekly fluorouracil plus leucovorin for colorectal cancer","title":"Weekly fluorouracil plus leucovorin for colorectal cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weekly fluorouracil plus leucovorin for colorectal cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 8 weeks.<br /> <strong>Duration of therapy:</strong> Maximum of 4 cycles (adjuvant setting). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Leucovorin*</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Dilute leucovorin with 250 mL 5% dextrose in water and administer over two hours.</td> <td>Days 1, 8, 15, 22, 29, 36</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Administer one hour after the start of the leucovorin infusion. Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as slow IV push over five minutes.</td> <td>Days 1, 8, 15, 22, 29, 36</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The exact incidence of febrile neutropenia is not reported with this regimen; however, only 4% of patients had grade 3 or 4 neutropenia. Primary prophylaxis with G-CSF is not routinely indicated but use should be individualized according to current guidelines.</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of fluorouracil may be needed for patients with liver impairment.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes, renal and liver function monthly during treatment.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias).</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold treatment for absolute neutrophil count &#60;1000 cells/microL or platelet count &#60;100,000/microL. In the original RPMI protocol (which used a higher dose of fluorouracil, 600 mg/m<sup>2</sup> per week),<sup>[2]</sup> the fluorouracil dose was decreased by 100 mg/m<sup>2</sup> if the WBC on the day of treatment was &#60;4000/microL or the platelet count was &#60;100,000/microL.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Prior to therapy, patients are required to have a serum creatinine of less than three times the upper limit of normal.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interruption of therapy and/or dose reduction of fluorouracil may be necessary for gastrointestinal toxicity. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, etc) provided as needed. For grade 2 or worse diarrhea, treatment should be withheld until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. In the original protocol,<sup>[2]</sup> the occurrence of grade 1 stomatitis, diarrhea, or vomiting prompted a decrease in the fluorouracil dose by 100 mg/m<sup>2</sup> for all future doses.</li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency.<sup>[3]</sup> Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol,<sup>[2]</sup> for grade 2 or higher skin rash, treatment was withheld until recovery.</li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; WBC: white blood count.<br />* Leucovorin dose is given for d,l-racemic mixture.<SUP>[4]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Haller DG, et al. J Clin Oncol 2005; 23:8671.</LI>&#xD;&#xA;<LI>Petrelli N, et al. J Clin Oncol 1989; 7:1419.</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed June 2, 2012).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 2, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86658 Version 7.0</div></div></div>"},"86660":{"type":"graphic_table","displayName":"Tolerable upper intake levels for vitamins","title":"Tolerable upper intake levels for vitamins: Dietary reference intakes (DRIs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tolerable upper intake levels for vitamins: Dietary reference intakes (DRIs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Life stage group</td> <td class=\"subtitle1\">Vitamin A <br /> (mcg/day)*<sup>&#182;</sup></td> <td class=\"subtitle1\">Vitamin C <br /> (mg/day)</td> <td class=\"subtitle1\">Vitamin D <br /> (mcg/day)<sup>&#916;</sup></td> <td class=\"subtitle1\">Vitamin E <br /> (mg/day)<sup>&#9674;</sup><sup>&#167;</sup></td> <td class=\"subtitle1\">Niacin <br /> (mg/day)<sup>&#167;</sup></td> <td class=\"subtitle1\">Vitamin B<sub>6</sub><br /> (mg/day)</td> <td class=\"subtitle1\">Folate <br /> (mcg/day)<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Males</td> </tr> <tr> <td class=\"indent1\">19 to 30 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"indent1\">31 to 50 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"indent1\">51 to 70 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;70 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Females</td> </tr> <tr> <td class=\"indent1\">19 to 30 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"indent1\">31 to 50 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"indent1\">51 to 70 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> <tr> <td class=\"indent1\">&#62;70 years</td> <td>3000</td> <td>2000</td> <td>100</td> <td>1000</td> <td>35</td> <td>100</td> <td>1000</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A tolerable upper intake level (UL) is the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects to almost all individuals in the general population. Unless otherwise specified, the UL represents total intake from food, water, and supplements.</div><div class=\"graphic_footnotes\">* As preformed vitamin A only.<br />&para; 1 mcg retinol = 3.33 IU retinol.<br />&Delta; 1 mcg = 40 IU.<br /><span class=\"lozenge\">&loz;</span> As alpha-tocopherol; applies to any form of supplemental alpha-tocopherol.<br />&sect; The tolerable upper intake levels for vitamin E, niacin, and folate apply to synthetic forms obtained from supplements, fortified foods, or a combination of the two.</div><div class=\"graphic_reference\">Data from: Otten JJ, Hellwig JP, Meyers LD (Eds). Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. The National Academies Press, Washington, 2006.</div><div id=\"graphicVersion\">Graphic 86660 Version 3.0</div></div></div>"},"86664":{"type":"graphic_algorithm","displayName":"Treatment of patients with carcinoma of unknown primary","title":"Treatment of patients with carcinoma of unknown primary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of patients with carcinoma of unknown primary</div><div class=\"cntnt\"><img style=\"width:380px; height:410px;\" src=\"images/ONC/86664_Trtmntcarcinmunknwnprmry.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Greco FA, Hainsworth JD. Cancer of Unknown Primary Site. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th Edition, DeVita VT, Lawrence TS, Rosenberg SA, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86664 Version 9.0</div></div></div>"},"86668":{"type":"graphic_picture","displayName":"Large duodenal ulcer","title":"Large duodenal ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large duodenal ulcer</div><div class=\"cntnt\"><img style=\"width:385px; height:394px;\" src=\"images/GAST/86668_Large_duodenal_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a relatively large and deep ulcer in the duodenum, without evidence of a visible vessel or active bleeding (a black spot in the base of the ulcer can be seen).</div><div id=\"graphicVersion\">Graphic 86668 Version 1.0</div></div></div>"},"86671":{"type":"graphic_picture","displayName":"Fixed drug eruption dark skin","title":"Fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86671_Fixeddrugeruptdark.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dark skin, fixed drug eruption presents as a dark brown/slate-gray patch.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86671 Version 5.0</div></div></div>"},"86672":{"type":"graphic_table","displayName":"Mixed additive challenge","title":"Mixed food additive challenge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mixed food additive challenge</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food additive</td> <td class=\"subtitle1\">Acceptable daily intake<br /> (mg/kg body weight)<sup>[1]</sup></td> <td class=\"subtitle1\">Dose per capsule</td> <td class=\"subtitle1\">Capsules administered in challenge</td> </tr> <tr> <td>1. Tartrazine (Yellow dye #5)</td> <td>0 to 0.75</td> <td>50 mg</td> <td>1 capsule</td> </tr> <tr> <td>2. Aspartame (NutraSweet)</td> <td>40</td> <td>50 mg</td> <td>1 capsule</td> </tr> <tr> <td>3. Potassium metabisulfite</td> <td>0 to 0.7</td> <td>100 mg</td> <td>1 capsule</td> </tr> <tr> <td>4. MSG (monosodium glutamate)</td> <td>Not specified</td> <td>500 mg</td> <td>5 capsules (2500 mg)</td> </tr> <tr> <td>5. Sodium benzoate</td> <td>0 to 5</td> <td>100 mg</td> <td>1 capsule</td> </tr> <tr> <td>6. Methylparaben</td> <td>0 to 10</td> <td>100 mg</td> <td>1 capsule</td> </tr> <tr> <td>7. BHA (butylated hydroxyanisole)</td> <td>0.5 to 2</td> <td>250 mg</td> <td>1 capsule</td> </tr> <tr> <td>8. BHT (butylated hydroxytoluene)</td> <td>0 to 0.5</td> <td>250 mg</td> <td>1 capsule</td> </tr> <tr> <td>9. Sunset yellow (Yellow dye #1)</td> <td>Approximately 8</td> <td>50 mg</td> <td>1 capsule</td> </tr> <tr> <td>10. Sodium nitrate</td> <td>0 to 5</td> <td>50 mg</td> <td>1 capsule</td> </tr> <tr> <td>11. Sodium nitrite</td> <td>0 to 0.4</td> <td>50 mg</td> <td>1 capsule</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics for a discussion of appropriate use of this challenge in assessing patients for allergic reactions to food additives.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Data gathered from reports of the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO).</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Ronald A Simon, MD.</div><div id=\"graphicVersion\">Graphic 86672 Version 5.0</div></div></div>"},"86673":{"type":"graphic_picture","displayName":"Fixed drug eruption patch testing","title":"Patch testing at the site of a fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Patch testing at the site of a fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:338px;\" src=\"images/DERM/86673_Fxd_drug_erupt_patch_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positive patch test reaction for the causative drug 10% in petrolatum. Note the positive reaction confined to the previously involved pigmented area.</div><div class=\"graphic_reference\">Reproduced with permission from: Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9:316. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86673 Version 4.0</div></div></div>"},"86674":{"type":"graphic_figure","displayName":"IT band PI","title":"Iliotibial band","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iliotibial band</div><div class=\"cntnt\"><img style=\"width:285px; height:602px;\" src=\"images/PI/86674_ITbandPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The iliotibial band runs down the outside of the thigh, from the hip bone to the top of the shinbone. It is sometimes called the \"IT band.\"</div><div id=\"graphicVersion\">Graphic 86674 Version 8.0</div></div></div>"},"86675":{"type":"graphic_table","displayName":"CKD Medicines PI","title":"Medicines for chronic kidney disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines for chronic kidney disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of medicine</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Sample US brand names</td> </tr> <tr> <td rowspan=\"2\">Angiotensin-converting enzyme inhibitors (ACE inhibitors)</td> <td>Enalapril</td> <td>Vasotec</td> </tr> <tr> <td>Lisinopril</td> <td>Zestril</td> </tr> <tr> <td rowspan=\"3\">Angiotensin receptor blockers (ARBs)</td> <td>Losartan</td> <td>Cozaar</td> </tr> <tr> <td>Candesartan</td> <td>Atacand</td> </tr> <tr> <td>Valsartan</td> <td>Diovan</td> </tr> <tr> <td>Diuretics</td> <td>Furosemide</td> <td>Lasix</td> </tr> <tr> <td>Other blood pressure medicines</td> <td>Calcium channel blockers (including diltiazem and verapamil)</td> <td> <p>Cardizem</p> Calan</td> </tr> <tr> <td rowspan=\"4\">Phosphate binders</td> <td>Calcium carbonate</td> <td>Many different brands and generics</td> </tr> <tr> <td>Calcium acetate</td> <td>PhosLo</td> </tr> <tr> <td>Sevelamer</td> <td>Renagel, Renvela</td> </tr> <tr> <td>Lanthanum</td> <td>Fosrenol</td> </tr> <tr> <td>Vitamin D</td> <td>Calcitriol</td> <td>Rocaltrol</td> </tr> <tr> <td rowspan=\"2\">Erythropoiesis-stimulating agents (ESAs) (These are given as shots, usually with dialysis)</td> <td>Erythropoietin</td> <td>Epogen, Procrit</td> </tr> <tr> <td>Darbepoetin alfa</td> <td>Aranesp</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86675 Version 2.0</div></div></div>"},"86677":{"type":"graphic_table","displayName":"Characteristics US postacute rehab settings","title":"Characteristics of US postacute care settings where rehabilitation may be provided","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of US postacute care settings where rehabilitation may be provided</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Rehabilitation site</td> <td class=\"subtitle1\">Medical coverage</td> <td class=\"subtitle1\">Therapy services</td> <td class=\"subtitle1\">Nursing</td> <td class=\"subtitle1\">Insurance</td> </tr> <tr> <td>Inpatient rehabilitation (acute)</td> <td>Clinician available 24 hours/day,&nbsp;seven days/week; active medical problem(s) requiring clinician supervision with visit five or more days/week</td> <td>PT, OT, and speech therapy available;&nbsp;patients must need two or more therapy services and must receive therapy three or more hours per day, five days per week. A multidisciplinary team conference is required within four days of admission and weekly thereafter.</td> <td>24-hour care</td> <td>Medicare Part A: days 1 to 20: 100 percent; days 21 to 100: 80 percent plus co-payment; &#62;100 days: no coverage</td> </tr> <tr> <td>Skilled nursing facility (subacute/transitional care unit)</td> <td>Clinician-supervised; clinician evaluation within two weeks of admission and every 30 days; clinician available in emergencies</td> <td>PT and OT available; typically one or more session per day</td> <td>24-hour care</td> <td>Same as inpatient rehabilitation</td> </tr> <tr> <td>Long-term acute care hospital</td> <td>Clinician available 24 hours/day; active/ongoing medical condition requiring clinician-level care (eg, ventilator-dependent) </td> <td>PT and OT available</td> <td>24-hour care</td> <td>Same as inpatient rehabilitation</td> </tr> <tr> <td>Home therapy/nursing</td> <td>Clinician referral and recertification every 60 days</td> <td>PT, OT, and speech therapy available</td> <td>Home health nursing</td> <td>Typically one to three visits per week by OT/PT for one to three weeks, one visit per week with RN, daily home health aid</td> </tr> <tr> <td>Outpatient (hospital or freestanding clinic)</td> <td>Clinician referral and recertification every 30 days </td> <td>PT, OT, and speech therapy available</td> <td>N/A</td> <td>May be limitations in number of visits per year</td> </tr> <tr> <td>Telehealth (may be utilized to/from any setting for care [eg, hospital, clinic, home], but without crossing state lines)</td> <td>Episodic and/or as needed. Referral parameters not defined.</td> <td>May be utilized for any non-invasive rehabilitation service (PT, OT, speech, rehabilitation medicine)</td> <td>N/A</td> <td>Variable, with coverage for use for rehabilitation in the Veterans Health Administration and Medicaid (most states), but not with Medicare or private insurance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OT: occupational therapy; PT: physical therapy; RN: registered nurse.</div><div class=\"graphic_reference\">Adapted from: Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine, 7th ed, Pacala JT, Sullivan GM (Eds), American Geriatrics Society, New York, 2010.</div><div id=\"graphicVersion\">Graphic 86677 Version 3.0</div></div></div>"},"86678":{"type":"graphic_table","displayName":"Heat or cold therapy contraindications","title":"Contraindications for heat and cold therapeutic modalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications for heat and cold therapeutic modalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Heat</td> <td class=\"subtitle1\">Cold</td> </tr> <tr> <td>Acute injury/trauma/hemorrhage</td> <td>Ischemia</td> </tr> <tr> <td>Insensate skin </td> <td>Insensate skin</td> </tr> <tr> <td>Ischemia</td> <td>Inability to communicate/respond to pain</td> </tr> <tr> <td>Edema</td> <td>Impaired thermal regulation</td> </tr> <tr> <td>Inability to communicate/respond to pain</td> <td>Raynaud phenomenon</td> </tr> <tr> <td>Impaired thermal regulation</td> <td rowspan=\"3\">Pronounced cold pressor response</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Cardiac disorders (eg, decompensated heart failure)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: DeLisa's Physcial Medicine and Rehabilitation: Principles and Practice, 5th edition, Frontera WR (Ed), Lippincott Williams &amp; Wilkins, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86678 Version 7.0</div></div></div>"},"86679":{"type":"graphic_table","displayName":"Heat and cold therapy indications","title":"Indications for heat and cold therapeutic modalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for heat and cold therapeutic modalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Heat</td> <td class=\"subtitle1\">Cold</td> </tr> <tr> <td>Analgesia</td> <td>Analgesia</td> </tr> <tr> <td>Muscle relaxation</td> <td>Muscle relaxation (eg, spasticity)</td> </tr> <tr> <td>Assist with connective tissue extensibility (ie, joint contracture, musculotendinous stretching)</td> <td>Edema/hemorrhage resolution (eg, initial 24 to 48 hours after acute musculoskeletal trauma)</td> </tr> <tr> <td>Hyperemia/acceleration of metabolic processes (eg, tenosynovitis, bursitis)</td> <td rowspan=\"2\">Reduction of metabolic processes</td> </tr> <tr> <td>Hematoma resolution</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: DeLisa's Physcial Medicine and Rehabilitation: Principles and Practice, 5th edition, Frontera WR (Ed), Lippincott Williams &amp; Wilkins, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 86679 Version 6.0</div></div></div>"},"86681":{"type":"graphic_picture","displayName":"Parapsoriasis dark skin","title":"Large plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/CALC/86681_Parapsoriasis_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread dark brown patches in a patient with large plaque parapsoriasis.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86681 Version 5.0</div></div></div>"},"86682":{"type":"graphic_picture","displayName":"Erythema multiforme-like FDE","title":"Fixed drug eruption resembling erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption resembling erythema multiforme</div><div class=\"cntnt\"><img style=\"width:540px; height:422px;\" src=\"images/DERM/86682_Erythema_multiform_like_FDE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A case of fixed drug eruption misdiagnosed as herpes-associated erythema multiforme. The lesions were reproduced by the administration of the suspected drug.</div><div id=\"graphicVersion\">Graphic 86682 Version 1.0</div></div></div>"},"86686":{"type":"graphic_picture","displayName":"Tinea capitis","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86686_Tineacapitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scaly plaque with associated hair loss is present on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86686 Version 4.0</div></div></div>"},"86687":{"type":"graphic_figure","displayName":"RHS classic arm position PI","title":"Arm position for Nursemaid's elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arm position for Nursemaid's elbow</div><div class=\"cntnt\"><img style=\"width:326px; height:401px;\" src=\"images/PI/86687_RHS_class_arm_position_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with nursemaid's elbow usually hold their injured arm close to their body. They keep their elbow straight or slightly bent, and their palm facing down.</div><div id=\"graphicVersion\">Graphic 86687 Version 1.0</div></div></div>"},"86688":{"type":"graphic_figure","displayName":"Nursemaids elbow PI","title":"Nursemaid’s elbow","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Nursemaid’s elbow</div><div class=\"cntnt\"><img style=\"width:515px; height:685px;\" src=\"images/PI/86688_Nursemaids_elbow_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nursemaid's elbow usually happens when someone pulls hard on a child's arm by the hand, wrist, or forearm when the child isn't expecting it. This might happen, for instance, when a child is about to fall (as shown in A). When the arm is pulled in this way, tissue moves between 2 of the bones of the elbow joint, called the radius and the humerus (as shown in B).</div><div id=\"graphicVersion\">Graphic 86688 Version 1.0</div></div></div>"},"86693":{"type":"graphic_picture","displayName":"Dorsal wrist external appearance","title":"Dorsal wrist external appearance","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Dorsal wrist external appearance</div><div class=\"cntnt\"><img style=\"width:503px; height:654px;\" src=\"images/EM/86693_Dorsal_wrist_external_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86693 Version 1.0</div></div></div>"},"86694":{"type":"graphic_picture","displayName":"Volar wrist external appearance","title":"Volar wrist external appearance","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Volar wrist external appearance</div><div class=\"cntnt\"><img style=\"width:511px; height:683px;\" src=\"images/EM/86694_Volar_wrist_external_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86694 Version 1.0</div></div></div>"},"86695":{"type":"graphic_algorithm","displayName":"Older adult multimorbidity eval and mgmt algo","title":"Approach to the evaluation and management of the older adult with multimorbidity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the evaluation and management of the older adult with multimorbidity</div><div class=\"cntnt\"><img style=\"width:401px; height:550px;\" src=\"images/PC/86695_Olderadultmultimorbeval.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc 2012. Reproduced with permission from the American Geriatrics Society. For more information, please visit <A href=\"http://www.americangeriatrics.org/\" target=_blank>www.americangeriatrics.org</A>.</div><div id=\"graphicVersion\">Graphic 86695 Version 5.0</div></div></div>"},"86696":{"type":"graphic_figure","displayName":"Anions - Cations and the anion gap","title":"Anions - Cations and the anion gap","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Anions - Cations and the anion gap</div><div class=\"cntnt\"><img style=\"width:536px; height:332px;\" src=\"images/NEPH/86696_Anions_Cations_anion_gap.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86696 Version 1.0</div></div></div>"},"86697":{"type":"graphic_figure","displayName":"Leptin pathway in hypertension development in obesity","title":"Leptin pathway in hypertension development in obesity","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Leptin pathway in hypertension development in obesity</div><div class=\"cntnt\"><img style=\"width:501px; height:623px;\" src=\"images/NEPH/86697_Leptin_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective leptin resistance helps explain how high levels of circulating leptin in obesity may contribute to hypertension and sympathetic overdrive despite resistance to metabolic effects of this hormone. Long-term renal sympathetic stimulation caused by high leptin levels could raise renal sympathetic tone, leading to hypertension, while loss of leptin's ability to decrease food intake and increase thermogenesis promotes obesity by increasing adiposity.</div><div id=\"graphicVersion\">Graphic 86697 Version 2.0</div></div></div>"},"86699":{"type":"graphic_picture","displayName":"Light micrograph showing fibronectin glomerulopathy","title":"Light micrograph showing fibronectin glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing fibronectin glomerulopathy</div><div class=\"cntnt\"><img style=\"width:370px; height:278px;\" src=\"images/NEPH/86699_Lght_micrgr_fibronec_glom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph (400x) of a glomerulus in a patient with fibronectin glomerulopathy.&nbsp;There is glomerular enlargement and minimal cellular proliferation, producing a&nbsp;lobular or clover-like appearance.</div><div id=\"graphicVersion\">Graphic 86699 Version 1.0</div></div></div>"},"86700":{"type":"graphic_picture","displayName":"Electron micrograph showing fibronectin glomerulopathy","title":"Electron micrograph showing fibronectin glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing fibronectin glomerulopathy</div><div class=\"cntnt\"><img style=\"width:371px; height:278px;\" src=\"images/NEPH/86700_Elecmicrgpfibronglom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron microscopy of a glomerulus in a patient with fibronectin glomerulopathy. There is mesangial expansion with nondescript, electron-dense material.</div><div id=\"graphicVersion\">Graphic 86700 Version 2.0</div></div></div>"},"86701":{"type":"graphic_picture","displayName":"Ulnar wrist external appearance","title":"Ulnar wrist external appearance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ulnar wrist external appearance</div><div class=\"cntnt\"><img style=\"width:504px; height:532px;\" src=\"images/EM/86701_Ulnar_wrist_external_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86701 Version 1.0</div></div></div>"},"86702":{"type":"graphic_picture","displayName":"Radial wrist external appearance","title":"Radial wrist external appearance","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Radial wrist external appearance</div><div class=\"cntnt\"><img style=\"width:505px; height:591px;\" src=\"images/EM/86702_Radial_wrist_external_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86702 Version 1.0</div></div></div>"},"86703":{"type":"graphic_picture","displayName":"Wrist flexion","title":"Wrist flexion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Wrist flexion</div><div class=\"cntnt\"><img style=\"width:504px; height:318px;\" src=\"images/EM/86703_Wrist_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86703 Version 1.0</div></div></div>"},"86704":{"type":"graphic_picture","displayName":"Wrist extension","title":"Wrist extension","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Wrist extension</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/EM/86704_Wrist_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86704 Version 2.0</div></div></div>"},"86705":{"type":"graphic_picture","displayName":"Wrist radial deviation","title":"Wrist radial deviation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist radial deviation</div><div class=\"cntnt\"><img style=\"width:417px; height:375px;\" src=\"images/EM/86705_Wrist_radial_deviation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86705 Version 2.0</div></div></div>"},"86706":{"type":"graphic_picture","displayName":"Wrist ulnar deviation","title":"Wrist ulnar deviation","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Wrist ulnar deviation</div><div class=\"cntnt\"><img style=\"width:468px; height:384px;\" src=\"images/EM/86706_Wrist_ulnar_deviation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86706 Version 2.0</div></div></div>"},"86707":{"type":"graphic_picture","displayName":"Intersection syndrome location","title":"Intersection syndrome location","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intersection syndrome location</div><div class=\"cntnt\"><img style=\"width:335px; height:504px;\" src=\"images/EM/86707_Intersec_syndrome_locat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intersection syndrome affects the dorsum of the forearm a few centimeters proximal to the wrist joint at the intersection of the muscle bellies of the abductor pollicis longus and extensor pollicis brevis, where they cross over the extensor carpi radialis longus and the extensor carpi radialis brevis tendons.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86707 Version 2.0</div></div></div>"},"86708":{"type":"graphic_picture","displayName":"de Quervain tenosynovitis location","title":"de Quervain tenosynovitis location","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">de Quervain tenosynovitis location</div><div class=\"cntnt\"><img style=\"width:312px; height:504px;\" src=\"images/EM/86708_de_Quervain_tenosyn_loc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">De Quervain's tenosynovitis refers to entrapment tendonitis or tenosynovitis of the abductor pollicis longus and extensor pollicis brevis tendons at the styloid process of the radius.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86708 Version 2.0</div></div></div>"},"86709":{"type":"graphic_figure","displayName":"Hamilton-Norwood scale for male androgenetic alopecia","title":"Hamilton-Norwood scale for male androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Hamilton-Norwood scale for male androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:531px; height:711px;\" src=\"images/DERM/86709_Male_androgenetic_alopecia.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86709 Version 3.0</div></div></div>"},"86710":{"type":"graphic_picture","displayName":"Treatment of skin laxity with an infrared device","title":"Treatment of skin laxity with an infrared device","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Treatment of skin laxity with an infrared device</div><div class=\"cntnt\"><img style=\"width:476px; height:656px;\" src=\"images/DERM/86710_Tx_skin_laxity_infrared_dev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical photographs of a 54-year-old woman with lower facial skin laxity prior to (A) and&nbsp;six months following (B) three monthly treatments with broad band infrared light (Titan, Cutera). These photographs demonstrate an average expected outcome from nonablative skin tightening treatment, with a modest reduction in melolabial folds and jowls observed.</div><div id=\"graphicVersion\">Graphic 86710 Version 1.0</div></div></div>"},"86711":{"type":"graphic_picture","displayName":"Treatment of lentigines with intense pulsed light","title":"Treatment of lentigines with intense pulsed light","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Treatment of lentigines with intense pulsed light</div><div class=\"cntnt\"><img style=\"width:584px; height:295px;\" src=\"images/DERM/86711_Tx_lentigin_inten_pul_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial lentigines (A) improved after treatment with intense pulsed light (B).</div><div id=\"graphicVersion\">Graphic 86711 Version 1.0</div></div></div>"},"86731":{"type":"graphic_picture","displayName":"Pterygium PI","title":"Pterygium ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pterygium </div><div class=\"cntnt\"><img style=\"width:402px; height:255px;\" src=\"images/PI/86731_Pterygium_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pterygium is a triangle-shaped area of tissue that grows from the corner of the eye towards the center.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 86731 Version 1.0</div></div></div>"},"86736":{"type":"graphic_table","displayName":"Treatment of filarial coinfection","title":"Approach to treatment of a patient with lymphatic filariasis, onchocerciasis, and/or loiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to treatment of a patient with lymphatic filariasis, onchocerciasis, and/or loiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"5%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lymphatic filariasis</td> <td class=\"subtitle1\">Onchocerciasis</td> <td class=\"subtitle1\">Loiasis</td> <td class=\"subtitle1\">Treatment of choice</td> <td class=\"subtitle1\">Alternative treatments</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td>DEC (6 mg/kg for 12 days)*</td> <td> <ol> <li>IVM (200 mcg/kg) + ALB (400 mg) </li> <li>IVM (200 mcg/kg) + DEC (6 mg/kg) </li> <li>ALB (200 mg&nbsp;twice daily&nbsp;for 21 days) </li> <li>DOXY (200 mg daily for six weeks) </li> </ol> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td>IVM (150 mcg/kg every 6 to 12 months)</td> <td>IVM (150 mcg/kg) + DOXY (200 mg daily for six weeks)</td> <td>DEC can cause severe post-treatment reactions and exacerbate ocular disease</td> </tr> <tr> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td> <p>Low microfilariae: DEC (8 mg/kg/day for 21 days)</p> High microfilariae: apheresis or ALB (200 mg&nbsp;twice daily&nbsp;for 21 days) to lower&nbsp;microfilariae count prior to DEC</td> <td>ALB (200 mg&nbsp;twice daily&nbsp;for 21 days)<sup>&#182;</sup></td> <td>DEC and IVM can provoke serious side effects in patients with high&nbsp;microfilariae counts</td> </tr> <tr> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td>IVM (150 mcg/kg) followed by DEC (6 mg/kg for 12 days)</td> <td> <ol> <li>IVM (200 mcg/kg) + ALB (400 mg) </li> <li>IVM + ALB (200 mg&nbsp;twice daily&nbsp;for 21 days) </li> <li>IVM + DOXY (200 mg daily for six weeks) </li> </ol> </td> <td>Pretreatment with IVM to clear <em>Onchocerca</em>&nbsp;microfilariae is necessary prior to administration of DEC for LF</td> </tr> <tr> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td>Same as <em>Loa</em> alone</td> <td>Same as <em>Loa</em> alone</td> <td>Same as <em>Loa</em> alone</td> </tr> <tr> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td> <p>Low microfilariae: IVM (150 mcg/kg) followed by DEC (8 mg/kg for 21 days)</p> High microfilariae: apheresis to lower&nbsp;microfilariae prior to IVM followed by DEC (as for low microfilariae)</td> <td>IVM (150 mcg/kg) + ALB (200 mg&nbsp;twice daily&nbsp;for 21 days) </td> <td>Due to the slow effect of ALB on <em>Loa</em> microfilariae, ALB should only be used as an alternative to apheresis to lower <em>Loa</em>&nbsp;microfilariae if there is no evidence of onchocercal eye involvement</td> </tr> <tr> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td>Same as <em>Onchocerca</em> + <em>Loa</em></td> <td>Same as <em>Onchocerca</em> + <em>Loa</em></td> <td>Same as <em>Onchocerca</em> + <em>Loa</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DEC: diethylcarbamazine; IVM: ivermectin; ALB: albendazole; DOXY: doxycycline.<br />* A longer course (14 to 21 days) is recommended for tropical pulmonary eosinophilia.<br />¶&nbsp;This regimen has only been demonstrated to be effective in DEC-refractory disease.</div><div id=\"graphicVersion\">Graphic 86736 Version 1.0</div></div></div>"},"86743":{"type":"graphic_table","displayName":"DRSP form","title":"Daily record of severity of problems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Daily record of severity of problems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"68%\"></colgroup><colgroup span=\"32\" width=\"1%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"33\">Please print and use as many sheets as you need for at least two FULL months of ratings.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Name or initials:</td> <td class=\"subtitle2_left\" colspan=\"16\">Month/year:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"33\">Each evening note the degree to which you experienced each of the problems listed below. Put an \"x\" in the box which corresponds to the severity:<br /> 1 - not at all, 2 - minimal, 3 - mild, 4 - moderate, 5 - severe, 6 - extreme.</td> </tr> <tr> <td style=\"text-align: right;\" colspan=\"2\">Enter day (Monday = \"M\", Thursday = \"R\", etc) &#62;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style=\"text-align: right;\" colspan=\"2\">Note spotting by entering \"S\" &#62;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style=\"text-align: right;\" colspan=\"2\">Note menses by entering \"M\" &#62;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style=\"text-align: right;\" colspan=\"2\">Begin rating on correct calendar day &#62;</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>6</td> <td>7</td> <td>8</td> <td>9</td> <td>10</td> <td>11</td> <td>12</td> <td>13</td> <td>14</td> <td>15</td> <td>16</td> <td>17</td> <td>18</td> <td>19</td> <td>20</td> <td>21</td> <td>22</td> <td>23</td> <td>24</td> <td>25</td> <td>26</td> <td>27</td> <td>28</td> <td>29</td> <td>30</td> <td>31</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>1.</strong> Felt depressed, sad, \"down\", or \"blue\" or felt hopeless; or felt worthless or guilty</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>2.</strong> Felt anxious, tense, \"keyed up\" or \"on edge\"</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>3.</strong> Had mood swings (ie, suddenly feeling sad or tearful) or was sensitive to rejection or feelings were easily hurt</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>4.</strong> Felt angry, or irritable</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>5.</strong> Had less interest in usual activities (work, school, friends, hobbies)</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>6.</strong> Had difficulty concentrating</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>7.</strong> Felt lethargic, tired, or fatigued; or had lack of energy</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>8.</strong> Had increased appetite or overate; or had cravings for specific foods</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>9.</strong> Slept more, took naps, found it hard to get up when intended; or had trouble getting to sleep or staying asleep</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>10.</strong> Felt overwhelmed or unable to cope; or felt out of control</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>11.</strong> Had breast tenderness, breast swelling, bloated sensation, weight gain, headache, joint or muscle pain, or other physical symptoms</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">At work, school, home, or in daily routine, at least one of the problems noted above caused reduction of productivity or inefficiency</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">At least one of the problems noted above caused avoidance of or less participation in hobbies or social activities</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">At least one of the problems noted above interfered with relationships with others</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright © 1997 Jean Endicott, Ph.D. and Wilma Harrison, M.D. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 86743 Version 2.0</div></div></div>"},"86745":{"type":"graphic_picture","displayName":"Skin popping in substance abuse","title":"\"Skin popping\" in substance abuse","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">\"Skin popping\" in substance abuse</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/EM/86745_Excoriations_neurotic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repeated subcutaneous or intramuscular injection by drug abusers can lead to chronic skin lesions, including abscesses and scarring, as seen in the photograph above.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86745 Version 3.0</div></div></div>"},"86746":{"type":"graphic_picture","displayName":"Skin excoriations in chronic methamphetamine abuse","title":"Skin excoriations in chronic methamphetamine abuse","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Skin excoriations in chronic methamphetamine abuse</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/EM/86746_Neurotic_excoriations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Many chronic methamphetamine abusers suffer multiple small skin excoriations from unremitting picking, as seen in the photograph above.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86746 Version 4.0</div></div></div>"},"86748":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis histopathology","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:540px; height:407px;\" src=\"images/DERM/86748_Dermatit_herpetiform_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subepidermal blistering, neutrophilic microabscesses, and a perivascular inflammatory infiltrate are present.</div><div class=\"graphic_reference\">Courtesy of Scott Florell, MD, Department of Dermatology, University of Utah.</div><div id=\"graphicVersion\">Graphic 86748 Version 2.0</div></div></div>"},"86749":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis knee","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/86749_Dermatit_herpetiformis_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and vesicles are present on the knee.</div><div id=\"graphicVersion\">Graphic 86749 Version 1.0</div></div></div>"},"86750":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis buttocks","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:381px;\" src=\"images/DERM/86750_Dermatit_herpet_buttocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriated, erythematous papules are present on the buttocks.</div><div id=\"graphicVersion\">Graphic 86750 Version 2.0</div></div></div>"},"86751":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis knees","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/DERM/86751_Dermatit_herpetiform_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and vesicles are present on the knees.</div><div id=\"graphicVersion\">Graphic 86751 Version 2.0</div></div></div>"},"86752":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis vesicles on elbow","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:438px;\" src=\"images/DERM/86752_Derm_herpetif_ves_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A few vesicles are present near the elbow.</div><div id=\"graphicVersion\">Graphic 86752 Version 1.0</div></div></div>"},"86753":{"type":"graphic_picture","displayName":"Hamate palpation","title":"Hamate palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hamate palpation</div><div class=\"cntnt\"><img style=\"width:340px; height:584px;\" src=\"images/EM/86753_Hamate_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hook of the hamate is easily fractured and should be evaluated in patients with volar wrist pain, particularly in the area of the hypothenar eminence. It is palpated by placing the interphalangeal joint of the examiner's thumb over the pisiform and rolling the thumb toward the space between the index and middle fingers.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86753 Version 2.0</div></div></div>"},"86754":{"type":"graphic_picture","displayName":"Combined Phalen wrist compression test","title":"Combined Phalen and compression test of the wrist","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Combined Phalen and compression test of the wrist</div><div class=\"cntnt\"><img style=\"width:571px; height:380px;\" src=\"images/EM/86754_Com_Phalen_wrist_compr_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combining the Phalen and compression tests is another way to look for signs of carpal tunnel syndrome. The test is performed by holding the patients wrist in flexion while applying direct pressure over the patient’s median nerve.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86754 Version 1.0</div></div></div>"},"86755":{"type":"graphic_picture","displayName":"Triangular fibrocartilage complex loading","title":"Loading the triangular fibrocartilage complex","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Loading the triangular fibrocartilage complex</div><div class=\"cntnt\"><img style=\"width:573px; height:380px;\" src=\"images/EM/86755_Triang_fibrocart_compl_load.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A clinician can provoke&nbsp;signs of a triangular fibrocartilage complex injury by&nbsp;holding the forearm and loading the wrist (ie, compressing the joint with an axial load) while it is&nbsp;kept in a position of ulnar deviation and extension.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86755 Version 2.0</div></div></div>"},"86756":{"type":"graphic_picture","displayName":"Piano key test for distal radioulnar joint stability","title":"Piano key test for distal radioulnar joint stability","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Piano key test for distal radioulnar joint stability</div><div class=\"cntnt\"><img style=\"width:572px; height:380px;\" src=\"images/EM/86756_Piano_key_test_joint_stabil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The piano key sign tests the stability of the distal radioulnar joint. With the patient’s elbow flexed and their forearm pronated, the examiner grasps the ulnar head between their index finger and thumb, and the distal radius with their opposite index finger and thumb, and then pushes the distal ulna in a dorsal and ventral direction</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 86756 Version 1.0</div></div></div>"},"86757":{"type":"graphic_picture","displayName":"Epidermolysis bullosa acquisita histopathology","title":"Epidermolysis bullosa acquisita","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa acquisita</div><div class=\"cntnt\"><img style=\"width:504px; height:331px;\" src=\"images/DERM/86757_Epider_bull_histopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pauci-inflammatory subepidermal blister, dermal fibroplasia, and milium formation are present.</div><div id=\"graphicVersion\">Graphic 86757 Version 1.0</div></div></div>"},"86759":{"type":"graphic_diagnosticimage","displayName":"Vagal paraganglioma","title":"MRI, CT scan, and octreotide scan of a vagal paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">MRI, CT scan, and octreotide scan of a vagal paraganglioma</div><div class=\"cntnt\"><img style=\"width:583px; height:429px;\" src=\"images/RADIOL/86759_Vagal_paraganglioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images demonstrate a left sided vagal paraganglioma that extends from the posterior fossa through the jugular foramen into the neck. The T1-weighted post-gadolinium MRI scans (images A, B, and C) show an intensely enhancing mass in the posterior fossa (arrow, A), extending through the jugular foramen (arrow, B), and into the neck (arrow, C) where the dark flow voids reflect blood vessels within the tumor. Image D is a sagittal reconstruction of a contrast-enhanced CT scan showing the extent of the tumor and the intimate relationship with the great vessels (arrows). Erosion of the bone in the region of the jugular foramen is shown (arrow, E) on the bone windows. The affinity of the paraganglioma for octreotide is shown by radionuclide imaging with 111-indium pentetreotide (image F).</div><div id=\"graphicVersion\">Graphic 86759 Version 1.0</div></div></div>"},"86760":{"type":"graphic_table","displayName":"Drugs associated with DRESS","title":"Drugs associated with drug reaction with eosinophilia and systemic symptoms (DRESS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with drug reaction with eosinophilia and systemic symptoms (DRESS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Frequently reported</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Lamotrigine</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Vancomycin</td> </tr> <tr> <td>Minocycline</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Sulfamethoxazole</td> </tr> <tr> <td class=\"subtitle1_single\">Also reported</td> </tr> <tr> <td>Phenindione</td> </tr> <tr> <td>Fluindione</td> </tr> <tr> <td>Beta-lactam antibiotics</td> </tr> <tr> <td>Nevirapine</td> </tr> <tr> <td>Olanzapine</td> </tr> <tr> <td>Oxcarbazepine</td> </tr> <tr> <td>Strontium ranelate</td> </tr> <tr> <td>Telaprevir</td> </tr> <tr> <td>Lenalidomide&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86760 Version 7.0</div></div></div>"},"86761":{"type":"graphic_table","displayName":"DRESS scoring system","title":"Scoring system for classifying drug reactions with eosinophilia and systemic symptoms (DRESS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scoring system for classifying drug reactions with eosinophilia and systemic symptoms (DRESS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Item</td> <td class=\"subtitle1\" colspan=\"2\">Present</td> <td class=\"subtitle1\">Absent</td> </tr> <tr> <td colspan=\"2\">Fever &#8805;38.5&#176;C (101.3&#176;F)</td> <td class=\"centered\" colspan=\"2\">0</td> <td class=\"centered\">&minus;1</td> </tr> <tr> <td colspan=\"2\">Enlarged lymph nodes (&#62;1 cm size, at least two sites)</td> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">0</td> </tr> <tr> <td>Eosinophilia: &#8805;700 or &#8805;10 percent (leucopenia)</td> <td>&#8805;1500 or &#8805;20 percent (leucopenia)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Atypical lymphocytes</td> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Rash &#8805;50 percent of body surface area</td> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Rash suggestive (&#8805;2 of facial edema, purpura, infiltration, desquamation)</td> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Skin biopsy suggesting alternative diagnosis</td> <td class=\"centered\" colspan=\"2\">&minus;1</td> <td class=\"centered\">0</td> </tr> <tr> <td>Organ involvement: one</td> <td>two or more</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Disease duration &#62;15 days</td> <td class=\"centered\" colspan=\"2\">0</td> <td class=\"centered\">&minus;2</td> </tr> <tr> <td colspan=\"2\">Investigation for alternative cause (blood cultures, ANA, serology for Hepatitis viruses, mycoplasma, Chlamydia) &#8805;3 done and negative</td> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total score &lt;2: excluded; 2-3: possible; 4-5: probable; &ge;6: definite.</div><div class=\"graphic_reference\">Adapted from: Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609.</div><div id=\"graphicVersion\">Graphic 86761 Version 5.0</div></div></div>"},"86762":{"type":"graphic_table","displayName":"DRESS lab tests and imaging","title":"Recommended laboratory and imaging investigations in patients with suspected drug reaction with eosinophilia and systemic symptoms (DRESS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended laboratory and imaging investigations in patients with suspected drug reaction with eosinophilia and systemic symptoms (DRESS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Confirmation of diagnosis</td> <td class=\"subtitle1\">Exclusion of alternative diagnosis</td> <td class=\"subtitle1\">Assessment of organ involvement</td> </tr> <tr> <td rowspan=\"2\"> <p>CBC with differential including research of atypical lymphocytes</p> <p>Inflammation markers</p> Viral infection (PCR for HHV-6, HHV-7, CMV, EBV)</td> <td rowspan=\"2\"> <p>Blood cultures</p> <p>Antinuclear antibodies</p> <p><em>Serology for viral hepatitis</em></p> <em>Lymph node biopsy</em></td> <td> <p><strong>Minimal screening</strong></p> Liver function test, creatinine, urinary protein and cells, pulse oximetry, creatine kinase, troponin, ECG</td> </tr> <tr> <td> <p><strong>Additional investigations</strong></p> <p>Prothrombin time/INR</p> <p><em>CT scan</em></p> <p><em>Sonography</em></p> <p><em>Endoscopy</em></p> <em>Biopsy</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In italics: secondary investigations based upon suspected organ involvement.</div><div id=\"graphicVersion\">Graphic 86762 Version 4.0</div></div></div>"},"86763":{"type":"graphic_picture","displayName":"DRESS rash 1","title":"Drug reaction with eosinophilia and systemic symptoms (DRESS)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/86763_Dress_rash_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent morbilliform skin eruption with follicular accentuation in a patient with DRESS.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86763 Version 6.0</div></div></div>"},"86765":{"type":"graphic_figure","displayName":"Crystal structure of the abacavir MHC peptide complex","title":"Crystal structure of the abacavir–MHC–peptide complex solved to a resolution limit of 2.0","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Crystal structure of the abacavir–MHC–peptide complex solved to a resolution limit of 2.0</div><div class=\"cntnt\"><img style=\"width:603px; height:265px;\" src=\"images/ID/86765_Crys_strc_abcv_MHC_ptd_cplx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diagram of HLA-B*57:01 in gray. The peptide HSITYLLPV is shown in cyan carbons. Abacavir is shown as spheres: orange for carbon, blue for nitrogen and red for oxygen. (B) Drug binding influences the peptide backbone conformation by shifting the main chain. Peptide bound to abacavir and HLA-B*57:01 is shown in cyan. Peptide bound in the absence of abacavir is shown in yellow.</div><div class=\"graphic_reference\">Reproduced with permission from: Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; 109:9959. Copyright &copy; 2012 National Academy of Sciences. All rights reserved.</div><div id=\"graphicVersion\">Graphic 86765 Version 1.0</div></div></div>"},"86767":{"type":"graphic_picture","displayName":"Active shoulder abduction against resistance","title":"Active shoulder abduction against resistance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active shoulder abduction against resistance</div><div class=\"cntnt\"><img style=\"width:324px; height:553px;\" src=\"images/EM/86767_Act_shoulder_abduct_resist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold a dumbbell using a \"full can\" position. Then, over a 2 second count, gradually lift your arms in the plane of the scapula, keeping the elbows straight, until your arms are parallel to the ground. Hold for a second, and then slowly lower your arms to the starting position over a 4 second count.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86767 Version 1.0</div></div></div>"},"86768":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis papules and vesicles","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:345px; height:504px;\" src=\"images/DERM/86768_Dermat_herpe_pap_vesicle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory papules and vesicles are present near the elbow.</div><div class=\"graphic_reference\">Courtesy of Scott Florell, MD, Department of Dermatology, University of Utah.</div><div id=\"graphicVersion\">Graphic 86768 Version 2.0</div></div></div>"},"86769":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis excoriated papules","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:332px; height:504px;\" src=\"images/DERM/86769_Dermit_herpe_excort_pap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriated papules and crusts are present near the elbow.</div><div id=\"graphicVersion\">Graphic 86769 Version 2.0</div></div></div>"},"86772":{"type":"graphic_picture","displayName":"Exserohilum rostratum","title":"<em>Exserohilum rostratum</em>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><em>Exserohilum rostratum</em></div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/86772_Exserohilum_rostratum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The genus is characterized by its conidia, which are ellipsoidal, distoseptate, and have a protruding and truncate hilum. <EM>Exserohilum</EM> spores have an inner cup-like structure, which is visible in the basal cell.<SUP>[1]</SUP> Colonies are grey to blackish-brown, suede-like to floccose in texture, and have an olivaceous black reverse. Conidia are straight, curved or slightly bent, ellipsoidal to fusiform, and are formed apically through a pore (poroconidia) on a sympodially elongating geniculate conidiophore. Conidia have a strongly protruding, truncate hilum and the septum above the hilum is usually thickened and dark. The end cells are often paler than the other cells and the walls are often finely roughened. Conidial germination is bipolar.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>American Air Testing, Inc. Available at: <A href=\"http://www.americanairtesting.com/\">http://www.americanairtesting.com/</A>&nbsp;(Accessed October 22, 2012).</LI>&#xD;&#xA;<LI>Mycology online. Exserohilum. The University of Adelaide. Available at:&nbsp;<A href=\"http://www.mycology.adelaide.edu.au/descriptions/hyphomycetes/exserohilum/\">http://www.mycology.adelaide.edu.au/descriptions/hyphomycetes/exserohilum/</A> (Accessed March 1, 2017).</LI></OL>Reproduced from: United States Centers for Disease Control and Prevention. Multistate Meningitis Outbreak Investigation. Additional information available at: <A style=\"FONT-STYLE: italic\" href=\"http://www.cdc.gov/HAI/outbreaks/meningitis.html\" target=_blank>http://www.cdc.gov/HAI/outbreaks/meningitis.html</A> (Accessed October 22, 2012).</div><div id=\"graphicVersion\">Graphic 86772 Version 7.0</div></div></div>"},"86773":{"type":"graphic_picture","displayName":"Intraoperative duplex renal system and ectopic ureter","title":"Duplex renal system with upper pole obstructed ectopic ureter ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Duplex renal system with upper pole obstructed ectopic ureter </div><div class=\"cntnt\"><img style=\"width:504px; height:435px;\" src=\"images/PEDS/86773_Intraop_dup_ren_ect_ur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative image of duplex renal system with upper pole obstructed ectopic ureter (black arrows). The dilated upper pole ureter is ~6 times the normal size compared to normal lower pole ureter (white arrowheads). Note the course of the ectopic ureter is underneath the normal lower pole ureter. It is&nbsp;headed to an ectopic location past the bladder, which is mostly covered by the metal retractor blade.</div><div id=\"graphicVersion\">Graphic 86773 Version 1.0</div></div></div>"},"86774":{"type":"graphic_table","displayName":"Medical therapy of active ulcerative colitis","title":"Medical therapy of active ulcerative colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical therapy of active ulcerative colitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Role</td> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Trade name (United States or as noted)</td> <td class=\"subtitle1\">Daily dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"26\">Induction of remission</td> <td class=\"subtitle2_left\" colspan=\"3\">Topical (rectal) mesalamine*</td> </tr> <tr> <td class=\"indent1\">Suppository</td> <td>Canasa</td> <td>1 gram (one suppository) twice daily</td> </tr> <tr> <td class=\"indent1\">Retention enema</td> <td>Rowasa</td> <td>4 grams (one 60 mL unit) twice daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical (rectal) glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Hydrocortisone suppository</td> <td>Proctocort, Hemril</td> <td>30 mg (one suppository) twice daily</td> </tr> <tr> <td class=\"indent1\">Hydrocortisone aerosol foam 10 percent</td> <td>Cortifoam</td> <td>90 mg (one applicatorful) twice daily</td> </tr> <tr> <td class=\"indent1\">Hydrocortisone enema</td> <td>Cortenema, Colocort</td> <td>100 mg (one 60 mL unit) twice daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral 5-aminosalycylic acid (5-ASA) derivatives</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> <td>Azulfidine, Salazopyrin<sup>&#182;</sup></td> <td>4 to 6 grams per day in four divided doses</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Mesalamine*</td> </tr> <tr> <td class=\"indent2\">Delayed release enteric coated tablet</td> <td>Asacol<sup>&#182;</sup>, Asacol HD</td> <td>2.4 to 4.8 grams daily in three divided doses</td> </tr> <tr> <td class=\"indent2\">Capsule containing delayed release enteric coated tablet</td> <td>Delzicol</td> <td>2.4 to 4.8 grams daily in three divided doses</td> </tr> <tr> <td class=\"indent2\">Delayed and extended release tablet, multimatrix (MMX)</td> <td>Lialda, Mezavant<sup>&#182;</sup></td> <td>2.4 to 4.8 grams daily once daily</td> </tr> <tr> <td class=\"indent2\">Capsule containing delayed release enteric coated granules</td> <td>Apriso</td> <td>1.5 to 4.5 grams once each morning</td> </tr> <tr> <td class=\"indent2\">Controlled release capsule</td> <td>Pentasa</td> <td>2 to 4 grams daily in four divided doses</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Mesalamine pellets</td> <td>Salofalk<sup>&#182;</sup></td> <td>1.5 to 4 grams daily in one to three divided doses</td> </tr> <tr> <td>Pentasa sachet<sup>&#182;</sup></td> <td>2 to 4 grams daily in two to four divided doses</td> </tr> <tr> <td class=\"indent1\">Olsalazine capsule</td> <td>Dipentum</td> <td>2 to 3 grams daily in two to four divided doses</td> </tr> <tr> <td class=\"indent1\">Balsalazide capsule</td> <td>Colazal</td> <td>2.25 to 6.75 grams daily in three divided doses</td> </tr> <tr> <td class=\"indent1\">Balsalazide tablet</td> <td>Giazo</td> <td>2.2 to 6.6 grams daily in two divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Budesonide delayed and extended release tablet, multimatrix (MMX)</td> <td>Uceris</td> <td>9 mg once each morning for eight weeks</td> </tr> <tr> <td class=\"indent1\">Prednisone or oral prednisolone</td> <td>&nbsp;</td> <td>40 to 60 mg once each morning or in two divided doses</td> </tr> <tr> <td class=\"indent1\">Intravenous prednisolone<sup>&#182;</sup></td> <td>&nbsp;</td> <td>30 mg IV every 12 hours</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> <td>Solu-Medrol</td> <td>16 to 20 mg IV every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydrocortisone</td> <td>Solu-Cortef</td> <td>100 mg IV every eight hours</td> </tr> <tr> <td rowspan=\"16\">Maintenance of remission</td> <td class=\"subtitle2_left\" colspan=\"3\">Topical (rectal) mesalamine*</td> </tr> <tr> <td class=\"indent1\">Suppository</td> <td>Canasa</td> <td>1 gram (1 suppository) at bedtime</td> </tr> <tr> <td class=\"indent1\">Enema</td> <td>Rowasa</td> <td>2 to 4 grams (30 to 60 mL) at bedtime</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral 5-aminosalycylic acid (5-ASA) derivatives</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> <td>Azulfidine, Salazopyrin<sup>&#182;</sup></td> <td>4 to 6 grams daily in three or four divided doses</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Mesalamine*</td> </tr> <tr> <td class=\"indent2\">Delayed release enteric coated tablet</td> <td>Asacol<sup>&#182;</sup>, Asacol HD</td> <td>1.6 to 2.4 grams daily in one to three divided doses (depending upon preparation)</td> </tr> <tr> <td class=\"indent2\">Capsule containing delayed release enteric coated tablet</td> <td>Delzicol</td> <td>1.6 to 2.4 grams daily in one to three divided doses</td> </tr> <tr> <td class=\"indent2\">Delayed and extended release tablet, multimatrix</td> <td>Lialda, Mezavant<sup>&#182;</sup></td> <td>2.4 grams once daily</td> </tr> <tr> <td class=\"indent2\">Capsule containing delayed release enteric coated granules</td> <td>Apriso</td> <td>1.5 to 3 grams once each morning</td> </tr> <tr> <td class=\"indent2\">Controlled release capsule</td> <td>Pentasa</td> <td>1.5 to 4 grams daily in four divided doses</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Mesalamine pellets</td> <td>Salofalk<sup>&#182;</sup></td> <td>0.75 to 4 grams daily in one to three divided doses</td> </tr> <tr> <td>Pentasa sachet<sup>&#182;</sup></td> <td>1.5 to 4 grams once daily</td> </tr> <tr> <td class=\"indent1\">Olsalazine capsule</td> <td>Dipentum</td> <td>1 gram daily in two divided doses</td> </tr> <tr> <td class=\"indent1\">Balsalazide capsule</td> <td>Colazal</td> <td>2.25 to 6.75 grams daily in three divided doses</td> </tr> <tr> <td class=\"indent1\">Balsalazide tablet</td> <td>Giazo</td> <td>2.2 to 6.6 grams daily in two divided doses</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Sulfasalazine and mesalamine (Delzicol, Asacol, Pentasa, and Lialda) are approved by the US Food and Drug Administration (FDA) for treatment and maintenance of remission of active ulcerative colitis; mesalamine (Asacol HD) and balsalazide (Colazal, Giazo) are approved for treatment of active ulcerative colitis (approval of Giazo is limited to male patients), while olsalazine (Dipentum) is approved for maintenance therapy in patients who are allergic to sulfasalazine. Encapsulated mesalamine granules (Apriso) is approved for maintenance of remission by the US FDA.</div><div class=\"graphic_footnotes\">5-ASA: 5-aminosalicylate; IV: intravenous; US: United States.<br />* Mesalamine is US generic name. Mesalazine is an international generic (nonproprietary) name.<br />¶ Not available in US. Trade names shown are for products commonly available in areas other than US including Canada, United Kingdom, and Europe.</div><div class=\"graphic_reference\">Data courtesy of authors with additional data from: Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.</div><div id=\"graphicVersion\">Graphic 86774 Version 7.0</div></div></div>"},"86775":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of renal duplex system and ectopic ureter","title":"Ultrasound of renal duplex system and ectopic ureter","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Ultrasound of renal duplex system and ectopic ureter</div><div class=\"cntnt\"><img style=\"width:513px; height:364px;\" src=\"images/PEDS/86775_Ultra_ren_dup_sys_ect_ur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound images of renal duplex system with ectopic upper pole ureter. Asterisks denote the ectopic ureter with its insertion behind the bladder. White arrowheads outline nonhydronephrotic normal lower pole.</div><div class=\"graphic_footnotes\">UP: upper pole.</div><div id=\"graphicVersion\">Graphic 86775 Version 1.0</div></div></div>"},"86776":{"type":"graphic_figure","displayName":"Alleged renal agenesis ectopic ureter and Mullerian defects","title":"Alleged renal agenesis in females with ectopic ureter and Müllerian abnormalities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alleged renal agenesis in females with ectopic ureter and Müllerian abnormalities</div><div class=\"cntnt\"><img style=\"width:404px; height:367px;\" src=\"images/PEDS/86776_Alleg_ren_agen_ect_ure_mul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathogenesis of&nbsp;alleged renal agenesis in females with unsuspected Müllerian abnormalities, consisting of a duplex vagina and uterus with a left-obstructed hemivagina and obstruction of the upper pole non-refluxing ectopic ureter.</div><div class=\"graphic_footnotes\"><EM>References:&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;</EM> &#xD;&#xA;<OL>&#xD;&#xA;<LI><EM>Schlomer B, Rodriquez E, Baskin L. Obstructed hemivagina and ipsilateral renal&nbsp;agenesis (OHVIRA) syndrome should be redefined as ipsilateral renal anomalies:&nbsp;cases of symptomatic atrophic and dysplastic kidney with ectopic ureter to obstructed hemivagina. J Pediatri Urol 2015; 77:e1.</EM></LI></OL></div><div id=\"graphicVersion\">Graphic 86776 Version 2.0</div></div></div>"},"86777":{"type":"graphic_diagnosticimage","displayName":"Pathologic fracture of a distal femur osteosarcoma ","title":"Osteosarcoma of the distal femur presenting as a pathologic fracture","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Osteosarcoma of the distal femur presenting as a pathologic fracture</div><div class=\"cntnt\"><img style=\"width:513px; height:511px;\" src=\"images/ONC/86777_Path_frac_extr_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Muchantef K, Pollock AN. Osteosarcoma of the lower extremity presenting as a pathologic fracture. Pediatr Emerg Care 2012; 28:936. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86777 Version 4.0</div></div></div>"},"86779":{"type":"graphic_picture","displayName":"Scapular strength T exercise","title":"Scapular strengthening \"T\" exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular strengthening \"T\" exercise</div><div class=\"cntnt\"><img style=\"width:346px; height:487px;\" src=\"images/EM/86779_Scapular_strength_T.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While maintaining a straight&nbsp;torso, slowly raise the arms straight out to each side, parallel to the floor. This exercise can be done with the thumbs up or down. Hold for a second, then return the arms to the starting position; repeat 10 to 15 times.&nbsp;It is important to focus on squeezing your shoulder blades down and backward towards the spine. <BR></div><div id=\"graphicVersion\">Graphic 86779 Version 1.0</div></div></div>"},"86780":{"type":"graphic_table","displayName":"Stages of vitamin D deficiency rickets","title":"Stages of vitamin D deficiency rickets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of vitamin D deficiency rickets</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Serum calcium (Ca)</td> <td class=\"subtitle1\">Serum inorganic phosphorus (Pi)</td> <td class=\"subtitle1\">Parathyroid hormone (PTH)</td> <td class=\"subtitle1\">Mechanisms</td> <td class=\"subtitle1\">Radiologic and clinical findings of rickets</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">Low or normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal or elevated</td> <td class=\"centered\">Vitamin D deficiency causes impaired intestinal absorption of calcium</td> <td class=\"centered\">None, or osteopenia only</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Low</td> <td class=\"centered\">Elevated</td> <td class=\"centered\">Elevated PTH mobilizes calcium from bone, retains calcium at the kidney, and promotes production of 1,25(OH)<sub>2</sub>D</td> <td class=\"centered\">Clinically apparent rickets (radiographic and/or physical findings in the skeleton)</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">Low</td> <td class=\"centered\">Low</td> <td class=\"centered\">Very elevated</td> <td class=\"centered\">Serum calcium falls as hyperparathyroidism is unable to compensate for impaired intestinal calcium absorption. Hyperparathyroidism may also lead to aminoaciduria and hyperphosphaturia.*</td> <td class=\"centered\">Severe radiographic and physical signs of rickets</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">1,25(OH)<sub>2</sub>D: 1,25 dihdroxyvitamin D.<br />* Urinary phosphate is inappropriately high relative to the low levels of phosphate in the blood (ie, the renal <strong>clearance</strong> of phosphate is elevated), but actual <strong>concentrations</strong> of phosphate in the urine may not be elevated.</div><div id=\"graphicVersion\">Graphic 86780 Version 4.0</div></div></div>"},"86782":{"type":"graphic_table","displayName":"Pneumococcal vaccination recommendations for adults","title":"UpToDate recommendations* for the administration of pneumococcal vaccines (PCV13 and PPSV23) in adults in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for the administration of pneumococcal vaccines (PCV13 and PPSV23) in adults in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk group</td> <td class=\"subtitle1\" rowspan=\"2\">Underlying condition</td> <td class=\"subtitle1\">PCV13&#182;</td> <td class=\"subtitle1\" colspan=\"2\">PPSV23</td> </tr> <tr> <td class=\"subtitle2\">Recommended</td> <td class=\"subtitle2\">Recommended</td> <td class=\"subtitle2\">Revaccination</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\"><strong>Immunocompetent persons</strong></td> <td>Chronic heart disease<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Chronic lung disease<sup>&#9674;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Diabetes mellitus</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cerebrospinal fluid leak</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cochlear implant</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Alcoholism</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Chronic liver disease, cirrhosis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cigarette smoking</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Age &#8805;65</td> <td class=\"centered\">&#167;</td> <td class=\"centered\">X</td> <td class=\"centered\">&#165;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Persons with functional or anatomic asplenia</strong></td> <td>Sickle cell disease/other hemoglobinopathy</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X<sup>&#135;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Congenital or acquired asplenia</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X<sup>&#135;</sup></td> </tr> <tr> <td rowspan=\"11\"><strong>Immunocompromised persons</strong></td> <td>Congenital or acquired immunodeficiency<sup>&#134;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Human immunodeficiency virus infection</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Chronic renal failure</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Nephrotic syndrome</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Leukemia</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Lymphoma</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Hodgkin disease</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Generalized malignancy</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Iatrogenic immunosuppression<sup>&#182;&#182;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Solid organ transplant</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> <tr> <td>Multiple myeloma</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X**</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13); PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23).<br />* For certain recommendations, UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP) as outlined in subsequent footnotes.<br />¶ For those with an indication for PCV13, only one dose is indicated during adulthood. <br />Δ&nbsp;Including congestive heart failure and cardiomyopathies, excluding hypertension.<br />◊&nbsp;Including chronic obstructive pulmonary disease, emphysema, and asthma.<br />§&nbsp;UpToDate authors do not recommend PCV13 for healthy individuals ≥65 years of age but do recommend PCV13 for patients ≥65 years of age who have one of the conditions for which PPSV23 is indicated before age 65 (cigarette smokers; patients with chronic heart disease, chronic lung disease, diabetes mellitus, alcoholism, or chronic liver disease) as well as for individuals ≥65 years of age who are planning to travel to a country that does not have a universal immunization program mandating pneumococcal conjugate vaccination for all infants and toddlers.&nbsp;By contrast, the ACIP recommends use of PCV13 in <STRONG>all </STRONG>individuals ≥65 years of age. Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.&nbsp;<br />¥ The ACIP recommends that all adults aged ≥65 years receive a dose of PPSV23 even if they were vaccinated when they were less than 65 years of age; however, a minimum interval of five years between PPSV23 doses should be maintained. UpToDate authors agree with the ACIP's recommendation for revaccination with PPSV23 at or after age 65 years; however, following this dose (and in contrast&nbsp;with the ACIP), UpToDate authors also favor revaccinating with PPSV23 at 10-year intervals because immunologic responses wane in older adult patients. A caveat is that insurance companies may not provide coverage for these subsequent doses. The ACIP recommends that those who are receiving PPSV23 for the first time at or after age 65 should receive only a single dose (and do not require revaccination).<br />‡&nbsp;For patients with anatomic or functional asplenia, UpToDate authors recommend revaccination with PPSV23 every five years.&nbsp;By contrast, the ACIP recommends that patients &lt;65 years of age who have functional or anatomic asplenia be revaccinated one time five years after the initial dose and again at or after age 65 (and at least five years after the previous dose).<br />†&nbsp;Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).<br />**&nbsp;Patients &lt;65 years of age who are immunocompromised should be revaccinated with PPSV23 one time five years after the initial dose and again at or after age 65 (and at least five years after the previous dose).&nbsp;Refer to&nbsp;footnote&nbsp;¥ above for additional recommendations for individuals ≥65 years of age.<br />¶¶&nbsp;Diseases requiring treatment with immunosuppressive drugs, including long-term systemic glucocorticoids and radiation therapy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102.</LI></OL></div><div id=\"graphicVersion\">Graphic 86782 Version 25.0</div></div></div>"},"86786":{"type":"graphic_picture","displayName":"Nail plate post-surgery 2","title":"Replacement of a partially avulsed nail plate after surgery","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Replacement of a partially avulsed nail plate after surgery</div><div class=\"cntnt\"><img style=\"width:579px; height:251px;\" src=\"images/DERM/86786_Nail_plate_post-surgery_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After partial avulsion, the nail plate is put back in place.</div><div id=\"graphicVersion\">Graphic 86786 Version 2.0</div></div></div>"},"86787":{"type":"graphic_figure","displayName":"Map of states with recalled methylprednisolone","title":"Map of healthcare facilities that received lots* of methylprednisolone acetate (PF) recalled from New England Compounding Center on September 26, 2012","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Map of healthcare facilities that received lots* of methylprednisolone acetate (PF) recalled from New England Compounding Center on September 26, 2012</div><div class=\"cntnt\"><img style=\"width:614px; height:343px;\" src=\"images/ID/86787_Map_states_recall_methylpre.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PF: preservative-free.<br />* Lot #05212012@68, BUD 11/17/2012; Lot #06292012@26, BUD 12/26/2012; Lot #08102012@51, BUD 2/6/2013.<br /><span class=\"bullet\">&bull;</span> All vials of methylprednisolone acetate that were sent to Nevada were recalled prior to use.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): Map of Healthcare Facilities which Received Three Lots of Methylprednisolone Acetate (PF) Recalled from New England Compounding Center on September 26, 2012. Available at: <A href=\"http://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html\" target=\"_blank\">http://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html</A> (Accessed October 11, 2012).</div><div id=\"graphicVersion\">Graphic 86787 Version 1.0</div></div></div>"},"86789":{"type":"graphic_picture","displayName":"Neti pot PI","title":"Using a neti pot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Using a neti pot</div><div class=\"cntnt\"><img style=\"width:346px; height:266px;\" src=\"images/PI/86789_Neti_pot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A neti pot is a small pot with a long spout. This woman is using a neti pot to rinse out her nose with salt water.</div><div class=\"graphic_reference\">Reproduced from: U.S. Food and Drug Administration. For Consumers: Is Rinsing Your Sinuses Safe? Available at:&nbsp;<A style=\"FONT-STYLE: italic\" href=\"http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm316375\" target=_blank>http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm316375</A> (Accessed October 12, 2012).</div><div id=\"graphicVersion\">Graphic 86789 Version 1.0</div></div></div>"},"86790":{"type":"graphic_figure","displayName":"Fibroid embolization PI","title":"Uterine artery embolization","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Uterine artery embolization</div><div class=\"cntnt\"><img style=\"width:552px; height:464px;\" src=\"images/PI/86790_fibroid_embolization_pi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a uterine artery embolization, a doctor inserts a thin tube called a \"catheter\" into the \"femoral artery\" at the top of 1 leg. Then he or she advances the tube until the tip of the tube reaches a smaller artery on the other side of the body, called the \"uterine artery,\" which carries blood to the uterus (on left). Next the doctor injects a special dye that can be seen on X-rays. The dye allows the doctor to see which arteries bring blood to the fibroid. Next, the doctor injects tiny plastic beads into those arteries to block the flow of blood (see panel on right). This cuts off the blood supply to the fibroid, which causes the fibroid to shrink.</div><div id=\"graphicVersion\">Graphic 86790 Version 3.0</div></div></div>"},"86793":{"type":"graphic_algorithm","displayName":"HCM treatment algorithm","title":"HCM treatment algorithm","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">HCM treatment algorithm</div><div class=\"cntnt\"><img style=\"width:606px; height:691px;\" src=\"images/CARD/86793_HCM_treatment_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; DM: diabetes mellitus; EF: ejection fraction; GL: guidelines; HCM: hypertrophic cardiomyopathy; HTN: hypertension; LV: left ventricular.<br />* Class I.<br />¶ Class IIa.<br />Δ Class IIb.</div><div class=\"graphic_reference\">Reproduced with permission from: Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 86793 Version 6.0</div></div></div>"},"86794":{"type":"graphic_picture","displayName":"Dactylitis in psoriatic juvenile idiopathic arthritis PI","title":"Finger and toe swelling in psoriatic arthritis in children","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Finger and toe swelling in psoriatic arthritis in children</div><div class=\"cntnt\"><img style=\"width:580px; height:260px;\" src=\"images/PI/86794_dactili_psoratic_jia_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photo A shows swelling of the 2<SUP>nd</SUP> and 4<SUP>th</SUP> toes. Photo B shows swelling of the thumb and pointer (1<SUP>st</SUP>) finger. The medical term for this type of swelling is \"dactylitis.\"</div><div id=\"graphicVersion\">Graphic 86794 Version 2.0</div></div></div>"},"86797":{"type":"graphic_table","displayName":"FCR for CLL","title":"Fludarabine, cyclophosphamide, and rituximab (FCR) for chronic lymphocytic leukemia<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fludarabine, cyclophosphamide, and rituximab (FCR) for chronic lymphocytic leukemia<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Rituximab</strong>*</td> <td> <p>Cycle 1: 375 mg/m<sup>2</sup> IV</p> Cycles 2 to 6: 375 to 500 mg/m<sup>2</sup> IV</td> <td>Dilute in 0.9 percent sodium chloride (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. Subsequent infusions: start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.<sup>&#9674;</sup></td> <td>All cycles: Day 1</td> </tr> <tr> <td><strong>Fludarabine</strong></td> <td>25 mg/m<sup>2</sup> IV</td> <td>Dilute in 100 mL NS or D5W and administer over 30 minutes.</td> <td> <p>Cycle 1: Days 2 to 4</p> Cycles 2 to 6: Days 1 to 3</td> </tr> <tr> <td><strong>Cyclophosphamide</strong></td> <td>250 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS or D5W and administer over 30 to 60 minutes<sup>&#916;</sup>.</td> <td> <p>Cycle 1: Days 2 to 4</p> Cycles 2 to 6: Days 1 to 3</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (30 to 90 percent frequency of emesis). Prophylaxis is indicated on the days that cyclophosphamide is given. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab<sup>[2]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Cyclophosphamide is classified as an irritant, and not a true vesicant. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for tumor lysis syndrome:</strong> Due to the significant risk of tumor lysis syndrome during the first cycle, all patients should be well hydrated prior to and during therapy and receive allopurinol 300 mg orally once daily beginning the day prior to the first dose of rituximab and continuing for 14 days<sup>[3]</sup>. Refer to UpToDate topic on \"Tumor lysis syndrome: Prevention and treatment\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> The rate of severe (grade 3/4) infection was 25 percent<sup>[1]</sup>. As such, we suggest prophylactic hematopoietic growth factors. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial, antifungal, and antiviral prophylaxis. Refer to UpToDate topics on \"Overview of infectious complications following purine analog therapy\" and \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Adjustment of initial cyclophosphamide and fludarabine may be required for renal dysfunction<sup>[4-7]</sup>. In addition, dose adjustments of cyclophosphamide may be needed for liver dysfunction. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatitis screening:</strong> Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for prophylaxis. Refer to UpToDate topic on&nbsp;\"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment and as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess renal and hepatic function prior to each cycle and as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess serum creatinine, potassium, phosphate, calcium, uric acid, and LDH daily during treatment for patients at risk for tumor lysis syndrome.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelosuppression:</strong> Treatment should be delayed until ANC greater than 1000 cells/microL and platelet count is greater than 80,000/microL. If blood counts do not recover to ANC &#62;1000 cells/microL or platelets &#62;80,000/microL within five weeks from the last course of therapy, the daily dose of fludarabine should be reduced to 20 mg/m<sup>2</sup> and the daily dose of cyclophosphamide should be reduced to 200 mg/m<sup>2</sup> for subsequent cycles. During these subsequent cycles, if blood counts do not recover to ANC &#62;1000 cells/microL or platelets &#62;80,000/microL within five weeks from the last course of therapy, the daily dose of fludarabine should be reduced to 15 mg/m<sup>2</sup> and the daily dose of cyclophosphamide should be reduced to 150 mg/m<sup>2</sup> for any remaining cycles.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; LD: lactate dehydrogenase; ANC: absolute neutrophil count.<br />* Although initial studies of the FCR regimen utilized higher doses (500 mg/m<SUP>2</SUP>) of rituximab in cycles 2 to 6, there have been no prospective studies that indicate that this increased dose is necessary. Some clinicians use the standard dose of rituximab (375 mg/m<SUP>2</SUP>) for all six cycles of FCR. <br />Δ The volume and rate of administration varies between institutions.<br />◊ A subcutaneous formulation (rituximab-hyaluronidase) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous rituximab<SUP>[8]</SUP>. Dosing varies by histology and clinicians should refer to the US Prescribing Information for details.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hallek M, et al. Lancet 2010; 376:1164.</LI>&#xD;&#xA;<LI>Rituximab injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed February 1, 2012).</LI>&#xD;&#xA;<LI>Keating MJ, et al. J Clin Oncol 2005; 23:4079.</LI>&#xD;&#xA;<LI>Wierda W et al. J Clin Oncol 2005; 23:4070.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed on 2/1/2012).</LI>&#xD;&#xA;<LI>Cooper K, Bennett WM. Nephrotoxicity of common drugs used in clinical practice. Arch Intern Med 1987; 147:1213.</LI>&#xD;&#xA;<LI>Fludarabine injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed 2/1/2012).</LI>&#xD;&#xA;<LI>Rituximab and hyaluronidase human injection for subcutaneous use. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed 6/30/2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 86797 Version 9.0</div></div></div>"},"86798":{"type":"graphic_table","displayName":"FR for CLL","title":"Fludarabine and rituximab (FR) for chronic lymphocytic leukemia<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fludarabine and rituximab (FR) for chronic lymphocytic leukemia<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Rituximab</strong></td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in 0.9 percent sodium chloride (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. Subsequent infusions: start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.</td> <td> <p>Cycle 1: Day 1 and 4</p> Cycles 2 through 6: Day 1</td> </tr> <tr> <td><strong>Fludarabine</strong></td> <td>25 mg/m<sup>2</sup> IV</td> <td>Dilute in 100 mL NS or D5W and administer over 30 minutes.</td> <td>All cycles: Days 1 through 5</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MINIMAL (&#60;10 percent frequency of emesis). No scheduled antiemetic prophylaxis is indicated. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab<sup>[2]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for tumor lysis syndrome:</strong> Due to the significant risk of tumor lysis syndrome during the first cycle, all patients should be well hydrated prior to and during therapy and receive allopurinol 300 mg orally once daily beginning the day prior to the first dose of rituximab and continuing for 14 days<sup>[3]</sup>. Refer to UpToDate topic on \"Tumor lysis syndrome: Prevention and treatment\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> The rate of severe (grade 3/4) infection was 20 percent<sup>[1]</sup>. As such, we suggest prophylactic hematopoietic growth factors. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial, antifungal, and antiviral prophylaxis. Refer to UpToDate topics on \"Prevention of infections in patients with chronic lymphocytic leukemia\" and \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Adjustment of initial fludarabine may be required for renal dysfunction<sup>[4]</sup>. Dose adjustment is not needed for rituximab. Dose adjustments for liver impairment are not needed for fludarabine and rituximab. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatitis screening:</strong> Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for prophylaxis. Refer to UpToDate topic on&nbsp;\"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment and as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess renal and hepatic function prior to each cycle and as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess serum creatinine, potassium, phosphate, calcium, uric acid, and LDH daily during treatment for patients at risk for tumor lysis syndrome.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelosuppression:</strong> Treatment should be delayed until the ANC is greater than 1000 cells/microL, the platelet count is greater than 80,000/microL, and the hemoglobin is greater than 8 g/dL. Treatment should be delayed until these parameters recover to these values or to within 20 percent of the baseline counts. For grade 3 hematologic toxicity, subsequent doses of fludarabine should be reduced by 25 percent from the original dose. If the patient develops grade 4 toxicity, subsequent doses of fludarabine should be reduced by 50 percent from the original dose.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; LD: lactate dehydrogenase; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Byrd JC, et al. Blood 2003; 101:6.</LI>&#xD;&#xA;<LI>Rituximab injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed February 1, 2012).</LI>&#xD;&#xA;<LI>Freifeld AG, et al. Clin Infect Dis 2011; 52:e56.</LI>&#xD;&#xA;<LI>Fludarabine injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed 2/1/2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86798 Version 6.0</div></div></div>"},"86799":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph normal ankle","title":"Plain radiograph normal ankle","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Plain radiograph normal ankle</div><div class=\"cntnt\"><img style=\"width:597px; height:330px;\" src=\"images/RADIOL/86799_Plain_xray_normal_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph&nbsp;of the normal right ankle in the anteroposterior (A), oblique&nbsp;(B), and lateral (C) projections. Image B exposes the mortise-like configuration of the joint, and this projection is commonly referred to as a mortise view.</div><div id=\"graphicVersion\">Graphic 86799 Version 2.0</div></div></div>"},"86800":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus direct immunofluorescence","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:399px;\" src=\"images/DERM/86800_Paraneoplastic_pemph_DIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intercellular deposition of IgG is evident on direct immunofluorescence microscopy.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86800 Version 2.0</div></div></div>"},"86801":{"type":"graphic_figure","displayName":"Lymphatic system female PI","title":"Lymphatic system in women","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Lymphatic system in women</div><div class=\"cntnt\"><img style=\"width:485px; height:709px;\" src=\"images/PI/86801_Lymphatic_system_female_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the organs of the lymphatic system, which include the bone marrow, thymus, spleen, and lymph nodes. These organs are connected by lymph vessels.</div><div id=\"graphicVersion\">Graphic 86801 Version 2.0</div></div></div>"},"86803":{"type":"graphic_picture","displayName":"Foil splint for fingertip avulsion","title":"Foil splint for fingertip avulsion","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Foil splint for fingertip avulsion</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/86803_Foil_splint_fingertip_avul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sterile foil from a suture packet is cut to fit in the proximal fold and secured in place through the lateral skin folds using skin glue (eg, cyanoacrylate glue) or absorbable 4-0 suture. This approach helps preserve the proximal fold as the new nail grows in.</div><div class=\"graphic_reference\">Courtesty of Richard A Saladino, MD.</div><div id=\"graphicVersion\">Graphic 86803 Version 3.0</div></div></div>"},"86804":{"type":"graphic_table","displayName":"Non-antineoplastic drugs that act as vesicants","title":"Common non-antineoplastic drugs that can act as vesicants or irritants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common non-antineoplastic drugs that can act as vesicants or irritants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Effect*</td> <td class=\"subtitle1\">Proposed mechanism(s) of tissue injury<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antiemetics</td> </tr> <tr> <td class=\"indent1\">Hydroxyzine</td> <td>Vesicant</td> <td> <p>Cytotoxicity</p> <strong>NOTE:</strong> IV administration of hydroxyzine has been associated with hemolysis, sterile abscess formation, and tissue necrosis; IV administration is contraindicated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Promethazine</td> <td>Vesicant</td> <td> <p>Cytotoxicity, acidic pH</p> <strong>NOTE:</strong> IV administration of promethazine is not a preferred method of administration; for additional information refer to topic on promethazine: drug information, section on administration, in Lexicomp reference included with UpToDate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antimicrobials</td> </tr> <tr> <td class=\"indent1\">Acyclovir &#62;7 mg/mL</td> <td class=\"divider_bottom\" rowspan=\"12\">In general, these agents can act as irritants; there are also reports of vesicant effects</td> <td class=\"divider_bottom\" rowspan=\"12\">Cytotoxicity, acidic or alkaline pH (agent specific)</td> </tr> <tr> <td class=\"indent1\">Amphotericin</td> </tr> <tr> <td class=\"indent1\">Cefotaxime</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> </tr> <tr> <td class=\"indent1\">Ganciclovir</td> </tr> <tr> <td class=\"indent1\">Gentamicin</td> </tr> <tr> <td class=\"indent1\">Mezlocillin</td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> </tr> <tr> <td class=\"indent1\">Penicillin</td> </tr> <tr> <td class=\"indent1\">Pentamidine</td> </tr> <tr> <td class=\"indent1\">Piperacillin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular agents and diuretics</td> </tr> <tr> <td class=\"indent1\">Acetazolamide</td> <td rowspan=\"2\">Irritants</td> <td rowspan=\"2\">Alkaline pH</td> </tr> <tr> <td class=\"indent1\">Chlorothiazide</td> </tr> <tr> <td class=\"indent1\">Digoxin</td> <td>Vesicant</td> <td>Cytotoxicity, vasoconstriction</td> </tr> <tr> <td class=\"indent1\">Dobutamine</td> <td>Irritant; there are rare reports of vesicant effects</td> <td>Cytotoxicity, acidic pH</td> </tr> <tr> <td class=\"indent1\">Dopamine</td> <td rowspan=\"5\">Vesicants</td> <td rowspan=\"5\">Vasoconstriction</td> </tr> <tr> <td class=\"indent1\">Epinephrine (adrenaline)</td> </tr> <tr> <td class=\"indent1\">Esmolol</td> </tr> <tr> <td class=\"indent1\">Mannitol &#62;5 percent</td> </tr> <tr> <td class=\"indent1\">Phenylephrine</td> </tr> <tr> <td class=\"indent1\">Nitroprusside</td> <td>Irritant</td> <td>Not reported</td> </tr> <tr> <td class=\"indent1\">Norepinephrine (noradrenaline)</td> <td class=\"divider_bottom\" rowspan=\"3\">Vesicants</td> <td>Vasoconstriction</td> </tr> <tr> <td class=\"indent1\">Tromethamine</td> <td>Alkaline pH, vasoconstriction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vasopressin</td> <td>Vasocontriction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Concentrated electrolytes and nutritional solutions</td> </tr> <tr> <td class=\"indent1\">Amino acid solutions &#8805;4.25 percent</td> <td rowspan=\"5\">Vesicants</td> <td>High osmolality, acidic pH, tissue compression (large volume)</td> </tr> <tr> <td class=\"indent1\">Arginine</td> <td>High osmolality, local arginine-induced hyperkalemia</td> </tr> <tr> <td class=\"indent1\">Calcium chloride</td> <td>High osmolality, calcium deposition (calcinosis cutis)</td> </tr> <tr> <td class=\"indent1\">Calcium gluconate 10 percent</td> <td>High osmolality, calcium deposition (calcinosis cutis)</td> </tr> <tr> <td class=\"indent1\">Dextrose &#62;10 percent</td> <td>High osmolality, tissue compression (large volume)</td> </tr> <tr> <td class=\"indent1\">Potassium acetate &#62;0.1 mEq per mL</td> <td rowspan=\"2\">Irritants</td> <td rowspan=\"2\">Cytotoxicity<br /> </td> </tr> <tr> <td class=\"indent1\">Potassium chloride &#62;0.1 mEq per mL</td> </tr> <tr> <td class=\"indent1\">Sodium bicarbonate &#8805;8.4 percent</td> <td class=\"divider_bottom\" rowspan=\"3\">Vesicants</td> <td>High osmolality, alkaline pH</td> </tr> <tr> <td class=\"indent1\">Sodium chloride &#8805;3 percent</td> <td>High osmolality</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Total parenteral nutrition</td> <td>High osmolality, acidic pH, tissue compression</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Radiographic contrast media</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diatrizoate meglumine, diatrizoate sodium, gadopentetate dimeglumine, iodipamide meglumine, iothalamate meglumine, iodixanol, iohexol, iopamidol, iopromide, iotrolan, ioversol, ioxaglate meglumine, ioxilan</td> <td>Vesicants</td> <td>High osmolality, cytotoxicity, local edema, tissue compression (large volume)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sedative and anesthetic agents</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td class=\"divider_bottom\" rowspan=\"4\">In general these agents can act as irritants; there are rare reports of vesicant effects</td> <td>Propylene glycol additive, intravascular precipitation</td> </tr> <tr> <td class=\"indent1\">Etomidate</td> <td>Cytotoxicity and propylene glycol additive</td> </tr> <tr> <td class=\"indent1\">Propofol</td> <td>Cytotoxicity; rare reports of tissue necrosis or burn injury</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thiopental</td> <td>Cytotoxicity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other agents</td> </tr> <tr> <td class=\"indent1\">Aminophylline</td> <td rowspan=\"2\">Vesicants</td> <td>Vasoconstriction</td> </tr> <tr> <td class=\"indent1\">Dantrolene</td> <td>Alkaline pH</td> </tr> <tr> <td class=\"indent1\">Epoprostenol</td> <td>Irritant</td> <td>Alkaline pH</td> </tr> <tr> <td class=\"indent1\">Methylene blue (methylthioninium chloride)</td> <td>Vesicant</td> <td>Cytotoxicity, alkaline pH</td> </tr> <tr> <td class=\"indent1\">Mycophenolate</td> <td>Irritant</td> <td>Acidic pH</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td>Vesicant</td> <td>Alkaline pH, intravascular precipitation, localized edema</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Irritant drugs can cause local pain and inflammation but rarely cause tissue destruction. Vesicants are inherently toxic and can cause pain, inflammation and burn-like injury including blistering, sloughing, deep tissue damage and necrosis.<br />¶ Soft tissue injury may be related to the following characteristics of the extravasate: osmolality (concentration), inherent cytotoxicity (potential for chemical irritation, burn and necrosis), infusion pressure, and vasoconstrictive effects.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hannon MG and Lee SK. Extravasation injuries; J Hand Surg 2011; 36A:2060-2065.</LI>&#xD;&#xA;<LI>Tonolini M, Cmapari A, Bianco R. Extravasation of radiographic contrast media: Prevention, diagnosis and treatment. Curr Probl Diagn Radiol 2012; 41:52-55.</LI>&#xD;&#xA;<LI>Lacy CF, et al (eds) Lexicomp Online. Copyright © 1978-2018 Lexi-Comp, Inc. All Rights Reserved. </LI></OL></div><div id=\"graphicVersion\">Graphic 86804 Version 15.0</div></div></div>"},"86805":{"type":"graphic_picture","displayName":"Pseudomembranous candidiasis soft palate and buccal mucosa","title":"Pseudomembranous candidiasis of the soft palate and buccal mucosa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous candidiasis of the soft palate and buccal mucosa</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/ONC/86805_Pseudomem_cand_soft_buc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Nathaniel Treister, DMD, DMSc.</div><div id=\"graphicVersion\">Graphic 86805 Version 1.0</div></div></div>"},"86806":{"type":"graphic_picture","displayName":"HSV recrudescence","title":"Herpex simplex virus (HSV) recrudescence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpex simplex virus (HSV) recrudescence</div><div class=\"cntnt\"><img style=\"width:388px; height:290px;\" src=\"images/ONC/86806_HSV_recrudescence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HSV recrudescence in a patient with chronic graft versus host disease following allogeneic hematopoietic cell transplantation.</div><div class=\"graphic_reference\">Courtesy of Nathaniel Treister, DMD, DMSc.</div><div id=\"graphicVersion\">Graphic 86806 Version 2.0</div></div></div>"},"86808":{"type":"graphic_figure","displayName":"Simplified risk scores for POV/PONV","title":"Simplified risk scores for POV/PONV","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Simplified risk scores for POV/PONV</div><div class=\"cntnt\"><img style=\"width:646px; height:438px;\" src=\"images/ANEST/86808_Simpl_PONV_risk_score.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) When 0, 1, 2, 3, or 4 of the depicted independent predictors are present, the corresponding risk for PONV is approximately 10%, 20%, 40%, 60%, or 80%.<br />(B) When 0, 1, 2, 3, or 4 of the depicted independent predictors are present, the corresponding risk for PONV is approximately 10%, 10%, 30%, 50%, or 70% respectively.</div><div class=\"graphic_footnotes\">POV: postoperative vomiting; PONV: postoperative nausea and vomiting.</div><div class=\"graphic_reference\">(A) Recommendations for adults reproduced from: Gan T, Meyer T, Apfel C, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007; 105:1615. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2007&amp;issue=12000&amp;article=00020&amp;type=abstract\" target=\"_blank\">10.1213/01.ane.0000295230.55439.f4</a>. Copyright &copy; 2007 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.<br />(B) Recommendations for children reproduced from: Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2014&amp;issue=01000&amp;article=00013&amp;type=abstract\" target=\"_blank\">10.1213/ANE.0000000000000002</a>. Copyright &copy; 2014 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 86808 Version 8.0</div></div></div>"},"86810":{"type":"graphic_table","displayName":"Diagnostic criteria PCOS","title":"Proposed diagnostic criteria for polycystic ovary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed diagnostic criteria for polycystic ovary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">NIH consensus criteria 1990<sup>[1]</sup><br /> (all required)</td> <td class=\"subtitle1\">Rotterdam criteria 2003*<sup>[2]</sup><br /> (two out of three required)</td> <td class=\"subtitle1\">AES definition 2008<sup>[3]</sup><br /> (all required)</td> </tr> <tr> <td>Menstrual irregularity due to oligo- or anovulation</td> <td>Oligo- or anovulation</td> <td>Clinical and/or biochemical signs of hyperandrogenism</td> </tr> <tr> <td>Clinical and/or biochemical signs of hyperandrogenism</td> <td>Clinical and/or biochemical signs of hyperandrogenism</td> <td>Ovarian dysfunction &ndash; oligo/anovulation and/or polycystic ovaries on ultrasound</td> </tr> <tr> <td>Exclusion of other disorders: NCCAH, androgen-secreting tumors</td> <td>Polycystic ovaries (by ultrasound)</td> <td>Exclusion of other androgen excess or ovulatory disorders</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; NIH: National Institutes of Health; AES: Androgen Excess Society; NCCAH: nonclassic congenital adrenal hyperplasia.<br />* Rotterdam criteria also require exclusion of other conditions that mimic PCOS. Criteria were developed at a 2003 consensus meeting held in Rotterdam&nbsp;(European Society of Human Reproduction and Embryology [ESHRE]/American Society of Reproductive Medicine [ASRM] consensus workshop group).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Dunaif A, Givens JR, Haseltine FP, Merriam GE (Eds), Blackwell Scientific Inc, Boston 1992. p.377. </LI>&#xD;&#xA;<LI>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41. </LI>&#xD;&#xA;<LI>Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009; 91:456.</LI></OL></div><div id=\"graphicVersion\">Graphic 86810 Version 7.0</div></div></div>"},"86811":{"type":"graphic_table","displayName":"Differential diagnosis of excessive daytime sleepiness","title":"Differential diagnosis of excessive daytime sleepiness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of excessive daytime sleepiness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Insufficient sleep</td> </tr> <tr> <td class=\"indent1\">Sleep deprivation</td> </tr> <tr> <td class=\"indent1\">Environmental intrusions</td> </tr> <tr> <td class=\"subtitle1_single\">Sleep disorders</td> </tr> <tr> <td class=\"indent1\">Obstructive sleep apnea</td> </tr> <tr> <td class=\"indent1\">Central sleep apnea</td> </tr> <tr> <td class=\"indent1\">Sleep-related hypoventilation or hypoxemia</td> </tr> <tr> <td class=\"indent1\">Central disorders of hypersomnolence&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Narcolepsy type 1 or 2</td> </tr> <tr> <td class=\"sublist2\">Kleine-Levin syndrome</td> </tr> <tr> <td class=\"sublist2\">Idiopathic hypersomnia</td> </tr> <tr> <td class=\"sublist2_start\">Circadian rhythm sleep-wake disorders</td> </tr> <tr> <td class=\"sublist2\">Delayed sleep phase disorder</td> </tr> <tr> <td class=\"sublist2\">Advanced sleep phase disorder</td> </tr> <tr> <td class=\"sublist2\">Jet lag</td> </tr> <tr> <td class=\"sublist2\">Shift work</td> </tr> <tr> <td class=\"indent1\">Restless legs syndrome</td> </tr> <tr> <td class=\"indent1\">Periodic limb movement disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Other neurologic disorders</td> </tr> <tr> <td class=\"sublist2_start\">Neurodegenerative disease</td> </tr> <tr> <td class=\"sublist2\">Parkinson disease</td> </tr> <tr> <td class=\"sublist2\">Dementia with Lewy bodies</td> </tr> <tr> <td class=\"sublist2\">Alzheimer disease</td> </tr> <tr> <td class=\"sublist2\">Multiple system atrophy</td> </tr> <tr> <td class=\"indent1\">Myotonic dystrophy</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Amyotrophic lateral sclerosis (via sleep-related breathing disorders)</td> </tr> <tr> <td class=\"indent1\">Structural lesions affecting thalamus, hypothalamus, or brainstem</td> </tr> <tr> <td class=\"indent1\">Traumatic brain injury</td> </tr> <tr> <td class=\"indent1\">Encephalitis lethargica</td> </tr> <tr> <td class=\"indent1\">Cerebral trypanosomiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Medical and genetic disorders</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">End-stage renal disease</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Hepatic encephalopathy</td> </tr> <tr> <td class=\"indent1\">Niemann-Pick type C</td> </tr> <tr> <td class=\"indent1\">Prader-Willi syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric disorders</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"sublist2_start\">Substance abuse</td> </tr> <tr> <td class=\"sublist2\">Alcohol</td> </tr> <tr> <td class=\"sublist2\">Narcotics</td> </tr> <tr> <td class=\"sublist2\">Prescription opioid abuse</td> </tr> <tr> <td class=\"sublist2\">Stimulant withdrawal</td> </tr> <tr> <td class=\"indent1\">Psychogenic sleepiness</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Nonbenzodiazepine sedatives</td> </tr> <tr> <td class=\"indent1\">Antipsychotics</td> </tr> <tr> <td class=\"indent1\">Opioid analgesics</td> </tr> <tr> <td class=\"indent1\">Beta-blockers (lipophilic)</td> </tr> <tr> <td class=\"indent1\">Barbiturates</td> </tr> <tr> <td class=\"indent1\">Antihistamines</td> </tr> <tr> <td class=\"indent1\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Sedative antidepressants</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86811 Version 10.0</div></div></div>"},"86812":{"type":"graphic_table","displayName":"Key questions for tired patient","title":"Key questions in evaluating the tired patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key questions in evaluating the tired patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key questions in the evaluation of a patient who complains of sleepiness, tiredness, fatigue, or low energy</td> </tr> <tr> <td class=\"subtitle2_single\">Questions about sleepiness</td> </tr> <tr> <td class=\"indent1\"> <p>Do you feel sleepy during the day?</p> <p>Is daytime sleepiness a problem for you?</p> <p>Is it difficult to keep your eyes open at times during the day?</p> <p>Do you struggle to stay awake during the day?</p> <p>Do you take naps?</p> <p>How often and how long do you nap during the day?</p> <p>Do you fall asleep at times you do not want to (ie, watching a movie, reading a book, or on long drives)?</p> </td> </tr> <tr> <td class=\"subtitle2_single\">Questions about tiredness, fatigue, and low energy</td> </tr> <tr> <td class=\"indent1\"> <p>Do you lack the energy to go about your daily activities?</p> <p>Do you tire easily, or sooner than others, when you are active?</p> <p>Do you feel physically or mentally exhausted?</p> </td> </tr> <tr> <td class=\"subtitle2_single\">Questions to differentiate sleepiness from related complaints</td> </tr> <tr> <td class=\"indent1\"> <p>Does your problem bother you more if you sit to read for an hour, or if you go out shopping for an hour?</p> <p>Which of the following is the single most important problem for you: sleepiness, tiredness, fatigue, or lack of energy?</p> <p>Which of the following most interferes with your ability to accomplish what you would like to: sleepiness, tiredness, fatigue, or lack of energy?</p> <p>Which of the following is the one problem you would most like to address effectively: sleepiness, tiredness, fatigue, or lack of energy?</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><ol>&#xD;&#xA;    <li>Bodkin CL, Manchanda S. Office evaluation of the \"tired\" or \"sleepy\" patient. Semin Neurol 2011; 31:42. </li>&#xD;&#xA;    <li>Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest 2000; 118:372. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86812 Version 2.0</div></div></div>"},"86813":{"type":"graphic_picture","displayName":"Lichen planopilaris with erythema","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/86813_Lichen_planopil_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarring alopecia due to lichen planopilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Ginat Mirowski.</div><div id=\"graphicVersion\">Graphic 86813 Version 1.0</div></div></div>"},"86815":{"type":"graphic_table","displayName":"DMARDs PI","title":"Commonly used disease modifying antirheumatic drugs (DMARDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used disease modifying antirheumatic drugs (DMARDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">US brand names</td> <td class=\"subtitle1\">How it is usually taken</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Traditional DMARDs</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> <td> <p>Pills: Rheumatrex, Trexall</p> Auto-injectors (these let you give yourself a shot): Otrexup, Rasuvo</td> <td> <p>Pill taken 1 time a week</p> <p>Shot under skin or in a muscle 1 time a week</p> <p>IMPORTANT: <strong>Methotrexate is only taken once per week.</strong> Always double check the instructions with your doctor and pharmacist when you get a new prescription.</p> </td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> <td>Azulfidine, Azulfidine EN tabs</td> <td>Pill taken 1 to&nbsp;2 times a day</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine</td> <td>Plaquenil</td> <td>Pill taken 1 to 2 times a day</td> </tr> <tr> <td class=\"indent1\">Leflunomide</td> <td>Arava</td> <td>Pill taken 1 time a day</td> </tr> <tr> <td class=\"indent1\">Cyclosporine (ciclosporin)</td> <td>Gengraf, Neoral, Sandimmune</td> <td>Pill taken 2 times a day</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> <td>Imuran, Azasan</td> <td>Pill taken 1 to 2 times a day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Biologic DMARDs</td> </tr> <tr> <td class=\"indent1\">Etanercept</td> <td>Enbrel</td> <td>Shot under skin 1 or 2 times a week</td> </tr> <tr> <td class=\"indent1\">Adalimumab</td> <td>Humira</td> <td>Shot under skin 1 time every 2 weeks</td> </tr> <tr> <td class=\"indent1\">Infliximab</td> <td>Remicade</td> <td>In a vein (IV) at clinic or doctor's office 1 time every 2 to 8 weeks</td> </tr> <tr> <td class=\"indent1\">Certolizumab pegol</td> <td>Cimzia</td> <td>Shot under skin 1 time every 2 weeks</td> </tr> <tr> <td class=\"indent1\">Golimumab</td> <td>Simponi</td> <td> <p>Shot under skin 1 time every month; or</p> In a vein (IV) at clinic or doctor's office 1 time every 8 weeks</td> </tr> <tr> <td class=\"indent1\">Anakinra</td> <td>Kineret</td> <td>Shot under skin 1 time a day</td> </tr> <tr> <td class=\"indent1\">Abatacept</td> <td>Orencia</td> <td> <p>Shot under skin 1 time a week; or</p> In a vein (IV) at clinic or doctor's office 1 time every 4 weeks</td> </tr> <tr> <td class=\"indent1\">Rituximab</td> <td>Rituxan</td> <td> <p>In a vein (IV) at clinic or doctor's office and repeated after 2 weeks and stopped;</p> It may be given again after 4 to 6 months</td> </tr> <tr> <td class=\"indent1\">Tocilizumab</td> <td>Actemra</td> <td> <p>Shot under skin 1 time every 1 or 2 weeks; or</p> In a vein (IV) at clinic or doctor's office 1 time every 4 weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"><strong>Other DMARDs</strong></td> </tr> <tr> <td class=\"indent1\">Tofacitinib</td> <td>Xeljanz</td> <td>Pill taken 2 times a day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: Intravenous is given through a small tube in a vein called an \"IV\". The IV medicines are given in a doctor's office or clinic over a period of a half-hour or longer.</div><div id=\"graphicVersion\">Graphic 86815 Version 5.0</div></div></div>"},"86816":{"type":"graphic_picture","displayName":"Prurigo nodularis 3","title":"Prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86816_Prurigonodularis3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A prurigo nodularis nodule showing peripheral hyperpigmentation and central scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86816 Version 6.0</div></div></div>"},"86817":{"type":"graphic_picture","displayName":"Prurigo nodularis 4","title":"Prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/86817_Prurigonodularis4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, firm nodules on the leg of a patient with prurigo nodularis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86817 Version 5.0</div></div></div>"},"86818":{"type":"graphic_table","displayName":"Sulfasalazine and 5-ASA formulations","title":"Sulfasalazine and 5-aminosalicylic acid (5-ASA) formulations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sulfasalazine and 5-aminosalicylic acid (5-ASA) formulations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Trade name (US or as noted)</td> <td class=\"subtitle1\">Strength of commonly available oral preparations (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral 5-aminosalycylic acid (5-ASA) derivatives</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Sulfasalazine</td> </tr> <tr> <td class=\"sublist2\">Non enteric-coated tablet (scored)</td> <td class=\"sublist_other\">Azulfidine, Sulfazine, Salazopyrin*</td> <td class=\"sublist_other\">500</td> </tr> <tr> <td class=\"sublist2\">Suspension</td> <td class=\"sublist_other\">Salazopyrin*</td> <td class=\"sublist_other\">250 per 5 mL*</td> </tr> <tr> <td class=\"sublist2\">Enteric-coated tablet (not scored)</td> <td class=\"sublist_other\">Azulfidine EC, Sulfazine EC, Salazopyrin EN-tabs*</td> <td class=\"sublist_other\">500</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Mesalamine<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Delayed release enteric-coated tablet</td> <td class=\"sublist_other\">Asacol<sup>&#916;</sup><sup>&#9674;</sup>, Asacol HD<sup>&#9674;</sup></td> <td class=\"sublist_other\">400<sup>&#916;</sup>, 800</td> </tr> <tr> <td class=\"sublist2\">Capsule containing delayed release tablet</td> <td class=\"sublist_other\">Delzicol</td> <td class=\"sublist_other\">400</td> </tr> <tr> <td class=\"sublist2\">Delayed and extended release tablet, multimatrix</td> <td class=\"sublist_other\">Lialda, Mezavant*</td> <td class=\"sublist_other\">1200</td> </tr> <tr> <td class=\"sublist2\">Capsule containing delayed release enteric-coated granules</td> <td class=\"sublist_other\">Apriso</td> <td class=\"sublist_other\">375</td> </tr> <tr> <td class=\"sublist2\">Controlled release capsule</td> <td class=\"sublist_other\">Pentasa<sup>&#167;</sup></td> <td class=\"sublist_other\">250, 500, 1000*</td> </tr> <tr> <td class=\"sublist2\">Enteric-coated delayed release granules (packet, sachet)</td> <td class=\"sublist_other\">Salofalk*, Pentasa Sachet*</td> <td class=\"sublist_other\">500, 1000, 1500, 2000 sachet*</td> </tr> <tr> <td class=\"indent1\">Olsalazine capsule</td> <td>Dipentum</td> <td>250, 500*</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Balsalazide</td> </tr> <tr> <td class=\"sublist2\">Capsule</td> <td class=\"sublist_other\">Colazal, Colazide*</td> <td class=\"sublist_other\">750</td> </tr> <tr> <td class=\"sublist2\">Tablet</td> <td class=\"sublist_other\">Giazo<sup>&#165;</sup></td> <td class=\"sublist_other\">1100</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: United States.<br />* Not available in US. Trade names shown are for products commonly available elsewhere (eg, Canada, United Kingdom, and Europe).<br />¶ Mesalamine is US generic name. Mesalazine is an international generic name.<br />Δ Asacol 400 mg tablets are no longer marketed in US. Asacol 400 mg delayed-release tablets and generic versions are available widely elsewhere.<br /><FONT class=lozenge>◊</FONT> Asacol HD (and Asacol, formerly available in US) are not considered safe in pregnancy due to dibutyl phthalate (DBP) inactive ingredient of enteric-coating; the manufacturer of Asacol HD is changing the preparation to no longer include DBP, but until that is complete, patients should be switched to a different 5-ASA during pregnancy; other US available mesalamine preparations listed within this table do not contain DBP. Consult product information for detail: <A href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/index.cfm</A>. <br />§ According to US prescribing information, Pentasa capsules can be swallowed whole or opened and contents sprinkled over spoonful of applesauce or yogurt and swallowed immediately; capsule contents should not be crushed or chewed.<br />¥ US approval is limited to treatment of ulcerative colitis in male patients; failed to demonstrate efficacy in female patients.</div><div class=\"graphic_reference\">Data courtesy of authors with additional data from: Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.</div><div id=\"graphicVersion\">Graphic 86818 Version 12.0</div></div></div>"},"86819":{"type":"graphic_picture","displayName":"Posterior shoulder capsule stretch","title":"Posterior shoulder capsule stretch","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder capsule stretch</div><div class=\"cntnt\"><img style=\"width:515px; height:209px;\" src=\"images/EM/86819_Post_should_cap_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow bent to 90 degrees, extend your shoulder until your forearm is parallel to the ground and directly in front of you. Using the opposite hand, grasp behind your elbow and gradually pull your arm across your body.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86819 Version 1.0</div></div></div>"},"86820":{"type":"graphic_movie","displayName":"Isometric internal rotation exercise for shoulder","title":"Isometric internal rotation exercise for shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Isometric internal rotation exercise for shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86820_Isointrotatexershvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/86820_Isointrotatexershimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric exercises for the subscapularis are often unnecessary, but may be performed if needed in the manner demonstrated in this video clip.</div><div class=\"graphic_reference\">Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.</div><div id=\"graphicVersion\">Graphic 86820 Version 1.0</div></div></div>"},"86821":{"type":"graphic_algorithm","displayName":"Algorithm for the diagnosis of abdominal aortic aneurysm","title":"Algorithm for the diagnosis of abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:714px; height:468px;\" src=\"images/SURG/86821_Algo_diagnosis_AAA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; H/P: history and physical; CT: computed tomography; OR: operating room; MRI: magnetic resonance imaging.<br />* Systolic BP persists &lt;90 mmHg, in spite of resuscitation.<br />&para; Intravenous contrast is not absolutely required to diagnose rupture, but is highly desired if endovascular repair is an option.<br />&Delta; Unrepaired, or prior open or endovascular repair.<br /><span class=\"lozenge\">&loz;</span> Ultrasound, abdominal CT, or MRI may be appropriate.<br />&sect; Can be performed at the bedside or in the operating room.</div><div id=\"graphicVersion\">Graphic 86821 Version 3.0</div></div></div>"},"86822":{"type":"graphic_picture","displayName":"Nail lichen planus pterygium","title":"Pterygium in lichen planus of the nail","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pterygium in lichen planus of the nail</div><div class=\"cntnt\"><img style=\"width:504px; height:426px;\" src=\"images/DERM/86822_Nail_lichen_planus_pteryg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proximal nail fold is adherent to the nail bed.</div><div class=\"graphic_reference\">Reproduced with permission from&nbsp;Bethanee J Schlosser, MD, PhD.</div><div id=\"graphicVersion\">Graphic 86822 Version 3.0</div></div></div>"},"86824":{"type":"graphic_figure","displayName":"Variation in causes of maternal mortality worldwide","title":"Variation in causes of maternal mortality worldwide","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Variation in causes of maternal mortality worldwide</div><div class=\"cntnt\"><img style=\"width:570px; height:549px;\" src=\"images/OBGYN/86824_Var_cs_matern_mort_world.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Khan KS, Wojdyla D, Say L, G&uuml;lmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066.</div><div id=\"graphicVersion\">Graphic 86824 Version 1.0</div></div></div>"},"86825":{"type":"graphic_table","displayName":"FEC plus paclitaxel for MBC","title":"Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel for metastatic breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel for metastatic breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days (FEC), 7 days (paclitaxel).<br /> <strong>Duration of therapy:</strong> 4 cycles (FEC), 8 weeks (paclitaxel).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td colspan=\"4\"><strong>Cycles 1 through 4</strong></td> </tr> <tr> <td>Fluorouracil</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as slow IV push over five minutes.</td> <td>Day 1</td> </tr> <tr> <td>Epirubicin</td> <td>90 mg/m<sup>2</sup> IV</td> <td>Administer as an IV push into a free flowing IV solution with normal saline (NS) or 5% dextrose (D5W), generally over 3 to 20 minutes. May dilute in NS or D5W and infuse over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS or D5W and administer over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>Cycles 5 through 12</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS* and administer over one hour; special tubing needed.<sup>&#182;</sup></td> <td>Weekly for 8 weeks</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days after) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>The emesis risk with FEC is HIGH (&#62;90% frequency of emesis). </li> <li>The emesis risk with paclitaxel monotherapy is LOW (10 to 30% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is a vesicant; avoid extravasation.<sup>[4]</sup> Paclitaxel can cause significant tissue damage; avoid extravasation.<sup>[3]</sup> Fluorouracil and cyclophosphamide are irritants. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment. A lower starting dose of fluorouracil may be needed for patients with liver impairment, dihydropyrimidine dehydrogenase (DPD) deficiency, or renal impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. A lower starting dose of epirubicin may be needed in patients with renal or hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess liver and renal function tests prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to and during each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment with paclitaxel. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative epirubicin dose. Reassess LVEF periodically during therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If the ANC &#8804;1500 cells/microL or platelets &#8804;75,000/microL on day 1 of each cycle, therapy should be delayed until counts recover. For grade 3 clinically relevant toxicity during treatment, reduce doses of all drugs by 25%.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold fluorouracil for grade 3 diarrhea or mucositis until recovery to &#8804;grade 1. Upon recovery, reduce fluorouracil dose by 25%.<sup>[1]</sup> Discontinue therapy for grade 4 gastrointestinal (or other non-hematologic) toxicity.<sup>[1]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 or higher peripheral neuropathy reduce paclitaxel doses by 20%.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue therapy for any clinically significant adverse cardiac events.<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; CBC: complete blood count; G-CSF: granulocyte-colony stimulating factor; IV: intravenous; ULN: upper limit of normal.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br />Δ For any clinically relevant grade 3 toxicity, consider reducing the dose of all drugs by 25%, and discontinue therapy for any nonhematologic grade 4 toxicity.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Martin M, et al. J Nat Cancer Inst 2008; 100:805.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86825 Version 7.0</div></div></div>"},"86826":{"type":"graphic_table","displayName":"FEC plus docetaxel for MBC","title":"Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by docetaxel for metastatic breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by docetaxel for metastatic breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> 6.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td colspan=\"4\"><strong>Cycles 1 through 3</strong></td> </tr> <tr> <td>Fluorouracil</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as slow IV push over five minutes.</td> <td>Day 1</td> </tr> <tr> <td>Epirubicin</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Administer as an IV push into a free flowing IV solution with normal saline (NS) or 5% dextrose (D5W), generally over 3 to 20 minutes. May dilute in NS or D5W and infuse over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS or D5W and administer over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>Cycles 4 through 6</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Docetaxel</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS or D5W to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days after) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>The emesis risk with FEC is HIGH (&#62;90% frequency of emesis). </li> <li>The emesis risk with docetaxel monotherapy is LOW (10 to 30% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is a vesicant; avoid extravasation.<sup>[4]</sup> Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation.<sup>[3]</sup> Fluorouracil and cyclophosphamide are irritants. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (incidence of neutropenic fever is 11%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of fluorouracil may be needed for patients with liver impairment, known dihydropyrimidine dehydrogenase (DPD) deficiency, or renal impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. A lower starting dose of epirubicin may be needed in patients with renal or hepatic impairment. Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 times the ULN in conjunction with alkaline phosphatase &#62;2.5 times the ULN.<sup>[3]</sup>. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess liver and renal function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to and during each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment with docetaxel. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative epirubicin dose. Reassess LVEF during therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If ANC &#8804;1000 cells/microL or platelets &#8804;100,000/microL on day 1 of each cycle, delay therapy until counts recover.<sup>[1]</sup> Dose reductions are suggested for ANC &#8804;500 cells/microL for &#62;5 days, ANC &#60;100 cells/microL for &#62;3 days, a platelet count &#60;25,000/microL, or febrile neutropenia. Reduce dose as follows upon recovery of counts to &#8804;grade 1: Fluorouracil (375 mg/m<sup>2</sup>), epirubicin (75 mg/m<sup>2</sup>), cyclophosphamide (375 mg/m<sup>2</sup>), and docetaxel (75 mg/m<sup>2</sup>).<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Grade 3 diarrhea or mucositis, reduce doses as follows upon recovery: Fluorouracil (375 mg/m<sup>2</sup>), epirubicin (75 mg/m<sup>2</sup>), cyclophosphamide (375 mg/m<sup>2</sup>), and docetaxel (75 mg/m<sup>2</sup>).<sup>[1]</sup> For grade 4 diarrhea, hold treatment.<sup>[4]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesias</strong></td> <td colspan=\"3\"> <ul> <li>Hold fluorouracil for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[5]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; CBC: complete blood count; G-CSF: granulocyte-colony stimulating factor; IV: intravenous.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Wildiers H, et al. Breast Cancer Res Treat 2009; 114:103.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86826 Version 8.0</div></div></div>"},"86827":{"type":"graphic_table","displayName":"IV CMF for breast cancer","title":"IV cyclophosphamide, methotrexate, and fluorouracil chemotherapy for breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IV cyclophosphamide, methotrexate, and fluorouracil chemotherapy for breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days.<br /> <strong>Total cycles:</strong> 6.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over 30 to 60 minutes.</td> <td>Days 1 and 8</td> </tr> <tr> <td>Methotrexate</td> <td>40 mg/m<sup>2</sup> IV</td> <td>Drug is available in a 25 mg/mL solution that needs no further dilution. It can be administered as a slow IV push.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as IV push.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients should maintain adequate oral hydration (2 to 3 L/day) and void frequently to reduce risk of hemorrhagic cystitis.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>No specific premedication regimen is indicated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting dose of methotrexate may be needed in patients with renal impairment and in those with third space fluid collections (eg, ascites, pleural effusion). Methotrexate should not be administered in the setting of liver impairment. A lower starting dose of fluorouracil may be needed for patients with liver impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential on days 1 and 8 of each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess serum electrolytes and liver and renal function tests on or prior to day 1. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If the ANC &#8804;1500 cells/microL or platelets &#8804;100,000/microL on day 1 and day 8 of each cycle, therapy should be delayed until counts recover. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold fluorouracil for grade 2 or worse diarrhea and restart at a lower dose after complete resolution. </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>Hold fluorouracil for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count; G-CSF: granulocyte-colony stimulating factor.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jakesz R, et al. J Clin Oncol 2002; 20:4621.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 30, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86827 Version 7.0</div></div></div>"},"86828":{"type":"graphic_table","displayName":"FEC for MBC","title":"Fluorouracil, epirubicin, and cyclophosphamide (FEC) for metastatic breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluorouracil, epirubicin, and cyclophosphamide (FEC) for metastatic breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> 6 to 8 cycles.* </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Fluorouracil</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as IV push.</td> <td>Day 1</td> </tr> <tr> <td>Epirubicin</td> <td>100 mg/m<sup>2</sup> IV<sup>&#182;</sup></td> <td>Administer into a free flowing IV solution with normal saline (NS), generally over 3 to 20 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclophosphamide</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 NS or 5% dextrose in water (D5W) and administer over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients should maintain adequate oral hydration (2 to 3 L/day) and void frequently to reduce risk of hemorrhagic cystitis.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is a vesicant, fluorouracil and cyclophosphamide are irritants; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of fluorouracil may be needed for patients with liver impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. A lower starting dose of epirubicin may be needed in patients with renal or hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction (LVEF &#60;50%), severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess liver and renal function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to and during each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative epirubicin dose. Reassess LVEF periodically during FEC therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If the ANC &#60;1500 cells/microL and platelets &#60;100,000/microL on day 1 of each cycle, therapy should be delayed until counts recover. For mid-cycle platelet count &#60;40,000/microL and ANC &#60;500 cells/microL, reduce epirubicin by 10 mg/m<sup>2</sup>.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For &#8805;grade 2 mucositis (or other non-hematologic toxicity), reduce epirubicin by 10 mg/m<sup>2</sup>.<sup>[1]</sup> Withhold fluorouracil for grade 2 or worse diarrhea and restart at a lower dose after complete resolution.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, if cardiac symptoms developed or if during treatment the LVEF decreased by &#8805;10% in absolute value below the lowest normal limit, or &#8805;15% below the patient's own baseline, treatment was discontinued.<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesias</strong></td> <td colspan=\"3\"> <ul> <li>Hold fluorouracil for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; CBC: complete blood count; IV: intravenous; G-CSF: granulocyte-colony stimulating factor.<br />* Anticipated treatment duration is six cycles. If a complete response is reached, two additional cycles may be given for a total of eight cycles.<br />¶ Epirubicin may be increased in successive cycles by 10 mg/m<SUP>2</SUP> until a maximal dose per cycle of 120 mg/m<SUP>2</SUP> if appropriate hematological toxicity parameters are met. Refer to section above on \"Suggested dose modifications for toxicity\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Brufman G, et al. Ann Oncol 1997; 8:155.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 86828 Version 9.0</div></div></div>"},"86829":{"type":"graphic_picture","displayName":"Perforating dermatosis 2","title":"Acquired reactive perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acquired reactive perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86829_Perforatingdermatosis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A group of umbilicated papules with a central keratinous plug on the legs of a patient with acquired perforating dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86829 Version 6.0</div></div></div>"},"86830":{"type":"graphic_picture","displayName":"Perforating dermatosis 3","title":"Acquired reactive perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acquired reactive perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86830_Perforatingdermatosis3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dome-shaped, umbilicated papules with a central keratinous plug on the legs of a patient with&nbsp;acquired perforating dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86830 Version 7.0</div></div></div>"},"86831":{"type":"graphic_picture","displayName":"Perforating dermatosis 4","title":"Acquired reactive perforating dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acquired reactive perforating dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86831_Perforatingdermatosis4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilicated papules with a central keratin plug on the fingers of a patient with perforating folliculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86831 Version 6.0</div></div></div>"},"86832":{"type":"graphic_figure","displayName":"Intraoperative hemodynamic stability with adequate alpha block","title":"Intraoperative hemodynamic stability during resection of a catecholamine-secreting tumor with adequate alpha blockade","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Intraoperative hemodynamic stability during resection of a catecholamine-secreting tumor with adequate alpha blockade</div><div class=\"cntnt\"><img style=\"width:504px; height:328px;\" src=\"images/ONC/86832_Intraop_hem_stab_ad_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative hemodynamic stability during resection of a catecholamine-secreting tumor&nbsp;is the goal of preoperative pharmacologic blockade. Depicted is the operative record of vital signs for an adult patient who underwent resection of a large functional paraganglioma located at the organ of Zuckerkandl. The anesthesiologist's notations document that throughout induction, mobilization of the tumor, resection and extubation, the heart rate remained stable at 84-98 and systolic blood pressure remained stable at 90-122.</div><div class=\"graphic_reference\">Courtesy of Dr. Sally Carty.</div><div id=\"graphicVersion\">Graphic 86832 Version 1.0</div></div></div>"},"86837":{"type":"graphic_table","displayName":"Diagnostic criteria for RLS","title":"Diagnostic criteria for restless legs syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for restless legs syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">RLS, a neurologic sensorimotor disease often profoundly disturbing sleep and quality of life, has variable expression influenced by genetic, environmental, and medical factors. The symptoms vary considerably in frequency from less than once a month or year to daily and severity from mildly annoying to disabling. Symptoms may also remit for various periods of time. RLS is diagnosed by ascertaining symptom patterns that meet the following five essential criteria, adding clinical specifiers where appropriate.</td> </tr> <tr> <td class=\"subtitle2_single\">Essential diagnostic criteria (all must be met):</td> </tr> <tr> <td class=\"indent2\">1. An urge to move the legs usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs.*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">2. The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying down or sitting.</td> </tr> <tr> <td class=\"indent2\">3. The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">4. The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">5. The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral condition (eg, myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping).<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Specifiers for clinical course of RLS:<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent2\">A. Chronic-persistent RLS: Symptoms when not treated would occur on average at least twice weekly for the past year.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">B. Intermittent RLS: Symptoms when not treated would occur on average &#60;2/week for the past year, with at least five lifetime events.</td> </tr> <tr> <td class=\"subtitle2_single\">Specifier for clinical significance of RLS:</td> </tr> <tr> <td class=\"indent2\">The symptoms of RLS cause significant distress or impairment in social, occupational, educational, or other important areas of functioning by their impact on sleep, energy/vitality, daily activities, behavior, cognition, or mood.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS: restless legs syndrome.<br />* Sometimes the urge to move the legs is present without the uncomfortable sensations, and sometimes the arms or other parts of the body are involved in addition to the legs.<br />¶ For children, the description of these symptoms should be in the child's own words.<br />Δ When symptoms are very severe, relief by activity may not be noticeable but must have been previously present.<br /><FONT class=lozenge>◊</FONT> When symptoms are very severe, the worsening in the evening or night may not be noticeable but must have been previously present.<br />§ These conditions, often referred to as \"RLS mimics,\" have been commonly confused with RLS particularly in surveys because they produce symptoms that meet or at least come very close to meeting criteria 1 to 4. The list here gives some examples that have been noted as particularly significant in epidemiologic studies and clinical practice. RLS may also occur with any of these conditions, but the RLS symptoms will then be more in degree, conditions of expression or character than those usually occurring as part of the other condition.<br />¥ The clinical course criteria do not apply for pediatric cases nor for some special cases of provoked RLS, such as pregnancy or drug-induced RLS, where the frequency may be high but limited to duration of the provocative condition.</div><div class=\"graphic_reference\">Reproduced with permission from: 2012 Revised IRLSSG Diagnostic Criteria for RLS. IRLSSG, 2012. Copyright &copy; 2012 International Restless Legs Syndrome Study Group. &nbsp;<a href=\"http://www.irlssg.org/\" spellcheck=\"true\" target=\"_blank\">www.irlssg.org</a>.</div><div id=\"graphicVersion\">Graphic 86837 Version 10.0</div></div></div>"},"86838":{"type":"graphic_table","displayName":"Considerations for the diagnosis of pediatric RLS","title":"Important considerations for the diagnosis of pediatric restless legs syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important considerations for the diagnosis of pediatric restless legs syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>The child must describe the RLS symptoms in his/her own words </li> </ul> </td> </tr> <tr> <td> <ul> <li>The diagnostician should be aware of the typical words children and adolescents use to describe RLS </li> </ul> </td> </tr> <tr> <td> <ul> <li>Language and cognitive development determine the applicability of the RLS diagnostic criteria, rather than age </li> </ul> </td> </tr> <tr> <td> <ul> <li>As in adults, a significant impact on sleep, mood, cognition, and function is found. However, impairment is manifest more often in behavioral and educational domains. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Periodic limb movement disorder (PLMD) may precede the diagnosis of RLS in some cases </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS: restless legs syndrome; PLMD: periodic limb movement disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: the International Restless Legs Syndrome Study Group (<a href=\"http://www.irlssg.org/\" target=\"_blank\">www.irlssg.org</a>). Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 86838 Version 1.0</div></div></div>"},"86839":{"type":"graphic_table","displayName":"Diagnostic criteria for periodic limb movement disorder","title":"Diagnostic criteria for periodic limb movement disorder (PLMD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for periodic limb movement disorder (PLMD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Polysomnography shows repetitive, highly stereotyped limb movements that are:</td> </tr> <tr> <td class=\"sublist1\">0.5 to 10 seconds in duration,</td> </tr> <tr> <td class=\"sublist1\">Minimum amplitude of 8 mV above resting EMG,</td> </tr> <tr> <td class=\"sublist1\">In a sequence of four or more movements, and</td> </tr> <tr> <td class=\"sublist1\">Separated by an interval of more than 5 seconds (from limb movement onset to limb movement onset) and less than 90 seconds</td> </tr> <tr> <td>The PLMS index is &#8805;5/hour in pediatric cases and &#8805;15/hour in adult cases</td> </tr> <tr> <td>PLMS cause clinical sleep disturbance&nbsp;(difficulty with sleep initiation, sleep maintenance, and/or unrefreshing sleep) or impaired daytime function*</td> </tr> <tr> <td>The PLMS are not better explained by another current sleep disorder,<sup>&#182;</sup> medical or neurologic disorder, mental disorder, medication use, or substance use disorder (eg, exclude from PLMS counts the movements at the termination of cyclically occurring apneas)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PLMD: periodic limb movement disorder; EMG: electromyogram; PLMS: periodic limb movements of sleep; RLS: restless legs syndrome.<br />* If PLMS are present without clinical sleep disturbance or impaired daytime function, the PLMS can be noted as a polysomnographic&nbsp;ﬁnding, but criteria are not met for a diagnosis of PLMD. <br />¶ A diagnosis of RLS supersedes a diagnosis of PLMD. Thus, a patient can have RLS with PLMS, but not RLS and PLMD.</div><div class=\"graphic_reference\">Modified from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.</LI>&#xD;&#xA;<LI>Berry RB, Brooks R, Gamaldo CE, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.3, American Academy of Sleep Medicine, Darien, IL 2016.&nbsp;Available at: www.aasmnet.org. </LI></OL></div><div id=\"graphicVersion\">Graphic 86839 Version 9.0</div></div></div>"},"86840":{"type":"graphic_table","displayName":"Differential diagnosis of pediatric restless legs syndrome","title":"Differential diagnosis of pediatric restless legs syndrome (RLS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pediatric restless legs syndrome (RLS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common conditions</td> </tr> <tr> <td>Positional discomfort</td> </tr> <tr> <td>Sore leg muscles</td> </tr> <tr> <td>Ligament sprain/tendon strain</td> </tr> <tr> <td>Positional ischemia (numbness)</td> </tr> <tr> <td>Dermatitis</td> </tr> <tr> <td>Bruises</td> </tr> <tr> <td>Growing pains</td> </tr> <tr> <td>Nocturnal leg cramps</td> </tr> <tr> <td class=\"subtitle1_single\">Less common</td> </tr> <tr> <td>Arthritis</td> </tr> <tr> <td>Other orthopedic disorders</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td>Radiculopathy</td> </tr> <tr> <td>Myelopathy</td> </tr> <tr> <td>Myopathy</td> </tr> <tr> <td>Fibromyalgia</td> </tr> <tr> <td>Complex regional pain syndrome</td> </tr> <tr> <td>Drug-induced akathisia</td> </tr> <tr> <td>Sickle cell disease</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Daniel Picchietti, MD.</div><div id=\"graphicVersion\">Graphic 86840 Version 1.0</div></div></div>"},"86842":{"type":"graphic_figure","displayName":"Proximal control of subclavian artery","title":"Proximal control of subclavian artery","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Proximal control of subclavian artery</div><div class=\"cntnt\"><img style=\"width:530px; height:387px;\" src=\"images/SURG/86842_Control_of_subclavian_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For open control of the proximal subclavian artery at the aortic arch, an anterior thoracotomy is the incision of choice. The incision is made medially on the anterior surface of the left chest in the second rib interspace and carried down along the superior margin of the third rib to avoid injury to the intercostal neurovascular bundle. After entering the left chest, a Finochietto retractor is inserted between the ribs to improve exposure. With a combination of sharp and blunt dissection, the aortic arch and the left subclavian origin can be exposed.</div><div id=\"graphicVersion\">Graphic 86842 Version 1.0</div></div></div>"},"86843":{"type":"graphic_diagnosticimage","displayName":"Subcapsular liver hematoma on MR","title":"Subcapsular liver hematoma on MR","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Subcapsular liver hematoma on MR</div><div class=\"cntnt\"><img style=\"width:513px; height:198px;\" src=\"images/RADIOL/86843_Subcaps_liv_hemat_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These magnetic resonance (MR) images are from a patient with HELLP (Hemolysis, Elevated Liver enzymes, Low platelet count) syndrome and a subcapsular liver hematoma.<br />(A) The T2 weighted image shows a 9 mm hyperintense focus (arrow) that could represent a small laceration or a hepatic cyst.<br />(B) The T1 weighted image shows an adjacent subcapsular hematoma (arrowhead) with both hyperintense and hypointense components reflecting a complex solid thrombus. The subcapsular hematoma was estimated as occupying less than 10 percent of the liver surface.</div><div id=\"graphicVersion\">Graphic 86843 Version 2.0</div></div></div>"},"86844":{"type":"graphic_diagnosticimage","displayName":"Grade II liver hematoma CT scan","title":"Grade II liver hematoma CT scan","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Grade II liver hematoma CT scan</div><div class=\"cntnt\"><img style=\"width:474px; height:329px;\" src=\"images/RADIOL/86844_Grad_II_liv_hem_ultra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan shows a lenticular-shaped high density collection (arrow) in segment IV of the liver consistent with a grade II acute hematoma. A small collection of fluid is noted in the left anterior pararenal space (arrowhead) that could represent acute pancreatic injury.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86844 Version 2.0</div></div></div>"},"86845":{"type":"graphic_diagnosticimage","displayName":"Grade II subcapsular liver hematoma on ultrasound and CT","title":"Grade II subcapsular liver hematoma on ultrasound and CT","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Grade II subcapsular liver hematoma on ultrasound and CT</div><div class=\"cntnt\"><img style=\"width:599px; height:224px;\" src=\"images/RADIOL/86845_Grad_II_subcap_liver_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan (A) shows a large subcapsular hematoma occupying more than 10 percent of the surface of the liver indicating a Grade II liver injury. The hematoma compresses the normal liver (small double arrowheads) and contains high density clotted blood (small double arrowheads). The ultrasound (B) shows the subcapsular hematoma with linear strands of fibrinous material (double arrow) and cystic spaces (large double arrowheads) of complex clotted blood.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86845 Version 2.0</div></div></div>"},"86846":{"type":"graphic_diagnosticimage","displayName":"Grade III liver laceration and hematoma on ultrasound and CT","title":"Grade III liver laceration and hematoma on ultrasound and CT","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Grade III liver laceration and hematoma on ultrasound and CT</div><div class=\"cntnt\"><img style=\"width:601px; height:273px;\" src=\"images/RADIOL/86846_Grad_III_liv_lac_hem_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound (A) shows an almost isoechoic intraparenchymal hematoma in the liver (arrow) that mesasures 4.4 cm (+---+). The CT scan, reformatted in the coronal plane (B), shows a 4 cm laceration (dashed arrow) with a subcapsular hematoma (arrowhead) that was estimated to occupy more than 10 percent of the surface of the liver. The depth of the laceration &gt;3 cm characterizes this as a grade III injury.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86846 Version 2.0</div></div></div>"},"86847":{"type":"graphic_diagnosticimage","displayName":"Grade IV traumatic liver injury on computed tomography","title":"Grade IV traumatic liver injury on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Grade IV traumatic liver injury on computed tomography</div><div class=\"cntnt\"><img style=\"width:600px; height:438px;\" src=\"images/RADIOL/86847_CT_liv_trauma_grade_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the abdomen shows a grade&nbsp;IV liver injury with multicentric involvement of the left lobe. Narrow CT windows are used to accentuate differences in contrast. There are two lacerations crossing segments II and III (double arrow), a focal hypodense contusion in segment III (arrowhead), and a cystic collection (dashed arrow)&nbsp;traversing segment II and IV. An acute subcapsular hematoma with high-density blood is noted posteriorly (short arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86847 Version 2.0</div></div></div>"},"86848":{"type":"graphic_diagnosticimage","displayName":"Grade IV liver trauma","title":"Grade IV liver trauma","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Grade IV liver trauma</div><div class=\"cntnt\"><img style=\"width:602px; height:211px;\" src=\"images/RADIOL/86848_Grade_IV_liver_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan shows a hypodense region greater than 10 cm in diameter within the dome of the liver (arrows in A and B) consistent with a grade IV liver injury. A moderate size subcapsular hematoma (arrowheads in A and B) is noted posteriorly.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86848 Version 1.0</div></div></div>"},"86849":{"type":"graphic_diagnosticimage","displayName":"Grade V liver laceration","title":"Grade V liver laceration","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Grade V liver laceration</div><div class=\"cntnt\"><img style=\"width:601px; height:237px;\" src=\"images/RADIOL/86849_Grad_V_liver_laceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the upper abdomen (A) shows a grade V complex liver laceration of the right lobe of the liver. The contrast difference between normal and injured tissue is better seen in the magnified, narrowed window (B). The &nbsp;linear and extensive nature of this pattern, which involves segments IV, V, and VI, is described as a 'bear claw injury.'</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86849 Version 1.0</div></div></div>"},"86850":{"type":"graphic_diagnosticimage","displayName":"Low grade liver laceration on computed tomography","title":"Low grade liver laceration on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Low grade liver laceration on computed tomography</div><div class=\"cntnt\"><img style=\"width:576px; height:375px;\" src=\"images/RADIOL/86850_CT_liv_lac_Grade_I_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the dome of the liver shows a small linear intraparenchymal laceration (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 86850 Version 1.0</div></div></div>"},"86853":{"type":"graphic_picture","displayName":"Thumb sign in Marfan syndrome","title":"Steinberg thumb sign in a patient with Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Steinberg thumb sign in a patient with Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:230px;\" src=\"images/CARD/86853_Thumb_sign_Marfan_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Steinberg thumb sign in a patient with Marfan syndrome. A positive test, such as this, consists of the distal phalanx of the thumb protruding beyond the ulnar border of the clenched fist and reflects both longitudinal laxity of the hand and a long thumb.</div><div class=\"graphic_reference\">Reproduced with permission from: Koopman WJ, Moreland LW. Arthritis and Allied Conditions A Textbook of Rheumatology. Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86853 Version 1.0</div></div></div>"},"86855":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray Marfan syndrome","title":"Chest radiograph in a patient with Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a patient with Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:474px; height:504px;\" src=\"images/CARD/86855_Chest_xray_Marfan_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with Marfan syndrome. Features include hyperinflation, bullous changes, dilated tortuous aorta, and \"tall\" lungs.</div><div class=\"graphic_reference\">Reproduced with permission from: Crapo JD, Glassroth J, Karlinsky JB, King TE. Baum's Textbook of Pulmonary Diseases, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86855 Version 1.0</div></div></div>"},"86856":{"type":"graphic_picture","displayName":"Oral lichen planus histopathology - Lichenoid infiltrate","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:236px;\" src=\"images/DERM/86856_Oral_lichen_plan_histo_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lichenoid (band-like) infiltrate is present in the submucosa. Subepithelial clefting is also evident.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Bethanee Schlosser.</div><div id=\"graphicVersion\">Graphic 86856 Version 2.0</div></div></div>"},"86857":{"type":"graphic_picture","displayName":"Oral lichen planus histopathology","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86857_Oral_lich_planus_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parakeratosis, apoptotic keratinocytes, subepithelial clefting, and a lichenoid lymphocytic infiltrate are present in this specimen of oral lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Bethanee Schlosser.</div><div id=\"graphicVersion\">Graphic 86857 Version 1.0</div></div></div>"},"86858":{"type":"graphic_picture","displayName":"Vulvovaginal lichen planus","title":"Vulvovaginal lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvovaginal lichen planus</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86858_Vulvovag_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vulvar erosions and perianal papules due to lichen planus are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Bethanee Schlosser.</div><div id=\"graphicVersion\">Graphic 86858 Version 1.0</div></div></div>"},"86859":{"type":"graphic_picture","displayName":"Drug reaction with eosinophilia and systemic symptoms 2","title":"Drug reaction with eosinophilia and systemic symptoms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug reaction with eosinophilia and systemic symptoms</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86859_Dress2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse and confluent skin eruption in a patient with DRESS.</div><div class=\"graphic_footnotes\">DRESS: drug reaction with eosinophilia and systemic symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86859 Version 8.0</div></div></div>"},"86860":{"type":"graphic_picture","displayName":"Drug reaction with eosinophilia and systemic symptoms 3","title":"Drug reaction with eosinophilia and systemic symptoms ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug reaction with eosinophilia and systemic symptoms </div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/86860_DRESS3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, confluent, infiltrated, erythematous skin eruption in a patient with DRESS.</div><div class=\"graphic_footnotes\">DRESS: drug reaction with eosinophilia and systemic symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86860 Version 8.0</div></div></div>"},"86861":{"type":"graphic_diagnosticimage","displayName":"MRI Exserohilum meningitis and stroke","title":"Brain and neck magnetic resonance imaging from a patient with <EM>Exserohilum </EM>meningitis and stroke","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Brain and neck magnetic resonance imaging from a patient with <EM>Exserohilum </EM>meningitis and stroke</div><div class=\"cntnt\"><img style=\"width:511px; height:327px;\" src=\"images/ID/86861_MRIexseromeninstroke.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial diffusion-weighted imaging from hospital days 4 (A) and 7 (B) shows progression of pontine infarction (arrows). Axial T2-weighted fluid attenuated inversion recovery imaging from hospital days 4 (C) and 7 (D) similarly shows disease progression as indicated by increasing hyperintensity in the midbrain (arrows) and interval development of ventriculomegaly secondary to brain stem edema (asterisks). Additional infarctions with comparable evolution were located in the medulla and cerebellar hemispheres (not shown). Coronal T1 imaging after the administration of intravenous gadolinium on hospital day 7 (E) shows diffuse leptomeningeal enhancement (arrows) and ventriculomegaly (asterisks). Axial T2-weighted short tau inversion recovery imaging (F) and T1-weighted imaging after the administration of intravenous gadolinium (G) of the neck show hyperintensity and abnormal enhancement in cervical paraspinal muscles at the epidural steroid injection site, suggesting subcutaneous edema and possible infected fluid collection (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Lyons JL, Gireesh ED, Trivedi JB, et al. Fatal Exserohilum meningitis and central nervous system vasculitis after cervical methylprednisolone injection. Ann Intern Med 2012. Copyright © 2012 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 86861 Version 11.0</div></div></div>"},"86863":{"type":"graphic_diagnosticimage","displayName":"Ultrasound acute cholecystitis gangrene","title":"Gallbladder gangrene on transabdominal ultrasound","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Gallbladder gangrene on transabdominal ultrasound</div><div class=\"cntnt\"><img style=\"width:597px; height:255px;\" src=\"images/RADIOL/86863_US_acute_cholecystitis_gang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound of a gangrenous gallbladder showing evidence of necrotic and denuded mucosa. The longitudinal view of the base of the gallbladder&nbsp;(A) shows a distended gallbladder, with multiple stones within gallbladder sludge (thin yellow arrow) casting an acoustic shadow (thick yellow arrow). The longitudinal view of the fundus&nbsp;(B) demonstrates denuded mucosa (yellow arrowhead), indicating early necrosis of the gallbladder wall.</div><div id=\"graphicVersion\">Graphic 86863 Version 1.0</div></div></div>"},"86864":{"type":"graphic_diagnosticimage","displayName":"MRI acute cholecystitis","title":"Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) in a patient with acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) in a patient with acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:597px; height:411px;\" src=\"images/RADIOL/86864_MRI_acute_cholecystitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI and MRCP images from a patient with acute cholecystitis. Contrast enhanced (A) and fat saturated T2-weighted imaging (B) reveal a hyperemic gallbladder wall (arrowheads). Multiple small stones are noted lying dependently in the base of the gallbladder (arrow). The MRCP in the coronal projections (C and D) reveals accumulation of pericholecystic fluid (dashed arrows). These findings are consistent with the diagnosis of acute cholecystitis.</div><div id=\"graphicVersion\">Graphic 86864 Version 3.0</div></div></div>"},"86865":{"type":"graphic_diagnosticimage","displayName":"CT scan peritoneal perforation of the gallbladder fundus","title":"Contained gallbladder perforation in a patient with acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Contained gallbladder perforation in a patient with acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:598px; height:342px;\" src=\"images/RADIOL/86865_CT_peri_perf_gallbl_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic (CT) scan showing a sealed perforation of the gallbladder. Transverse (A) and reformatted coronal projections (B) of the CT scan demonstrate a focal accumulation of fluid near the fundus of the gallbladder (white arrowhead) with significant induration in the pericholecystic fat (yellow arrow). At surgery a necrotic and perforated gallbladder was identified.</div><div id=\"graphicVersion\">Graphic 86865 Version 1.0</div></div></div>"},"86866":{"type":"graphic_diagnosticimage","displayName":"CT scan and US acute calculous cholecystitis","title":"Computed tomographic (CT) scan and ultrasound in a patient with acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Computed tomographic (CT) scan and ultrasound in a patient with acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:598px; height:483px;\" src=\"images/RADIOL/86866_CT_US_acute_calcul_cholecys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan (A and B) shows a thick walled and distended gallbladder (arrow) with pericholecystic induration (small arrowheads). However, it does not reveal gallstones. The radiologic differential diagnosis includes acute calculous and acalculous cholecystitis. The ultrasound (C and D) confirms the presence of a distended gallbladder (arrow) with stones (large arrowhead), and the presence of tumefactive sludge (dashed arrow). The thick arrow shows a small amount of fluid in the gallbladder fossa. These findings are consistent with acute calculous cholecystitis.</div><div id=\"graphicVersion\">Graphic 86866 Version 2.0</div></div></div>"},"86867":{"type":"graphic_diagnosticimage","displayName":"CT of liver abscess in acute cholecystitis","title":"Liver abscess complicating acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Liver abscess complicating acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:598px; height:501px;\" src=\"images/RADIOL/86867_CT_liver_absc_acute_cholecy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic (CT) scan in a patient with acute cholecystitis complicated by perforation and liver abscess formation.<br />(A) The CT scan shows a gall stone (yellow arrow) surrounded by an irregular accumulation of fluid with a hyperemic rim (yellow arrowhead).<br />(B) The fluid can be seen extending from the gallbladder fossa into the liver parenchyma (yellow arrowhead).<br />(C) Percutaneous aspiration of pus confirmed the presence of an abscess and a drain was placed (yellow arrow). Following drainage of the abscess, a small amount of contrast was injected into the decompressed cavity.</div><div id=\"graphicVersion\">Graphic 86867 Version 1.0</div></div></div>"},"86875":{"type":"graphic_picture","displayName":"Ocular lichen planus","title":"Ocular lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ocular lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:472px;\" src=\"images/DERM/86875_Ocular_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ocular lichen planus with symblepharon formation resulting in reduced ocular range of motion on lateral gaze.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Bethanee Schlosser.</div><div id=\"graphicVersion\">Graphic 86875 Version 1.0</div></div></div>"},"86877":{"type":"graphic_movie","displayName":"Echo AV valve regurgitation postsurgery of AV canal defect","title":"Echocardiogram of atrioventricular (AV) valve regurgitation after surgical repair of AV canal defect","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of atrioventricular (AV) valve regurgitation after surgical repair of AV canal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/86877_EchoAVvalveregurgvideo.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:627px; height:510px;\" src=\"images/PEDS/86877_EchoAVvalveregurgimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram in a patient following surgical repair atrioventricular (AV) canal demonstrates left AV valve regurgitation (mitral valve regurgitation) (arrow) viewed from the apical 4 chamber view.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; LAVV: left atrioventricular valve; LAVVR: left atrioventricular valve regurgitation; bpm: beats per minute.</div><div id=\"graphicVersion\">Graphic 86877 Version 1.0</div></div></div>"},"86878":{"type":"graphic_diagnosticimage","displayName":"Ultrasound acute cholecystitis and Mirizzi syndrome","title":"Ultrasound from a patient with acute cholecystitis and Mirizzi syndrome","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound from a patient with acute cholecystitis and Mirizzi syndrome</div><div class=\"cntnt\"><img style=\"width:598px; height:223px;\" src=\"images/RADIOL/86878_US_acute_cholecyst_Mirizzi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound from a patient with acute cholecystitis and Mirizzi syndrome. The patient presented with right upper quadrant pain and jaundice. Acute cholecystitis and Mirizzi syndrome are confirmed by the ultrasound findings of a positive sonographic Murphy's sign (pain with compression of the gallbladder by the ultrasound probe), a large shadowing stone impacted in the infundibulum of the gallbladder (arrow), cholestasis with sludge (small arrowhead), and a dilated common hepatic duct (large arrowheads in B).</div><div id=\"graphicVersion\">Graphic 86878 Version 2.0</div></div></div>"},"86879":{"type":"graphic_diagnosticimage","displayName":"Acute cholecystitis positive HIDA scan","title":"HIDA scan in a patient with acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">HIDA scan in a patient with acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:590px; height:426px;\" src=\"images/RADIOL/86879_Acute_cholecy_pos_HIDA_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hepatic iminodiacetic acid (HIDA) scan is abnormal and shows absence of filling of the gallbladder, indicating obstruction of the cystic duct. The duodenum starts to fill with radioisotope at about 20 minutes (white arrow). The radioisotope flows directly into the duodenum (white arrow) starting at 20 minutes. The gallbladder never fills during the course of the 60 minute examination. These findings are consistent with the diagnosis of acute cholecystitis.</div><div id=\"graphicVersion\">Graphic 86879 Version 1.0</div></div></div>"},"86880":{"type":"graphic_table","displayName":"Frequency of specific symptoms during mania","title":"Frequency of specific symptoms during mania","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of specific symptoms during mania</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Weighted mean<br /> (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mood*</td> </tr> <tr> <td class=\"indent1\">Irritability</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"indent1\">Euphoria</td> <td class=\"centered\">63</td> </tr> <tr> <td class=\"indent1\">Expansiveness</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"indent1\">Lability (\"mood swings\")</td> <td class=\"centered\">49</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td class=\"centered\">46</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cognitive<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Flight of ideas, racing thoughts</td> <td class=\"centered\">76</td> </tr> <tr> <td class=\"indent1\">Distractibility, poor concentration</td> <td class=\"centered\">75</td> </tr> <tr> <td class=\"indent1\">Grandiosity, over confident</td> <td class=\"centered\">73</td> </tr> <tr> <td class=\"indent1\">Confusion, disorientation, impaired memory</td> <td class=\"centered\">29</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Activity and behavior<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Hyperactivity</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"indent1\">Increased speech output</td> <td class=\"centered\">89</td> </tr> <tr> <td class=\"indent1\">Rapid, pressured speech</td> <td class=\"centered\">88</td> </tr> <tr> <td class=\"indent1\">Decreased need for sleep, insomnia</td> <td class=\"centered\">83</td> </tr> <tr> <td class=\"indent1\">Increased libido</td> <td class=\"centered\">51</td> </tr> <tr> <td class=\"indent1\">Violent, assaultive behavior</td> <td class=\"centered\">47</td> </tr> <tr> <td class=\"indent1\">Religiosity</td> <td class=\"centered\">39</td> </tr> <tr> <td class=\"indent1\">Extravagant spending sprees </td> <td class=\"centered\">32</td> </tr> <tr> <td class=\"indent1\">Nudity, sexual exposure</td> <td class=\"centered\">29</td> </tr> <tr> <td class=\"indent1\">Pronounced regression</td> <td class=\"centered\">28</td> </tr> <tr> <td class=\"indent1\">Catatonia</td> <td class=\"centered\">24</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based upon a pooled analysis of 16 studies (1121 manic patients).<br />&#182; Based upon a pooled analysis of 13 studies (968 manic patients).<br />&Delta; Based upon a pooled analysis of 16 studies (1857 manic patients).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Goodwin F, Jamison K. Manic-Depressive Illness: Bipolar disorders and recurrent depression, 2nd ed, Oxford University Press, New York 2007. </li>&#xD;&#xA;    <li>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:255.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 86880 Version 2.0</div></div></div>"},"86882":{"type":"graphic_picture","displayName":"Trypanosomal chancre","title":"Trypanosomal chancre","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trypanosomal chancre</div><div class=\"cntnt\"><img style=\"width:412px; height:504px;\" src=\"images/ID/86882_Trypanosomal_chancre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical skin reaction two weeks after the first onset of local symptoms following the bite of an infected tsetse fly.</div><div class=\"graphic_reference\">Courtesy of August Stich, MD, MSc, DTMH.</div><div id=\"graphicVersion\">Graphic 86882 Version 1.0</div></div></div>"},"86884":{"type":"graphic_picture","displayName":"Maintaining tsetse trap","title":"Maintaining a tsetse trap","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Maintaining a tsetse trap</div><div class=\"cntnt\"><img style=\"width:504px; height:386px;\" src=\"images/ID/86884_Maintain_tsetse_trap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Local team during maintenance work of tsetse traps (type Lancien) in Northern Angola.</div><div class=\"graphic_reference\">Courtesy of August Stich, MD, MSc, DTMH.</div><div id=\"graphicVersion\">Graphic 86884 Version 1.0</div></div></div>"},"86885":{"type":"graphic_picture","displayName":"Oral lichen planus - desquamative gingivitis","title":"Desquamative gingivitis in oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Desquamative gingivitis in oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86885_Oral_lich_plan_amat_ging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive erosions are present on the gingiva.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86885 Version 3.0</div></div></div>"},"86886":{"type":"graphic_picture","displayName":"Oral lichen planus - lower lip","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86886_Oral_lich_plan_low_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticular white plaque is present on the lower lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86886 Version 3.0</div></div></div>"},"86887":{"type":"graphic_picture","displayName":"Oral lichen planus - tongue","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86887_Oral_lichen_planus_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular white plaques are present on the tongue. A small ulcer is visible in the upper left corner of this image.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86887 Version 3.0</div></div></div>"},"86888":{"type":"graphic_picture","displayName":"Oral lichen planus - multiple features","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86888_Oral_lich_plan_multi_feat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular white plaques, erythema, and ulceration are present.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86888 Version 3.0</div></div></div>"},"86889":{"type":"graphic_picture","displayName":"Oral lichen planus - reticular","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/86889_Oral_lichen_planus_retic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticular white plaque is present on the buccal mucosa.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86889 Version 3.0</div></div></div>"},"86890":{"type":"graphic_picture","displayName":"Leukoedema","title":"Leukoedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Leukoedema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86890_Leukoedema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White-gray edematous plaques are present on the buccal mucosa.</div><div class=\"graphic_reference\">Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86890 Version 3.0</div></div></div>"},"86891":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture of thumb proximal phalanx","title":"Avulsion fracture and ulnar collateral ligament injury of the thumb","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture and ulnar collateral ligament injury of the thumb</div><div class=\"cntnt\"><img style=\"width:597px; height:298px;\" src=\"images/RADIOL/86891_Xray_avulsion_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three views of the right hand in posteroanterior (A), oblique (B), and lateral (C) projections demonstrate a non-displaced fracture at the ulnar base of the first proximal phalanx with intra-articular extension to the metacarpophalangeal (MCP) joint (white arrowhead), indicative of an ulnar collateral ligament injury with associated avulsion fracture secondary to forced hyperabduction of the flexed thumb. Associated soft tissue swelling of the thenar eminence is shown (C, white arrow).</div><div class=\"graphic_reference\">Courtesy of Robert Ward, MD.</div><div id=\"graphicVersion\">Graphic 86891 Version 1.0</div></div></div>"},"86892":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture with ulnar collateral ligament injury","title":"Avulsion fracture associated with ulnar collateral ligament injury of the thumb","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture associated with ulnar collateral ligament injury of the thumb</div><div class=\"cntnt\"><img style=\"width:528px; height:540px;\" src=\"images/RADIOL/86892_Xray_avuls_fract_magnified.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnified view of lateral hand radiograph demonstrates the avulsion fracture at the base of the first proximal phalanx (white arrow).</div><div class=\"graphic_reference\">Courtesy of Robert Ward, MD.</div><div id=\"graphicVersion\">Graphic 86892 Version 1.0</div></div></div>"},"86893":{"type":"graphic_diagnosticimage","displayName":"CT of talar body fracture with dislocation","title":"CT of talar body fracture with dislocation","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT of talar body fracture with dislocation</div><div class=\"cntnt\"><img style=\"width:598px; height:268px;\" src=\"images/RADIOL/86893_Xray_CT_frac_disloc_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral x-ray (A) of a crush fracture of the talar body with dislocation of part of the subtalar joint (arrow). Transverse (B) and coronal (C) CT scans showing comminution of the crushed talar body (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86893 Version 3.0</div></div></div>"},"86894":{"type":"graphic_diagnosticimage","displayName":"CT talar head fracture","title":"CT of talar head fracture","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT of talar head fracture</div><div class=\"cntnt\"><img style=\"width:598px; height:337px;\" src=\"images/RADIOL/86894_Xray_comp_tomog_frac_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 45-year-old male was the unrestrained driver of a front impact motor vehicle accident. An intra-articular talar head fracture, with involvement of the talonavicular joint, is noted on lateral radiographs of the left ankle (A, arrow). Subsequent CT examination more clearly demonstrates the talar head fracture with talonavicular joint involvement (B, arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 86894 Version 3.0</div></div></div>"},"86895":{"type":"graphic_picture","displayName":"Walking boot or brace","title":"Walking boot or brace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Walking boot or brace</div><div class=\"cntnt\"><img style=\"width:447px; height:324px;\" src=\"images/EM/86895_Walking_boot_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A walking boot or brace is used in the treatment of a number of fractures or soft tissue injuries of the leg.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO.</div><div id=\"graphicVersion\">Graphic 86895 Version 1.0</div></div></div>"},"86896":{"type":"graphic_figure","displayName":"Epidermal basement membrane zone - EM","title":"Ultrastructural view of the epidermal basement membrane zone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrastructural view of the epidermal basement membrane zone</div><div class=\"cntnt\"><img style=\"width:422px; height:536px;\" src=\"images/DERM/86896_Epid_basement_mem_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Marinkovich MP. Inherited epidermolysis bullosa. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright &copy; 2012 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 86896 Version 2.0</div></div></div>"},"86897":{"type":"graphic_diagnosticimage","displayName":"Thoracic spinous process fracture","title":"Thoracic spinous process fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic spinous process fracture</div><div class=\"cntnt\"><img style=\"width:331px; height:655px;\" src=\"images/RADIOL/86897_Radiogr_thora_spine_spinous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the thoracolumbar spine in lateral projection (A, and magnified in B) reveals an equivocal abnormality of the spinous process of T12. A CT scan using sagittal reformatting (C) and transverse projection (D) are more convincing for fractures through the spinous process of T11 (white arrowhead) and T12 (small white arrow). A fracture of a left sided 11th rib is of incidental note.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 86897 Version 1.0</div></div></div>"},"86898":{"type":"graphic_diagnosticimage","displayName":"Lumbar spinous process and vertebral body fractures","title":"Lumbar spinous process and vertebral body fractures","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Lumbar spinous process and vertebral body fractures</div><div class=\"cntnt\"><img style=\"width:597px; height:386px;\" src=\"images/RADIOL/86898_Spinous_process_trans_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph of the lumbar spine (A, magnified in B). The 54-year-old male sustained hyperflexion injury with distraction resulting in a transverse fracture through the T12 spinous process (arrow) and a compression fracture of the vertebral body (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Robert Ward, MD.</div><div id=\"graphicVersion\">Graphic 86898 Version 2.0</div></div></div>"},"86899":{"type":"graphic_picture","displayName":"T brucei in blood film","title":"<EM>Trypanosoma brucei</EM> in Giemsa-stained blood film","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Trypanosoma brucei</EM> in Giemsa-stained blood film</div><div class=\"cntnt\"><img style=\"width:396px; height:282px;\" src=\"images/ID/86899_T_brucei_Giemsa_bld_flm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long, slender form of <EM>T. b. gambiense</EM>, Giemsa stain, x100 oil immersion.</div><div class=\"graphic_reference\">Courtesy of August Stich, MD, MSc, DTMH.</div><div id=\"graphicVersion\">Graphic 86899 Version 2.0</div></div></div>"},"86902":{"type":"graphic_table","displayName":"Cardiovascular causes for hemodynamic VBI","title":"Cardiovascular causes for hemodynamic vertebrobasilar insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular causes for hemodynamic vertebrobasilar insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Antihypertensive therapy</td> </tr> <tr> <td>Cardiac arrhythmia</td> </tr> <tr> <td>Pacemaker malfunction</td> </tr> <tr> <td>Large artery atherosclerosis</td> </tr> <tr> <td>Vasculitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86902 Version 2.0</div></div></div>"},"86903":{"type":"graphic_picture","displayName":"Healing deep partial-thickness burn","title":"Healing deep partial-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healing deep partial-thickness burn</div><div class=\"cntnt\"><img style=\"width:259px; height:554px;\" src=\"images/EM/86903_Healdeeppartthickburn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show a deep partial-thickness burn of the proximal leg at different stages of healing. The top image was taken at one week, the middle image at four weeks, and bottom image at 10 months after the initial injury was sustained. As this burn crosses the knee joint, referral to a burn center for care is appropriate. </div><div class=\"graphic_reference\">Courtesy of Simon G Talbot, MD.</div><div id=\"graphicVersion\">Graphic 86903 Version 3.0</div></div></div>"},"86904":{"type":"graphic_picture","displayName":"Superficial burn of the forearm","title":"Superficial burn of the forearm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial burn of the forearm</div><div class=\"cntnt\"><img style=\"width:383px; height:287px;\" src=\"images/EM/86904_Superfic_burn_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial, or epidermal, burns involve only the epidermal layer of skin. They do not blister but are painful, dry, red, and blanch with pressure. Note the absence of hair and areas of redness in the exposed portion of the forearm.</div><div class=\"graphic_reference\">Courtesy of Simon G Talbot, MD.</div><div id=\"graphicVersion\">Graphic 86904 Version 2.0</div></div></div>"},"86905":{"type":"graphic_picture","displayName":"Lower extremity escharotomy","title":"Lower extremity escharotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lower extremity escharotomy</div><div class=\"cntnt\"><img style=\"width:383px; height:288px;\" src=\"images/EM/86905_Lower_extrem_escharotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decompressive escharotomy of the lower extremity is shown in this photograph of a burn victim. Escharotomy may be required for circumferential full-thickness burns, if edema causes constriction and distal ischemia.</div><div class=\"graphic_reference\">Courtesy of Simon G Talbot, MD.</div><div id=\"graphicVersion\">Graphic 86905 Version 1.0</div></div></div>"},"86906":{"type":"graphic_movie","displayName":"Application of a basic burn dressing","title":"Application of a basic burn dressing","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Application of a basic burn dressing</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/86906_Appbasicburndressvideo.mp4\" style=\"width:528px;height:320px\"></div><img style=\"width:598px; height:324px;\" src=\"images/EM/86906_Appbasicburndressimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Simon G Talbot, MD.</div><div id=\"graphicVersion\">Graphic 86906 Version 1.0</div></div></div>"},"86907":{"type":"graphic_table","displayName":"Symptoms requiring immediate evaluation (SCD)","title":"Illnesses requiring immediate medical evaluation (within four hours of occurrence) for children with sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Illnesses requiring immediate medical&nbsp;evaluation (within four hours of occurrence) for children with sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Immediate medical&nbsp;evaluation is appropriate for any of the following symptoms:</td> </tr> <tr> <td> <ul> <li>Fever (typically, a single oral temperature of&nbsp;101.5&#176;F [38.6&#176;C] or above) </li> </ul> <ul> <li>Significant respiratory symptoms (eg, severe cough, shortness of breath, chest pain) </li> </ul> <ul> <li>Newly palpable spleen or further enlargement of previously enlarged spleen </li> </ul> <ul> <li>Severe abdominal pain, especially right upper quadrant pain&nbsp;or with an&nbsp;increase in jaundice </li> </ul> <ul> <li>Any neurologic symptom or sign (even if transient) </li> </ul> <ul> <li>Significant increase in pallor, fatigue and/or lethargy </li> </ul> <ul> <li>Priapism episode persisting more than four hours </li> </ul> <ul> <li>Pain inadequately relieved by home medications </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on sickle cell disease for details.</div><div class=\"graphic_reference\">Modified from: Lane P, Buchanan G, Hutter J, et al. Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications 2001. Available at: <a href=\"http://www.dshs.state.tx.us/newborn/sickle.shtm\" target=\"_blank\">http://www.dshs.state.tx.us/newborn/sickle.shtm</a>.</div><div id=\"graphicVersion\">Graphic 86907 Version 2.0</div></div></div>"},"86909":{"type":"graphic_picture","displayName":"AGEP histo 1","title":"Histologic features of acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histologic features of acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><img style=\"width:576px; height:391px;\" src=\"images/DERM/86909_AGEP_histo_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic sections of skin show epidermal acanthosis with spongiosis and microvesicle and pustule formation. The dermis shows a perivascular and interstitial infiltrate, extending to mid-reticular dermal levels.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 86909 Version 5.0</div></div></div>"},"86910":{"type":"graphic_picture","displayName":"AGEP histo 2","title":"Histopathologic features of acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><img style=\"width:576px; height:481px;\" src=\"images/DERM/86910_AGEP_histo_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This higher power field shows epidermal spongiosis with exocytosis of neutrophils and eosinophils. Small microvesicles/microabscesses are developing. In other fields (not shown), there is subcorneal pustule formation.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 86910 Version 5.0</div></div></div>"},"86911":{"type":"graphic_picture","displayName":"AGEP 1","title":"Acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86911_AGEP_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical flexural accentuation of AGEP.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86911 Version 5.0</div></div></div>"},"86912":{"type":"graphic_picture","displayName":"AGEP detail 2","title":"Acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><img style=\"width:576px; height:371px;\" src=\"images/DERM/86912_AGEP_detail_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonfollicular, pinhead-sized pustules on a background of edematous erythema are characteristic of AGEP.</div><div id=\"graphicVersion\">Graphic 86912 Version 3.0</div></div></div>"},"86913":{"type":"graphic_picture","displayName":"Herpes keratitis fluorescein stain","title":"Fluorescein staining patterns in a case of herpes keratitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fluorescein staining patterns in a case of herpes keratitis</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/PC/86913_Herpes_kerat_fluor_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fine branching elements distinguish this from the linear or geographic pattern of a traumatic corneal abrasion, although the clinical presentations may be quite similar.</div><div class=\"graphic_reference\">Courtesy of Deborah Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 86913 Version 1.0</div></div></div>"},"86914":{"type":"graphic_picture","displayName":"Mucosal leishmaniasis","title":"Mucosal leishmaniasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mucosal leishmaniasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/86914_Mucosal_leishmaniasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86914 Version 3.0</div></div></div>"},"86916":{"type":"graphic_table","displayName":"AGEP inducing drugs 1","title":"Antimicrobials most frequently reported as cause of acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobials most frequently reported as cause of acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Aminopenicillins</td> </tr> <tr> <td class=\"indent1\">Macrolides</td> </tr> <tr> <td class=\"indent1\">Cephalosporins</td> </tr> <tr> <td class=\"indent1\">Quinolones</td> </tr> <tr> <td class=\"indent1\">Tetracyclines</td> </tr> <tr> <td class=\"indent2\">Chloramphenicol</td> </tr> <tr> <td class=\"indent2\">Clindamycin</td> </tr> <tr> <td class=\"indent2\">Gentamicin</td> </tr> <tr> <td class=\"indent2\">Isoniazid</td> </tr> <tr> <td class=\"indent2\">Lincomycin</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> </tr> <tr> <td class=\"indent2\">Trimethoprim/sulfamethoxazole</td> </tr> <tr> <td class=\"indent2\">Telavancin</td> </tr> <tr> <td class=\"indent2\">Vancomycin</td> </tr> <tr> <td class=\"subtitle1_single\">Antimycotics</td> </tr> <tr> <td class=\"indent1\">Amphotericin B</td> </tr> <tr> <td class=\"indent1\">Fluconazole</td> </tr> <tr> <td class=\"indent1\">Griseofulvin</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Nystatin</td> </tr> <tr> <td class=\"indent1\">Terbinafine</td> </tr> <tr> <td class=\"subtitle1_single\">Other antimicrobials</td> </tr> <tr> <td class=\"indent1\">(Hydroxy-)chloroquine</td> </tr> <tr> <td class=\"indent1\">Diaphenylsulfone</td> </tr> <tr> <td class=\"indent1\">Nifuroxazide</td> </tr> <tr> <td class=\"indent1\">Pyrimethamine</td> </tr> <tr> <td class=\"indent1\">Protease inhibitors</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86916 Version 6.0</div></div></div>"},"86917":{"type":"graphic_table","displayName":"AGEP inducing drugs 2","title":"Non-antimicrobial drugs reported as cause of acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-antimicrobial drugs reported as cause of acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acarbose</td> </tr> <tr> <td>Acetylsalicylic acid</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Allylisopropylacetylurea</td> </tr> <tr> <td>Amoxapine</td> </tr> <tr> <td>Azathioprine</td> </tr> <tr> <td>Bamifylline</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Boldoflorine</td> </tr> <tr> <td>Buphenine</td> </tr> <tr> <td>Bufexamac</td> </tr> <tr> <td>Calcium channel blockers</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Carbimazole</td> </tr> <tr> <td>Carbutamide</td> </tr> <tr> <td>Celecoxib</td> </tr> <tr> <td>Cetirizine and levocetirizine (due to similarity&nbsp;with hydroxyzine)</td> </tr> <tr> <td>Chemotherapy (high dose)</td> </tr> <tr> <td>Chromium picolinate</td> </tr> <tr> <td>Cimetidine</td> </tr> <tr> <td>Clemastine</td> </tr> <tr> <td>Clobazam</td> </tr> <tr> <td>Clopidogrel</td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td>Contrast media</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Cytarabine</td> </tr> <tr> <td>Dalteparin</td> </tr> <tr> <td>Dextropropoxyphene</td> </tr> <tr> <td>Dihydrocodeine phosphate</td> </tr> <tr> <td>Disulfiram</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Enalapril</td> </tr> <tr> <td>Eperisone hydrochloride</td> </tr> <tr> <td>Epoetin alpha</td> </tr> <tr> <td>Eprazinone</td> </tr> <tr> <td>Etoricoxib</td> </tr> <tr> <td>Etodolac</td> </tr> <tr> <td>Fenoterol</td> </tr> <tr> <td>Fluindione</td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td>Gefitinib</td> </tr> <tr> <td>Herbal medications</td> </tr> <tr> <td>Hydrochlorothiazide</td> </tr> <tr> <td>Hydroxyzine</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Icodextrin</td> </tr> <tr> <td>Illicit street drugs</td> </tr> <tr> <td>Imatinib</td> </tr> <tr> <td>Isotretinoin</td> </tr> <tr> <td>Laquer chicken</td> </tr> <tr> <td>Meladinine</td> </tr> <tr> <td>Mercury</td> </tr> <tr> <td>Metamizole</td> </tr> <tr> <td>Methylphenidate</td> </tr> <tr> <td>Milk thistle tea</td> </tr> <tr> <td>Morphine</td> </tr> <tr> <td>Nadoxolol</td> </tr> <tr> <td>Nifedipine</td> </tr> <tr> <td>Nimesulide</td> </tr> <tr> <td>Omeprazole</td> </tr> <tr> <td>Paracetamol (acetaminophen)</td> </tr> <tr> <td>Pemetrexed</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Piperazine ethionamide</td> </tr> <tr> <td>Propafenone</td> </tr> <tr> <td>Prostaglandin E1</td> </tr> <tr> <td>Pseudoephedrine</td> </tr> <tr> <td>Psoralen plus ultraviolet A (PUVA)</td> </tr> <tr> <td>Quinidine</td> </tr> <tr> <td>Ranibizumab (intravitreal)</td> </tr> <tr> <td>Ranitidine</td> </tr> <tr> <td>Rhus (lacquer)</td> </tr> <tr> <td>Sennoside</td> </tr> <tr> <td>Sertraline</td> </tr> <tr> <td>Simvastatin</td> </tr> <tr> <td>Spider bites</td> </tr> <tr> <td>Sulbutiamine</td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Teicoplanin</td> </tr> <tr> <td>Terazosin hydrochloride</td> </tr> <tr> <td>Tetrazepam</td> </tr> <tr> <td>Thalidomide</td> </tr> <tr> <td>Thallium</td> </tr> <tr> <td>Ticlopidine</td> </tr> <tr> <td>Topical agents</td> </tr> <tr> <td>Vaccines</td> </tr> <tr> <td>Valdecoxib</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86917 Version 5.0</div></div></div>"},"86920":{"type":"graphic_figure","displayName":"Back anatomy general PI","title":"Anatomy of the back","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Anatomy of the back</div><div class=\"cntnt\"><img style=\"width:543px; height:572px;\" src=\"images/PI/86920_Back_anatomy_gen_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the different structures in the back.</div><div id=\"graphicVersion\">Graphic 86920 Version 1.0</div></div></div>"},"86922":{"type":"graphic_table","displayName":"Foods that contain gluten PI","title":"Foods that contain gluten","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods that contain gluten</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Foods that definitely contain gluten:</td> </tr> <tr> <td class=\"indent1\">Wheat (einkorn, durum, faro, graham, kamut, semolina, spelt)</td> </tr> <tr> <td class=\"indent1\">Rye</td> </tr> <tr> <td class=\"indent1\">Barley</td> </tr> <tr> <td class=\"indent1\">Malt, malt flavoring, malt extract derived from barley</td> </tr> <tr> <td class=\"indent1\">Malt vinegar</td> </tr> <tr> <td class=\"indent1\">Triticale</td> </tr> <tr> <td class=\"indent1\">Beers, ales and lagers*</td> </tr> <tr> <td class=\"indent1\">Breading, bread crumbs, and coating mixes*</td> </tr> <tr> <td class=\"indent1\">Croutons*</td> </tr> <tr> <td class=\"indent1\">Matzo and matzo meal*</td> </tr> <tr> <td class=\"indent1\">Pasta*</td> </tr> <tr> <td class=\"indent1\">Stuffing (for poultry)*</td> </tr> <tr> <td class=\"subtitle1_single\">Foods that might contain gluten:</td> </tr> <tr> <td class=\"indent1\">Brewer's yeast</td> </tr> <tr> <td class=\"indent1\">Broth, bouillon, or soup stock</td> </tr> <tr> <td class=\"indent1\">Brown rice syrup</td> </tr> <tr> <td class=\"indent1\">Cake frosting</td> </tr> <tr> <td class=\"indent1\">Candy and licorice</td> </tr> <tr> <td class=\"indent1\">Communion wafers</td> </tr> <tr> <td class=\"indent1\">Condiments</td> </tr> <tr> <td class=\"indent1\">Dates (if rolled in oat flour)</td> </tr> <tr> <td class=\"indent1\">Drink mixes</td> </tr> <tr> <td class=\"indent1\">Energy bars</td> </tr> <tr> <td class=\"indent1\">Flavored teas and coffees</td> </tr> <tr> <td class=\"indent1\">Flavored spirits (such as rasperry vodka)</td> </tr> <tr> <td class=\"indent1\">Flour or cereal products</td> </tr> <tr> <td class=\"indent1\">Imitation products, like bacon or seafood</td> </tr> <tr> <td class=\"indent1\">Medicines (both over-the-counter and prescription, including probiotics)</td> </tr> <tr> <td class=\"indent1\">Oats (unless they are labeled \"gluten free\")</td> </tr> <tr> <td class=\"indent1\">Processed lunch meats</td> </tr> <tr> <td class=\"indent1\">Rice pilaf and other packaged rice mixtures</td> </tr> <tr> <td class=\"indent1\">Salad dressing</td> </tr> <tr> <td class=\"indent1\">Sauces, gravies, marinades, and thickeners</td> </tr> <tr> <td class=\"indent1\">Seasonings, spices, and smoke flavoring</td> </tr> <tr> <td class=\"indent1\">Seasoned chips, nuts, and seeds</td> </tr> <tr> <td class=\"indent1\">Self-basting poultry</td> </tr> <tr> <td class=\"indent1\">Soy sauce</td> </tr> <tr> <td class=\"indent1\">Vitamins and herbal supplements</td> </tr> <tr> <td class=\"subtitle1_single\">Play products for children:</td> </tr> <tr> <td class=\"indent1\">Play-dough</td> </tr> <tr> <td class=\"indent1\">Paper mach&#233;</td> </tr> <tr> <td class=\"indent1\">Glue</td> </tr> <tr> <td class=\"indent1\">Some other art supplies</td> </tr> <tr> <td class=\"indent1\">Some of these play products are made from flour or contain gluten. Children with celiac disease can play with these products, but they should wash their hands after playing.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the foods that might contain gluten, it depends on their ingredients and where they were made. To know for sure, you will need to check the ingredient label.</div><div class=\"graphic_footnotes\">* These products usually contain gluten, unless specially labeled \"gluten-free.\"</div><div id=\"graphicVersion\">Graphic 86922 Version 5.0</div></div></div>"},"86924":{"type":"graphic_diagnosticimage","displayName":"Emphysema and aortic dissection in Marfan syndrome","title":"Emphysema and aortic dissection in Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emphysema and aortic dissection in Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:359px; height:448px;\" src=\"images/CARD/86924_AorticdissectruptMarfan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 25-year-old male patient with a history of Marfan syndrome had undergone prior dissecting aneurysm repair and presented with acute chest pain.<br />(A) PA chest x-ray.<br />(B) Lateral chest x-ray. Note the gracile osteopenic appearance of the ribs, consistent with Marfans syndrome. Note also the hyperinflated lungs consistent with emphysema. These studies were taken after surgery for a dissecting aortic aneurysm; note the metallic surgical sutures in the sternum.<br />(C) CT, mid-thorax. Note the descending aortic dissection with a false lumen with contrast (arrow) and non-effaced true lumen with contrast and surrounding thrombus.</div><div class=\"graphic_reference\">Reproduced with permission from: Seron MA, Yochum TR, Barry MS, Rowe LJ. Skeletal dysplasias. In: Essentials of Skeletal Radiology, 3rd Edition, Yochum TR, Rowe LJ (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 86924 Version 9.0</div></div></div>"},"86925":{"type":"graphic_figure","displayName":"Common mechanisms for ankle sprains","title":"Common mechanisms for ankle sprains","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Common mechanisms for ankle sprains</div><div class=\"cntnt\"><img style=\"width:488px; height:686px;\" src=\"images/EM/86925_Ankle_sprains.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic presents some common mechanisms for ankle sprains.&nbsp;Inversion injuries are most common.</div><div id=\"graphicVersion\">Graphic 86925 Version 1.0</div></div></div>"},"86926":{"type":"graphic_picture","displayName":"Microscopic images of secondary breast angiosarcoma","title":"Microscopic images of secondary breast angiosarcoma","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Microscopic images of secondary breast angiosarcoma</div><div class=\"cntnt\"><img style=\"width:597px; height:229px;\" src=\"images/ONC/86926_Micro_img_br_angiosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel reveals a low power view of a photomicrograph of a radiation-associated angiosarcoma. Note the cellular proliferation within the dermis, including pockets of cells, single cells percolating between dermal collagen, and columns of cells that appear to raise the epidermis, forming blisters/nodules (corresponding to the gross appearance of these tumors on the chest wall). Right panel reveals a higher power view of the same tumor showing predominantly spindle cells (and rare epithelioid cells) with large, oval to round vesicular nuclei containing one or more prominent nucleoli and basophilic cytoplasm. These malignant cells form vasoformative channels (arrows)&nbsp;containing erythrocytes.</div><div class=\"graphic_reference\">Courtesy of Drs. Alero Inyang and David Lucas.</div><div id=\"graphicVersion\">Graphic 86926 Version 1.0</div></div></div>"},"86927":{"type":"graphic_picture","displayName":"Fallopian tube intraepithelial carcinoma","title":"Fallopian tube intraepithelial carcinoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Fallopian tube intraepithelial carcinoma</div><div class=\"cntnt\"><img style=\"width:515px; height:391px;\" src=\"images/ONC/86927_Fallop_tb_intraepith_car.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tubal intraepithelial carcinoma.<br />(A, B) Hematoxylin and eosin stained section depicting disorganized epithelial growth in a tubal plica.<br />(C) Intense nuclear staining for p53, characteristic of an inactivating mutation.<br />(D) Staining for KI67, a cell cycle marker, discloses increased proliferative activity.</div><div id=\"graphicVersion\">Graphic 86927 Version 3.0</div></div></div>"},"86928":{"type":"graphic_table","displayName":"Tubal neoplasia rrBSO specimens","title":"Frequency of serous fallopian tubal intraepithelial carcinoma (STIC) in risk reducing salpingo-oophorectomy specimens of women with BRCA mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of serous fallopian tubal intraepithelial carcinoma (STIC) in risk reducing salpingo-oophorectomy specimens of women with BRCA mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\"> <p>Pelvic serous neoplasm</p> <p>n (percent)</p> </td> <td class=\"subtitle1\"> <p>Tubal involvement</p> <p>n (percent)</p> </td> </tr> <tr> <td>Colgan 2001</td> <td class=\"centered\">39</td> <td class=\"centered\">5 (13)</td> <td class=\"centered\">4 (80)</td> </tr> <tr> <td>Leeper 2002</td> <td class=\"centered\">30</td> <td class=\"centered\">5 (17)</td> <td class=\"centered\">3 (60)</td> </tr> <tr> <td>Powell 2005</td> <td class=\"centered\">67</td> <td class=\"centered\">7 (10)</td> <td class=\"centered\">4 (57)</td> </tr> <tr> <td>Carcangiu 2006</td> <td class=\"centered\">50</td> <td class=\"centered\">6 (12)</td> <td class=\"centered\">4 (67)</td> </tr> <tr> <td>Finch 2006</td> <td class=\"centered\">159</td> <td class=\"centered\">7 (4)</td> <td class=\"centered\">6 (86)</td> </tr> <tr> <td>Callahan 2007</td> <td class=\"centered\">100</td> <td class=\"centered\">7 (7)</td> <td class=\"centered\">7 (100)</td> </tr> <tr class=\"divider_bottom\"> <td>Hirst 2009</td> <td class=\"centered\">45</td> <td class=\"centered\">4 (9)</td> <td class=\"centered\">4 (100)</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>490</strong></td> <td class=\"centered\"><strong>41 (8)</strong></td> <td class=\"centered\"><strong>32 (78)</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86928 Version 3.0</div></div></div>"},"86929":{"type":"graphic_table","displayName":"Procedural bleeding risk","title":"Procedural bleeding risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedural bleeding risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High bleeding risk procedure&nbsp;(two-day risk of major bleed 2 to 4 percent)</td> </tr> <tr> <td>Any major operation of duration &#62;45 minutes</td> </tr> <tr> <td>Abdominal aortic aneurysm repair</td> </tr> <tr> <td>Coronary artery bypass</td> </tr> <tr> <td>Endoscopically guided fine-needle aspiration</td> </tr> <tr> <td>Foot/hand/shoulder surgery</td> </tr> <tr> <td>Heart valve replacement</td> </tr> <tr> <td>Hip replacement</td> </tr> <tr> <td>Kidney biopsy</td> </tr> <tr> <td>Knee replacement</td> </tr> <tr> <td>Laminectomy</td> </tr> <tr> <td>Neurosurgical/urologic/head and neck/abdominal/breast cancer surgery</td> </tr> <tr> <td>Polypectomy, variceal treatment, biliary sphincterectomy, pneumatic dilatation</td> </tr> <tr> <td>Transurethral prostate resection</td> </tr> <tr> <td>Vascular and general surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Low bleeding risk procedure (two-day risk of major bleed 0 to 2 percent)</td> </tr> <tr> <td>Abdominal hernia repair</td> </tr> <tr> <td>Abdominal hysterectomy</td> </tr> <tr> <td>Arthroscopic surgery lasting &#60;45 minutes</td> </tr> <tr> <td>Axillary node dissection</td> </tr> <tr> <td>Bronchoscopy&nbsp;with or without&nbsp;biopsy</td> </tr> <tr> <td>Carpal tunnel repair</td> </tr> <tr> <td>Cataract and noncataract eye surgery</td> </tr> <tr> <td>Central venous catheter removal</td> </tr> <tr> <td>Cholecystectomy</td> </tr> <tr> <td>Cutaneous and bladder/prostate/thyroid/breast/lymph node biopsies</td> </tr> <tr> <td>Dilatation and curettage</td> </tr> <tr> <td>Gastrointestinal endoscopy &#177; biopsy, enteroscopy, biliary/pancreatic stent without sphincterotomy, endosonography without fine-needle aspiration</td> </tr> <tr> <td>Hemorrhoidal surgery</td> </tr> <tr> <td>Hydrocele repair</td> </tr> <tr> <td>Noncoronary angiography</td> </tr> <tr> <td>Pacemaker and cardiac defibrillator insertion and electrophysiologic testing</td> </tr> <tr> <td>Tooth&nbsp;extractions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is based on definitions derived from surgical/subspecialty societies in anticoagulant bridging or anticoagulant bridging management studies. Refer to UpToDate content on management of anticoagulants in patients undergoing&nbsp;gastrointestinal procedures for information on bleeding risks of&nbsp;additional gastrointestinal procedures.</div><div class=\"graphic_reference\">Adapted from research originally published in Blood. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120:2954. Copyright © 2012 the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 86929 Version 4.0</div></div></div>"},"86930":{"type":"graphic_table","displayName":"Perioperative thrombotic risk","title":"Perioperative thrombotic risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative thrombotic risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk stratum</td> <td class=\"subtitle1\" colspan=\"3\">Indication for&nbsp;anticoagulant therapy</td> </tr> <tr> <td class=\"subtitle2\">Mechanical heart valve</td> <td class=\"subtitle2\">Atrial fibrillation</td> <td class=\"subtitle2\">VTE</td> </tr> <tr> <td>Very high thrombotic risk*</td> <td> <p>Any mitral valve prosthesis</p> <p>Any caged-ball or tilting disc aortic valve prosthesis</p> Recent (within six months) stroke or transient ischemic attack</td> <td> <p>CHA<sub>2</sub>DS<sub>2</sub>-VASc score of &#8805;6</p> <p>(or CHADS<sub>2</sub> score of 5-6)</p> <p>Recent (within three months) stroke or transient ischemic attack</p> Rheumatic valvular heart disease</td> <td> <p>Recent (within three months) VTE</p> Severe thrombophilia (eg, deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple abnormalities)</td> </tr> <tr> <td>High&nbsp;thrombotic risk</td> <td>Bileaflet aortic valve prosthesis and one or more of the of following risk factors: atrial fibrillation, prior stroke or transient ischemic attack, hypertension, diabetes, congestive heart failure, age &#62;75 years </td> <td>CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 4-5 or CHADS<sub>2</sub> score of 3-4</td> <td> <p>VTE within the past 3 to 12 months</p> <p>Nonsevere thrombophilia (eg, heterozygous factor V Leiden or prothrombin gene mutation)</p> <p>Recurrent VTE</p> Active cancer (treated within six months or palliative)</td> </tr> <tr> <td>Moderate&nbsp;thrombotic risk</td> <td>Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke</td> <td>CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 2-3 or CHADS<sub>2</sub> score of 0-2 (assuming no prior stroke or transient ischemic attack) </td> <td>VTE &#62;12 months previous and no other risk factors</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on perioperative anticoagulation management for details.</div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; CHADS<SUB>2</SUB>: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack; CHA<SUB>2</SUB>DS<SUB>2</SUB>-VASc: congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism (2 points), vascular disease (peripheral artery disease, myocardial infarction, or aortic plaque), age 65-74 years, sex category female.&nbsp;&nbsp;<br />* Very high risk patients may also include those with a prior stroke or transient ischemic attack occurring &gt;3 months before the planned surgery and a CHA<SUB>2</SUB>DS<SUB>2</SUB>-VASc score&nbsp;&lt;6 (or CHADS<SUB>2</SUB> score &lt;5), those with prior thromboembolism during temporary interruption of anticoagulation, or those undergoing certain types of surgery associated with an increased risk for stroke or other thromboembolism (eg, cardiac valve replacement, carotid endarterectomy, major vascular surgery).</div><div class=\"graphic_reference\">Modified from Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e326S. Copyright © 2012. Reproduced with permission from the American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 86930 Version 4.0</div></div></div>"},"86931":{"type":"graphic_table","displayName":"Fallopian neoplasia with advanced dz","title":"Frequency of serous fallopian tubal intraepithelial serous carcinoma (STIC) in pelvic high grade serous carcinomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of serous fallopian tubal intraepithelial serous carcinoma (STIC) in pelvic high grade serous carcinomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">STIC: n (percent)</td> </tr> <tr> <td class=\"centered\">Kindelberger 2007</td> <td class=\"centered\">44</td> <td class=\"centered\">OVCA</td> <td class=\"centered\">20 (45)</td> </tr> <tr> <td class=\"centered\">Carlson 2008</td> <td class=\"centered\">19</td> <td class=\"centered\">PPCA</td> <td class=\"centered\">9 (47)</td> </tr> <tr> <td class=\"centered\">Roh 2009</td> <td class=\"centered\">78</td> <td class=\"centered\">OVCA</td> <td class=\"centered\">28 (36)</td> </tr> <tr> <td class=\"centered\">Przybycin 2010</td> <td class=\"centered\">41</td> <td class=\"centered\">OVCA/PPCA</td> <td class=\"centered\">24 (59)</td> </tr> <tr> <td class=\"centered\">Seidman 2011</td> <td class=\"centered\">51</td> <td class=\"centered\">PPCA</td> <td class=\"centered\">28 (56)</td> </tr> <tr> <td class=\"centered\">Leonhardt 2011</td> <td class=\"centered\">9</td> <td class=\"centered\">PPCA</td> <td class=\"centered\">3 (33)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OVCA: ovarian carcinoma; PPCA: primary peritoneal carcinoma.</div><div id=\"graphicVersion\">Graphic 86931 Version 1.0</div></div></div>"},"86932":{"type":"graphic_picture","displayName":"Fallopian tube p53 staining","title":"Staining for p53 is fallopian tube specimens","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Staining for p53 is fallopian tube specimens</div><div class=\"cntnt\"><img style=\"width:515px; height:383px;\" src=\"images/ONC/86932_Fallopian_tube_p53_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Benign tubal mucosa with a p53 mutation (p53 signature) and (B) following staining for p53. Note the absence of atypia seen in serous tubal intraepithelial carcinoma.<br />(C) An expansile p53 signature and (D) following staining for p53. The latter entity is more in keeping with a premalignant atypia but lacks the more striking atypia seen in a tubal intraepithelial carcinoma.</div><div id=\"graphicVersion\">Graphic 86932 Version 4.0</div></div></div>"},"86933":{"type":"graphic_picture","displayName":"Fallopian tube mucosal proliferations","title":"Fallopian tube mucosal proliferations","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Fallopian tube mucosal proliferations</div><div class=\"cntnt\"><img style=\"width:515px; height:391px;\" src=\"images/ONC/86933_Fallop_tub_mucos_prolif.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete mucosal proliferations seen in the tube that are not directly connected to serous carcinoma.<br />(A) A secretory cell outgrowth (boxed area); (B) note the lack of PAX2 immunostaining, suggesting dysregulation of expression. The inset contrast normal epithelium (upper) and that lacking PAX2 expression (lower).<br />(C) A discrete papillary proliferation which at higher power (in D) exhibits both secretory and ciliated differentiation. These are uncommon and bear a resemblance to low-grade serous tumors seen in the ovary.</div><div id=\"graphicVersion\">Graphic 86933 Version 3.0</div></div></div>"},"86935":{"type":"graphic_picture","displayName":"Low grade serous ovarian carcinoma","title":"Low grade serous ovarian carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Low grade serous ovarian carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/86935_Low_grd_sero_ova_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A low grade serous carcinoma of the ovary. This variant is not associated with p53 mutations and is more tightly linked to the ovary than fallopian tube.</div><div id=\"graphicVersion\">Graphic 86935 Version 3.0</div></div></div>"},"86936":{"type":"graphic_picture","displayName":"Endoscopic staging upper GI-GVHD","title":"Endoscopic and histological staging of upper gastrointestinal graft-versus-host disease (GI-GVHD)","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Endoscopic and histological staging of upper gastrointestinal graft-versus-host disease (GI-GVHD)</div><div class=\"cntnt\"><img style=\"width:519px; height:324px;\" src=\"images/HEME/86936_Endoscop_stag_upper_GI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper panel: Endoscopic views of duodenum with the four grades of GI-GVHD. Grade 1 = loss of vascular markings and/or focal mild erythema; grade 2 = moderate edema and/or erythema; grade 3 = edema, erythema, erosions, and/or bleeding; grade 4 = ulceration, exudates, and bleeding.<br />Lower panel: Photomicrographs of the duodenum corresponding to the above endoscopic images. Grade 1 = increased crypt apoptosis (arrow); grade 2 = apoptosis with crypt abscess (arrow); grade 3 = individual crypt necrosis (arrows); grade 4 = total denudation of areas of mucosa (hematoxylin and eosin [H &amp; E]; x220).</div><div class=\"graphic_reference\">Reproduced with permission from: Cruz-Correa M, Poonawala A, Abraham SC, et al. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 2002; 34:808. Copyright © 2002 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 86936 Version 1.0</div></div></div>"},"86937":{"type":"graphic_picture","displayName":"Endoscopic staging lower GI-GVHD","title":"Endoscopic and histological staging of lower gastrointestinal graft-versus-host disease (GI-GVHD)","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Endoscopic and histological staging of lower gastrointestinal graft-versus-host disease (GI-GVHD)</div><div class=\"cntnt\"><img style=\"width:519px; height:323px;\" src=\"images/HEME/86937_Endoscop_stag_lower_GI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper panel: Endoscopic views of the colon with the four grades of GI-GvHD. Grade 1 = loss of vascular markings and/or focal mild erythema; grade 2 = moderate edema and/or erythema; grade 3 = edema, erythema, erosions, and/or bleeding; grade 4 = ulceration, exudates, and bleeding. <BR>Lower panel: Photomicrograph of the colon corresponding to the above endoscopic images: grade 1 = increased crypt apoptosis (arrows); grade 2 = apoptosis with crypt abscess (arrow); grade 3 = individual crypt necrosis (arrow); grade 4 = total denudation of areas of mucosa (H &amp; E; x220).</div><div class=\"graphic_reference\">Reproduced with permission from: Cruz-Correa M, Poonawala A, Abraham SC, et al. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 2002; 34:808. Copyright © 2002 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 86937 Version 1.0</div></div></div>"},"86939":{"type":"graphic_table","displayName":"Distinguishing TRALI and TACO","title":"Helpful features in distinguishing TRALI and TACO","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful features in distinguishing TRALI and TACO</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">TRALI</td> <td class=\"subtitle1\">TACO</td> </tr> <tr> <td>Body temperature</td> <td>Fever may be present</td> <td>Unchanged</td> </tr> <tr> <td>Blood pressure</td> <td>Hypotension may be present</td> <td>Hypertension may be present</td> </tr> <tr> <td>Respiratory symptoms</td> <td>Acute dyspnea</td> <td>Acute dyspnea</td> </tr> <tr> <td>Neck veins</td> <td>Unchanged</td> <td>May be distended</td> </tr> <tr> <td>Auscultation</td> <td>Rales</td> <td>Rales and S3 may be present</td> </tr> <tr> <td>Chest radiograph</td> <td>Diffuse bilateral infiltrates</td> <td>Diffuse bilateral infiltrates</td> </tr> <tr> <td>Ejection fraction</td> <td>Normal</td> <td>Decreased</td> </tr> <tr> <td>PAOP</td> <td>Most often 18 mmHg or less</td> <td>Greater than 18 mmHg</td> </tr> <tr> <td>Pulmonary edema fluid</td> <td>Exudate</td> <td>Transudate</td> </tr> <tr> <td>Fluid balance</td> <td>Neutral or negative</td> <td>Positive</td> </tr> <tr> <td>Response to diuretics</td> <td>Inconsistent</td> <td>Significant improvement</td> </tr> <tr> <td>White cell count</td> <td>Transient leukopenia may be present</td> <td>Unchanged</td> </tr> <tr> <td>BNP</td> <td>&#60;250 pg/mL</td> <td>&#62;1200 pg/mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TRALI: transfusion-related acute lung injury; TACO: transfusion-associated circulatory overload; PAOP: pulmonary artery occlusion pressure; BNP: brain natriuretic peptide.</div><div class=\"graphic_reference\">Modified with permission from: Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14:682. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 86939 Version 4.0</div></div></div>"},"86941":{"type":"graphic_table","displayName":"Aspirin for CVD and cancer prevention","title":"Aspirin (75 to 100 mg) compared with no aspirin in the primary prevention of cardiovascular disease and cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aspirin (75 to 100 mg) compared with no aspirin in the primary prevention of cardiovascular disease and cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Outcomes</td> <td class=\"subtitle1\" rowspan=\"2\">Participants (studies), follow-up</td> <td class=\"subtitle1\" rowspan=\"2\">Quality of the evidence<br /> (GRADE)</td> <td class=\"subtitle1\" rowspan=\"2\">Relative effect<br /> (95% CI)</td> <td class=\"subtitle1\" colspan=\"2\">Anticipated absolute effects over 10 years</td> </tr> <tr> <td class=\"subtitle2\">Risk without aspirin</td> <td class=\"subtitle2\">Risk difference with aspirin<br /> (95% CI)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Total mortality*</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">100,076 (9), 3.8 to 10 years<sup>[1]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">&oplus;&oplus;&oplus;<br /> <strong>MODERATE</strong> due to imprecision<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>RR 0.94</strong><br /> (0.88-1.00)</td> <td class=\"subtitle2_left\" colspan=\"2\">60 year old male<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\">100 deaths per 1000<sup>&#916;</sup></td> <td class=\"divider_bottom\">6 fewer deaths per 1000<br /> (from 12 fewer to 0 fewer)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Myocardial infarction (MI)</strong> nonfatal events</td> <td class=\"divider_bottom\" rowspan=\"6\">100,076 (9), 3.8 to 10 years<sup>[1]</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">&oplus;&oplus;&oplus;&oplus;<br /> <strong>HIGH</strong></td> <td class=\"divider_bottom\" rowspan=\"6\"><strong>RR 0.80</strong><br /> (0.67-0.96)</td> <td class=\"subtitle2_left\" colspan=\"2\">Low cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td>27 MI per 1000<sup>&#167;</sup></td> <td>5 fewer MI per 1000<br /> (from 9 fewer to 1 fewer)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td>83 MI per 1000<sup>&#167;</sup></td> <td>17 fewer MI per 1000<br /> (from 27 fewer to 3 fewer)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\">136 per 1000<sup>&#167;</sup></td> <td class=\"divider_bottom\">27 fewer per 1000<br /> (from 45 fewer to 5 fewer)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Stroke</strong><br /> includes nonfatal ischemic and hemorrhagic strokes<sup>&#165;</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">95,000 (9), 3.8 to 10 years<sup>[2]</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">&oplus;&oplus;&oplus;<br /> <strong>MODERATE</strong> due to imprecision<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"6\"><strong>RR 0.95</strong><br /> (0.85-1.06)</td> <td class=\"subtitle2_left\" colspan=\"2\">Low cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td>23 strokes per 1000<sup>&#167;</sup></td> <td>No significant difference<br /> 1 fewer stroke per 1000<br /> (from 3 fewer to 1 more)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td>65 strokes per 1000<sup>&#167;</sup></td> <td>No significant difference<br /> 3 fewer strokes per 1000<br /> (from 10 fewer to 4 more)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High cardiovascular risk population<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\">108 strokes per 1000<sup>&#167;</sup></td> <td class=\"divider_bottom\">No significant difference<br /> 5 fewer strokes per 1000<br /> (from 16 fewer to 8 more)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Major extracranial bleed<sup>&#182;&#182;</sup></strong></td> <td class=\"divider_bottom\" rowspan=\"6\">95,000 (6), 3.8 to 10 years<sup>[3]</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">&oplus;&oplus;&oplus;&oplus;<br /> <strong>HIGH</strong></td> <td class=\"divider_bottom\" rowspan=\"6\"><strong>RR 1.54</strong><br /> (1.30-1.82)</td> <td class=\"subtitle2_left\" colspan=\"2\">Low cardiovascular risk population<sup>&#135;</sup></td> </tr> <tr> <td>8 bleeds per 1000<sup>&#167;</sup></td> <td>4 more bleeds per 1000<br /> (from 2 more to 7 more)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate cardiovascular risk population<sup>&#135;</sup></td> </tr> <tr> <td>24 bleeds per 1000<sup>&#167;</sup></td> <td>16 more bleeds per 1000<br /> (from 7 more to 20 more)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High cardiovascular risk population<sup>&#135;</sup></td> </tr> <tr> <td class=\"divider_bottom\">40 bleeds per 1000<sup>&#167;</sup></td> <td class=\"divider_bottom\">22 more bleeds per 1000<br /> (from 12 more to 33 more)</td> </tr> <tr> <td rowspan=\"6\"><strong>Colorectal cancer (incidence)</strong></td> <td rowspan=\"6\">14,033 (4), median follow-up 18.3 years<sup>[4]</sup></td> <td rowspan=\"6\">&oplus;&oplus;<br /> <strong>LOW</strong> due to imprecision<sup>&#134;</sup> and risk of bias<sup>&#916;&#916;</sup></td> <td rowspan=\"6\"><strong>HR 0.76</strong><br /> (0.60-0.96)</td> <td class=\"subtitle2_left\" colspan=\"2\">Low colorectal cancer risk population: Anticipated absolute effect over 20 years&nbsp;</td> </tr> <tr> <td>30 cancers per 1000**</td> <td>7&nbsp;fewer cancers per 1000<br /> (from 12 fewer to&nbsp;1 fewer)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate colorectal cancer risk population</td> </tr> <tr> <td>53 cancers per 1000**</td> <td>13&nbsp;fewer cancers per 1000<br /> (from&nbsp;21 fewer to&nbsp;2 fewer)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High colorectal cancer risk population</td> </tr> <tr> <td>100 cancers per 1000**</td> <td>24&nbsp;fewer cancers per 1000<br /> (from 40 fewer to&nbsp;4 fewer)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GRADE: Grades of Recommendations, Assessment, Development, and Evaluation; RR: risk ratio.<br />* This systematic review reports total mortality and includes the most recent trials. Other meta-analyses that utilize individual patient data report relative risk estimates for vascular mortality (RR 0.97, 95% CI 0.87-1.09), cancer mortality (RR 0.66, 95% CI 0.50-0.87), and fatal intracranial bleeds (RR 1.73, 95% CI 0.96-3.13). The risk of a fatal bleed (including extracranial and intracranial) was low (0.3 percent with aspirin and 0.2 percent with control).<br />¶ The 95% CI for the absolute effect includes no benefit of aspirin. We did not rate down for risk of bias, but this was a borderline decision. Three of the trials did not blind patients, caregivers, or outcome adjudicator. Sensitivity analyses in meta-analysis by Raju et al did not show evidence of risk of bias.<br />Δ Control group risk estimate for 10-year mortality apply to a 60-year-old male and comes from population-based data from Statistics Norway. Mortality increases with age (eg, 50-year-old male; 50 deaths per 1000 in 10 years) and is lower in females than in males (eg, 3 percent in women aged 50 years versus 5 percent in men aged 50 years).<br /><FONT class=lozenge>◊</FONT> Risk groups correspond to low (5 percent), medium (15 percent), and high risk (25 percent) according to the Framingham score (or other risk tool) to estimate 10-year risk.<br />§ Control group risk estimates in low, moderate, and high cardiovascular risk groups are based on the Framingham score. We have used data from an individual patient data meta-analysis to provide estimated risks for patient-important outcomes not covered by the Framingham risk score. We have also adjusted for 20 percent overestimation associated with Framingham risk score.<br />¥ Of the strokes in the trials, 89 of 682 (13 percent) without aspirin were hemorrhagic and 116 of 655 (18 percent) with aspirin were hemorrhagic.<br />‡ In the individual patient data meta-analysis, risk for future major bleeding correlated with risk for future cardiovascular events. Therefore, we make the assumption that a patient at low, medium, or high risk of future cardiovascular events (determined by Framingham score) will be at low, medium, or high risk of future major bleeding events, respectively.<br />† The 95% CI for absolute effect borders no benefit of aspirin.<br />** Moderate control group risk estimate derived from meta-analysis by Rothwell et al.<br />¶¶ Major extracranial bleeds are usually from the gastrointestinal tract and are most often defined in those requiring transfusion or resulting in death.<br />ΔΔ Treatment with aspirin during the included studies ranged from 2.6 to 6.9 years.&nbsp; Colorectal cancer incidence was determined using cancer and death registries for a median of 18.3 years without knowledge of post-treatment period aspirin use.<br />◊◊ Control group risk estimates based on NCI Colorectal Cancer Risk Predictor Tool.&nbsp; Average lifetime risk for 60-year-old female of 4.9%; 60-year old-male of&nbsp;5.7%.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209. </LI>&#xD;&#xA;<LI>Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.</LI>&#xD;&#xA;<LI>Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of Aspirin on Cardiovascular and All-Cause Mortality in Primary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. Am J Med 2011; 124:621.</LI>&#xD;&#xA;<LI>Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741.</LI></OL>Modified with permission from: the American College of Chest Physicians. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S. Copyright © 2012.</div><div id=\"graphicVersion\">Graphic 86941 Version 11.0</div></div></div>"},"86942":{"type":"graphic_diagnosticimage","displayName":"Bilateral DDH plain radiograph","title":"Plain radiograph: Bilateral developmental dysplasia of the hips","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plain radiograph: Bilateral developmental dysplasia of the hips</div><div class=\"cntnt\"><img style=\"width:504px; height:332px;\" src=\"images/PEDS/86942_Bilat_DDH_plain_radiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that both femoral heads are displaced laterally and superiorly. The acetabular index (AI) is also increased (&gt;40&deg;) bilaterally.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 86942 Version 1.0</div></div></div>"},"86943":{"type":"graphic_figure","displayName":"Clinical features bilateral DDH","title":"Clinical features of bilateral developmental dysplasia of the hips","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Clinical features of bilateral developmental dysplasia of the hips</div><div class=\"cntnt\"><img style=\"width:474px; height:523px;\" src=\"images/PEDS/86943_Bilateral_DDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical features of bilateral developmental dysplasia of the hips include a wide perineum (because of lateral displacement of the femoral heads and neck) and hyperlordosis (because of superior and posterior displacement of the femoral heads and neck).</div><div id=\"graphicVersion\">Graphic 86943 Version 1.0</div></div></div>"},"86944":{"type":"graphic_algorithm","displayName":"Algorithm for cell-free DNA testing for fetal RHD status","title":"Algorithm for determining the results of cell-free DNA testing to determine the fetal <em>RHD</em> status","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for determining the results of cell-free DNA testing to determine the fetal <em>RHD</em> status</div><div class=\"cntnt\"><img style=\"width:333px; height:371px;\" src=\"images/OBGYN/86944_MgmntRhalmnztnnprgncy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SNP: single-nucleotide polymorphism; <EM>RHD</EM>: Rhesus D gene.</div><div class=\"graphic_reference\">Reproduced with permission from: Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: A systematic review. Obstet Gynecol 2012; 120:1132. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 86944 Version 7.0</div></div></div>"},"86946":{"type":"graphic_table","displayName":"Causes of oral lichenoid contact reactions","title":"Causes of oral lichenoid contact reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of oral lichenoid contact reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dental adhesives</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acrylate compounds </li> <li>Eugenol </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Dental metals</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Beryllium </li> <li>Cobalt </li> <li>Copper </li> <li>Chromium </li> <li>Gold </li> <li>Mercury </li> <li>Nickel </li> <li>Palladium </li> <li>Silver </li> <li>Tin </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other dental restoration materials</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Composite </li> <li>Glass ionomer </li> <li>Porcelain </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Flavorings</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Balsam of Peru (<em>Myroxylon pereirae</em>)</li> <li>Cinnamon, cinnamic aldehyde </li> <li>Eugenol </li> <li>Menthol </li> <li>Peppermint </li> <li>Vanillin </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther 2010; 23:251. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2010.01322.x/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2010.01322.x/abstract</A>. Copyright © 2010 Wiley Periodicals Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 86946 Version 1.0</div></div></div>"},"86947":{"type":"graphic_picture","displayName":"Oral hairy leukoplakia","title":"Oral hairy leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral hairy leukoplakia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86947_Oral_hairy_leukoplakia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White plaques are present on the tongue.</div><div class=\"graphic_reference\">Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86947 Version 3.0</div></div></div>"},"86948":{"type":"graphic_picture","displayName":"White sponge nevus","title":"White sponge nevus of the oral mucosa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">White sponge nevus of the oral mucosa</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86948_White_sponge_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, white plaque is present on the oral mucosa. White sponge nevi represent a rare genetic condition caused by mutations in keratin 4 or keratin 13 genes. Lesions usually first appear during childhood.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86948 Version 3.0</div></div></div>"},"86949":{"type":"graphic_picture","displayName":"Oral condyloma acuminatum","title":"Oral condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86949_Oral_condyloma_acuminatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86949 Version 3.0</div></div></div>"},"86950":{"type":"graphic_picture","displayName":"Bullous pemphigoid direct immunofluorescence C3 deposits","title":"Linear C3 basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Linear C3 basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:540px; height:407px;\" src=\"images/DERM/86950_Bull_pemph_dir_immfl_C3_dep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence microscopy of perilesional skin from a patient with bullous pemphigoid reveals characteristic linear C3 basement membrane zone staining.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86950 Version 2.0</div></div></div>"},"86951":{"type":"graphic_picture","displayName":"N-serrated pattern on direct immunofluorescence","title":"N-serrated pattern of IgG basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">N-serrated pattern of IgG basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:576px; height:434px;\" src=\"images/DERM/86951_N-sratd_ptrn_drct_imnflscnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The positive direct immunofluorescence staining along the basement membrane zone in this section of a perilesional skin specimen demonstrates what is described as an n-serrated linear pattern interspersed with segments of true linear IgG basement membrane zone antibody reactivity. This pattern is associated with bullous pemphigoid, mucous membrane pemphigoid, anti-laminin gamma-1 pemphigoid, and linear IgA bullous dermatosis.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86951 Version 2.0</div></div></div>"},"86952":{"type":"graphic_picture","displayName":"U-serrated pattern on direct immunofluorescence","title":"U-serrated IgG basement membrane zone antibody staining in epidermolysis bullosa acquisita by direct immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">U-serrated IgG basement membrane zone antibody staining in epidermolysis bullosa acquisita by direct immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:576px; height:434px;\" src=\"images/DERM/86952_Lnr_IgG_400_X_u-srtd_ptrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The positive direct immunofluorescence staining along the basement membrane zone in this section of a perilesional skin specimen demonstrates what is described as a u-serrated linear pattern interspersed with segments of true linear IgG basement membrane zone antibody reactivity. This pattern is associated with epidermolysis bullosa acquisita and bullous systemic lupus erythematosus.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 86952 Version 2.0</div></div></div>"},"86954":{"type":"graphic_table","displayName":"ESC surgery for primary MR","title":"European Society of Cardiology guideline recommendations for mitral valve surgery in patients with severe primary mitral regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology guideline recommendations for mitral valve surgery in patients with severe primary mitral regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Levels<sup>&#182;</sup></td> <td class=\"subtitle1\">Ref<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Mitral valve repair should be the preferred technique when it is expected to be durable.</td> <td>I</td> <td>C</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery is indicated in symptomatic patients with LVEF &#62;30 percent and LVESD &#60;55 mm.</td> <td>I</td> <td>B</td> <td>1,2</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD &#8805;40 mm.</td> <td>I</td> <td>C</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery should be considered in patients with severe LV dysfunction (LVEF &#60;30 percent and/or LVESD &#62;55 mm) refractory to medical therapy with high likelihood of durable repair and low comorbidity.</td> <td>IIa</td> <td>C</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD &#8805;45 mm and/or LVEF &#8804;60 percent).</td> <td>IIa</td> <td>C</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary pressure at rest &#62;50 mmHg).</td> <td>IIa</td> <td>C</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery may be considered in patients with severe LV dysfunction (LVEF &#60;30 percent and/or LVESD &#62;55 mm) refractory to medical therapy with low likelihood of durable repair and low comorbidity.</td> <td>IIb</td> <td>C</td> <td>&nbsp;</td> </tr> <tr> <td>Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: <ul> <li>Left atrial dilatation (volume index &#8805;60 mL/m<sup>2</sup> BSA) and sinus rhythm, or </li> <li>Pulmonary hypertension on exercise (SPAP &#8805;60 mmHg at exercise). </li> </ul> </td> <td>IIb</td> <td>C</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BSA: body surface area; LV: left ventricle; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; SPAP: systolic pulmonary artery pressure.<br />* Class of recommendation.<br />&para; Level of evidence.<br />&Delta; Reference(s) supporting class I (A + B) and IIa + IIb (A + B) recommendations.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Haan CK, Cabral CI, Conetta DA, Coombs LP, Edwards FH. Selecting patients with mitral regurgitation and left ventricular dysfunction for isolated mitral valve surgery. Ann Thorac Surg 2004; 78:820-825.</LI>&#xD;&#xA;<LI>Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR, Frye RL. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994; 24:1536-1543. </LI></OL>Reproduced from: Vahanian A, Alifieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33:2451. By permission of European Society of Cardiology. Copyright © 2013 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org/</A>.</div><div id=\"graphicVersion\">Graphic 86954 Version 14.0</div></div></div>"},"86955":{"type":"graphic_table","displayName":"Prevalence of comorbid depression in anxiety disorders","title":"Prevalence of comorbid depression in anxiety disorders (data from large epidemiological surveys)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of comorbid depression in anxiety disorders (data from large epidemiological surveys)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author/year</td> <td class=\"subtitle1\">Population/study</td> <td class=\"subtitle1\">Anxiety disorder</td> <td class=\"subtitle1\">Prevalence of comorbid MDD</td> </tr> <tr class=\"divider_bottom\"> <td>Schneier et al.<br /> 1992<sup>[1]</sup></td> <td>ECA</td> <td>SAD</td> <td>16.6% (lifetime)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Flint<br /> 1994<sup>[2]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">ECA</td> <td>All anxiety disorders</td> <td>21% (12-month)</td> </tr> <tr class=\"divider_bottom\"> <td>GAD</td> <td>60% (12-month)</td> </tr> <tr class=\"divider_bottom\"> <td>Wittchen et al.<br /> 1994<sup>[3]</sup></td> <td>NCS</td> <td>GAD</td> <td>38.6% (30 day GAD); 62.4% (lifetime)</td> </tr> <tr class=\"divider_bottom\"> <td>Kessler et al.<br /> 1995<sup>[4]</sup></td> <td>NCS</td> <td>PTSD</td> <td>47.9% (males, lifetime); 48.5% (females, lifetime)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Magee et al.<br /> 1996<sup>[5]</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">NCS</td> <td>SAD</td> <td>37.2% (lifetime)</td> </tr> <tr> <td>AGOR</td> <td>45.9% (lifetime)</td> </tr> <tr class=\"divider_bottom\"> <td>SP</td> <td>42.3% (lifetime)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Kessler et al.<br /> 1999<sup>[6]</sup></td> <td>NCS</td> <td class=\"divider_bottom\" rowspan=\"2\">GAD</td> <td>58.1% (12-month)</td> </tr> <tr class=\"divider_bottom\"> <td>MDUSS</td> <td>69.7% (12-month)</td> </tr> <tr class=\"divider_bottom\"> <td>Lieb et al.<br /> 2005<sup>[7]</sup></td> <td>ESEMeD</td> <td>GAD</td> <td>59% (12-month)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Alonso et al.<br /> 2007<sup>[8]</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">ESEMeD</td> <td>SAD</td> <td>14.5% (all 12-month)</td> </tr> <tr> <td>GAD</td> <td>37.1%</td> </tr> <tr> <td>PTSD</td> <td>7.8%</td> </tr> <tr> <td>PD</td> <td>29.8%</td> </tr> <tr> <td>AGOR</td> <td>15.5%</td> </tr> <tr class=\"divider_bottom\"> <td>SP</td> <td>15.5%</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Eisenberg et al.<br /> 2007<sup>[9]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">WHO, WMHS</td> <td>GAD</td> <td>30.4% (2 weeks)</td> </tr> <tr class=\"divider_bottom\"> <td>PD</td> <td>9.4% (2 weeks)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Gabilondo et al.<br /> 2010<sup>[10]</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">ESEMeD</td> <td>SAD</td> <td>7.7% (all 12-month)</td> </tr> <tr> <td>GAD</td> <td>15%</td> </tr> <tr> <td>PTSD</td> <td>7.3%</td> </tr> <tr> <td>PD</td> <td>9%</td> </tr> <tr> <td>AGOR</td> <td>3%</td> </tr> <tr class=\"divider_bottom\"> <td>SP</td> <td>14.4%</td> </tr> <tr class=\"divider_bottom\"> <td>Kessler et al.<br /> 2010<sup>[11]</sup></td> <td>WHO, WMHS</td> <td>Any anxiety disorder</td> <td>49.7% (12-month)</td> </tr> <tr class=\"divider_bottom\"> <td>Ruscio et al.<br /> 2010<sup>[12]</sup></td> <td>NCS-R</td> <td>OCD</td> <td>40.7% (lifetime)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Kessler et al.<br /> 2015<sup>[13]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">WHO, WMHS</td> <td>Any anxiety disorder</td> <td>45.7% (lifetime)</td> </tr> <tr class=\"divider_bottom\"> <td>Any anxiety disorder</td> <td>41.6% (12-month)</td> </tr> <tr> <td rowspan=\"2\">Adams et al.<br /> 2016<sup>[14]</sup></td> <td rowspan=\"2\">CPES</td> <td>Any anxiety disorder (except SAD)</td> <td>3.71% (lifetime)</td> </tr> <tr> <td>Any anxiety disorder (&#8805;2)</td> <td>7.43% (lifetime)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECA: Epidemiologic Catchment Area Study; SAD: social anxiety disorder; GAD: generalized anxiety disorder; NCS: National Comorbidity Survey; PTSD: posttraumatic stress disorder; AGOR: agoraphobia; SP: specific/simple phobia; MDUSS: Midlife Development in the United States Survey; ESEMeD: European Study of the Epidemiology of Mental Disorders; PD: panic disorder; WHO: World Health Organization; WMHS: World Health Organization Mental Health Survey Initiative; NCS-R: National Comorbidity Survey-Replication; OCD: obsessive-compulsive disorder; CPES: Collaborative Psychiatric Epidemiology Surveys.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen 49:282, 1992.</LI>&#xD;&#xA;<LI>Flint AJ. Epidemiology and Comorbidity of Anxiety Disorders in the Elderly. Am J Psychiatry 151:640, 1994.</LI>&#xD;&#xA;<LI>Wittchen HU, Zhao SY, Kessler RC, Eaton WW. Dsm-Iii-R Generalized Anxiety Disorder in the National-Comorbidity-Survey. Arch Gen Psychiatry 51:355, 1994.</LI>&#xD;&#xA;<LI>Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic-Stress-Disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52:1048, 1995.</LI>&#xD;&#xA;<LI>Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the national comorbidity survey. Arch Gen Psychiatry 53:159, 1996.</LI>&#xD;&#xA;<LI>Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915, 1999.</LI>&#xD;&#xA;<LI>Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. European Neuropsychopharmacology 15:445, 2005.</LI>&#xD;&#xA;<LI>Alonso J, Lépine JP, ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry 68 Suppl 2:3, 2007.</LI>&#xD;&#xA;<LI>Eisenberg D, Gollust SE, Golberstein E, Hefner JL. Prevalence and correlates of depression, anxiety, and suicidality among university students. Am J Orthopsychiatry 77:534, 2007.</LI>&#xD;&#xA;<LI>Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM, Fernandez A, Pinto-Meza A, et al. Epidemiology of major depressive episode in a southern European country: Results from the ESEMeD-Spain project. J Affect Disord 120:76, 2010.</LI>&#xD;&#xA;<LI>Kessler RC, Birnbaum HG, Shahly V, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 27:351, 2010.</LI>&#xD;&#xA;<LI>Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15:53, 2010.</LI>&#xD;&#xA;<LI>Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epi Psychiatric Sci 24:210, 2015.</LI>&#xD;&#xA;<LI>Adams CG, Balbuena L, Meng X, Asmundson G. When social anxiety and depression go together: a population study of comorbidity and associated consequences. J Affective Dis 206:48, 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 86955 Version 3.0</div></div></div>"},"86956":{"type":"graphic_picture","displayName":"Bullous impetigo 2","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86956_Bullous_impetigo_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles, flaccid bullae, and erosions with surrounding erythema on the buttock of a patient with bullous impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86956 Version 8.0</div></div></div>"},"86957":{"type":"graphic_picture","displayName":"Bullous impetigo crusts","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86957_Bullous_impetigo_crusts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86957 Version 3.0</div></div></div>"},"86959":{"type":"graphic_picture","displayName":"Circumcision complication - Meatal stenosis","title":"Meatal stenosis with ventral scarring (black arrows) after neonatal circumcision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meatal stenosis with ventral scarring (black arrows) after neonatal circumcision</div><div class=\"cntnt\"><img style=\"width:346px; height:426px;\" src=\"images/PEDS/86959_Crcumcsn_cmplctn-Mtl_stnoss.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86959 Version 1.0</div></div></div>"},"86960":{"type":"graphic_picture","displayName":"Circumcision complication - Excess ventral skin","title":"Excess ventral skin after neonatal circumcision","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Excess ventral skin after neonatal circumcision</div><div class=\"cntnt\"><img style=\"width:540px; height:388px;\" src=\"images/PEDS/86960_Cir_comp_exc_ventral_skin.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86960 Version 1.0</div></div></div>"},"86961":{"type":"graphic_picture","displayName":"Circumcision complication - Loss penile shaft skin","title":"Inadvertent removal of penile shaft skin during neonatal circumcision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inadvertent removal of penile shaft skin during neonatal circumcision</div><div class=\"cntnt\"><img style=\"width:418px; height:540px;\" src=\"images/PEDS/86961_removal_of_shaft_skin.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86961 Version 1.0</div></div></div>"},"86963":{"type":"graphic_picture","displayName":"Prurigo nodularis histopathology","title":"Histologic features of prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histologic features of prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:504px; height:146px;\" src=\"images/DERM/86963_Prurigonodularhisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On histopathologic examination, prurigo nodularis shows irregular epidermal hyperplasia, marked hyperkeratosis and parakeratosis, and dermal fibrosis.</div><div class=\"graphic_reference\">Courtesy of Jennifer McNiff, MD.</div><div id=\"graphicVersion\">Graphic 86963 Version 3.0</div></div></div>"},"86964":{"type":"graphic_picture","displayName":"Prurigo nodularis arms ","title":"Prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:504px; height:246px;\" src=\"images/DERM/86964_Prurigonodularisarms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriated nodules&nbsp;on the arms of a patient with nodular prurigo.</div><div id=\"graphicVersion\">Graphic 86964 Version 5.0</div></div></div>"},"86968":{"type":"graphic_diagnosticimage","displayName":"Apical 4C echo MAC and TAC","title":"Apical four-chamber echocardiogram with MAC and TAC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four-chamber echocardiogram with MAC and&nbsp;TAC</div><div class=\"cntnt\"><img style=\"width:386px; height:441px;\" src=\"images/CARD/86968_Apical4CechoMACTAC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-chamber echocardiographic image from a patient with end-stage renal disease. There is tricuspid annular calcification (TAC) and mitral annular calcification (MAC).</div><div class=\"graphic_reference\">Courtesy of Rosario V Freeman, MD, MS.</div><div id=\"graphicVersion\">Graphic 86968 Version 2.0</div></div></div>"},"86969":{"type":"graphic_diagnosticimage","displayName":"Doppler MV MAC","title":"Spectral Doppler recording across the mitral valve in a patient with severe mitral annular calcification","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Spectral Doppler recording across the mitral valve in a patient with severe mitral annular calcification</div><div class=\"cntnt\"><img style=\"width:504px; height:301px;\" src=\"images/CARD/86969_Doppler_MV_MAC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transmitral diastolic mean gradient is 6 mmHg, consistent with moderate left ventricular inflow obstruction.</div><div class=\"graphic_reference\">Courtesy of Rosario V Freeman, MD, MS.</div><div id=\"graphicVersion\">Graphic 86969 Version 1.0</div></div></div>"},"86970":{"type":"graphic_diagnosticimage","displayName":"Apical 2C echo MAC","title":"Apical two-chamber view of the left ventricle and mitral valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical two-chamber view of the left ventricle and mitral valve</div><div class=\"cntnt\"><img style=\"width:373px; height:413px;\" src=\"images/CARD/86970_Apical2CechoMAC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mitral annular calcification (MAC) is seen as a bright echodense&nbsp;structure&nbsp;along the posterior mitral valve annulus as calcium is a dense ultrasound reflector. In the lower portion of the image, there is absence of ultrasound penetration in the far field distal to the MAC&nbsp;due to acoustic shadowing. With severe acoustic shadowing, the left atrium may be obscured, making it difficult to identify and quantify mitral regurgitation.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Rosario V Freeman, MD, MS.</div><div id=\"graphicVersion\">Graphic 86970 Version 2.0</div></div></div>"},"86977":{"type":"graphic_diagnosticimage","displayName":"Angiosarcoma of the breast","title":"Mammogram, CT scan, and MRI angiosarcoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Mammogram, CT scan, and MRI angiosarcoma of the breast</div><div class=\"cntnt\"><img style=\"width:638px; height:523px;\" src=\"images/RADIOL/86977_Angiosarcoma_of_the_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 55-year-old patient has angiosarcoma of the left breast secondary to radiation therapy for breast carcinoma eight years prior. She presented with breast enlargement and bluish discoloration of the skin which was clinically initially felt to correspond to an \"expanding hematoma\". The mammogram of the left breast (A) reveals multiple nodular masses (arrows) in the outer part of the breast with overall increased trabecular background markings and skin thickening (small arrowhead). The CT scan through the mid chest (B) shows a skin nodule (large arrowhead), breast nodules (arrows), and thickened skin (dashed arrow) of the left breast. There are increased trabecular background markings throughout the left breast. The T1 weighted fat suppressed MRI post contrast images show three suspiciously enhancing masses (arrows in C) and thickened and enhancing skin (thick arrow, D). The T1 weighted MRI image in axial projection (E) shows nodular foci of skin thickening (double arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 86977 Version 2.0</div></div></div>"},"86979":{"type":"graphic_picture","displayName":"Gross images of breast angiosarcoma","title":"Gross images of breast angiosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross images of breast angiosarcoma</div><div class=\"cntnt\"><img style=\"width:399px; height:597px;\" src=\"images/ONC/86979_Gross_imgs_br_angiosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Mastectomy specimen from a patient with a radiation-associated angiosarcoma. Note the diffuse purple-blue discoloration of the skin and multiple raised red-black nodules on the skin.<BR>B)&nbsp;A close up image of the nodules which appear to be blood-filled, scabbed, and within an indurated patch.</div><div class=\"graphic_reference\">Courtesy of Drs. Alero Inyang and David Lucas.</div><div id=\"graphicVersion\">Graphic 86979 Version 1.0</div></div></div>"},"86980":{"type":"graphic_picture","displayName":"Bullous myringitis 2","title":"Bullous myringitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous myringitis</div><div class=\"cntnt\"><img style=\"width:391px; height:422px;\" src=\"images/PEDS/86980_Bullous_myringitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous myringitis is characterized by painful bullae that appear on the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 86980 Version 3.0</div></div></div>"},"86981":{"type":"graphic_picture","displayName":"Anti-Ro60 staining","title":"Staining pattern produced by anti-Ro60 antibodies","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Staining pattern produced by anti-Ro60 antibodies</div><div class=\"cntnt\"><img style=\"width:451px; height:437px;\" src=\"images/RHEUM/86981_Anti_Ro60_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human serum containing antibodies directed against Ro60 did not stain the nuclei of the traditional HEp-2 cell substrate (green, panel A). Human anti-Ro60 antibodies did stain the nuclei of cells using the HEp-2000 substrate, which has been genetically engineered to overexpress the protein in approximately 20 percent of the cells (red, panel C). Anti-Ro60 antibodies produced a nucleolar and nuclear speckled pattern in transfected cells. The human serum did not stain cells that did not overexpress Ro60. DAPI staining in panels B and D (blue) indicates the location of nuclei. White arrows in C and D identify HEp-2000 cells over-expressing Ro60. Human serum containing anti-Ro60 antibodies was provided by the Centers for Disease Control and Prevention from the international ANA reference serum panel.</div><div class=\"graphic_footnotes\">DAPI: 4',6'-diamidino-2-phenylindole; ANA: antinuclear antibody.</div><div class=\"graphic_reference\">Courtesy of Donald B Bloch, MD.</div><div id=\"graphicVersion\">Graphic 86981 Version 1.0</div></div></div>"},"86982":{"type":"graphic_picture","displayName":"Anti-Ro52 staining","title":"Staining pattern produced by anti-Ro52 antibodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staining pattern produced by anti-Ro52 antibodies</div><div class=\"cntnt\"><img style=\"width:349px; height:345px;\" src=\"images/RHEUM/86982_Anti_Ro52_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human serum containing antibodies directed against Ro52 stained the cytoplasm of HEp-2 cells. To demonstrate the cytoplasmic staining pattern produced by these antibodies, a plasmid encoding Ro52 fused to green fluorescent protein (GFP) was expressed in HEp-2 cells and was stained with mouse anti-GFP (green, panel A). Two of the five cells in the field were successfully transfected with the plasmid (indicated by white arrows). Human anti-Ro52 antibodies stained the cytoplasm of all the HEp-2 cells in the field, but staining was especially intense in cells over-expressing Ro52-GFP (red, panel B). DAPI staining (blue) in panel C indicates the location of nuclei.</div><div class=\"graphic_footnotes\">DAPI: 4',6'-diamidino-2-phenylindole.</div><div class=\"graphic_reference\">Courtesy of Donald B Bloch, MD.</div><div id=\"graphicVersion\">Graphic 86982 Version 1.0</div></div></div>"},"86983":{"type":"graphic_picture","displayName":"Anti-La staining","title":"Staining pattern produced by anti-La antibodies","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Staining pattern produced by anti-La antibodies</div><div class=\"cntnt\"><img style=\"width:461px; height:421px;\" src=\"images/RHEUM/86983_Anti_La_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human serum containing anti-La antibodies stained the nuclei of HEp-2 cells in a finely speckled pattern (A and C). DAPI staining in panels B and D indicate the location of nuclei. Note that in dividing cells (white arrow), anti-La antibodies did not react with chromosomes. Human serum containing anti-La antibodies was provided by the Centers for Disease Control and Prevention from the international ANA reference serum panel.</div><div class=\"graphic_footnotes\">DAPI: 4',6'-diamidino-2-phenylindole; ANA: antinuclear antibody.</div><div class=\"graphic_reference\">Courtesy of Donald B Bloch, MD.</div><div id=\"graphicVersion\">Graphic 86983 Version 1.0</div></div></div>"},"86985":{"type":"graphic_figure","displayName":"Lung ca IIIA PI","title":"Stage IIIA lung cancer","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Stage IIIA lung cancer</div><div class=\"cntnt\"><img style=\"width:509px; height:464px;\" src=\"images/ONC/86985_Stage_IIIA_NSCLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a stage IIIA cancer. In stage IIIA cancer, the tumor has spread to lymph nodes in the middle of the chest or it has spread into the structures in the middle of the chest like the main windpipe (called the trachea) or the swallowing tube (called the esophagus).</div><div id=\"graphicVersion\">Graphic 86985 Version 5.0</div></div></div>"},"86986":{"type":"graphic_figure","displayName":"Lung ca IIIB PI","title":"Stage IIIB lung cancer","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Stage IIIB lung cancer</div><div class=\"cntnt\"><img style=\"width:509px; height:464px;\" src=\"images/ONC/86986_Stage_IIIB_rev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a stage IIIB cancer. In stage IIIB cancer, the tumor has spread to lymph nodes on the other side of the mediastinum or to the lymph nodes above or behind the clavicle (collar bone). Stage IIIB also includes large tumors that have spread to the rib cage, heart, swallowing tube (called the esophagus), or trachea,&nbsp;in addition to involving the mediastinal lymph nodes.</div><div id=\"graphicVersion\">Graphic 86986 Version 4.0</div></div></div>"},"86987":{"type":"graphic_table","displayName":"Clinician response to gender nonconformity","title":"Examples of responses to caregiver concerns about gender nonconformity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of responses to caregiver concerns about gender nonconformity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Example of question</td> <td class=\"subtitle1\">Poor response</td> <td class=\"subtitle1\">Supportive response</td> </tr> <tr> <td>I am worried about how often my son plays with his sister's dolls. What do you think? Do you think my son may be gay?</td> <td>Playing with dolls is not typical of boys. He may be gay. Maybe I should refer you to a psychiatrist.</td> <td>Tell me more about what sort of play and activities your son enjoys? How do you and the family support and encourage the range of his play? All children experiment with&nbsp;and explore the other gender's toys and play. What is most important is for you to help your child explore his interests.</td> </tr> <tr> <td>My school-age daughter refuses to wear a dress. She is always playing with the neighborhood boys. I think she may be a lesbian. I am worried. </td> <td>Lots of girls hate dresses. But you as the parent can make her wear what you think is appropriate. You need to set better limits on her clothing choices. </td> <td>Tell me more about the conversations you and your daughter have had around wearing dresses, girls' clothing, etc. Why does your daughter refuse? Has she talked about other aspects of being a girl or gender? What would she wear if it was all up to her?</td> </tr> <tr> <td>We found out that my daughter thinks she is a boy trapped in a girl's body from a Facebook post. Can we help her not be a lesbian?</td> <td>Being gay is not so bad anymore. Being gay is more accepted and cool for kids.</td> <td>Let's talk some more and try to understand about her identity and feelings about her gender, versus her feelings, attractions, and possible sexual orientation. Gender and sexual orientation get confusing but they are very different aspects of each person.</td> </tr> <tr> <td>My son is driving his father crazy with the feminine clothes he wears, his long hair, etc. My son and his father fight all the time. I am so worried. What should I do?</td> <td>You should tell your son to get a haircut and wear normal clothing. Being effeminate is only going to&nbsp;get him beat up at school.</td> <td>Why do you think this upsets his dad? Does it upset you? Have you talked to your son about his preference for feminine clothes? Have you asked him how he feels about his dad's reactions and the fighting?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson-Kennedy, MD.</div><div id=\"graphicVersion\">Graphic 86987 Version 3.0</div></div></div>"},"86988":{"type":"graphic_table","displayName":"Cutaneous leishmaniasis species","title":"Classification of <em>Leishmania</em> species that cause human cutaneous disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of <em>Leishmania</em> species that cause human cutaneous disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Subgenus</td> <td class=\"subtitle1\">Complex</td> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Main geographic locations</td> <td class=\"subtitle1\">Main clinical manifestations</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Old World</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\"><em>Leishmania</em></td> <td><em>L.L. major</em></td> <td><em>L.L. major</em></td> <td>India, Pakistan, Central and Southwest Asia, Turkey, areas in Africa, Middle East</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L.L. tropica</em></td> <td><em>L.L. tropica</em></td> <td>Central and Southwest Asia, Middle East, Turkey, Greece, India, Pakistan, Yemen, Northern Africa, Ethiopia, Kenya</td> <td>Cutaneous leishmaniasis</td> <td>Leishmaniasis recidivans (LR), occasionally viscerotropic leishmaniasis</td> </tr> <tr> <td><em>L.L. aethiopica</em></td> <td><em>L.L. aethiopica</em></td> <td>Ethiopia, Kenya, Uganda</td> <td>Cutaneous leishmaniasis</td> <td>Diffuse cutaneous leishmaniasis (DCL)</td> </tr> <tr> <td><em>L.L. infantum chagasi</em></td> <td><em>L.L. infantum chagasi</em></td> <td>Mediterranean, Northern Africa, Middle East, Central and Southwest Asia, Balkans, China,&nbsp; sporadic in sub-Saharan Africa</td> <td>Visceral leishmaniasis</td> <td>Localized cutaneous leishmaniasis (LCL)</td> </tr> <tr> <td><em>L.L. donovani</em></td> <td><em>L.L. donovani</em></td> <td>India, China, Pakistan, Southwest Asia, Horn of Africa (Ethiopia, Somalia, Sudan, Kenya, Uganda)</td> <td>Visceral leishmaniasis</td> <td>Post kala-azar dermal leishmaniasis (PKDL), occasional localized cutaneous leishmaniasis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">New World</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\"><em>Leishmania</em></td> <td rowspan=\"3\"><em>L.L. mexicana</em></td> <td><em>L.L. mexicana</em></td> <td>Central and South America, Mexico, sporadic Texas and Oklahoma, United States</td> <td>Cutaneous leishmaniasis</td> <td>DCL</td> </tr> <tr> <td><em>L.L. venezuelensis</em></td> <td>Venezuela</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L.L. amazonensis</em></td> <td>Panama, South America (especially Amazon Basin)</td> <td>Cutaneous leishmaniasis</td> <td>DCL, occasionally visceral or mucosal leishmaniasis</td> </tr> <tr> <td><em>L.L. donovani</em></td> <td><em>L.L. infantum chagasi</em></td> <td>Central and South America</td> <td>Visceral leishmaniasis</td> <td>Occasional cutaneous leishmaniasis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\"><em>Viannia</em></td> <td rowspan=\"2\"><em>L.V. braziliensis</em></td> <td><em>L.V. braziliensis</em></td> <td>Central and South America</td> <td>Cutaneous and mucocutaneous leishmaniasis</td> <td>Mucosal leishmaniasis (especially Bolivia, Brazil, Peru)</td> </tr> <tr> <td><em>L.V. peruviana</em></td> <td>Peru and Argentina (western Andes slope)</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\"><em>L.V. guyanensis</em></td> <td><em>L.V. guyanensis</em></td> <td>South America (especially Northern Amazon Basin, Guyana, French Guiana)</td> <td>Cutaneous leishmaniasis</td> <td>Mucosal leishmaniasis</td> </tr> <tr> <td><em>L.V. panamensis</em></td> <td>Panama, Costa Rica, Colombia, Ecuador, Peru, Venezuela</td> <td>Cutaneous leishmaniasis</td> <td>Occasional mucosal leishmaniasis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 86988 Version 5.0</div></div></div>"},"86989":{"type":"graphic_picture","displayName":"Leishmania amastigote","title":"<em>Leishmania</em> amastigote","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><em>Leishmania</em> amastigote</div><div class=\"cntnt\"><img style=\"width:504px; height:500px;\" src=\"images/ID/86989_Leishmania_amastigote.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Leishmania</em> infected white blood cell on touch imprint, Giemsa stain, 250x magnification. The arrow shows an amastigote with the characteristic rod-shaped kinetoplast perpendicular to the nucleus.</div><div class=\"graphic_reference\">Courtesy of Naomi Aronson, MD, Walter Reed Army Medical Center.</div><div id=\"graphicVersion\">Graphic 86989 Version 3.0</div></div></div>"},"86991":{"type":"graphic_figure","displayName":"Hypoglossal nerve","title":"Hypoglossal nerve","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hypoglossal nerve</div><div class=\"cntnt\"><img style=\"width:504px; height:496px;\" src=\"images/SURG/86991_Hypoglossal_nerve.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 86991 Version 1.0</div></div></div>"},"86992":{"type":"graphic_picture","displayName":"New World CL ulcer with fibrinous material","title":"New World cutaneous leishmaniasis due to <em>L. (Viannia) panamensis</em>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">New World cutaneous leishmaniasis due to <em>L. (Viannia) panamensis</em></div><div class=\"cntnt\"><img style=\"width:504px; height:427px;\" src=\"images/ID/86992_New_wrld_CL_ulc_fib_mat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circle shows a good location for skin punch biopsy.</div><div class=\"graphic_reference\">Courtesy of Naomi Aronson, MD.</div><div id=\"graphicVersion\">Graphic 86992 Version 3.0</div></div></div>"},"86993":{"type":"graphic_table","displayName":"Terms used to describe various aspects of gender and sexuality","title":"Terms used to describe various aspects of gender and sexuality*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terms used to describe various aspects of gender and sexuality*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td><strong>Gender identity</strong></td> <td>An individual's innate sense of feeling male, female, neither, or some combination of both</td> </tr> <tr> <td><strong>Natal or birth-assigned sex</strong></td> <td>Typically assigned according to external genitalia or chromosomes</td> </tr> <tr> <td><strong>Gender expression</strong></td> <td>How gender is presented to the outside world (eg, feminine, masculine, androgynous); gender expression does not necessarily correlate with&nbsp;birth-assigned sex&nbsp;or gender identity</td> </tr> <tr> <td><strong>Gender nonconformity</strong></td> <td>Variation from the cultural norm in gender expression or gender role behavior (eg, in choices of toys, playmates, etc)</td> </tr> <tr> <td><strong>\"Transgender\" (\"trans\" as an abbreviation)</strong></td> <td>Umbrella term that is used to describe individuals with gender nonconformity; it includes individuals whose gender identity is different from their birth-assigned sex and/or whose gender expression does not fall within stereotypical definitions of masculinity and femininity;&nbsp;\"transgender\"&nbsp;is used as an adjective (\"transgender people\"), not a noun (\"transgenders\")</td> </tr> <tr> <td><strong>Gender dysphoria or incongruence</strong></td> <td>Distress or discomfort that may occur when gender identity and birth-assigned sex are not completely congruent</td> </tr> <tr> <td><strong>Transsexual</strong></td> <td>Older, clinical term that has fallen out of favor;&nbsp;historically, it&nbsp;was used to refer to transgender people who sought medical or surgical interventions for gender affirmation</td> </tr> <tr> <td><strong>Sexual orientation</strong></td> <td>An individual's pattern of physical and emotional arousal (including fantasies, activities, and behaviors) and the gender(s) of persons to whom an individual is physically or sexually attracted (gay/lesbian, straight, bisexual); sexual orientation is an entirely different construct than gender identity, but is often confused with it; the sexual orientation of transgender people is based upon their identified gender (eg,&nbsp;a transgender man who is attracted to other men&nbsp;might identify as&nbsp;a gay man; a transgender woman who is attracted to other women&nbsp;might&nbsp;identify as&nbsp;a lesbian) </td> </tr> <tr> <td><strong>Sexual behaviors</strong></td> <td>Specific behaviors involving sexual activities that are useful for screening and risk assessment; many youth reject traditional labeling (homosexual, heterosexual, bisexual) but still have same-sex partners</td> </tr> <tr> <td><strong>Transgender man/transman</strong></td> <td>Person with a masculine gender identity who was assigned a female sex at birth</td> </tr> <tr> <td><strong>Transgender woman/transwoman</strong></td> <td>Person&nbsp;with a feminine gender identity who was assigned a male sex at birth</td> </tr> <tr> <td><strong>Genderqueer/Nonbinary</strong></td> <td>Person of any birth-assigned sex who has a gender identity that is neither masculine nor feminine, is some combination of the two,&nbsp;or is fluid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These are cultural and descriptive terms, not diagnostic terms, which are specific to medical and pathology-based paradigms.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Perrin EC. Sexual Orientation in Child and Adolescent Health Care, Springer, New York 2002.</LI>&#xD;&#xA;<LI>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 2017.</LI>&#xD;&#xA;<LI>Adelson SL, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter on gay, lesbian, or bisexual sexual orientation, gender nonconformity, and gender discordance in children and adolescents. J Am Acad Child Adolesc Psychiatry 2012; 51:957.</LI>&#xD;&#xA;<LI>Frankowski BL, American Academy of Pediatrics Committee on Adolescence. Sexual orientation and adolescents. Pediatrics 2004; 113:1827.</LI>&#xD;&#xA;<LI>Edwards-Leeper L, Spack NP. Psychological evaluation and medical treatment of transgender youth in an interdisciplinary \"Gender Management Service\" (GeMS) in a major pediatric center. J Homosex 2012; 59:321. </LI></OL></div><div id=\"graphicVersion\">Graphic 86993 Version 8.0</div></div></div>"},"86994":{"type":"graphic_picture","displayName":"Steroid acne 1","title":"Steroid acne","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Steroid acne</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86994_Steroid_acne_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Monomorphous inflammatory papular eruption involving the trunk of a patient treated with systemic corticosteroids.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86994 Version 4.0</div></div></div>"},"86995":{"type":"graphic_picture","displayName":"Steroid acne 2","title":"Steroid acne","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Steroid acne</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86995_Steroid_acne_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papulopustular eruption secondary to prolonged use of topical corticosteroids.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86995 Version 4.0</div></div></div>"},"86996":{"type":"graphic_diagnosticimage","displayName":"Ultrasound gallbladder sludge","title":"Ultrasound of gallbladder sludge","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound of gallbladder sludge</div><div class=\"cntnt\"><img style=\"width:598px; height:247px;\" src=\"images/RADIOL/86996_US_gallbladder_sludge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of the gallbladder in sagittal (A) and transverse (B) projections in an 80-year-old male with right upper quadrant pain reveals a normal sized gallbladder with layering sludge (arrow). Some brighter non shadowing foci are appreciated in the sludge (arrowhead). One month after the ultrasound, the patient had a cholecystectomy. Noted within the sludge were small stones, the largest of which was 0.5 mm. The gallbladder was not inflamed at that time.</div><div id=\"graphicVersion\">Graphic 86996 Version 2.0</div></div></div>"},"86997":{"type":"graphic_picture","displayName":"Pityrosporum folliculitis 1","title":"<EM>Pityrosporum </EM>folliculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Pityrosporum </EM>folliculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86997_Pityrosp_folliculitis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular papules and pustules on the upper back of a patient with <EM>Pityrosporum</EM> folliculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86997 Version 7.0</div></div></div>"},"86998":{"type":"graphic_picture","displayName":"Pityrosporum folliculitis 2","title":"<EM>Pityrosporum</EM> folliculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Pityrosporum</EM> folliculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86998_Pityrosporum_folliculitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pinpoint&nbsp;follicular papules and pustules are characteristic of<EM> Pityrosporum</EM> folliculitis. The eruption most often involves the upper trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86998 Version 5.0</div></div></div>"},"86999":{"type":"graphic_picture","displayName":"Tinea barbae 1","title":"Tinea barbae","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea barbae</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/86999_Tinea_barbae_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, erythematous papulopustular lesions in the beard area of a patient with <EM>Trichophyton</EM> infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 86999 Version 5.0</div></div></div>"}};